1	Clinica	NNP	PERSON	Clinica	nn	3	SENT_1	[p1l811t81r890b103],
2	Chimica	NNP	PERSON	Chimica	nn	3	SENT_1	[p1l900t81r996b103],
3	Acta	NNP	PERSON	Acta	_	0	SENT_1	[p1l1005t82r1057b103],
4	413	CD	NUMBER	413	number	5	SENT_1	[p1l1066t82r1110b103],
5	(	CD	NUMBER	(	dep	3	SENT_1	[p1l1122t81r1202b108],
6	2012	CD	DATE	2012	dep	5	SENT_1	[p1l1122t81r1202b108],
7	)	CD	NUMBER	)	num	8	SENT_1	[p1l1122t81r1202b108],
8	1284-1287	CD	DATE	1284-1287	dep	3	SENT_1	[p1l1214t82r1348b103],

1	Contents	NNS	O	contents	_	0	SENT_2	[p1l713t193r847b217],
2	lists	NNS	O	list	dep	1	SENT_2	[p1l861t193r918b217],
3	available	JJ	O	available	amod	2	SENT_2	[p1l931t193r1058b217],
4	at	IN	O	at	_	0	SENT_2	[p1l1071t196r1098b217],
5	SciVerse	NNP	O	SciVerse	nn	6	SENT_2	[p1l1111t193r1240b217],
6	ScienceDirect	NNP	O	ScienceDirect	prep_at	3	SENT_2	[p1l1253t193r1458b217],

1	Clinica	NNP	PERSON	Clinica	nn	5	SENT_3	[p1l818t289r991b336],
2	Chimica	NNP	PERSON	Chimica	nn	5	SENT_3	[p1l1012t289r1220b336],
3	Acta	NNP	PERSON	Acta	nn	5	SENT_3	[p1l1239t291r1353b336],
4	journal	NN	O	journal	nn	5	SENT_3	[p1l582t424r706b453],
5	homepage	NN	O	homepage	_	0	SENT_3	[p1l724t424r919b453],
6	:	:	O	:	_	0	SENT_3	[p1l724t424r919b453],
7	www.elsevier.com/locate/clinchim	NN	O	www.elsevier.com/locate/clinchim	dep	5	SENT_3	[p1l938t424r1586b449],

1	High	JJ	O	high	amod	2	SENT_4	[p1l6t571r124b627],
2	incidence	NN	O	incidence	_	0	SENT_4	[p1l145t571r385b616],
3	of	IN	O	of	_	0	SENT_4	[p1l406t571r458b616],
4	severe	JJ	O	severe	amod	5	SENT_4	[p1l473t584r633b616],
5	neutropenia	NN	O	neutropenia	prep_of	2	SENT_4	[p1l655t572r963b627],
6	after	IN	O	after	_	0	SENT_4	[p1l983t571r1101b616],
7	gemcitabine	NN	O	gemcitabine	nn	8	SENT_4	[p1l1119t571r1599b627],
8	—	NN	O	—	prepc_after	5	SENT_4	[p1l1119t571r1599b627],
9	based	VBN	O	base	dep	8	SENT_4	[p1l1119t571r1599b627],
10	chemotherapy	NN	O	chemotherapy	dep	9	SENT_4	[p1l1621t571r1989b627],
11	in	IN	O	in	_	0	SENT_4	[p1l2009t572r2055b615],
12	Chinese	JJ	MISC	chinese	amod	14	SENT_4	[p1l6t638r202b684],
13	cancer	NN	O	cancer	nn	14	SENT_4	[p1l223t651r388b684],
14	patients	NNS	O	patient	prep_in	10	SENT_4	[p1l406t639r608b695],
15	with	IN	O	with	_	0	SENT_4	[p1l628t638r745b684],
16	CDA	NNP	ORGANIZATION	CDA	nn	17	SENT_4	[p1l766t640r866b684],
17	79A	NNP	O	79A	prep_with	10	SENT_4	[p1l887t640r1062b684],
18	>	JJR	O	>	amod	20	SENT_4	[p1l887t640r1062b684],
19	C	NN	O	c	nn	20	SENT_4	[p1l887t640r1062b684],
20	mutation	NN	O	mutation	dep	17	SENT_4	[p1l1082t639r1314b684],
21	Jialin	NNP	PERSON	Jialin	nn	22	SENT_4	[p1l6t742r109b786],
22	Xu	NNP	PERSON	Xu	dep	17	SENT_4	[p1l124t744r178b777],
23	5	CD	NUMBER	5	number	24	SENT_4	[p1l193t735r247b783],
24	”	CD	NUMBER	”	dep	22	SENT_4	[p1l193t735r247b783],
25	,	,	O	,	_	0	SENT_4	[p1l193t735r247b783],
26	Yuhong	NNP	PERSON	Yuhong	nn	27	SENT_4	[p1l261t742r416b786],
27	Zhou	NNP	PERSON	Zhou	appos	17	SENT_4	[p1l430t742r531b777],
28	"	``	O	"	punct	10	SENT_4	[p1l545t734r692b786],
29	'	''	O	'	_	0	SENT_4	[p1l545t734r692b786],
30	1	CD	NUMBER	1	dep	5	SENT_4	[p1l545t734r692b786],
31	,	,	O	,	_	0	SENT_4	[p1l545t734r692b786],
32	]	CD	NUMBER	]	num	33	SENT_4	[p1l545t734r692b786],
33	ing	NN	O	ing	appos	30	SENT_4	[p1l545t734r692b786],
34	Zhang	NNP	ORGANIZATION	Zhang	nn	35	SENT_4	[p1l707t742r830b786],
35	C	NNP	ORGANIZATION	C	rcmod	33	SENT_4	[p1l844t741r866b783],
36	,	,	O	,	_	0	SENT_4	[p1l844t741r866b783],
37	Yuancheng	NNP	PERSON	Yuancheng	nn	39	SENT_4	[p1l882t742r1104b786],
38	Chen	NNP	PERSON	Chen	nn	39	SENT_4	[p1l1119t742r1219b777],
39	C	NNP	PERSON	C	appos	35	SENT_4	[p1l1234t741r1256b783],
40	,	,	O	,	_	0	SENT_4	[p1l1234t741r1256b783],
41	Rongyuan	NNP	PERSON	Rongyuan	nn	42	SENT_4	[p1l1273t744r1471b786],
42	Zhuang	NNP	PERSON	Zhuang	appos	35	SENT_4	[p1l1486t742r1635b786],
43	'	POS	O	'	_	0	SENT_4	[p1l1650t734r1676b783],
44	3	CD	NUMBER	3	dep	42	SENT_4	[p1l1650t734r1676b783],
45	,	,	O	,	_	0	SENT_4	[p1l1650t734r1676b783],
46	Tianshu	NNP	PERSON	Tianshu	nn	48	SENT_4	[p1l1691t742r1849b777],
47	Liu	NNP	PERSON	Liu	nn	48	SENT_4	[p1l1865t743r1922b777],
48	b	NN	O	b	appos	35	SENT_4	[p1l1937t734r1963b783],
49	,	,	O	,	_	0	SENT_4	[p1l1937t734r1963b783],
50	Weimin	NNP	PERSON	Weimin	nn	51	SENT_4	[p1l1978t743r2138b777],
51	Cai	NNP	PERSON	Cai	appos	35	SENT_4	[p1l6t795r64b830],
52	3	CD	NUMBER	3	dep	51	SENT_4	[p1l79t788r126b814],
53	*	NN	O	*	nn	55	SENT_4	[p1l79t788r126b814],
54	3	CD	NUMBER	3	num	55	SENT_4	[p1l6t860r15b870],
55	Department	NNP	ORGANIZATION	Department	dep	51	SENT_4	[p1l26t862r166b888],
56	of	IN	ORGANIZATION	of	_	0	SENT_4	[p1l174t861r199b888],
57	Clinical	JJ	ORGANIZATION	clinical	amod	58	SENT_4	[p1l204t861r289b883],
58	Pharmacy	NN	ORGANIZATION	pharmacy	prep_of	55	SENT_4	[p1l297t861r417b888],
59	,	,	ORGANIZATION	,	_	0	SENT_4	[p1l297t861r417b888],
60	School	NNP	ORGANIZATION	School	appos	35	SENT_4	[p1l427t861r502b883],
61	of	IN	ORGANIZATION	of	_	0	SENT_4	[p1l511t861r536b888],
62	Pharmacy	NNP	ORGANIZATION	Pharmacy	prep_of	60	SENT_4	[p1l540t861r660b888],
63	,	,	O	,	_	0	SENT_4	[p1l540t861r660b888],
64	Fudan	NNP	ORGANIZATION	Fudan	nn	65	SENT_4	[p1l670t861r741b883],
65	University	NNP	ORGANIZATION	University	appos	35	SENT_4	[p1l752t861r873b888],
66	,	,	O	,	_	0	SENT_4	[p1l752t861r873b888],
67	Shanghai	NNP	LOCATION	Shanghai	appos	35	SENT_4	[p1l883t861r994b888],
68	,	,	O	,	_	0	SENT_4	[p1l883t861r994b888],
69	China	NNP	LOCATION	China	nn	71	SENT_4	[p1l1005t861r1070b883],
70	b	NN	O	b	nn	71	SENT_4	[p1l6t891r16b906],
71	Department	NNP	ORGANIZATION	Department	appos	35	SENT_4	[p1l28t897r167b923],
72	of	IN	ORGANIZATION	of	_	0	SENT_4	[p1l176t896r201b923],
73	Oncology	NNP	ORGANIZATION	Oncology	prep_of	71	SENT_4	[p1l206t896r316b923],
74	,	,	O	,	_	0	SENT_4	[p1l206t896r316b923],
75	Zhongshan	NNP	LOCATION	Zhongshan	nn	76	SENT_4	[p1l325t896r452b923],
76	Hospital	NNP	LOCATION	Hospital	appos	35	SENT_4	[p1l461t896r561b923],
77	,	,	O	,	_	0	SENT_4	[p1l461t896r561b923],
78	Fudan	NNP	ORGANIZATION	Fudan	nn	79	SENT_4	[p1l571t896r642b918],
79	University	NNP	ORGANIZATION	University	appos	35	SENT_4	[p1l653t896r774b923],
80	,	,	O	,	_	0	SENT_4	[p1l653t896r774b923],
81	Shanghai	NNP	LOCATION	Shanghai	appos	35	SENT_4	[p1l783t896r895b923],
82	,	,	O	,	_	0	SENT_4	[p1l783t896r895b923],
83	China	NNP	ORGANIZATION	China	nn	85	SENT_4	[p1l906t896r971b918],
84	C	NNP	ORGANIZATION	C	nn	85	SENT_4	[p1l6t931r14b941],
85	Institute	NNP	ORGANIZATION	Institute	appos	35	SENT_4	[p1l25t932r121b953],
86	of	IN	ORGANIZATION	of	_	0	SENT_4	[p1l130t931r155b959],
87	Antibiotics	NNPS	ORGANIZATION	Antibiotics	prep_of	85	SENT_4	[p1l158t932r287b957],
88	,	,	O	,	_	0	SENT_4	[p1l158t932r287b957],
89	Huashan	NNP	ORGANIZATION	Huashan	nn	90	SENT_4	[p1l297t932r398b953],
90	Hospital	NNP	ORGANIZATION	Hospital	appos	35	SENT_4	[p1l408t932r508b959],
91	,	,	O	,	_	0	SENT_4	[p1l408t932r508b959],
92	Fudan	NNP	ORGANIZATION	Fudan	nn	93	SENT_4	[p1l518t932r589b953],
93	University	NNP	ORGANIZATION	University	appos	35	SENT_4	[p1l600t932r721b959],
94	,	,	O	,	_	0	SENT_4	[p1l600t932r721b959],
95	Shanghai	NNP	LOCATION	Shanghai	dep	33	SENT_4	[p1l731t932r842b959],
96	,	,	O	,	_	0	SENT_4	[p1l731t932r842b959],
97	China	NNP	LOCATION	China	appos	30	SENT_4	[p1l853t931r918b953],

1	ARTICLE	NN	O	article	_	0	SENT_5	[p1l6t1070r230b1092],
2	INFO	NN	O	info	nn	3	SENT_5	[p1l278t1070r401b1092],
3	ABSTRACT	NN	O	abstract	dep	1	SENT_5	[p1l691t1070r960b1092],

1	Article	NNP	O	Article	nn	2	SENT_6	[p1l6t1147r82b1169],
2	history	NN	O	history	_	0	SENT_6	[p1l91t1147r178b1174],
3	:	:	O	:	_	0	SENT_6	[p1l91t1147r178b1174],
4	Cytidine	NN	O	cytidine	nn	5	SENT_6	[p1l7t1198r119b1228],
5	deaminase	NN	O	deaminase	nsubj	12	SENT_6	[p1l129t1198r273b1222],
6	(	CD	NUMBER	(	num	7	SENT_6	[p1l285t1198r364b1228],
7	CDA	NNP	ORGANIZATION	CDA	dep	5	SENT_6	[p1l285t1198r364b1228],
8	)	CD	NUMBER	)	num	7	SENT_6	[p1l285t1198r364b1228],
9	is	VBZ	O	be	cop	12	SENT_6	[p1l376t1198r395b1222],
10	a	DT	O	a	det	12	SENT_6	[p1l405t1205r419b1222],
11	crucial	JJ	O	crucial	amod	12	SENT_6	[p1l429t1198r517b1222],
12	enzyme	NN	O	enzyme	dep	2	SENT_6	[p1l527t1205r632b1228],
13	in	IN	O	in	_	0	SENT_6	[p1l642t1198r667b1222],
14	gemcitabine	NN	O	gemcitabine	nn	15	SENT_6	[p1l676t1198r842b1228],
15	inactivation	NN	O	inactivation	prep_in	12	SENT_6	[p1l852t1198r1018b1223],
16	.	.	O	.	_	0	SENT_6	[p1l852t1198r1018b1223],

1	Mutations	NNS	O	mutation	nsubjpass	7	SENT_7	[p1l1028t1198r1165b1222],
2	in	IN	O	in	_	0	SENT_7	[p1l1175t1198r1200b1222],
3	CDA	NNP	ORGANIZATION	CDA	nn	4	SENT_7	[p1l1210t1199r1264b1222],
4	gene	NN	O	gene	prep_in	1	SENT_7	[p1l1273t1205r1337b1228],
5	have	VBP	O	have	aux	7	SENT_7	[p1l1347t1198r1410b1222],
6	been	VBN	O	be	auxpass	7	SENT_7	[p1l1419t1198r1484b1222],
7	Received	VBN	O	receive	_	0	SENT_7	[p1l7t1232r113b1253],
8	7	CD	DATE	7	dobj	7	SENT_7	[p1l124t1233r136b1253],
9	March	NNP	DATE	March	tmod	7	SENT_7	[p1l147t1232r222b1253],
10	2012	CD	DATE	2012	num	9	SENT_7	[p1l232t1233r290b1253],
11	Received	VBN	O	receive	dep	7	SENT_7	[p1l7t1268r113b1289],
12	in	IN	O	in	_	0	SENT_7	[p1l123t1268r145b1289],
13	revised	JJ	O	revised	amod	14	SENT_7	[p1l155t1268r241b1289],
14	form	NN	O	form	prep_in	11	SENT_7	[p1l251t1268r308b1289],
15	10	CD	DATE	10	num	14	SENT_7	[p1l319t1269r346b1289],
16	April	NNP	DATE	April	tmod	14	SENT_7	[p1l355t1268r414b1295],
17	2012	CD	DATE	2012	num	16	SENT_7	[p1l424t1269r482b1289],
18	Accepted	JJ	O	accepted	amod	19	SENT_7	[p1l6t1303r116b1330],
19	16	CD	DATE	16	dobj	11	SENT_7	[p1l128t1304r155b1325],
20	April	NNP	DATE	April	tmod	19	SENT_7	[p1l164t1303r222b1330],
21	2012	CD	DATE	2012	num	20	SENT_7	[p1l232t1304r290b1325],
22	Available	JJ	O	available	amod	19	SENT_7	[p1l6t1339r116b1360],
23	online	NN	O	online	prep	19	SENT_7	[p1l126t1339r201b1360],
24	23	CD	DATE	23	dep	23	SENT_7	[p1l210t1340r238b1360],
25	April	NNP	DATE	April	tmod	19	SENT_7	[p1l248t1339r307b1366],
26	2012	CD	DATE	2012	num	25	SENT_7	[p1l317t1340r375b1360],

1	found	VBN	O	find	_	0	SENT_8	[p1l7t1456r84b1480],
2	to	TO	O	to	aux	3	SENT_8	[p1l93t1460r119b1480],
3	inﬂuence	VB	O	inﬂuence	xcomp	1	SENT_8	[p1l128t1456r252b1480],
4	the	DT	O	the	det	5	SENT_8	[p1l261t1456r304b1480],
5	activity	NN	O	activity	dobj	3	SENT_8	[p1l312t1456r412b1486],
6	of	IN	O	of	_	0	SENT_8	[p1l420t1456r448b1480],
7	CDA	NNP	ORGANIZATION	CDA	nn	8	SENT_8	[p1l453t1457r511b1480],
8	enzyme	NN	O	enzyme	prep_of	5	SENT_8	[p1l518t1463r630b1486],
9	,	,	O	,	_	0	SENT_8	[p1l518t1463r630b1486],
10	which	WDT	O	which	nsubj	12	SENT_8	[p1l639t1456r722b1480],
11	might	MD	O	might	aux	12	SENT_8	[p1l731t1456r811b1486],
12	lead	VB	O	lead	rcmod	8	SENT_8	[p1l819t1456r874b1480],
13	to	TO	O	to	_	0	SENT_8	[p1l883t1460r909b1480],
14	altered	JJ	O	altered	amod	15	SENT_8	[p1l917t1456r1011b1480],
15	pharmacokinetics	NNS	O	pharmacokinetic	prep_to	12	SENT_8	[p1l1020t1456r1261b1486],
16	proﬁle	NN	O	proﬁle	nn	19	SENT_8	[p1l1270t1456r1357b1486],
17	and	CC	O	and	_	0	SENT_8	[p1l1365t1456r1414b1480],
18	clinical	JJ	O	clinical	nn	19	SENT_8	[p1l1423t1456r1483b1480, p1l7t1496r51b1520],
19	outcome	NN	O	outcome	dobj	12	SENT_8	[p1l63t1500r180b1520],
20	of	IN	O	of	_	0	SENT_8	[p1l193t1496r221b1520],
21	gemcitabine	NN	O	gemcitabine	prep_of	19	SENT_8	[p1l229t1496r401b1526],
22	.	.	O	.	_	0	SENT_8	[p1l229t1496r401b1526],

1	In	IN	O	in	_	0	SENT_9	[p1l414t1498r439b1520],
2	this	DT	O	this	det	3	SENT_9	[p1l450t1496r499b1520],
3	study	NN	O	study	prep_in	23	SENT_9	[p1l512t1496r592b1526],
4	,	,	O	,	_	0	SENT_9	[p1l512t1496r592b1526],
5	the	DT	O	the	det	6	SENT_9	[p1l604t1496r647b1520],
6	screening	NN	O	screening	nsubjpass	23	SENT_9	[p1l659t1496r789b1526],
7	for	IN	O	for	_	0	SENT_9	[p1l800t1496r838b1520],
8	the	DT	O	the	det	9	SENT_9	[p1l849t1496r891b1520],
9	presence	NN	O	presence	prep_for	6	SENT_9	[p1l904t1503r1023b1527],
10	of	IN	O	of	_	0	SENT_9	[p1l1035t1496r1063b1520],
11	CDA	NNP	ORGANIZATION	CDA	nn	12	SENT_9	[p1l1072t1497r1125b1520],
12	79A	NNP	O	79A	prep_of	9	SENT_9	[p1l1138t1497r1231b1520],
13	>	JJR	O	>	amod	14	SENT_9	[p1l1138t1497r1231b1520],
14	C	NN	O	c	dep	12	SENT_9	[p1l1138t1497r1231b1520],
15	and	CC	O	and	_	0	SENT_9	[p1l1242t1496r1291b1520],
16	CDA	NNP	ORGANIZATION	CDA	nn	17	SENT_9	[p1l1304t1497r1358b1520],
17	208G	NN	O	208g	conj_and	12	SENT_9	[p1l1369t1497r1484b1520],
18	>	JJR	O	>	dep	17	SENT_9	[p1l1369t1497r1484b1520],
19	A	DT	O	a	det	20	SENT_9	[p1l1369t1497r1484b1520],
20	Keywords	NNPS	O	Keywords	dep	6	SENT_9	[p1l1599t1513r1720b1540],
21	:	:	O	:	_	0	SENT_9	[p1l1599t1513r1720b1540],
22	was	VBD	O	be	auxpass	23	SENT_9	[p1l6t1543r58b1560],
23	performed	VBN	O	perform	_	0	SENT_9	[p1l69t1536r211b1566],
24	by	IN	O	by	_	0	SENT_9	[p1l222t1536r254b1566],
25	allele-speciﬁc	JJ	O	allele-speciﬁc	amod	26	SENT_9	[p1l263t1536r448b1566],
26	PCR	NN	O	pcr	agent	23	SENT_9	[p1l458t1537r510b1560],
27	and	CC	O	and	_	0	SENT_9	[p1l519t1536r568b1560],
28	restriction	NN	O	restriction	nn	31	SENT_9	[p1l579t1536r718b1560],
29	fragment	NN	O	fragment	nn	31	SENT_9	[p1l728t1536r852b1566],
30	length	NN	O	length	nn	31	SENT_9	[p1l861t1536r947b1566],
31	polymorphism	NN	O	polymorphism	agent	23	SENT_9	[p1l957t1536r1162b1566],
32	,	,	O	,	_	0	SENT_9	[p1l957t1536r1162b1566],
33	respectively	RB	O	respectively	advmod	23	SENT_9	[p1l1173t1536r1342b1566],
34	.	.	O	.	_	0	SENT_9	[p1l1173t1536r1342b1566],

1	No	DT	O	no	nsubj	2	SENT_10	[p1l1353t1537r1389b1560],
2	differ	VBP	O	differ	_	0	SENT_10	[p1l1400t1536r1483b1560],
3	-	:	O	-	_	0	SENT_10	[p1l1400t1536r1483b1560],
4	Cytidine	NN	O	cytidine	nn	6	SENT_10	[p1l1599t1549r1699b1576],
5	deaminase	NN	O	deaminase	nn	6	SENT_10	[p1l1709t1549r1837b1570],
6	ence	NN	O	ence	nsubjpass	12	SENT_10	[p1l7t1583r68b1600],
7	in	IN	O	in	_	0	SENT_10	[p1l79t1576r104b1600],
8	CDA	NNP	ORGANIZATION	CDA	nn	10	SENT_10	[p1l116t1577r169b1600],
9	allele	NN	O	allele	nn	10	SENT_10	[p1l180t1576r251b1600],
10	frequencies	NNS	O	frequency	prep_in	6	SENT_10	[p1l262t1576r417b1606],
11	was	VBD	O	be	auxpass	12	SENT_10	[p1l428t1583r481b1600],
12	found	VBN	O	find	parataxis	2	SENT_10	[p1l492t1576r570b1600],
13	between	IN	O	between	_	0	SENT_10	[p1l581t1576r698b1600],
14	Chinese	JJ	LOCATION	chinese	amod	16	SENT_10	[p1l709t1576r814b1600],
15	cancer	NN	O	cancer	nn	16	SENT_10	[p1l825t1583r913b1600],
16	patients	NNS	O	patient	prep_between	12	SENT_10	[p1l924t1576r1031b1606],
17	and	CC	O	and	_	0	SENT_10	[p1l1043t1576r1092b1600],
18	healthy	JJ	O	healthy	amod	19	SENT_10	[p1l1103t1576r1205b1606],
19	volunteers	NNS	O	volunteer	prep_between	12	SENT_10	[p1l1214t1576r1365b1601],
20	.	.	O	.	_	0	SENT_10	[p1l1214t1576r1365b1601],

1	The	DT	O	the	det	5	SENT_11	[p1l1375t1576r1424b1600],
2	fre	NN	O	fre	nn	5	SENT_11	[p1l1436t1576r1483b1600],
3	—	NN	O	—	nn	5	SENT_11	[p1l1436t1576r1483b1600],
4	cancer	NN	O	cancer	nn	5	SENT_11	[p1l1599t1586r1681b1606],
5	quencies	NNS	O	quency	nsubj	24	SENT_11	[p1l7t1616r125b1646],
6	for	IN	O	for	_	0	SENT_11	[p1l136t1616r174b1640],
7	CDA	NNP	ORGANIZATION	CDA	nn	8	SENT_11	[p1l184t1617r238b1640],
8	79A	NNP	O	79A	prep_for	5	SENT_11	[p1l250t1617r343b1640],
9	>	JJR	O	>	amod	10	SENT_11	[p1l250t1617r343b1640],
10	C	NN	O	c	dep	8	SENT_11	[p1l250t1617r343b1640],
11	and	CC	O	and	_	0	SENT_11	[p1l354t1616r403b1640],
12	208G	NN	O	208g	npadvmod	13	SENT_11	[p1l414t1617r529b1640],
13	>	JJR	O	>	prep_for	5	SENT_11	[p1l414t1617r529b1640],
14	A	DT	O	a	dep	13	SENT_11	[p1l414t1617r529b1640],
15	in	IN	O	in	_	0	SENT_11	[p1l539t1616r564b1640],
16	the	DT	O	the	det	18	SENT_11	[p1l575t1616r618b1640],
17	studied	VBN	O	study	amod	18	SENT_11	[p1l630t1616r728b1640],
18	population	NN	O	population	prep_in	13	SENT_11	[p1l740t1616r887b1646],
19	were	VBD	O	be	cop	24	SENT_11	[p1l897t1623r965b1640],
20	12.2	CD	PERCENT	12.2	number	24	SENT_11	[p1l978t1617r1051b1640],
21	%	NN	PERCENT	%	dep	24	SENT_11	[p1l978t1617r1051b1640],
22	and	CC	O	and	_	0	SENT_11	[p1l1062t1616r1111b1640],
23	1.0	CD	PERCENT	1.0	conj_and	24	SENT_11	[p1l1124t1617r1186b1644],
24	%	NN	PERCENT	%	_	0	SENT_11	[p1l1124t1617r1186b1644],
25	,	,	O	,	_	0	SENT_11	[p1l1124t1617r1186b1644],
26	respectively	RB	O	respectively	advmod	24	SENT_11	[p1l1198t1616r1367b1646],
27	.	.	O	.	_	0	SENT_11	[p1l1198t1616r1367b1646],

1	While	IN	O	while	mark	10	SENT_12	[p1l1378t1616r1459b1640],
2	a	DT	O	a	det	4	SENT_12	[p1l1470t1623r1484b1640],
3	high	JJ	O	high	amod	4	SENT_12	[p1l7t1656r66b1686],
4	incidence	NN	O	incidence	nsubjpass	10	SENT_12	[p1l77t1656r205b1680],
5	of	IN	O	of	_	0	SENT_12	[p1l216t1656r244b1680],
6	grade	NN	O	grade	nn	8	SENT_12	[p1l251t1656r326b1686],
7	3-4	CD	NUMBER	3-4	num	8	SENT_12	[p1l336t1657r387b1680],
8	neutropenia	NN	O	neutropenia	prep_of	4	SENT_12	[p1l397t1656r562b1686],
9	was	VBD	O	be	auxpass	10	SENT_12	[p1l572t1663r624b1680],
10	noted	VBN	O	note	advcl	30	SENT_12	[p1l636t1656r712b1680],
11	as	IN	O	as	_	0	SENT_12	[p1l723t1663r749b1680],
12	5	CD	NUMBER	5	number	15	SENT_12	[p1l761t1657r775b1680],
13	out	IN	O	out	quantmod	15	SENT_12	[p1l786t1659r831b1680],
14	of	IN	O	of	quantmod	15	SENT_12	[p1l841t1656r869b1680],
15	8	CD	PERCENT	8	prep_as	10	SENT_12	[p1l876t1657r891b1680],
16	(	RB	PERCENT	(	advmod	10	SENT_12	[p1l904t1656r1001b1686],
17	62.5	CD	PERCENT	62.5	num	18	SENT_12	[p1l904t1656r1001b1686],
18	%	NN	PERCENT	%	nsubj	30	SENT_12	[p1l904t1656r1001b1686],
19	)	CD	NUMBER	)	num	20	SENT_12	[p1l904t1656r1001b1686],
20	patients	NNS	O	patient	npadvmod	21	SENT_12	[p1l1014t1656r1122b1686],
21	heterozygous	JJ	O	heterozygous	amod	18	SENT_12	[p1l1133t1656r1314b1686],
22	or	CC	O	or	_	0	SENT_12	[p1l1326t1663r1354b1680],
23	homozygous	JJ	O	homozygous	amod	18	SENT_12	[p1l1364t1656r1483b1686, p1l6t1703r68b1726],
24	for	IN	O	for	_	0	SENT_12	[p1l81t1696r118b1720],
25	CDA	NNP	ORGANIZATION	CDA	nn	26	SENT_12	[p1l129t1697r183b1720],
26	79A	NNP	O	79A	prep_for	23	SENT_12	[p1l195t1697r289b1720],
27	>	JJR	O	>	amod	29	SENT_12	[p1l195t1697r289b1720],
28	C	NN	O	c	nn	29	SENT_12	[p1l195t1697r289b1720],
29	mutation	NN	O	mutation	dep	26	SENT_12	[p1l300t1696r424b1720],
30	developed	VBD	O	develop	_	0	SENT_12	[p1l436t1696r575b1726],
31	it	PRP	O	it	nsubj	47	SENT_12	[p1l588t1696r612b1724],
32	,	,	O	,	_	0	SENT_12	[p1l588t1696r612b1724],
33	in	IN	O	in	_	0	SENT_12	[p1l624t1696r649b1720],
34	patients	NNS	O	patient	prep_in	47	SENT_12	[p1l661t1696r769b1726],
35	homozygous	JJ	O	homozygous	amod	34	SENT_12	[p1l781t1696r952b1726],
36	for	IN	O	for	_	0	SENT_12	[p1l965t1696r1002b1720],
37	the	DT	O	the	det	39	SENT_12	[p1l1013t1696r1056b1720],
38	wild-type	JJ	O	wild-type	amod	39	SENT_12	[p1l1067t1696r1199b1726],
39	allele	NN	O	allele	prep_for	35	SENT_12	[p1l1211t1696r1288b1724],
40	,	,	O	,	_	0	SENT_12	[p1l1211t1696r1288b1724],
41	the	DT	O	the	det	43	SENT_12	[p1l1300t1696r1343b1720],
42	incidence	NN	O	incidence	nn	43	SENT_12	[p1l1355t1696r1483b1720],
43	Gemcitabine	NN	O	gemcitabine	nsubj	47	SENT_12	[p1l6t1740r157b1762],
44	was	VBD	O	be	cop	47	SENT_12	[p1l696t1743r748b1760],
45	only	RB	O	only	quantmod	46	SENT_12	[p1l764t1736r823b1766],
46	17.2	CD	PERCENT	17.2	num	47	SENT_12	[p1l839t1737r913b1760],
47	%	NN	PERCENT	%	ccomp	30	SENT_12	[p1l839t1737r913b1760],
48	(	CD	NUMBER	(	number	49	SENT_12	[p1l930t1736r956b1766],
49	5	CD	NUMBER	5	num	47	SENT_12	[p1l930t1736r956b1766],
50	out	IN	O	out	_	0	SENT_12	[p1l973t1740r1017b1760],
51	of	IN	O	of	_	0	SENT_12	[p1l1032t1736r1060b1760],
52	29	CD	NUMBER	29	number	53	SENT_12	[p1l1073t1736r1117b1766],
53	)	CD	NUMBER	)	num	55	SENT_12	[p1l1073t1736r1117b1766],
54	(	NN	O	(	nn	55	SENT_12	[p1l1136t1736r1162b1766],
55	p	NN	O	p	prep_out_of	47	SENT_12	[p1l1136t1736r1162b1766],
56	=	JJ	O	=	advmod	47	SENT_12	[p1l1175t1746r1199b1755],
57	0.021	CD	NUMBER	0.021	num	58	SENT_12	[p1l1212t1737r1282b1760],
58	)	NN	O	)	dep	56	SENT_12	[p1l1295t1736r1310b1766],
59	.	.	O	.	_	0	SENT_12	[p1l1295t1736r1310b1766],

1	Our	PRP$	O	we	poss	2	SENT_13	[p1l1327t1737r1376b1760],
2	study	NN	O	study	nsubj	3	SENT_13	[p1l1392t1736r1466b1766],
3	suggests	VBZ	O	suggest	_	0	SENT_13	[p1l1482t1740r1595b1766],
4	that	IN	O	that	complm	16	SENT_13	[p1l1611t1736r1665b1760],
5	CDA	NNP	ORGANIZATION	CDA	nn	6	SENT_13	[p1l1680t1737r1734b1760],
6	79A	NNP	O	79A	nsubj	16	SENT_13	[p1l1750t1737r1844b1760],
7	>	JJR	O	>	amod	9	SENT_13	[p1l1750t1737r1844b1760],
8	C	NN	O	c	nn	9	SENT_13	[p1l1750t1737r1844b1760],
9	mutation	NN	O	mutation	dep	6	SENT_13	[p1l1859t1736r1983b1760],
10	might	MD	O	might	aux	16	SENT_13	[p1l1998t1736r2078b1766],
11	be	VB	O	be	cop	16	SENT_13	[p1l2093t1736r2124b1760],
12	a	DT	O	a	det	16	SENT_13	[p1l2140t1743r2154b1760],
13	Potefltial	JJ	O	potefltial	amod	16	SENT_13	[p1l6t1775r126b1806],
14	P01ym0rPhiSm	NN	O	p01ym0rphism	nn	16	SENT_13	[p1l137t1776r313b1803],
15	risk	NN	O	risk	nn	16	SENT_13	[p1l822t1775r871b1800],
16	factor	NN	O	factor	ccomp	3	SENT_13	[p1l882t1775r959b1800],
17	of	IN	O	of	_	0	SENT_13	[p1l969t1775r997b1800],
18	gemcitabine-induced	JJ	O	gemcitabine-induced	amod	20	SENT_13	[p1l1004t1775r1292b1806],
19	neutropenia	NN	O	neutropenia	nn	20	SENT_13	[p1l1303t1776r1468b1806],
20	toxicity	NN	O	toxicity	prep_of	16	SENT_13	[p1l1479t1776r1586b1806],
21	.	.	O	.	_	0	SENT_13	[p1l1479t1776r1586b1806],

1	Pharmacogenetrcs	NNP	O	Pharmacogenetrcs	_	0	SENT_14	[p1l9t1817r436b1869],
2	Adverse	JJ	O	adverse	amod	4	SENT_14	[p1l7t1886r197b1928],
3	drug	NN	O	drug	nn	4	SENT_14	[p1l216t1886r325b1938],
4	reaction	NN	O	reaction	dep	1	SENT_14	[p1l344t1887r534b1928],

1	1	LS	NUMBER	1	_	0	SENT_15	[p1l11t2177r59b2227],
2	.	.	O	.	_	0	SENT_15	[p1l11t2177r59b2227],

1	Introduction	NN	O	introduction	_	0	SENT_16	[p1l82t2174r479b2226],

1	Gemcitabine-based	JJ	O	gemcitabine-based	amod	3	SENT_17	[p1l107t2344r674b2397],
2	chemotherapy	NN	O	chemotherapy	nn	3	SENT_17	[p1l708t2344r1135b2410],
3	regimens	NNS	O	regimen	nsubj	5	SENT_17	[p1l1168t2345r1438b2410],
4	have	VBP	O	have	aux	5	SENT_17	[p1l1473t2344r1610b2397],
5	demonstrated	VBN	O	demonstrate	_	0	SENT_17	[p1l1644t2344r2055b2397],
6	activity	NN	O	activity	dobj	5	SENT_17	[p1l9t2431r226b2495],
7	in	IN	O	in	_	0	SENT_17	[p1l249t2431r303b2482],
8	various	JJ	O	various	amod	10	SENT_17	[p1l325t2431r539b2482],
9	solid	JJ	O	solid	amod	10	SENT_17	[p1l565t2430r701b2482],
10	tumors	NNS	O	tumor	prep_in	5	SENT_17	[p1l725t2438r949b2490],
11	,	,	O	,	_	0	SENT_17	[p1l725t2438r949b2490],
12	including	VBG	O	include	_	0	SENT_17	[p1l974t2430r1249b2495],
13	non-small	JJ	O	non-small	amod	19	SENT_17	[p1l1272t2430r1568b2482],
14	cell	NN	O	cell	nn	19	SENT_17	[p1l1592t2430r1690b2482],
15	lung	NN	O	lung	nn	19	SENT_17	[p1l1714t2430r1843b2495],
16	cancer	NN	O	cancer	nn	19	SENT_17	[p1l1866t2445r2057b2482],
17	(	CD	NUMBER	(	num	19	SENT_17	[p1l14t2515r267b2580],
18	NSCLC	NN	O	nsclc	nn	19	SENT_17	[p1l14t2515r267b2580],
19	)	NN	O	)	prep_including	5	SENT_17	[p1l14t2515r267b2580],
20	,	,	O	,	_	0	SENT_17	[p1l14t2515r267b2580],
21	breast	NN	O	breast	nn	22	SENT_17	[p1l291t2515r472b2567],
22	cancer	NN	O	cancer	conj_and	19	SENT_17	[p1l495t2530r686b2567],
23	and	CC	O	and	_	0	SENT_17	[p1l708t2515r814b2567],
24	pancreatic	JJ	O	pancreatic	amod	25	SENT_17	[p1l839t2516r1144b2580],
25	cancer	NN	O	cancer	conj_and	19	SENT_17	[p1l1167t2530r1370b2568],
26	.	.	O	.	_	0	SENT_17	[p1l1167t2530r1370b2568],

1	It	PRP	O	it	nsubjpass	4	SENT_18	[p1l1395t2518r1436b2567],
2	is	VBZ	O	be	auxpass	4	SENT_18	[p1l1459t2516r1501b2567],
3	widely	RB	O	widely	advmod	4	SENT_18	[p1l1524t2515r1725b2580],
4	prescribed	VBN	O	prescribe	_	0	SENT_18	[p1l1747t2515r2055b2580],
5	in	IN	O	in	_	0	SENT_18	[p1l10t2600r64b2651],
6	China	NNP	LOCATION	China	prep_in	4	SENT_18	[p1l91t2599r270b2652],
7	.	.	O	.	_	0	SENT_18	[p1l91t2599r270b2652],

1	However	RB	O	however	advmod	5	SENT_19	[p1l298t2603r577b2660],
2	,	,	O	,	_	0	SENT_19	[p1l298t2603r577b2660],
3	gemcitabine	NN	O	gemcitabine	nsubjpass	5	SENT_19	[p1l604t2599r965b2665],
4	is	VBZ	O	be	auxpass	5	SENT_19	[p1l992t2600r1034b2652],
5	characterized	VBN	O	characterize	_	0	SENT_19	[p1l1062t2599r1457b2651],
6	by	IN	O	by	_	0	SENT_19	[p1l1484t2599r1555b2665],
7	a	DT	O	a	det	13	SENT_19	[p1l1580t2615r1610b2651],
8	narrow	JJ	O	narrow	amod	13	SENT_19	[p1l1637t2615r1851b2651],
9	therapeutic	JJ	O	therapeutic	amod	13	SENT_19	[p1l1876t2599r2055b2652, p1l10t2685r190b2750],
10	index	NN	O	index	nn	13	SENT_19	[p1l211t2684r374b2736],
11	[	NN	O	[	nn	13	SENT_19	[p1l397t2684r487b2750],
12	1	CD	NUMBER	1	num	13	SENT_19	[p1l397t2684r487b2750],
13	]	NN	O	]	agent	5	SENT_19	[p1l397t2684r487b2750],
14	.	.	O	.	_	0	SENT_19	[p1l397t2684r487b2750],

1	The	DT	O	the	det	2	SENT_20	[p1l507t2684r614b2736],
2	combination	NN	O	combination	nsubjpass	12	SENT_20	[p1l636t2684r1005b2737],
3	of	IN	O	of	_	0	SENT_20	[p1l1026t2684r1087b2737],
4	gemcitabine	NN	O	gemcitabine	nn	7	SENT_20	[p1l1099t2684r1459b2750],
5	and	CC	O	and	_	0	SENT_20	[p1l1482t2684r1588b2737],
6	cisplatin	NN	O	cisplatin	nn	7	SENT_20	[p1l1610t2684r1856b2750],
7	therapy	NN	O	therapy	prep_of	2	SENT_20	[p1l1876t2684r2055b2737, p1l10t2785r81b2835],
8	(	CD	NUMBER	(	num	10	SENT_20	[p1l113t2770r240b2835],
9	GP	NN	O	gp	nn	10	SENT_20	[p1l113t2770r240b2835],
10	)	NN	O	)	dep	7	SENT_20	[p1l113t2770r240b2835],
11	was	VBD	O	be	auxpass	12	SENT_20	[p1l273t2785r387b2822],
12	associated	VBN	O	associate	_	0	SENT_20	[p1l417t2770r718b2822],
13	with	IN	O	with	_	0	SENT_20	[p1l747t2770r882b2822],
14	substantial	JJ	O	substantial	amod	15	SENT_20	[p1l912t2770r1231b2822],
15	toxicity	NN	O	toxicity	prep_with	12	SENT_20	[p1l1261t2770r1495b2835],
16	,	,	O	,	_	0	SENT_20	[p1l1261t2770r1495b2835],
17	including	VBG	O	include	_	0	SENT_20	[p1l1526t2770r1800b2835],
18	grade	NN	O	grade	nn	20	SENT_20	[p1l1828t2770r1992b2835],
19	4	CD	NUMBER	4	num	20	SENT_20	[p1l2021t2772r2056b2821],
20	thrombocytopenia	NN	O	thrombocytopenia	prep_including	12	SENT_20	[p1l9t2854r555b2920],
21	and	CC	O	and	_	0	SENT_20	[p1l587t2854r693b2907],
22	grade	NN	O	grade	nn	24	SENT_20	[p1l726t2854r890b2920],
23	4	CD	NUMBER	4	num	24	SENT_20	[p1l922t2857r958b2906],
24	neutropenia	NN	O	neutropenia	prep_including	12	SENT_20	[p1l992t2855r1350b2920],
25	in	IN	O	in	_	0	SENT_20	[p1l1383t2855r1436b2906],
26	25.4	CD	PERCENT	25.4	number	30	SENT_20	[p1l1470t2857r1633b2907],
27	%	NN	PERCENT	%	dep	30	SENT_20	[p1l1470t2857r1633b2907],
28	and	CC	O	and	_	0	SENT_20	[p1l1665t2854r1772b2907],
29	35.3	CD	PERCENT	35.3	conj_and	30	SENT_20	[p1l1805t2857r1969b2907],
30	%	NN	PERCENT	%	prep_in	24	SENT_20	[p1l1805t2857r1969b2907],
31	of	IN	O	of	_	0	SENT_20	[p1l2002t2854r2063b2907],
32	NSCLC	NN	ORGANIZATION	nsclc	nn	33	SENT_20	[p1l10t2943r197b2992],
33	patients	NNS	O	patient	prep_of	30	SENT_20	[p1l235t2941r484b3005],
34	,	,	O	,	_	0	SENT_20	[p1l235t2941r484b3005],
35	respectively	RB	O	respectively	advmod	38	SENT_20	[p1l525t2940r879b3005],
36	[	CD	NUMBER	[	number	37	SENT_20	[p1l920t2940r1010b3005],
37	2	CD	NUMBER	2	num	38	SENT_20	[p1l920t2940r1010b3005],
38	]	NN	O	]	rcmod	24	SENT_20	[p1l920t2940r1010b3005],
39	.	.	O	.	_	0	SENT_20	[p1l920t2940r1010b3005],

1	The	DT	O	the	det	2	SENT_21	[p1l1047t2940r1155b2992],
2	combination	NN	O	combination	nsubj	7	SENT_21	[p1l1194t2940r1564b2992],
3	of	IN	O	of	_	0	SENT_21	[p1l1603t2940r1664b2992],
4	gemcitabine	NN	O	gemcitabine	prep_of	2	SENT_21	[p1l1695t2940r2055b3005],
5	and	CC	O	and	_	0	SENT_21	[p1l9t3025r116b3077],
6	carboplatin	NN	O	carboplatin	prep_of	2	SENT_21	[p1l143t3025r475b3090],
7	showed	VBD	O	show	_	0	SENT_21	[p1l503t3025r729b3077],
8	improved	VBN	O	improve	amod	9	SENT_21	[p1l756t3025r1039b3090],
9	tolerability	NN	O	tolerability	dobj	7	SENT_21	[p1l1066t3025r1389b3090],
10	as	IN	O	as	prep	7	SENT_21	[p1l1414t3040r1471b3077],
11	compared	VBN	O	compare	_	0	SENT_21	[p1l1498t3025r1791b3090],
12	with	IN	O	with	prepc_compared_with	7	SENT_21	[p1l1816t3025r1951b3077],
13	GP	NN	O	gp	nn	14	SENT_21	[p1l1977t3028r2056b3077],
14	therapy	NN	O	therapy	pobj	7	SENT_21	[p1l9t3109r249b3175],
15	,	,	O	,	_	0	SENT_21	[p1l9t3109r249b3175],
16	but	CC	O	but	_	0	SENT_21	[p1l289t3109r387b3162],
17	grade	NN	O	grade	nsubjpass	22	SENT_21	[p1l424t3109r588b3175],
18	3/4	CD	NUMBER	3/4	num	19	SENT_21	[p1l627t3112r723b3170],
19	myelotoxicity	NN	O	myelotoxicity	dep	17	SENT_21	[p1l763t3109r1167b3175],
20	was	VBD	O	be	auxpass	22	SENT_21	[p1l1204t3125r1318b3162],
21	still	RB	O	still	advmod	22	SENT_21	[p1l1359t3109r1463b3162],
22	observed	VBN	O	observe	conj_but	7	SENT_21	[p1l1503t3109r1769b3162],
23	in	IN	O	in	_	0	SENT_21	[p1l1809t3110r1863b3161],
24	more	JJR	O	more	mwe	25	SENT_21	[p1l1904t3125r2055b3161],
25	than	IN	O	than	quantmod	26	SENT_21	[p1l9t3194r141b3246],
26	20	CD	PERCENT	20	num	27	SENT_21	[p1l164t3197r275b3246],
27	%	NN	PERCENT	%	prep_in	22	SENT_21	[p1l164t3197r275b3246],
28	of	IN	O	of	_	0	SENT_21	[p1l298t3194r359b3246],
29	patients	NNS	O	patient	prep_of	27	SENT_21	[p1l375t3195r610b3260],
30	[	CD	NUMBER	[	number	31	SENT_21	[p1l637t3194r779b3260],
31	3,4	CD	NUMBER	3,4	num	32	SENT_21	[p1l637t3194r779b3260],
32	]	NN	O	]	dep	29	SENT_21	[p1l637t3194r779b3260],
33	.	.	O	.	_	0	SENT_21	[p1l637t3194r779b3260],

1	90	CD	PERCENT	90	num	2	SENT_22	[p1l107t3282r216b3332],
2	%	NN	PERCENT	%	nsubjpass	6	SENT_22	[p1l107t3282r216b3332],
3	of	IN	O	of	_	0	SENT_22	[p1l238t3279r298b3332],
4	gemcitabine	NN	O	gemcitabine	prep_of	2	SENT_22	[p1l312t3279r666b3345],
5	is	VBZ	O	be	auxpass	6	SENT_22	[p1l688t3280r729b3332],
6	metabolized	VBN	O	metabolize	_	0	SENT_22	[p1l752t3279r1106b3332],
7	by	IN	O	by	_	0	SENT_22	[p1l1128t3279r1199b3345],
8	cytidine	NN	O	cytidine	nn	9	SENT_22	[p1l1218t3279r1448b3345],
9	deaminase	NN	O	deaminase	agent	6	SENT_22	[p1l1470t3279r1778b3332],
10	(	CD	NUMBER	(	num	11	SENT_22	[p1l1804t3279r1974b3345],
11	CDA	NNP	ORGANIZATION	CDA	dobj	6	SENT_22	[p1l1804t3279r1974b3345],
12	)	CD	NUMBER	)	num	11	SENT_22	[p1l1804t3279r1974b3345],
13	to	TO	O	to	_	0	SENT_22	[p1l2000t3287r2055b3332],
14	an	DT	O	a	prep_to	11	SENT_22	[p1l9t3380r78b3417],
15	inactivated	VBN	O	inactivate	partmod	14	SENT_22	[p1l115t3364r431b3417],
16	metabolite	NN	O	metabolite	dobj	15	SENT_22	[p1l469t3364r789b3425],
17	,	,	O	,	_	0	SENT_22	[p1l469t3364r789b3425],
18	diﬂuorodeoxyuridine	NN	O	diﬂuorodeoxyuridine	nn	20	SENT_22	[p1l828t3364r1440b3430],
19	(	NN	O	(	nn	20	SENT_22	[p1l1481t3364r1678b3430],
20	dFdU	NN	O	dfdu	appos	16	SENT_22	[p1l1481t3364r1678b3430],
21	)	CD	NUMBER	)	number	22	SENT_22	[p1l1481t3364r1678b3430],
22	[	CD	NUMBER	[	dep	20	SENT_22	[p1l1722t3364r1810b3430],
23	5	CD	NUMBER	5	num	24	SENT_22	[p1l1722t3364r1810b3430],
24	]	NN	O	]	dep	22	SENT_22	[p1l1722t3364r1810b3430],
25	.	.	O	.	_	0	SENT_22	[p1l1722t3364r1810b3430],

1	Studies	NNS	O	study	nsubj	3	SENT_23	[p1l1849t3364r2055b3417],
2	have	VBP	O	have	aux	3	SENT_23	[p1l10t3450r144b3502],
3	shown	VBN	O	show	dep	17	SENT_23	[p1l162t3450r353b3502],
4	that	IN	O	that	complm	11	SENT_23	[p1l368t3450r483b3502],
5	patients	NNS	O	patient	nsubj	11	SENT_23	[p1l499t3451r727b3515],
6	with	IN	O	with	_	0	SENT_23	[p1l743t3450r876b3502],
7	reduced	VBN	O	reduce	amod	9	SENT_23	[p1l892t3450r1122b3502],
8	CDA	NNP	ORGANIZATION	CDA	nn	9	SENT_23	[p1l1140t3452r1264b3502],
9	activity	NN	O	activity	prep_with	5	SENT_23	[p1l1277t3451r1489b3515],
10	may	MD	O	may	aux	11	SENT_23	[p1l1504t3465r1627b3515],
11	suffer	VB	O	suffer	ccomp	3	SENT_23	[p1l1642t3450r1805b3502],
12	from	IN	O	from	_	0	SENT_23	[p1l1820t3450r1956b3502],
13	severe	JJ	O	severe	amod	16	SENT_23	[p1l1973t3465r2054b3502, p1l8t3550r132b3587],
14	adverse	JJ	O	adverse	amod	16	SENT_23	[p1l152t3535r373b3587],
15	drug	NN	O	drug	nn	16	SENT_23	[p1l393t3535r528b3600],
16	reactions	NNS	O	reaction	prep_from	11	SENT_23	[p1l546t3536r806b3587],
17	[	VBP	O	[	_	0	SENT_23	[p1l829t3535r917b3600],
18	6	CD	NUMBER	6	num	19	SENT_23	[p1l829t3535r917b3600],
19	]	NN	O	]	nsubj	17	SENT_23	[p1l829t3535r917b3600],
20	.	.	O	.	_	0	SENT_23	[p1l829t3535r917b3600],

1	Human	JJ	O	human	amod	3	SENT_24	[p1l939t3538r1150b3587],
2	CDA	NNP	ORGANIZATION	CDA	nn	3	SENT_24	[p1l1170t3537r1285b3587],
3	gene	NN	O	gene	nsubj	5	SENT_24	[p1l1304t3550r1441b3600],
4	is	VBZ	O	be	cop	5	SENT_24	[p1l1462t3536r1503b3587],
5	prone	JJ	O	prone	_	0	SENT_24	[p1l1524t3550r1692b3600],
6	to	TO	O	to	_	0	SENT_24	[p1l1711t3543r1767b3587],
7	polymorphisms	NNS	O	polymorphism	prep_to	5	SENT_24	[p1l1787t3535r2054b3600, p1l10t3619r214b3685],
8	[	CD	NUMBER	[	number	9	SENT_24	[p1l278t3619r366b3685],
9	7	CD	NUMBER	7	num	10	SENT_24	[p1l278t3619r366b3685],
10	]	NN	O	]	dep	7	SENT_24	[p1l278t3619r366b3685],
11	.	.	O	.	_	0	SENT_24	[p1l278t3619r366b3685],

1	The	DT	O	the	det	3	SENT_25	[p1l424t3619r530b3671],
2	CDA	NNP	ORGANIZATION	CDA	nn	3	SENT_25	[p1l591t3622r706b3671],
3	208G	NN	O	208g	dep	7	SENT_25	[p1l766t3622r1012b3672],
4	>	JJR	O	>	dep	3	SENT_25	[p1l766t3622r1012b3672],
5	A	DT	O	a	det	6	SENT_25	[p1l766t3622r1012b3672],
6	(	CD	NUMBER	(	dep	7	SENT_25	[p1l1073t3619r1463b3685],
7	rs60369023	NN	O	rs60369023	dep	13	SENT_25	[p1l1073t3619r1463b3685],
8	)	CD	NUMBER	)	num	11	SENT_25	[p1l1073t3619r1463b3685],
9	single	JJ	O	single	amod	11	SENT_25	[p1l1528t3619r1693b3685],
10	nucleotide	NN	O	nucleotide	nn	11	SENT_25	[p1l1754t3619r2055b3671],
11	polymorphism	NN	O	polymorphism	dep	7	SENT_25	[p1l10t3705r435b3770],
12	(	CD	NUMBER	(	num	13	SENT_25	[p1l456t3705r634b3770],
13	SNP	NN	ORGANIZATION	snp	_	0	SENT_25	[p1l456t3705r634b3770],
14	)	NN	O	)	nsubj	24	SENT_25	[p1l456t3705r634b3770],
15	,	,	O	,	_	0	SENT_25	[p1l456t3705r634b3770],
16	which	WDT	O	which	nsubjpass	19	SENT_25	[p1l651t3705r830b3757],
17	is	VBZ	O	be	auxpass	19	SENT_25	[p1l849t3705r890b3757],
18	only	RB	O	only	advmod	19	SENT_25	[p1l909t3705r1035b3770],
19	detected	VBN	O	detect	rcmod	14	SENT_25	[p1l1051t3705r1299b3757],
20	in	IN	O	in	_	0	SENT_25	[p1l1318t3705r1371b3756],
21	Asians	NNPS	MISC	Asians	prep_in	19	SENT_25	[p1l1387t3705r1587b3765],
22	,	,	O	,	_	0	SENT_25	[p1l1387t3705r1587b3765],
23	can	MD	O	can	aux	24	SENT_25	[p1l1606t3720r1703b3757],
24	result	VB	O	result	rcmod	13	SENT_25	[p1l1722t3705r1886b3757],
25	in	IN	O	in	_	0	SENT_25	[p1l1903t3705r1956b3756],
26	reduced	VBN	O	reduce	prep_in	13	SENT_25	[p1l1974t3720r2054b3757, p2l10t16r182b69],

1	enzymatic	JJ	O	enzymatic	amod	2	SENT_26	[p2l205t17r502b82],
2	activity	NN	O	activity	_	0	SENT_26	[p2l523t17r735b82],
3	with	IN	O	with	dep	2	SENT_26	[p2l754t16r887b69],
4	subsequent	JJ	O	subsequent	amod	7	SENT_26	[p2l910t16r1240b82],
5	reduced	VBN	O	reduce	amod	7	SENT_26	[p2l1261t16r1492b69],
6	drug	NN	O	drug	nn	7	SENT_26	[p2l1515t16r1649b82],
7	clearance	NN	O	clearance	pobj	3	SENT_26	[p2l1670t16r1952b77],
8	,	,	O	,	_	0	SENT_26	[p2l1670t16r1952b77],
9	increased	VBN	O	increase	amod	11	SENT_26	[p2l1977t17r2055b68, p2l10t102r225b154],
10	drug	NN	O	drug	nn	11	SENT_26	[p2l247t102r381b167],
11	exposure	NN	O	exposure	appos	7	SENT_26	[p2l400t117r662b167],
12	in	FW	O	in	prep	11	SENT_26	[p2l684t103r734b154],
13	vivo	FW	O	vivo	pobj	12	SENT_26	[p2l754t103r868b154],
14	and	CC	O	and	_	0	SENT_26	[p2l889t102r994b154],
15	increased	VBD	O	increase	amod	16	SENT_26	[p2l1016t102r1288b154],
16	incidences	NNS	O	incidence	conj_and	11	SENT_26	[p2l1310t102r1609b154],
17	of	IN	O	of	_	0	SENT_26	[p2l1631t102r1691b154],
18	neutropenia	NN	O	neutropenia	prep_of	16	SENT_26	[p2l1706t103r2056b167],

1	*	NN	O	*	_	0	SENT_27	[p2l52t330r73b355],
2	Corresponding	VBG	O	correspond	partmod	1	SENT_27	[p2l107t330r454b382],
3	author	NN	O	author	dobj	2	SENT_27	[p2l477t330r633b372],
4	at	IN	O	at	_	0	SENT_27	[p2l655t336r712b372],
5	:	:	O	:	_	0	SENT_27	[p2l655t336r712b372],
6	Department	NNP	ORGANIZATION	Department	prep_at	2	SENT_27	[p2l739t333r1023b382],
7	of	IN	ORGANIZATION	of	_	0	SENT_27	[p2l1046t330r1094b372],
8	Clinical	JJ	ORGANIZATION	clinical	amod	9	SENT_27	[p2l1112t330r1282b372],
9	Pharmacy	NN	ORGANIZATION	pharmacy	prep_of	6	SENT_27	[p2l1306t330r1549b382],
10	,	,	ORGANIZATION	,	_	0	SENT_27	[p2l1306t330r1549b382],
11	School	NNP	ORGANIZATION	School	appos	6	SENT_27	[p2l1573t330r1726b372],
12	of	IN	ORGANIZATION	of	_	0	SENT_27	[p2l1750t330r1798b372],
13	Pharmacy	NNP	ORGANIZATION	Pharmacy	prep_of	11	SENT_27	[p2l1816t330r2058b382],
14	,	,	O	,	_	0	SENT_27	[p2l1816t330r2058b382],
15	Fudan	NNP	ORGANIZATION	Fudan	nn	16	SENT_27	[p2l9t399r151b441],
16	University	NNP	ORGANIZATION	University	appos	6	SENT_27	[p2l170t400r423b452],
17	,	,	O	,	_	0	SENT_27	[p2l170t400r423b452],
18	826	CD	NUMBER	826	num	20	SENT_27	[p2l444t401r529b441],
19	Zhangheng	NN	O	zhangheng	nn	20	SENT_27	[p2l548t399r812b452],
20	Rd	NN	O	rd	appos	16	SENT_27	[p2l830t399r900b447],
21	,	,	O	,	_	0	SENT_27	[p2l830t399r900b447],
22	Shanghai	NNP	LOCATION	Shanghai	appos	16	SENT_27	[p2l920t399r1134b452],
23	201203	CD	NUMBER	201203	num	22	SENT_27	[p2l1154t401r1341b448],
24	,	,	O	,	_	0	SENT_27	[p2l1154t401r1341b448],
25	China	NNP	LOCATION	China	appos	16	SENT_27	[p2l1361t399r1504b441],
26	.	.	O	.	_	0	SENT_27	[p2l1361t399r1504b441],

1	E-mail	NN	O	e-mail	nn	2	SENT_28	[p2l105t475r254b516],
2	address	NN	O	address	_	0	SENT_28	[p2l272t475r456b517],
3	:	:	O	:	_	0	SENT_28	[p2l272t475r456b517],
4	weimincai@fudan.edu.cn	NN	O	weimincai@fudan.edu.cn	nn	8	SENT_28	[p2l476t475r1067b517],
5	(	CD	NUMBER	(	num	8	SENT_28	[p2l1089t475r1171b527],
6	W.	NNP	PERSON	W.	nn	8	SENT_28	[p2l1089t475r1171b527],
7	Cai	NNP	PERSON	Cai	nn	8	SENT_28	[p2l1191t475r1295b527],
8	)	NNP	O	)	dep	2	SENT_28	[p2l1191t475r1295b527],
9	.	.	O	.	_	0	SENT_28	[p2l1191t475r1295b527],

1	1	CD	NUMBER	1	nsubj	4	SENT_29	[p2l55t536r68b562],
2	These	DT	O	these	det	3	SENT_29	[p2l100t544r236b586],
3	authors	NNS	O	author	dep	1	SENT_29	[p2l255t544r432b586],
4	contributed	VBD	O	contribute	_	0	SENT_29	[p2l453t544r726b586],
5	equally	RB	O	equally	advmod	4	SENT_29	[p2l747t544r918b596],
6	to	TO	O	to	_	0	SENT_29	[p2l935t550r980b586],
7	this	DT	O	this	det	8	SENT_29	[p2l999t544r1084b586],
8	work	NN	O	work	prep_to	4	SENT_29	[p2l1102t544r1235b586],
9	.	.	O	.	_	0	SENT_29	[p2l1102t544r1235b586],

1	0009-8981	CD	DURATION	0009-8981	_	0	SENT_30	[p2l9t685r259b725],
2	/	:	O	/	punct	1	SENT_30	[p2l267t682r311b732],
3	$	$	MONEY	$	nsubj	5	SENT_30	[p2l267t682r311b732],
4	—	CD	MONEY	—	num	3	SENT_30	[p2l331t708r356b712],
5	see	VBP	O	see	dep	1	SENT_30	[p2l376t695r449b725],
6	front	JJ	O	front	amod	7	SENT_30	[p2l469t683r584b725],
7	matter	NN	O	matter	nsubj	14	SENT_30	[p2l602t689r761b725],
8	©	CD	NUMBER	©	num	13	SENT_30	[p2l778t686r816b725],
9	2012	CD	DATE	2012	num	13	SENT_30	[p2l835t685r949b725],
10	Elsevier	NNP	O	Elsevier	nn	13	SENT_30	[p2l970t683r1154b725],
11	B.V.	NNP	O	B.V.	nn	13	SENT_30	[p2l1172t686r1256b725],
12	All	NNP	O	All	nn	13	SENT_30	[p2l1274t683r1337b724],
13	rights	NNS	O	rights	dep	7	SENT_30	[p2l1356t683r1490b735],
14	reserved	VBD	O	reserve	ccomp	5	SENT_30	[p2l1510t683r1723b725],
15	.	.	O	.	_	0	SENT_30	[p2l1510t683r1723b725],

1	doi	FW	O	doi	_	0	SENT_31	[p2l9t753r714b805],
2	:10.1016	CD	NUMBER	:10.1016	dep	1	SENT_31	[p2l9t753r714b805],
3	/	:	O	/	punct	1	SENT_31	[p2l9t753r714b805],
4	j.	NN	O	j.	nn	5	SENT_31	[p2l9t753r714b805],
5	CCa	NN	O	cca	dep	1	SENT_31	[p2l9t753r714b805],
6	.20	CD	NUMBER	.20	num	7	SENT_31	[p2l9t753r714b805],
7	l2	NN	O	l2	nn	9	SENT_31	[p2l9t753r714b805],
8	.04.0	CD	NUMBER	.04.0	dep	7	SENT_31	[p2l9t753r714b805],
9	l8	NN	O	l8	dep	5	SENT_31	[p2l9t753r714b805],

1	©	RB	O	©	advmod	7	SENT_32	[p2l1059t838r1103b882],
2	2012	CD	DATE	2012	num	6	SENT_32	[p2l1124t837r1257b882],
3	Elsevier	NNP	MISC	Elsevier	nn	6	SENT_32	[p2l1280t834r1493b882],
4	B.V.	NNP	MISC	B.V.	nn	6	SENT_32	[p2l1513t837r1611b883],
5	All	NNP	MISC	All	nn	6	SENT_32	[p2l1631t835r1704b882],
6	rights	NNS	O	rights	nsubj	7	SENT_32	[p2l1727t834r1881b894],
7	reserved	VBD	O	reserve	_	0	SENT_32	[p2l1903t834r2149b883],
8	.	.	O	.	_	0	SENT_32	[p2l1903t834r2149b883],

1	when	WRB	O	when	advmod	2	SENT_33	[p2l50t1193r218b1246],
2	coadministered	VBN	O	coadminister	_	0	SENT_33	[p2l246t1193r703b1246],
3	with	IN	O	with	_	0	SENT_33	[p2l730t1193r867b1246],
4	platinum	NN	O	platinum	nn	5	SENT_33	[p2l894t1193r1505b1260],
5	—	NN	O	—	prep_with	2	SENT_33	[p2l894t1193r1505b1260],
6	containing	VBG	O	contain	partmod	5	SENT_33	[p2l894t1193r1505b1260],
7	drugs	NNS	O	drug	nsubj	10	SENT_33	[p2l1531t1193r1694b1260],
8	[	CD	NUMBER	[	number	9	SENT_33	[p2l1727t1193r1869b1260],
9	8,9	CD	NUMBER	8,9	num	10	SENT_33	[p2l1727t1193r1869b1260],
10	]	NN	O	]	xcomp	6	SENT_33	[p2l1727t1193r1869b1260],
11	.	.	O	.	_	0	SENT_33	[p2l1727t1193r1869b1260],

1	The	DT	O	the	det	3	SENT_34	[p2l1895t1193r2003b1246],
2	CDA	NNP	ORGANIZATION	CDA	nn	3	SENT_34	[p2l2033t1195r2151b1246],
3	79A	NNP	O	79A	nsubj	10	SENT_34	[p2l53t1282r258b1333],
4	>	JJR	O	>	amod	6	SENT_34	[p2l53t1282r258b1333],
5	C	NN	O	c	nn	6	SENT_34	[p2l53t1282r258b1333],
6	SNP	NN	O	snp	dep	3	SENT_34	[p2l281t1282r398b1333],
7	(	CD	NUMBER	(	num	9	SENT_34	[p2l424t1280r787b1346],
8	rs2072671	NN	O	rs2072671	nn	9	SENT_34	[p2l424t1280r787b1346],
9	)	NN	O	)	dep	3	SENT_34	[p2l424t1280r787b1346],
10	reduces	VBZ	O	reduce	_	0	SENT_34	[p2l816t1279r1041b1333],
11	the	DT	O	the	det	12	SENT_34	[p2l1066t1279r1160b1333],
12	level	NN	O	level	dobj	10	SENT_34	[p2l1185t1279r1321b1333],
13	of	IN	O	of	_	0	SENT_34	[p2l1346t1279r1408b1333],
14	CDA	NNP	ORGANIZATION	CDA	nn	15	SENT_34	[p2l1425t1282r1552b1333],
15	activity	NN	O	activity	prep_of	12	SENT_34	[p2l1573t1280r1790b1346],
16	moderately	RB	O	moderately	advmod	10	SENT_34	[p2l1813t1279r2152b1346],
17	[	CD	NUMBER	[	number	18	SENT_34	[p2l55t1365r182b1432],
18	10	CD	NUMBER	10	num	19	SENT_34	[p2l55t1365r182b1432],
19	]	NN	O	]	pobj	16	SENT_34	[p2l55t1365r182b1432],
20	.	.	O	.	_	0	SENT_34	[p2l55t1365r182b1432],

1	Studies	NNS	O	study	nsubj	3	SENT_35	[p2l219t1365r430b1419],
2	have	VBP	O	have	aux	3	SENT_35	[p2l465t1366r604b1419],
3	shown	VBN	O	show	_	0	SENT_35	[p2l639t1365r835b1419],
4	the	DT	O	the	det	5	SENT_35	[p2l869t1365r963b1419],
5	correlation	NN	O	correlation	dobj	3	SENT_35	[p2l998t1365r1319b1419],
6	between	IN	O	between	_	0	SENT_35	[p2l1352t1365r1609b1419],
7	CDA	NNP	ORGANIZATION	CDA	nn	8	SENT_35	[p2l1643t1368r1762b1419],
8	79A	NNP	O	79A	prep_between	5	SENT_35	[p2l1797t1368r2002b1419],
9	>	JJR	O	>	amod	11	SENT_35	[p2l1797t1368r2002b1419],
10	C	NN	O	c	nn	11	SENT_35	[p2l1797t1368r2002b1419],
11	SNP	NN	O	snp	dep	8	SENT_35	[p2l2036t1368r2152b1419],
12	and	CC	O	and	_	0	SENT_35	[p2l52t1452r159b1505],
13	lower	JJR	O	lower	amod	14	SENT_35	[p2l186t1452r357b1505],
14	response	NN	O	response	prep_between	5	SENT_35	[p2l381t1467r642b1518],
15	and	CC	O	and	_	0	SENT_35	[p2l668t1452r776b1505],
16	poorer	JJR	O	poorer	amod	18	SENT_35	[p2l803t1467r1001b1518],
17	overall	JJ	O	overall	amod	18	SENT_35	[p2l1025t1452r1224b1505],
18	survival	NN	O	survival	conj_and	14	SENT_35	[p2l1251t1452r1481b1505],
19	of	IN	O	of	_	0	SENT_35	[p2l1507t1452r1569b1505],
20	gemcitabine	NN	O	gemcitabine	prep_of	5	SENT_35	[p2l1586t1452r1949b1518],
21	in	IN	O	in	_	0	SENT_35	[p2l1975t1453r2030b1504],
22	advanced	JJ	O	advanced	amod	24	SENT_35	[p2l2055t1452r2150b1505, p2l50t1538r259b1591],
23	NSCLC	NN	O	nsclc	nn	24	SENT_35	[p2l292t1541r481b1591],
24	patients	NNS	O	patient	prep_in	3	SENT_35	[p2l512t1539r746b1604],
25	[	CD	NUMBER	[	number	26	SENT_35	[p2l783t1538r910b1604],
26	11	CD	NUMBER	11	num	27	SENT_35	[p2l783t1538r910b1604],
27	]	NN	O	]	dep	3	SENT_35	[p2l783t1538r910b1604],
28	.	.	O	.	_	0	SENT_35	[p2l783t1538r910b1604],

1	However	RB	O	however	advmod	16	SENT_36	[p2l944t1541r1224b1599],
2	,	,	O	,	_	0	SENT_36	[p2l944t1541r1224b1599],
3	whether	IN	O	whether	dep	6	SENT_36	[p2l1255t1538r1509b1591],
4	it	PRP	O	it	nsubj	6	SENT_36	[p2l1539t1539r1579b1591],
5	would	MD	O	would	aux	6	SENT_36	[p2l1608t1538r1794b1591],
6	lead	VB	O	lead	csubj	16	SENT_36	[p2l1828t1538r1948b1591],
7	to	TO	O	to	_	0	SENT_36	[p2l1980t1546r2038b1591],
8	increased	VBN	O	increase	amod	9	SENT_36	[p2l2070t1539r2151b1590, p2l52t1623r273b1676],
9	incidences	NNS	O	incidence	prep_to	6	SENT_36	[p2l295t1623r603b1676],
10	of	IN	O	of	_	0	SENT_36	[p2l625t1623r687b1676],
11	adverse	JJ	O	adverse	amod	13	SENT_36	[p2l700t1623r926b1676],
12	drug	NN	O	drug	nn	13	SENT_36	[p2l949t1623r1085b1690],
13	reactions	NNS	O	reaction	prep_of	9	SENT_36	[p2l1106t1624r1372b1676],
14	is	VBZ	O	be	cop	16	SENT_36	[p2l1394t1624r1437b1676],
15	still	RB	O	still	advmod	16	SENT_36	[p2l1460t1623r1563b1676],
16	controversial	JJ	O	controversial	_	0	SENT_36	[p2l1585t1623r1983b1677],
17	.	.	O	.	_	0	SENT_36	[p2l1585t1623r1983b1677],

1	Recently	RB	DATE	recently	advmod	7	SENT_37	[p2l152t1709r418b1776],
2	,	,	O	,	_	0	SENT_37	[p2l152t1709r418b1776],
3	Soo	NNP	PERSON	Soo	nsubj	7	SENT_37	[p2l438t1712r541b1762],
4	et	FW	O	et	nn	5	SENT_37	[p2l561t1717r617b1762],
5	al.	FW	O	al.	dep	3	SENT_37	[p2l634t1709r697b1763],
6	have	VBP	O	have	aux	7	SENT_37	[p2l717t1709r856b1762],
7	characterized	VBN	O	characterize	_	0	SENT_37	[p2l875t1709r1271b1762],
8	the	DT	O	the	det	9	SENT_37	[p2l1290t1709r1384b1762],
9	distribution	NN	O	distribution	nsubj	21	SENT_37	[p2l1404t1709r1749b1762],
10	of	IN	O	of	_	0	SENT_37	[p2l1769t1709r1830b1762],
11	variants	NNS	O	variant	prep_of	9	SENT_37	[p2l1840t1710r2076b1762],
12	in	IN	O	in	_	0	SENT_37	[p2l2096t1710r2150b1762],
13	genes	NNS	O	gene	prep_in	11	SENT_37	[p2l51t1811r218b1862],
14	involved	VBN	O	involve	partmod	13	SENT_37	[p2l238t1795r491b1849],
15	in	IN	O	in	_	0	SENT_37	[p2l511t1796r565b1848],
16	gemcitabine	NN	O	gemcitabine	nn	17	SENT_37	[p2l583t1795r946b1862],
17	pharmacology	NN	O	pharmacology	prep_in	14	SENT_37	[p2l965t1795r1387b1862],
18	in	IN	O	in	_	0	SENT_37	[p2l1404t1796r1459b1848],
19	a	DT	O	a	det	20	SENT_37	[p2l1477t1811r1508b1849],
20	population	NN	O	population	prep_in	17	SENT_37	[p2l1526t1795r1846b1862],
21	constituted	VBD	O	constitute	ccomp	7	SENT_37	[p2l1864t1796r2150b1849, p2l52t1881r121b1935],
22	of	IN	O	of	_	0	SENT_37	[p2l138t1881r199b1935],
23	Chinese	NNP	MISC	Chinese	prep_of	21	SENT_37	[p2l208t1882r451b1943],
24	,	,	O	,	_	0	SENT_37	[p2l208t1882r451b1943],
25	Malay	NNP	MISC	Malay	prep_of	21	SENT_37	[p2l469t1881r649b1948],
26	and	CC	O	and	_	0	SENT_37	[p2l663t1881r770b1935],
27	Indian	NNP	MISC	Indian	prep_of	21	SENT_37	[p2l788t1881r986b1935],
28	.	.	O	.	_	0	SENT_37	[p2l788t1881r986b1935],

1	The	DT	O	the	det	2	SENT_38	[p2l1002t1881r1111b1935],
2	correlation	NN	O	correlation	nsubjpass	14	SENT_38	[p2l1127t1881r1448b1935],
3	of	IN	O	of	_	0	SENT_38	[p2l1464t1881r1526b1935],
4	the	DT	O	the	det	5	SENT_38	[p2l1534t1881r1628b1935],
5	variants	NNS	O	variant	prep_of	2	SENT_38	[p2l1643t1882r1878b1935],
6	and	CC	O	and	_	0	SENT_38	[p2l1896t1881r2003b1935],
7	clinical	JJ	O	clinical	amod	8	SENT_38	[p2l2020t1882r2150b1935, p2l52t1968r149b2021],
8	outcomes	NNS	O	outcome	nsubjpass	14	SENT_38	[p2l172t1976r456b2021],
9	of	IN	O	of	_	0	SENT_38	[p2l479t1968r540b2021],
10	gemcitabine	NN	O	gemcitabine	prep_of	8	SENT_38	[p2l554t1968r916b2034],
11	have	VBP	O	have	aux	14	SENT_38	[p2l939t1968r1076b2021],
12	also	RB	O	also	advmod	14	SENT_38	[p2l1099t1968r1212b2021],
13	been	VBN	O	be	auxpass	14	SENT_38	[p2l1234t1968r1377b2021],
14	tested	VBN	O	test	_	0	SENT_38	[p2l1397t1968r1576b2021],
15	in	IN	O	in	_	0	SENT_38	[p2l1598t1969r1654b2020],
16	their	PRP$	O	they	poss	17	SENT_38	[p2l1674t1968r1815b2021],
17	study	NN	O	study	prep_in	14	SENT_38	[p2l1836t1968r1999b2034],
18	[	CD	NUMBER	[	number	19	SENT_38	[p2l2022t1968r2149b2034],
19	12	CD	NUMBER	12	num	20	SENT_38	[p2l2022t1968r2149b2034],
20	]	NN	O	]	dep	14	SENT_38	[p2l2022t1968r2149b2034],
21	.	.	O	.	_	0	SENT_38	[p2l2022t1968r2149b2034],

1	However	RB	O	however	advmod	18	SENT_39	[p2l52t2057r333b2115],
2	,	,	O	,	_	0	SENT_39	[p2l52t2057r333b2115],
3	to	TO	O	to	_	0	SENT_39	[p2l355t2062r412b2107],
4	our	PRP$	O	we	poss	5	SENT_39	[p2l434t2069r535b2107],
5	knowledge	NN	O	knowledge	prep_to	18	SENT_39	[p2l555t2054r894b2120],
6	,	,	O	,	_	0	SENT_39	[p2l555t2054r894b2120],
7	the	DT	O	the	det	8	SENT_39	[p2l915t2054r1009b2107],
8	association	NN	O	association	nsubjpass	18	SENT_39	[p2l1031t2055r1356b2107],
9	of	IN	O	of	_	0	SENT_39	[p2l1377t2054r1440b2107],
10	genetic	JJ	O	genetic	amod	11	SENT_39	[p2l1452t2055r1666b2120],
11	polymorphisms	NNS	O	polymorphism	prep_of	8	SENT_39	[p2l1687t2054r2150b2120],
12	and	CC	O	and	_	0	SENT_39	[p2l52t2139r159b2192],
13	gemcitabine	NN	O	gemcitabine	nn	14	SENT_39	[p2l183t2139r545b2206],
14	toxicity	NN	O	toxicity	conj_and	11	SENT_39	[p2l569t2140r790b2206],
15	has	VBZ	O	have	aux	18	SENT_39	[p2l813t2139r910b2192],
16	not	RB	O	not	neg	18	SENT_39	[p2l935t2147r1032b2192],
17	been	VBN	O	be	auxpass	18	SENT_39	[p2l1054t2139r1196b2192],
18	tested	VBN	O	test	_	0	SENT_39	[p2l1219t2139r1398b2192],
19	in	IN	O	in	_	0	SENT_39	[p2l1423t2140r1478b2192],
20	residents	NNS	O	resident	prep_in	18	SENT_39	[p2l1501t2139r1768b2192],
21	in	IN	O	in	_	0	SENT_39	[p2l1794t2140r1848b2192],
22	mainland	NN	O	mainland	nn	23	SENT_39	[p2l1872t2139r2150b2192],
23	China	NNP	LOCATION	China	prep_in	20	SENT_39	[p2l52t2225r231b2279],
24	.	.	O	.	_	0	SENT_39	[p2l52t2225r231b2279],

1	The	DT	O	the	det	2	SENT_40	[p2l256t2225r364b2278],
2	aim	NN	O	aim	nsubj	7	SENT_40	[p2l390t2226r500b2278],
3	of	IN	O	of	_	0	SENT_40	[p2l525t2225r587b2278],
4	the	DT	O	the	det	6	SENT_40	[p2l605t2225r699b2278],
5	present	JJ	DATE	present	amod	6	SENT_40	[p2l725t2233r948b2292],
6	study	NN	O	study	prep_of	2	SENT_40	[p2l972t2225r1135b2292],
7	is	VBZ	O	be	_	0	SENT_40	[p2l1159t2226r1202b2278],
8	to	TO	O	to	aux	9	SENT_40	[p2l1227t2233r1284b2278],
9	investigate	VB	O	investigate	ccomp	7	SENT_40	[p2l1311t2226r1631b2292],
10	the	DT	O	the	det	18	SENT_40	[p2l1657t2225r1751b2278],
11	distributions	NNS	O	distribution	nn	18	SENT_40	[p2l1777t2225r2150b2278],
12	of	IN	O	of	_	0	SENT_40	[p2l52t2311r114b2365],
13	CDA	NNP	ORGANIZATION	CDA	nn	14	SENT_40	[p2l126t2314r244b2365],
14	208A	NN	O	208a	prep_of	11	SENT_40	[p2l263t2314r526b2373],
15	>	JJR	O	>	dep	16	SENT_40	[p2l263t2314r526b2373],
16	G	NN	O	g	amod	14	SENT_40	[p2l263t2314r526b2373],
17	,	,	O	,	_	0	SENT_40	[p2l263t2314r526b2373],
18	79A	NN	O	79a	dobj	9	SENT_40	[p2l548t2314r754b2365],
19	>	JJR	O	>	dep	20	SENT_40	[p2l548t2314r754b2365],
20	C	NN	O	c	amod	18	SENT_40	[p2l548t2314r754b2365],
21	in	IN	O	in	_	0	SENT_40	[p2l771t2312r825b2364],
22	Chinese	JJ	LOCATION	chinese	amod	23	SENT_40	[p2l845t2311r1075b2365],
23	population	NN	O	population	prep_in	9	SENT_40	[p2l1094t2311r1413b2378],
24	and	CC	O	and	_	0	SENT_40	[p2l1433t2311r1540b2365],
25	to	TO	O	to	aux	26	SENT_40	[p2l1560t2319r1616b2365],
26	examine	VB	O	examine	ccomp	7	SENT_40	[p2l1637t2312r1889b2365],
27	their	PRP$	O	they	poss	28	SENT_40	[p2l1908t2311r2049b2365],
28	associations	NNS	O	association	dobj	26	SENT_40	[p2l2066t2327r2150b2365, p2l53t2398r342b2451],
29	with	IN	O	with	_	0	SENT_40	[p2l362t2398r499b2451],
30	severe	JJ	O	severe	amod	31	SENT_40	[p2l520t2413r707b2451],
31	myelotoxicity	NN	O	myelotoxicity	nsubj	36	SENT_40	[p2l729t2398r1135b2464],
32	in	IN	O	in	_	0	SENT_40	[p2l1155t2398r1209b2450],
33	Chinese	JJ	MISC	chinese	amod	35	SENT_40	[p2l1230t2397r1459b2451],
34	cancer	NN	O	cancer	nn	35	SENT_40	[p2l1480t2413r1674b2451],
35	patients	NNS	O	patient	prep_in	31	SENT_40	[p2l1692t2398r1927b2464],
36	receiving	VBG	O	receive	prepc_with	26	SENT_40	[p2l1950t2398r2150b2451, p2l52t2485r144b2550],
37	gemcitabine	NN	O	gemcitabine	nn	38	SENT_40	[p2l162t2484r722b2550],
38	—	NN	O	—	dobj	36	SENT_40	[p2l162t2484r722b2550],
39	based	VBN	O	base	partmod	38	SENT_40	[p2l162t2484r722b2550],
40	chemotherapy	NN	O	chemotherapy	dobj	39	SENT_40	[p2l745t2484r1185b2550],
41	.	.	O	.	_	0	SENT_40	[p2l745t2484r1185b2550],

1	2	LS	NUMBER	2	_	0	SENT_41	[p2l51t2661r103b2712],
2	.	.	O	.	_	0	SENT_41	[p2l51t2661r103b2712],

1	Materials	NNPS	O	Materials	_	0	SENT_42	[p2l125t2658r421b2711],
2	and	CC	O	and	_	0	SENT_42	[p2l443t2658r561b2711],
3	methods	NNS	O	method	conj_and	1	SENT_42	[p2l584t2658r862b2711],

1	2.1	CD	NUMBER	2.1	_	0	SENT_43	[p2l48t2835r148b2886],
2	.	.	O	.	_	0	SENT_43	[p2l48t2835r148b2886],

1	Patients	NNS	O	patient	_	0	SENT_44	[p2l172t2834r403b2886],
2	and	CC	O	and	_	0	SENT_44	[p2l427t2832r534b2886],
3	healthy	JJ	O	healthy	amod	5	SENT_44	[p2l557t2832r772b2899],
4	volunteer	NN	O	volunteer	nn	5	SENT_44	[p2l794t2832r1071b2886],
5	selection	NN	O	selection	conj_and	1	SENT_44	[p2l1089t2832r1341b2886],

1	A	DT	O	a	det	2	SENT_45	[p2l149t3009r194b3059],
2	total	NN	O	total	_	0	SENT_45	[p2l214t3007r350b3060],
3	of	IN	O	of	_	0	SENT_45	[p2l374t3007r436b3060],
4	50	CD	NUMBER	50	num	5	SENT_45	[p2l452t3010r523b3060],
5	patients	NNS	O	patient	prep_of	2	SENT_45	[p2l547t3008r787b3073],
6	with	IN	O	with	_	0	SENT_45	[p2l810t3007r948b3060],
7	cancer	NN	O	cancer	prep_with	5	SENT_45	[p2l971t3022r1168b3060],
8	(	CD	NUMBER	(	number	9	SENT_45	[p2l1193t3007r1289b3073],
9	27	CD	NUMBER	27	num	10	SENT_45	[p2l1193t3007r1289b3073],
10	women	NNS	O	woman	dep	7	SENT_45	[p2l1312t3022r1555b3068],
11	,	,	O	,	_	0	SENT_45	[p2l1312t3022r1555b3068],
12	23	CD	NUMBER	23	num	13	SENT_45	[p2l1579t3010r1648b3060],
13	men	NNS	O	man	appos	7	SENT_45	[p2l1674t3022r1824b3068],
14	;	:	O	;	_	0	SENT_45	[p2l1674t3022r1824b3068],
15	mean	VB	O	mean	dep	2	SENT_45	[p2l1852t3022r2018b3060],
16	and	CC	O	and	_	0	SENT_45	[p2l2041t3007r2150b3060],
17	standard	JJ	O	standard	amod	19	SENT_45	[p2l53t3092r315b3145],
18	deviation	NN	O	deviation	nn	19	SENT_45	[p2l342t3092r623b3145],
19	age	NN	O	age	nsubjpass	48	SENT_45	[p2l650t3108r765b3159],
20	,	,	O	,	_	0	SENT_45	[p2l650t3108r765b3159],
21	58.4	CD	NUMBER	58.4	appos	19	SENT_45	[p2l794t3095r983b3149],
22	:	:	O	:	_	0	SENT_45	[p2l794t3095r983b3149],
23	l	NN	O	l	dep	21	SENT_45	[p2l794t3095r983b3149],
24	:	:	O	:	_	0	SENT_45	[p2l794t3095r983b3149],
25	10.5	CD	DURATION	10.5	num	26	SENT_45	[p2l1003t3095r1124b3146],
26	years	NNS	NUMBER	year	dep	23	SENT_45	[p2l1145t3108r1322b3159],
27	;	:	O	;	_	0	SENT_45	[p2l1145t3108r1322b3159],
28	Table	NNP	O	Table	nn	30	SENT_45	[p2l1351t3092r1512b3145],
29	1	CD	NUMBER	1	num	30	SENT_45	[p2l1542t3092r1597b3159],
30	)	NN	O	)	dep	26	SENT_45	[p2l1542t3092r1597b3159],
31	who	WP	O	who	nsubjpass	33	SENT_45	[p2l1627t3092r1759b3145],
32	were	VBD	O	be	auxpass	33	SENT_45	[p2l1784t3108r1935b3145],
33	hospitalized	VBN	O	hospitalize	rcmod	30	SENT_45	[p2l1962t3092r2150b3159, p2l51t3178r251b3231],
34	at	IN	O	at	_	0	SENT_45	[p2l270t3186r326b3231],
35	the	DT	O	the	det	36	SENT_45	[p2l343t3178r438b3231],
36	Department	NNP	ORGANIZATION	Department	prep_at	33	SENT_45	[p2l458t3182r822b3245],
37	of	IN	ORGANIZATION	of	_	0	SENT_45	[p2l839t3178r902b3231],
38	Oncology	NNP	ORGANIZATION	Oncology	prep_of	36	SENT_45	[p2l913t3178r1209b3245],
39	,	,	O	,	_	0	SENT_45	[p2l913t3178r1209b3245],
40	Zhongshan	NNP	LOCATION	Zhongshan	nn	41	SENT_45	[p2l1227t3178r1560b3245],
41	Hospital	NNP	LOCATION	Hospital	appos	38	SENT_45	[p2l1579t3178r1840b3245],
42	,	,	O	,	_	0	SENT_45	[p2l1579t3178r1840b3245],
43	Shanghai	NNP	LOCATION	Shanghai	appos	38	SENT_45	[p2l1861t3178r2150b3245],
44	,	,	O	,	_	0	SENT_45	[p2l1861t3178r2150b3245],
45	China	NNP	LOCATION	China	appos	38	SENT_45	[p2l52t3265r235b3326],
46	,	,	O	,	_	0	SENT_45	[p2l52t3265r235b3326],
47	were	VBD	O	be	auxpass	48	SENT_45	[p2l265t3280r416b3318],
48	enrolled	VBN	O	enrol	conj_and	15	SENT_45	[p2l447t3265r695b3318],
49	in	IN	O	in	_	0	SENT_45	[p2l726t3265r782b3317],
50	this	DT	O	this	det	51	SENT_45	[p2l812t3265r920b3318],
51	study	NN	O	study	prep_in	48	SENT_45	[p2l953t3265r1118b3331],
52	from	IN	O	from	_	0	SENT_45	[p2l1147t3264r1291b3318],
53	December	NNP	DATE	December	prep_from	51	SENT_45	[p2l1321t3265r1628b3318],
54	2010	CD	DATE	2010	num	53	SENT_45	[p2l1656t3267r1804b3318],
55	to	TO	O	to	_	0	SENT_45	[p2l1834t3273r1892b3318],
56	January	NNP	DATE	January	prep_to	48	SENT_45	[p2l1916t3268r2152b3331],
57	2012	CD	DATE	2012	num	56	SENT_45	[p2l52t3353r215b3404],
58	.	.	O	.	_	0	SENT_45	[p2l52t3353r215b3404],

1	Patients	NNS	O	patient	dep	2	SENT_46	[p2l254t3351r493b3404],
2	eligible	JJ	O	eligible	_	0	SENT_46	[p2l532t3350r749b3417],
3	for	IN	O	for	_	0	SENT_46	[p2l788t3350r872b3404],
4	this	DT	O	this	det	5	SENT_46	[p2l908t3350r1017b3404],
5	study	NN	O	study	prep_for	2	SENT_46	[p2l1057t3350r1222b3417],
6	had	VBD	O	have	rcmod	5	SENT_46	[p2l1259t3350r1368b3404],
7	late-stage	JJ	O	late-stage	amod	5	SENT_46	[p2l1408t3350r1701b3417],
8	or	CC	O	or	_	0	SENT_46	[p2l1739t3366r1801b3404],
9	metastatic	JJ	O	metastatic	amod	5	SENT_46	[p2l1839t3351r2152b3404],

1	J.	NNP	PERSON	J.	nn	2	SENT_47	[p2l372t3493r388b3519],
2	Xu	NNP	PERSON	Xu	_	0	SENT_47	[p2l396t3493r428b3514],
3	et	FW	O	et	nn	4	SENT_47	[p2l437t3495r460b3514],
4	al.	FW	O	al.	dep	2	SENT_47	[p2l467t3492r492b3514],
5	/	:	O	/	punct	2	SENT_47	[p2l501t3493r511b3517],
6	Clinica	NNP	PERSON	Clinica	nn	8	SENT_47	[p2l519t3492r596b3514],
7	Chimica	NNP	PERSON	Chimica	nn	8	SENT_47	[p2l606t3492r698b3514],
8	Acta	NNP	PERSON	Acta	dep	2	SENT_47	[p2l705t3493r757b3514],
9	413	CD	NUMBER	413	number	10	SENT_47	[p2l766t3493r809b3514],
10	(	CD	NUMBER	(	num	11	SENT_47	[p2l820t3492r898b3519],
11	2012	CD	DATE	2012	dep	8	SENT_47	[p2l820t3492r898b3519],
12	)	CD	NUMBER	)	number	13	SENT_47	[p2l820t3492r898b3519],
13	1284-1287 1285	CD	DURATION	1284-1287 1285	num	11	SENT_47	[p2l1731t3493r1788b3514],[p2l912t3493r1042b3514],

1	cancer	NN	O	cancer	_	0	SENT_48	[p3l11t79r211b117],
2	(	CD	NUMBER	(	num	1	SENT_48	[p3l252t63r566b131],
3	including	VBG	O	include	_	0	SENT_48	[p3l252t63r566b131],
4	non-small	JJ	O	non-small	amod	7	SENT_48	[p3l605t63r913b117],
5	cell	NN	O	cell	nn	7	SENT_48	[p3l954t63r1056b117],
6	lung	NN	O	lung	nn	7	SENT_48	[p3l1096t63r1230b131],
7	cancer	NN	O	cancer	prep_including	1	SENT_48	[p3l1270t79r1482b125],
8	,	,	O	,	_	0	SENT_48	[p3l1270t79r1482b125],
9	bladder	NN	O	bladder	nn	10	SENT_48	[p3l1522t63r1757b117],
10	cancer	NN	O	cancer	prep_including	1	SENT_48	[p3l1795t79r1995b117],
11	and	CC	O	and	_	0	SENT_48	[p3l2033t63r2144b117],
12	cholangiocellular	JJ	O	cholangiocellular	amod	13	SENT_48	[p3l11t150r537b218],
13	carcinoma	NN	O	carcinoma	conj_and	7	SENT_48	[p3l571t151r901b213],
14	,	,	O	,	_	0	SENT_48	[p3l571t151r901b213],
15	etc.	FW	O	etc.	nn	16	SENT_48	[p3l938t150r1078b217],
16	)	FW	O	)	appos	13	SENT_48	[p3l938t150r1078b217],
17	.	.	O	.	_	0	SENT_48	[p3l938t150r1078b217],

1	All	DT	O	all	det	2	SENT_49	[p3l1112t150r1193b204],
2	patients	NNS	O	patient	nsubj	3	SENT_49	[p3l1226t151r1465b218],
3	were	VBD	O	be	_	0	SENT_49	[p3l1497t166r1647b204],
4	below	IN	O	below	_	0	SENT_49	[p3l1680t150r1865b204],
5	80	CD	DURATION	80	num	6	SENT_49	[p3l1895t153r1968b204],
6	years	NNS	NUMBER	year	prep_below	3	SENT_49	[p3l1986t166r2144b218],
7	of	IN	O	of	_	0	SENT_49	[p3l11t237r74b291],
8	age	NN	O	age	prep_of	6	SENT_49	[p3l90t253r205b305],
9	.	.	O	.	_	0	SENT_49	[p3l90t253r205b305],

1	All	DT	O	all	nsubj	4	SENT_50	[p3l228t237r308b291],
2	of	IN	O	of	_	0	SENT_50	[p3l333t237r396b291],
3	them	PRP	O	they	prep_of	1	SENT_50	[p3l413t237r570b292],
4	had	VBD	O	have	ccomp	16	SENT_50	[p3l594t237r703b291],
5	a	DT	O	a	det	8	SENT_50	[p3l728t253r760b291],
6	Karnofsky	NNP	PERSON	Karnofsky	nn	8	SENT_50	[p3l784t237r1085b305],
7	performance	NN	O	performance	nn	8	SENT_50	[p3l1108t237r1491b305],
8	status	NN	O	status	nsubj	12	SENT_50	[p3l1516t245r1690b292],
9	(	CD	NUMBER	(	num	10	SENT_50	[p3l1720t237r1881b305],
10	KPS	NN	O	kp	npadvmod	11	SENT_50	[p3l1720t237r1881b305],
11	)	JJ	O	)	amod	12	SENT_50	[p3l1720t237r1881b305],
12	score	NN	NUMBER	score	xcomp	4	SENT_50	[p3l1911t253r2064b292],
13	of	IN	O	of	_	0	SENT_50	[p3l2089t237r2153b292],
14	280	CD	NUMBER	280	prep_of	12	SENT_50	[p3l12t327r157b388],
15	,	,	O	,	_	0	SENT_50	[p3l12t327r157b388],
16	had	VBD	O	have	_	0	SENT_50	[p3l196t324r304b379],
17	adequate	JJ	O	adequate	amod	20	SENT_50	[p3l342t325r617b393],
18	bone	NN	O	bone	nn	20	SENT_50	[p3l654t325r801b379],
19	marrow	NN	O	marrow	nn	20	SENT_50	[p3l839t341r1079b379],
20	function	NN	O	function	dobj	16	SENT_50	[p3l1116t324r1364b379],
21	(	CD	NUMBER	(	num	22	SENT_50	[p3l1405t314r2143b393],
22	leucocytes24	NN	O	leucocytes24	nsubj	16	SENT_50	[p3l1405t314r2143b393],
23	.	.	O	.	_	0	SENT_50	[p3l1405t314r2143b393],

1	O	NN	O	o	nsubj	24	SENT_51	[p3l1405t314r2143b393],
2	>	JJR	O	>	npadvmod	3	SENT_51	[p3l1405t314r2143b393],
3	<	JJR	O	<	amod	1	SENT_51	[p3l1405t314r2143b393],
4	109/L	CD	NUMBER	109/l	_	0	SENT_51	[p3l1405t314r2143b393],
5	,	,	O	,	_	0	SENT_51	[p3l1405t314r2143b393],
6	platelets	NNS	O	platelet	dobj	4	SENT_51	[p3l11t413r263b481],
7	2100	CD	DATE	2100	dep	6	SENT_51	[p3l278t416r447b469],
8	x	CC	O	x	_	0	SENT_51	[p3l461t431r498b465],
9	109/L	CD	NUMBER	109/l	dobj	4	SENT_51	[p3l518t403r689b477],
10	,	,	O	,	_	0	SENT_51	[p3l518t403r689b477],
11	hemoglobin	NN	O	hemoglobin	appos	9	SENT_51	[p3l732t413r1090b481],
12	2	CD	NUMBER	2	number	13	SENT_51	[p3l1103t421r1149b469],
13	100	CD	NUMBER	100	num	14	SENT_51	[p3l1166t416r1273b468],
14	g/L	NN	O	g/l	dep	11	SENT_51	[p3l1292t415r1386b481],
15	and	CC	O	and	_	0	SENT_51	[p3l1424t413r1534b468],
16	neutrophils	NNS	O	neutrophil	appos	9	SENT_51	[p3l1576t413r1920b481],
17	2	CD	NUMBER	2	number	18	SENT_51	[p3l1934t421r1980b469],
18	2.0	CD	NUMBER	2.0	dep	19	SENT_51	[p3l1993t416r2080b468],
19	x	NN	O	x	dep	21	SENT_51	[p3l2095t431r2132b465],
20	109/L	NN	O	109/l	nn	21	SENT_51	[p3l14t491r213b569],
21	)	NN	O	)	dep	16	SENT_51	[p3l14t491r213b569],
22	,	,	O	,	_	0	SENT_51	[p3l14t491r213b569],
23	and	CC	O	and	_	0	SENT_51	[p3l232t501r341b556],
24	had	VBD	O	have	conj_and	4	SENT_51	[p3l360t501r469b556],
25	adequate	JJ	O	adequate	amod	26	SENT_51	[p3l487t501r762b569],
26	hepatic	JJ	O	hepatic	nsubj	30	SENT_51	[p3l780t501r999b569],
27	and	CC	O	and	_	0	SENT_51	[p3l1016t501r1125b556],
28	renal	JJ	O	renal	amod	29	SENT_51	[p3l1144t501r1294b556],
29	functions	NNS	O	function	nsubj	30	SENT_51	[p3l1312t501r1589b556],
30	(	VBP	O	(	ccomp	24	SENT_51	[p3l1611t501r1911b569],
31	aspartate	NN	O	aspartate	nn	33	SENT_51	[p3l1611t501r1911b569],
32	aminotransferase/alanine	NN	O	aminotransferase/alanine	nn	33	SENT_51	[p3l1930t502r2144b556, p3l10t588r584b651],
33	aminotransferase	NN	O	aminotransferase	dobj	30	SENT_51	[p3l604t588r1171b642],
34	<	JJR	O	<	amod	33	SENT_51	[p3l604t588r1171b642],
35	2	CD	NUMBER	2	number	36	SENT_51	[p3l1182t591r1215b642],
36	x	NN	O	x	amod	38	SENT_51	[p3l1231t606r1268b639],
37	upper	JJ	O	upper	amod	38	SENT_51	[p3l1284t604r1462b656],
38	limit	NN	O	limit	dep	47	SENT_51	[p3l1480t588r1620b642],
39	of	IN	O	of	_	0	SENT_51	[p3l1638t588r1700b642],
40	normal	JJ	O	normal	amod	42	SENT_51	[p3l1713t588r1926b642],
41	(	NN	O	(	nn	42	SENT_51	[p3l1951t588r2144b655],
42	ULN	NN	O	uln	prep_of	38	SENT_51	[p3l1951t588r2144b655],
43	)	NN	O	)	nn	46	SENT_51	[p3l1951t588r2144b655],
44	,	,	O	,	_	0	SENT_51	[p3l1951t588r2144b655],
45	total	JJ	O	total	amod	46	SENT_51	[p3l10t675r145b730],
46	bilirubin	NN	O	bilirubin	dep	47	SENT_51	[p3l172t675r473b729],
47	<	JJR	O	<	dep	54	SENT_51	[p3l172t675r473b729],
48	1.25	CD	NUMBER	1.25	num	50	SENT_51	[p3l489t678r609b730],
49	x	NN	O	x	nn	50	SENT_51	[p3l624t693r661b727],
50	ULN	NN	O	uln	dep	47	SENT_51	[p3l677t679r802b730],
51	and	CC	O	and	_	0	SENT_51	[p3l829t675r939b730],
52	serum	NN	O	serum	nn	53	SENT_51	[p3l968t691r1156b730],
53	creatinine	NN	O	creatinine	dep	47	SENT_51	[p3l1182t676r1527b730],
54	<	JJR	O	<	dep	58	SENT_51	[p3l1182t676r1527b730],
55	1.5	CD	NUMBER	1.5	num	57	SENT_51	[p3l1542t678r1624b730],
56	x	NN	O	x	nn	57	SENT_51	[p3l1640t693r1677b727],
57	ULN	NNP	O	ULN	dep	54	SENT_51	[p3l1693t675r1861b743],
58	)	CD	NUMBER	)	dep	30	SENT_51	[p3l1693t675r1861b743],
59	.	.	O	.	_	0	SENT_51	[p3l1693t675r1861b743],

1	Previous	JJ	O	previous	amod	2	SENT_52	[p3l1889t676r2144b730],
2	therapy	NN	O	therapy	nsubjpass	5	SENT_52	[p3l10t762r243b830],
3	must	MD	O	must	aux	5	SENT_52	[p3l261t770r413b817],
4	be	VB	O	be	auxpass	5	SENT_52	[p3l429t762r499b816],
5	completed	VBN	O	complete	_	0	SENT_52	[p3l517t762r834b830],
6	21	CD	DURATION	21	num	7	SENT_52	[p3l853t765r918b816],
7	days	NNS	NUMBER	day	npadvmod	5	SENT_52	[p3l946t762r1080b830],
8	before	IN	O	before	_	0	SENT_52	[p3l1098t762r1288b817],
9	study	NN	O	study	nn	10	SENT_52	[p3l1308t762r1473b830],
10	entry	NN	O	entry	prep_before	5	SENT_52	[p3l1490t770r1649b830],
11	with	IN	O	with	_	0	SENT_52	[p3l1664t762r1804b816],
12	full	JJ	O	full	amod	13	SENT_52	[p3l1822t762r1916b816],
13	resolution	NN	O	resolution	prep_with	5	SENT_52	[p3l1936t762r2144b817, p3l10t852r128b905],
14	of	IN	O	of	_	0	SENT_52	[p3l149t851r212b905],
15	toxicities	NNS	O	toxicity	prep_of	13	SENT_52	[p3l226t852r509b906],
16	.	.	O	.	_	0	SENT_52	[p3l226t852r509b906],

1	In	IN	O	in	_	0	SENT_53	[p3l113t941r170b991],
2	addition	NN	O	addition	prep_in	14	SENT_53	[p3l189t938r458b1000],
3	,	,	O	,	_	0	SENT_53	[p3l189t938r458b1000],
4	during	IN	O	during	_	0	SENT_53	[p3l478t938r680b1005],
5	July	NNP	DATE	July	prep_during	14	SENT_53	[p3l690t938r813b1005],
6	2011	CD	DATE	2011	num	5	SENT_53	[p3l830t941r974b992],
7	to	TO	O	to	_	0	SENT_53	[p3l1000t946r1059b992],
8	November	NNP	DATE	November	prep_to	5	SENT_53	[p3l1079t938r1400b992],
9	2011	CD	DATE	2011	num	8	SENT_53	[p3l1417t941r1582b1000],
10	,	,	O	,	_	0	SENT_53	[p3l1417t941r1582b1000],
11	unrelated	JJ	O	unrelated	amod	13	SENT_53	[p3l1602t938r1896b992],
12	healthy	JJ	O	healthy	amod	13	SENT_53	[p3l1916t938r2146b1005],
13	volunteers	NNS	O	volunteer	nsubj	14	SENT_53	[p3l9t1024r334b1078],
14	(	VBP	O	(	_	0	SENT_53	[p3l364t1024r464b1092],
15	46	CD	NUMBER	46	num	16	SENT_53	[p3l364t1024r464b1092],
16	females	NNS	O	female	dobj	14	SENT_53	[p3l490t1024r739b1087],
17	,	,	O	,	_	0	SENT_53	[p3l490t1024r739b1087],
18	56	CD	NUMBER	56	num	19	SENT_53	[p3l766t1027r838b1078],
19	males	NNS	O	male	appos	16	SENT_53	[p3l864t1024r1060b1087],
20	;	:	O	;	_	0	SENT_53	[p3l864t1024r1060b1087],
21	mean	VB	O	mean	dep	16	SENT_53	[p3l1091t1040r1259b1078],
22	and	CC	O	and	_	0	SENT_53	[p3l1284t1024r1395b1078],
23	standard	JJ	O	standard	amod	25	SENT_53	[p3l1422t1024r1689b1078],
24	deviation	NN	O	deviation	nn	25	SENT_53	[p3l1715t1024r2002b1078],
25	age	NN	O	age	dep	35	SENT_53	[p3l2026t1040r2143b1092],
26	,	,	O	,	_	0	SENT_53	[p3l2026t1040r2143b1092],
27	24.0	CD	NUMBER	24.0	appos	25	SENT_53	[p3l11t1114r138b1166],
28	:	:	O	:	_	0	SENT_53	[p3l154t1119r204b1168],
29	I	PRP	O	I	dep	25	SENT_53	[p3l154t1119r204b1168],
30	:	:	O	:	_	0	SENT_53	[p3l154t1119r204b1168],
31	3.7	CD	DURATION	3.7	num	32	SENT_53	[p3l220t1114r309b1166],
32	years	NNS	NUMBER	year	dep	29	SENT_53	[p3l330t1111r517b1179],
33	)	CD	NUMBER	)	nsubjpass	35	SENT_53	[p3l330t1111r517b1179],
34	were	VBD	O	be	auxpass	35	SENT_53	[p3l576t1127r730b1165],
35	enrolled	VBN	O	enrol	conj_and	21	SENT_53	[p3l788t1111r1040b1165],
36	as	IN	O	as	_	0	SENT_53	[p3l1097t1127r1157b1165],
37	control	NN	O	control	prep_as	35	SENT_53	[p3l1215t1111r1431b1165],
38	for	IN	O	for	_	0	SENT_53	[p3l1490t1111r1575b1165],
39	the	DT	O	the	det	40	SENT_53	[p3l1630t1111r1726b1165],
40	purpose	NN	O	purpose	prep_for	35	SENT_53	[p3l1784t1127r2031b1179],
41	of	IN	O	of	_	0	SENT_53	[p3l2089t1111r2152b1165],
42	genotyping	VBG	O	genotype	prepc_of	40	SENT_53	[p3l10t1199r357b1266],
43	study	NN	O	study	dobj	42	SENT_53	[p3l381t1198r549b1266],
44	from	IN	O	from	_	0	SENT_53	[p3l571t1198r717b1252],
45	the	DT	O	the	det	46	SENT_53	[p3l739t1198r836b1252],
46	Institute	NNP	ORGANIZATION	Institute	prep_from	42	SENT_53	[p3l860t1199r1116b1253],
47	of	IN	ORGANIZATION	of	_	0	SENT_53	[p3l1140t1198r1203b1253],
48	Antibiotics	NNPS	ORGANIZATION	Antibiotics	prep_of	46	SENT_53	[p3l1217t1198r1561b1261],
49	,	,	O	,	_	0	SENT_53	[p3l1217t1198r1561b1261],
50	Huashan	NNP	ORGANIZATION	Huashan	nn	51	SENT_53	[p3l1587t1198r1853b1253],
51	Hospital	NNP	ORGANIZATION	Hospital	appos	48	SENT_53	[p3l1877t1198r2143b1266],
52	,	,	O	,	_	0	SENT_53	[p3l1877t1198r2143b1266],
53	Shanghai	NNP	LOCATION	Shanghai	appos	48	SENT_53	[p3l11t1285r305b1353],
54	,	,	O	,	_	0	SENT_53	[p3l11t1285r305b1353],
55	China	NNP	LOCATION	China	appos	48	SENT_53	[p3l330t1285r517b1340],
56	.	.	O	.	_	0	SENT_53	[p3l330t1285r517b1340],

1	The	DT	O	the	det	2	SENT_54	[p3l110t1373r222b1427],
2	studies	NNS	O	study	nsubjpass	10	SENT_54	[p3l246t1373r460b1427],
3	in	IN	O	in	_	0	SENT_54	[p3l484t1374r541b1426],
4	patients	NNS	O	patient	prep_in	2	SENT_54	[p3l564t1374r808b1440],
5	and	CC	O	and	_	0	SENT_54	[p3l832t1373r943b1427],
6	in	IN	O	in	_	0	SENT_54	[p3l968t1374r1024b1426],
7	healthy	JJ	O	healthy	amod	8	SENT_54	[p3l1047t1373r1277b1440],
8	volunteers	NNS	O	volunteer	prep_in	2	SENT_54	[p3l1297t1373r1622b1427],
9	were	VBD	O	be	auxpass	10	SENT_54	[p3l1644t1388r1797b1427],
10	performed	VBN	O	perform	_	0	SENT_54	[p3l1821t1373r2144b1440],
11	in	IN	O	in	_	0	SENT_54	[p3l11t1460r67b1513],
12	accordance	NN	O	accordance	prep_in	10	SENT_54	[p3l98t1459r440b1514],
13	with	IN	O	with	_	0	SENT_54	[p3l469t1460r610b1514],
14	the	DT	O	the	det	16	SENT_54	[p3l640t1460r737b1514],
15	Helsinki	NNP	LOCATION	Helsinki	nn	16	SENT_54	[p3l769t1460r1017b1514],
16	Declaration	NNP	O	Declaration	prep_with	10	SENT_54	[p3l1048t1459r1398b1514],
17	and	CC	O	and	_	0	SENT_54	[p3l1428t1460r1540b1514],
18	were	VBD	O	be	auxpass	19	SENT_54	[p3l1569t1475r1723b1514],
19	approved	VBN	O	approve	conj_and	10	SENT_54	[p3l1753t1460r2042b1527],
20	by	IN	O	by	_	0	SENT_54	[p3l2072t1460r2146b1527],
21	the	DT	O	the	det	23	SENT_54	[p3l10t1546r107b1600],
22	ethics	NNS	O	ethic	nn	23	SENT_54	[p3l134t1546r311b1600],
23	committees	NNS	O	committee	agent	19	SENT_54	[p3l338t1547r696b1600],
24	of	IN	O	of	_	0	SENT_54	[p3l723t1546r787b1600],
25	Zhongshan	NNP	LOCATION	Zhongshan	nn	26	SENT_54	[p3l803t1546r1142b1614],
26	Hospital	NNP	LOCATION	Hospital	prep_of	23	SENT_54	[p3l1167t1546r1419b1614],
27	and	CC	O	and	_	0	SENT_54	[p3l1446t1546r1557b1600],
28	Huashan	NNP	LOCATION	Huashan	nn	29	SENT_54	[p3l1584t1546r1851b1600],
29	Hospital	NNP	LOCATION	Hospital	prep_of	23	SENT_54	[p3l1877t1546r2143b1614],
30	,	,	O	,	_	0	SENT_54	[p3l1877t1546r2143b1614],
31	respectively	RB	O	respectively	advmod	19	SENT_54	[p3l11t1633r393b1701],
32	.	.	O	.	_	0	SENT_54	[p3l11t1633r393b1701],

1	Written	VBN	O	write	csubjpass	5	SENT_55	[p3l417t1634r659b1687],
2	informed	JJ	O	informed	amod	3	SENT_55	[p3l683t1633r964b1687],
3	consent	NN	O	consent	dobj	1	SENT_55	[p3l989t1641r1228b1687],
4	was	VBD	O	be	auxpass	5	SENT_55	[p3l1249t1649r1368b1687],
5	obtained	VBN	O	obtain	_	0	SENT_55	[p3l1393t1633r1661b1687],
6	from	IN	O	from	_	0	SENT_55	[p3l1687t1633r1832b1687],
7	each	DT	O	each	det	8	SENT_55	[p3l1856t1633r1995b1687],
8	participant	NN	O	participant	prep_from	5	SENT_55	[p3l2019t1649r2144b1701, p3l10t1721r245b1788],
9	before	IN	O	before	_	0	SENT_55	[p3l266t1720r460b1775],
10	recruitment	NN	O	recruitment	prep_before	5	SENT_55	[p3l485t1721r864b1775],
11	.	.	O	.	_	0	SENT_55	[p3l485t1721r864b1775],

1	2.2	CD	NUMBER	2.2	_	0	SENT_56	[p3l7t1944r108b1996],
2	.	.	O	.	_	0	SENT_56	[p3l7t1944r108b1996],

1	Treatment	NN	O	treatment	nn	2	SENT_57	[p3l136t1945r441b1996],
2	plans	NNS	O	plan	_	0	SENT_57	[p3l456t1941r615b2009],

1	All	PDT	O	all	predet	3	SENT_58	[p3l110t2119r192b2173],
2	the	DT	O	the	det	3	SENT_58	[p3l215t2119r313b2173],
3	patients	NNS	O	patient	nsubj	4	SENT_58	[p3l336t2120r581b2187],
4	involved	VBN	O	involve	dep	8	SENT_58	[p3l606t2119r868b2173],
5	in	IN	O	in	_	0	SENT_58	[p3l892t2120r948b2173],
6	the	DT	O	the	det	7	SENT_58	[p3l971t2119r1068b2173],
7	study	NN	O	study	prep_in	4	SENT_58	[p3l1093t2119r1261b2187],
8	received	VBD	O	receive	_	0	SENT_58	[p3l1283t2119r1539b2173],
9	gemcitabine-based	JJ	O	gemcitabine-based	amod	10	SENT_58	[p3l1562t2119r2144b2187],
10	chemotherapy	NN	O	chemotherapy	iobj	8	SENT_58	[p3l11t2206r456b2275],
11	(	FW	O	(	dobj	8	SENT_58	[p3l487t2207r683b2275],
12	mean	VB	O	mean	dep	8	SENT_58	[p3l487t2207r683b2275],
13	dose	NN	O	dose	dobj	12	SENT_58	[p3l712t2207r865b2270],
14	,	,	O	,	_	0	SENT_58	[p3l712t2207r865b2270],
15	975	CD	NUMBER	975	appos	13	SENT_58	[p3l895t2209r1005b2261],
16	:	:	O	:	_	0	SENT_58	[p3l1024t2209r1162b2265],
17	l	NN	O	l	dep	13	SENT_58	[p3l1024t2209r1162b2265],
18	:98	CD	NUMBER	:98	num	19	SENT_58	[p3l1024t2209r1162b2265],
19	mg/m2	NN	O	mg/m2	nsubj	8	SENT_58	[p3l1185t2196r1412b2275],
20	,	,	O	,	_	0	SENT_58	[p3l1185t2196r1412b2275],
21	Table	NNP	O	Table	appos	19	SENT_58	[p3l1440t2207r1604b2261],
22	1	CD	NUMBER	1	number	23	SENT_58	[p3l1637t2206r1713b2275],
23	)	CD	NUMBER	)	dep	21	SENT_58	[p3l1637t2206r1713b2275],
24	.	.	O	.	_	0	SENT_58	[p3l1637t2206r1713b2275],

1	For	IN	O	for	_	0	SENT_59	[p3l1743t2210r1840b2261],
2	most	JJS	O	most	amod	3	SENT_59	[p3l1868t2215r2019b2261],
3	patients	NNS	O	patient	prep_for	7	SENT_59	[p3l2047t2223r2144b2275, p3l10t2295r196b2357],
4	,	,	O	,	_	0	SENT_59	[p3l2047t2223r2144b2275, p3l10t2295r196b2357],
5	gemcitabine	NN	O	gemcitabine	nsubjpass	7	SENT_59	[p3l218t2294r595b2362],
6	was	VBD	O	be	auxpass	7	SENT_59	[p3l616t2310r734b2349],
7	associated	VBN	O	associate	_	0	SENT_59	[p3l757t2294r1071b2349],
8	with	IN	O	with	_	0	SENT_59	[p3l1092t2294r1233b2349],
9	platinum	NN	O	platinum	nn	11	SENT_59	[p3l1256t2294r1534b2362],
10	(	CD	NUMBER	(	num	11	SENT_59	[p3l1560t2295r1623b2362],
11	n	NN	O	n	prep_with	7	SENT_59	[p3l1560t2295r1623b2362],
12	=	JJ	O	=	amod	11	SENT_59	[p3l1639t2317r1693b2338],
13	36	CD	NUMBER	36	num	14	SENT_59	[p3l1709t2295r1828b2362],
14	)	NN	O	)	dep	12	SENT_59	[p3l1709t2295r1828b2362],
15	.	.	O	.	_	0	SENT_59	[p3l1709t2295r1828b2362],

1	Other	JJ	O	other	amod	2	SENT_60	[p3l1852t2294r2026b2349],
2	patients	NNS	O	patient	nsubj	3	SENT_60	[p3l2047t2310r2144b2362, p3l10t2383r181b2436],
3	were	VBD	O	be	_	0	SENT_60	[p3l217t2398r370b2436],
4	given	VBN	O	give	prep	3	SENT_60	[p3l405t2383r572b2449],
5	gemcitabine	NN	O	gemcitabine	nn	6	SENT_60	[p3l607t2382r983b2449],
6	monotherapy	NN	O	monotherapy	dep	4	SENT_60	[p3l1021t2382r1437b2449],
7	or	CC	O	or	_	0	SENT_60	[p3l1471t2397r1535b2436],
8	with	IN	O	with	conj_or	4	SENT_60	[p3l1568t2382r1709b2436],
9	various	JJ	O	various	amod	11	SENT_60	[p3l1743t2383r1967b2436],
10	drug	NN	O	drug	nn	11	SENT_60	[p3l2004t2382r2146b2449],
11	combinations	NNS	O	combination	pobj	8	SENT_60	[p3l11t2469r440b2531],
12	,	,	O	,	_	0	SENT_60	[p3l11t2469r440b2531],
13	including	VBG	O	include	_	0	SENT_60	[p3l466t2469r753b2536],
14	ﬂuorouracil	NN	O	ﬂuorouracil	nn	18	SENT_60	[p3l776t2468r1145b2531],
15	,	,	O	,	_	0	SENT_60	[p3l776t2468r1145b2531],
16	docetaxel	NN	O	docetaxel	dep	18	SENT_60	[p3l1172t2469r1478b2531],
17	,	,	O	,	_	0	SENT_60	[p3l1172t2469r1478b2531],
18	capecitabine	NN	O	capecitabine	prep_including	11	SENT_60	[p3l1505t2469r1902b2536],
19	,	,	O	,	_	0	SENT_60	[p3l1505t2469r1902b2536],
20	etc.	FW	O	etc.	dep	18	SENT_60	[p3l1927t2477r2021b2523],
21	.	.	O	.	_	0	SENT_60	[p3l1927t2477r2021b2523],

1	For	IN	O	for	_	0	SENT_61	[p3l2050t2472r2146b2523],
2	patients	NNS	O	patient	prep_for	12	SENT_61	[p3l11t2556r256b2624],
3	that	IN	O	that	nsubj	4	SENT_61	[p3l294t2555r417b2610],
4	suffered	VBN	O	suffer	rcmod	2	SENT_61	[p3l454t2555r700b2610],
5	from	IN	O	from	_	0	SENT_61	[p3l739t2555r884b2610],
6	sarcoma	NN	O	sarcoma	prep_from	4	SENT_61	[p3l922t2571r1190b2618],
7	,	,	O	,	_	0	SENT_61	[p3l922t2571r1190b2618],
8	675	CD	NUMBER	675	num	10	SENT_61	[p3l1229t2558r1339b2610],
9	mg/m2	NN	O	mg/m2	nn	10	SENT_61	[p3l1363t2545r1574b2624],
10	gemcitabine	NN	O	gemcitabine	nsubjpass	12	SENT_61	[p3l1612t2555r1988b2624],
11	was	VBD	O	be	auxpass	12	SENT_61	[p3l2025t2571r2144b2610],
12	given	VBN	O	give	_	0	SENT_61	[p3l10t2644r176b2711],
13	over	IN	O	over	_	0	SENT_61	[p3l202t2659r337b2697],
14	90	CD	DURATION	90	num	15	SENT_61	[p3l361t2646r435b2697],
15	min	NN	DURATION	min	prep_over	12	SENT_61	[p3l457t2644r575b2697],
16	in	IN	O	in	_	0	SENT_61	[p3l602t2644r658b2697],
17	day	NN	DURATION	day	prep_in	15	SENT_61	[p3l684t2643r793b2711],
18	1	CD	NUMBER	1	num	17	SENT_61	[p3l821t2646r844b2697],
19	and	CC	O	and	_	0	SENT_61	[p3l878t2643r989b2697],
20	day	NN	DURATION	day	prep_over	12	SENT_61	[p3l1016t2643r1125b2711],
21	8	CD	NUMBER	8	num	20	SENT_61	[p3l1150t2646r1182b2697],
22	for	IN	O	for	_	0	SENT_61	[p3l1211t2643r1296b2697],
23	every	DT	SET	every	det	25	SENT_61	[p3l1320t2659r1489b2711],
24	3	CD	SET	3	num	25	SENT_61	[p3l1512t2646r1545b2697],
25	weeks	NNS	NUMBER	week	prep_for	20	SENT_61	[p3l1567t2643r1760b2697],
26	while	IN	O	while	mark	29	SENT_61	[p3l1785t2643r1956b2697],
27	other	JJ	O	other	amod	28	SENT_61	[p3l1982t2643r2146b2697],
28	patients	NNS	O	patient	nsubj	29	SENT_61	[p3l11t2731r256b2799],
29	received	VBD	O	receive	conj_or	29	SENT_61	[p3l296t2731r553b2785],
30	1.0-1	CD	NUMBER	1.0-1	num	33	SENT_61	[p3l596t2733r812b2786],
31	.2	NN	NUMBER	.2	nn	33	SENT_61	[p3l596t2733r812b2786],
32	g/m2	NN	O	g/m2	nn	33	SENT_61	[p3l834t2720r985b2799],
33	gemcitabine	NN	O	gemcitabine	dobj	29	SENT_61	[p3l1025t2730r1401b2799],
34	over	IN	O	over	_	0	SENT_61	[p3l1441t2747r1576b2785],
35	30	CD	DURATION	30	num	36	SENT_61	[p3l1612t2733r1687b2785],
36	min	NN	DURATION	min	prep_over	29	SENT_61	[p3l1709t2731r1827b2785],
37	in	IN	O	in	_	0	SENT_61	[p3l1867t2731r1923b2785],
38	day	NN	DURATION	day	prep_in	36	SENT_61	[p3l1963t2731r2072b2799],
39	1	CD	NUMBER	1	num	38	SENT_61	[p3l2113t2733r2137b2785],
40	and	CC	O	and	_	0	SENT_61	[p3l11t2818r122b2872],
41	day	NN	DURATION	day	conj_and	36	SENT_61	[p3l165t2818r274b2886],
42	8	CD	NUMBER	8	num	41	SENT_61	[p3l314t2821r347b2873],
43	for	IN	O	for	_	0	SENT_61	[p3l392t2818r476b2873],
44	every	DT	O	every	det	45	SENT_61	[p3l517t2834r686b2886],
45	3weel	NN	O	3weel	prep_for	41	SENT_61	[p3l725t2818r972b2873],
46	<	JJR	O	<	amod	47	SENT_61	[p3l725t2818r972b2873],
47	s	NNS	O	s	dep	41	SENT_61	[p3l725t2818r972b2873],
48	or	CC	O	or	_	0	SENT_61	[p3l1016t2834r1079b2873],
49	in	IN	O	in	_	0	SENT_61	[p3l1120t2819r1176b2872],
50	days	NNS	DURATION	day	prep_in	29	SENT_61	[p3l1218t2818r1354b2886],
51	1	CD	NUMBER	1	dep	50	SENT_61	[p3l1401t2821r1446b2881],
52	,	,	O	,	_	0	SENT_61	[p3l1401t2821r1446b2881],
53	8	CD	NUMBER	8	num	51	SENT_61	[p3l1490t2821r1539b2881],
54	,	,	O	,	_	0	SENT_61	[p3l1490t2821r1539b2881],
55	and	CC	NUMBER	and	_	0	SENT_61	[p3l1582t2818r1693b2873],
56	14	CD	NUMBER	14	dep	50	SENT_61	[p3l1739t2821r1810b2872],
57	for	IN	O	for	_	0	SENT_61	[p3l1852t2818r1937b2873],
58	every	DT	O	every	det	59	SENT_61	[p3l1977t2834r2146b2886],
59	4weeks	NNS	O	4week	prep_for	29	SENT_61	[p3l9t2906r272b2960],
60	.	.	O	.	_	0	SENT_61	[p3l9t2906r272b2960],

1	Whole	JJ	O	whole	amod	2	SENT_62	[p3l303t2906r506b2960],
2	blood	NN	O	blood	nsubjpass	4	SENT_62	[p3l539t2906r710b2960],
3	was	VBD	O	be	auxpass	4	SENT_62	[p3l742t2921r861b2960],
4	collected	VBN	O	collect	_	0	SENT_62	[p3l895t2906r1166b2960],
5	after	IN	O	after	_	0	SENT_62	[p3l1200t2906r1342b2960],
6	gemcitabine	NN	O	gemcitabine	nn	7	SENT_62	[p3l1372t2906r1748b2973],
7	infusion	NN	O	infusion	prep_after	4	SENT_62	[p3l1782t2906r2028b2960],
8	for	IN	O	for	_	0	SENT_62	[p3l2062t2906r2146b2960],
9	genetic	JJ	O	genetic	amod	10	SENT_62	[p3l10t2993r232b3060],
10	analysis	NN	O	analysis	prep_for	7	SENT_62	[p3l255t2993r511b3060],
11	.	.	O	.	_	0	SENT_62	[p3l255t2993r511b3060],

1	Table	NNP	O	Table	nn	3	SENT_63	[p3l8t3189r146b3233],
2	1	CD	NUMBER	1	num	3	SENT_63	[p3l167t3191r189b3232],
3	Patients	NNS	O	patient	_	0	SENT_63	[p3l11t3261r204b3303],
4	treated	VBN	O	treat	partmod	3	SENT_63	[p3l224t3260r399b3303],
5	with	IN	O	with	_	0	SENT_63	[p3l418t3260r530b3303],
6	gemcitabine	NN	O	gemcitabine	prep_with	4	SENT_63	[p3l549t3260r850b3314],
7	alone	RB	O	alone	advmod	4	SENT_63	[p3l870t3260r1002b3303],
8	or	CC	O	or	_	0	SENT_63	[p3l1022t3272r1072b3303],
9	in	IN	O	in	_	0	SENT_63	[p3l1091t3261r1136b3303],
10	combination	NN	O	combination	prep_in	4	SENT_63	[p3l1155t3260r1479b3304],
11	:	:	O	:	_	0	SENT_63	[p3l1155t3260r1479b3304],
12	demographics	NNS	O	demographic	dep	3	SENT_63	[p3l1503t3260r1848b3314],
13	and	CC	O	and	_	0	SENT_63	[p3l1869t3260r1957b3303],
14	clinical	JJ	O	clinical	amod	15	SENT_63	[p3l1978t3260r2148b3303],
15	characteristics	NNS	O	characteristic	conj_and	12	SENT_63	[p3l10t3332r374b3376],
16	.	.	O	.	_	0	SENT_63	[p3l10t3332r374b3376],

1	Characteristics	NNS	O	characteristic	_	0	SENT_64	[p3l61t3456r420b3500],
2	Patients	NNS	O	patient	dep	1	SENT_64	[p3l1449t3457r1643b3500],

1	No.	NN	PERCENT	no.	nn	2	SENT_65	[p3l1450t3569r1528b3611],
2	%	NN	PERCENT	%	_	0	SENT_65	[p3l2008t3569r2038b3610],

1	No.	NN	O	no.	_	0	SENT_66	[p4l61t24r139b65],
2	of	IN	O	of	_	0	SENT_66	[p4l160t21r211b65],
3	patients	NNS	O	patient	prep_of	1	SENT_66	[p4l225t22r420b76],
4	50	CD	NUMBER	50	number	5	SENT_66	[p4l1450t23r1507b65],
5	100	CD	NUMBER	100	num	6	SENT_66	[p4l2011t23r2098b65],
6	Age	NNP	O	Age	dep	1	SENT_66	[p4l59t94r162b146],
7	,	,	O	,	_	0	SENT_66	[p4l59t94r162b146],
8	years	NNS	DURATION	year	appos	6	SENT_66	[p4l182t105r310b146],

1	Median	JJ	MISC	median	amod	2	SENT_67	[p4l116t163r299b207],
2	59.5	CD	NUMBER	59.5	_	0	SENT_67	[p4l1450t166r1549b207],
3	Range	NNP	O	Range	dep	2	SENT_67	[p4l116t238r263b289],
4	33-77	CD	NUMBER	33-77	num	3	SENT_67	[p4l1448t237r1599b278],

1	Body	NN	O	body	nn	3	SENT_68	[p4l61t306r183b360],
2	surface	NN	O	surface	nn	3	SENT_68	[p4l203t306r375b350],
3	area	NN	O	area	_	0	SENT_68	[p4l395t319r509b356],
4	,	,	O	,	_	0	SENT_68	[p4l395t319r509b356],
5	m2	NN	O	m2	appos	3	SENT_68	[p4l530t298r600b349],

1	Median	JJ	MISC	median	amod	2	SENT_69	[p4l116t377r299b421],
2	1.63	CD	NUMBER	1.63	_	0	SENT_69	[p4l1452t380r1549b421],
3	Range	NNP	O	Range	dep	2	SENT_69	[p4l116t452r263b503],
4	1.44-1	CD	NUMBER	1.44-1	num	3	SENT_69	[p4l1452t451r1687b493],
5	.97	CD	NUMBER	.97	dep	2	SENT_69	[p4l1452t451r1687b493],

1	Female	JJ	O	female	_	0	SENT_70	[p4l61t521r234b565],
2	27	CD	NUMBER	27	number	3	SENT_70	[p4l1449t523r1506b564],
3	54	CD	NUMBER	54	dep	1	SENT_70	[p4l2009t523r2067b565],
4	Primary	JJ	O	primary	amod	6	SENT_70	[p4l61t593r257b646],
5	tumor	NN	O	tumor	nn	6	SENT_70	[p4l275t598r427b636],
6	location	NN	O	location	dep	3	SENT_70	[p4l446t592r641b636],

1	Lung	NN	O	lung	nn	3	SENT_71	[p4l116t666r234b718],
2	Gynecologic	JJ	O	gynecologic	amod	3	SENT_71	[p4l116t734r414b788],
3	Sarcoma	NN	O	sarcoma	_	0	SENT_71	[p4l116t808r324b850],
4	Cholangiocellular	JJ	O	cholangiocellular	amod	5	SENT_71	[p4l116t877r544b932],
5	Non-Hodgkin	NNP	PERSON	Non-Hodgkin	poss	11	SENT_71	[p4l116t948r483b1002],
6	's	POS	O	's	_	0	SENT_71	[p4l116t948r483b1002],
7	disease	NN	O	disease	nn	11	SENT_71	[p4l504t948r680b991],
8	Bladder	NN	MISC	bladder	nn	11	SENT_71	[p4l116t1020r304b1064],
9	Pancreatic	JJ	MISC	pancreatic	amod	11	SENT_71	[p4l116t1093r368b1136],
10	Gallbladder	NN	MISC	gallbladder	nn	11	SENT_71	[p4l116t1164r400b1208],
11	Other/cancer	NN	O	other/cancer	dep	3	SENT_71	[p4l116t1234r436b1285],
12	of	IN	O	of	_	0	SENT_71	[p4l455t1234r506b1278],
13	unknown	JJ	O	unknown	amod	14	SENT_71	[p4l519t1235r753b1278],
14	primary	JJ	O	primary	prep_of	11	SENT_71	[p4l773t1235r970b1289],

1	Treatment	NN	O	treatment	_	0	SENT_72	[p4l59t1310r318b1350],

1	Gemcitabine	NN	O	gemcitabine	_	0	SENT_73	[p4l116t1378r424b1422],
2	+	CC	O	+	_	0	SENT_73	[p4l439t1384r479b1424],
3	cisplatin	NN	O	cisplatin	nn	4	SENT_73	[p4l493t1378r699b1432],
4	Gemcitabine	NN	O	gemcitabine	conj_+	1	SENT_73	[p4l116t1448r424b1492],
5	+	CC	O	+	_	0	SENT_73	[p4l439t1455r479b1495],
6	oxaplatin	NN	O	oxaplatin	nn	7	SENT_73	[p4l493t1448r723b1503],
7	Gemcitabine	NN	O	gemcitabine	conj_+	4	SENT_73	[p4l116t1520r424b1563],
8	monotherapy	NN	O	monotherapy	nn	9	SENT_73	[p4l445t1520r779b1574],
9	Gemcitabine	NN	O	gemcitabine	dep	1	SENT_73	[p4l116t1591r424b1635],
10	+	CC	O	+	_	0	SENT_73	[p4l439t1597r479b1637],
11	carboplatin	NN	O	carboplatin	nn	12	SENT_73	[p4l493t1591r771b1646],
12	Gemcitabine	NN	O	gemcitabine	dep	1	SENT_73	[p4l116t1662r424b1706],
13	+	CC	O	+	_	0	SENT_73	[p4l439t1669r479b1709],
14	docetaxel	NN	O	docetaxel	nn	15	SENT_73	[p4l493t1662r728b1706],
15	Gemcitabine	NN	O	gemcitabine	conj_+	9	SENT_73	[p4l116t1735r424b1779],
16	+	CC	O	+	_	0	SENT_73	[p4l439t1741r479b1781],
17	othera	NN	O	othera	conj_+	9	SENT_73	[p4l493t1734r646b1779],

1	Gemcitabine	JJ	O	gemcitabine	amod	2	SENT_74	[p4l61t1806r370b1849],
2	dosage	NN	O	dosage	_	0	SENT_74	[p4l390t1806r570b1860],
3	,	,	O	,	_	0	SENT_74	[p4l390t1806r570b1860],
4	mg/m2	NN	O	mg/m2	appos	2	SENT_74	[p4l591t1797r760b1860],

1	Median	JJ	MISC	median	amod	2	SENT_75	[p4l116t1878r300b1922],
2	1000	CD	DATE	1000	_	0	SENT_75	[p4l1452t1880r1570b1922],
3	Range	NNP	O	Range	dep	2	SENT_75	[p4l116t1951r263b2003],
4	675-1200	CD	NUMBER	675-1200	num	3	SENT_75	[p4l1450t1951r1694b1992],

1	O5-B	NN	O	o5-b	_	0	SENT_76	[p4l1448t1380r1477b1779],
2	»	SYM	O	»	dep	4	SENT_76	[p4l1448t1380r1477b1779],
3	-	:	O	-	_	0	SENT_76	[p4l1448t1380r1477b1779],
4	hU‘IU	NN	O	hu‘iu	dep	1	SENT_76	[p4l1448t1380r1477b1779],
5	‘	CD	NUMBER	‘	num	4	SENT_76	[p4l1448t1380r1477b1779],
6	I	PRP	O	I	nsubj	7	SENT_76	[p4l1448t1380r1477b1779],
7	[	VBP	O	[	rcmod	4	SENT_76	[p4l1448t1380r1477b1779],
8	\	CD	NUMBER	\	dobj	7	SENT_76	[p4l1448t1380r1477b1779],
9	.	.	O	.	_	0	SENT_76	[p4l1448t1380r1477b1779],

1	J	NN	O	j	nn	2	SENT_77	[p4l1448t1380r1477b1779],
2	U‘Il	NN	O	u‘il	dep	7	SENT_77	[p4l1448t666r1477b1278],
3	\	CD	NUMBER	\	num	6	SENT_77	[p4l1448t666r1477b1278],
4	JUJUO	NNP	O	JUJUO	nn	6	SENT_77	[p4l1448t666r1477b1278],
5	»	CD	NUMBER	»	num	6	SENT_77	[p4l1448t666r1477b1278],
6	J	NNP	O	J	dep	2	SENT_77	[p4l1448t666r1477b1278],
7	>	JJR	O	>	_	0	SENT_77	[p4l1448t666r1477b1278],
8	-	:	O	-	_	0	SENT_77	[p4l1448t666r1477b1278],
9	hU‘ILD	NN	O	hu‘ild	dep	10	SENT_77	[p4l1448t666r1477b1278],
10	>	JJR	O	>	parataxis	7	SENT_77	[p4l1448t666r1477b1278],
11	-	:	O	-	_	0	SENT_77	[p4l1448t666r1477b1278],
12	‘	NN	O	‘	dep	15	SENT_77	[p4l1448t666r1477b1278],
13	03	CD	NUMBER	03	num	12	SENT_77	[p4l1480t1380r1508b1422],
14	U	NNP	O	U	nn	15	SENT_77	[p4l1481t666r1506b707],
15	‘	NNP	O	‘	parataxis	7	SENT_77	[p4l1481t666r1506b707],
16	!	.	O	!	_	0	SENT_77	[p4l1481t666r1506b707],

1	oo	NN	O	oo	nn	3	SENT_78	[p4l2009t1593r2034b1635],
2	U1	NN	O	u1	nn	3	SENT_78	[p4l2009t1381r2034b1422],
3	Uo	NN	O	uo	_	0	SENT_78	[p4l2007t665r2034b707],
4	[	CD	NUMBER	[	dep	3	SENT_78	[p4l2039t1380r2065b1421],
5	U	NNP	O	U	nn	6	SENT_78	[p4l2039t1380r2065b1421],
6	C	NNP	O	C	dep	3	SENT_78	[p4l2039t665r2066b707],

1	a	DT	O	a	det	3	SENT_79	[p4l56t2057r74b2077],
2	Other	JJ	O	other	amod	3	SENT_79	[p4l111t2058r250b2102],
3	drugs	NNS	O	drug	_	0	SENT_79	[p4l269t2058r404b2112],
4	including	VBG	O	include	_	0	SENT_79	[p4l425t2058r654b2112],
5	nedaplatin	NN	O	nedaplatin	prep_including	3	SENT_79	[p4l674t2058r947b2112],
6	,	,	O	,	_	0	SENT_79	[p4l674t2058r947b2112],
7	ﬂuoracil	NN	O	ﬂuoracil	prep_including	3	SENT_79	[p4l968t2058r1179b2108],
8	,	,	O	,	_	0	SENT_79	[p4l968t2058r1179b2108],
9	and	CC	O	and	_	0	SENT_79	[p4l1199t2058r1288b2102],
10	capecitabine	NN	O	capecitabine	conj_and	5	SENT_79	[p4l1309t2058r1628b2112],
11	.	.	O	.	_	0	SENT_79	[p4l1309t2058r1628b2112],

1	2.3	CD	NUMBER	2.3	_	0	SENT_80	[p4l7t2148r108b2200],
2	.	.	O	.	_	0	SENT_80	[p4l7t2148r108b2200],

1	CDA	NNP	ORGANIZATION	CDA	_	0	SENT_81	[p4l137t2147r258b2199],
2	gene	NN	O	gene	nn	4	SENT_81	[p4l277t2161r417b2213],
3	mutation	NN	O	mutation	nn	4	SENT_81	[p4l441t2146r709b2199],
4	screening	NN	O	screening	dep	1	SENT_81	[p4l731t2146r1015b2213],

1	Blood	NN	O	blood	nn	2	SENT_82	[p4l113t2322r284b2377],
2	samples	NNS	O	sample	nsubjpass	10	SENT_82	[p4l311t2322r557b2390],
3	from	IN	O	from	_	0	SENT_82	[p4l583t2322r729b2376],
4	the	DT	O	the	det	5	SENT_82	[p4l753t2322r849b2377],
5	patients	NNS	O	patient	prep_from	2	SENT_82	[p4l876t2323r1120b2390],
6	and	CC	O	and	_	0	SENT_82	[p4l1146t2322r1257b2377],
7	the	DT	O	the	det	8	SENT_82	[p4l1282t2322r1379b2377],
8	volunteers	NNS	O	volunteer	prep_from	2	SENT_82	[p4l1403t2322r1728b2377],
9	were	VBD	O	be	auxpass	10	SENT_82	[p4l1752t2338r1905b2377],
10	kept	VBN	O	keep	_	0	SENT_82	[p4l1932t2322r2066b2390],
11	at	IN	O	at	_	0	SENT_82	[p4l2089t2330r2146b2377],
12	4	CD	NUMBER	4	number	13	SENT_82	[p4l9t2412r46b2463],
13	°	CD	NUMBER	°	num	14	SENT_82	[p4l68t2409r131b2464],
14	C	NN	O	c	prep_at	10	SENT_82	[p4l68t2409r131b2464],
15	for	IN	O	for	_	0	SENT_82	[p4l164t2409r249b2463],
16	up	RB	O	up	quantmod	18	SENT_82	[p4l281t2425r357b2477],
17	to	TO	O	to	dep	18	SENT_82	[p4l390t2417r449b2463],
18	24	CD	NUMBER	24	num	19	SENT_82	[p4l484t2412r558b2463],
19	h	NN	O	h	prep_for	14	SENT_82	[p4l579t2409r615b2463],
20	before	IN	O	before	_	0	SENT_82	[p4l648t2409r841b2464],
21	analysis	NN	O	analysis	prep_before	10	SENT_82	[p4l875t2409r1131b2477],
22	.	.	O	.	_	0	SENT_82	[p4l875t2409r1131b2477],

1	Genomic	JJ	O	genomic	amod	2	SENT_83	[p4l1166t2410r1438b2464],
2	DNAs	NNS	O	dna	nsubjpass	15	SENT_83	[p4l1471t2412r1637b2464],
3	were	VBD	O	be	auxpass	4	SENT_83	[p4l1670t2425r1823b2464],
4	extracted	VBN	O	extract	_	0	SENT_83	[p4l1858t2409r2144b2464],
5	from	IN	O	from	_	0	SENT_83	[p4l11t2497r157b2551],
6	blood	NN	O	blood	nn	7	SENT_83	[p4l181t2497r352b2551],
7	samples	NNS	O	sample	prep_from	4	SENT_83	[p4l378t2497r623b2564],
8	using	VBG	O	use	xcomp	4	SENT_83	[p4l649t2498r813b2564],
9	phenol	NN	O	phenol	nn	12	SENT_83	[p4l837t2497r1433b2564],
10	—	NN	O	—	nn	12	SENT_83	[p4l837t2497r1433b2564],
11	chloroform	NN	O	chloroform	nn	12	SENT_83	[p4l837t2497r1433b2564],
12	method	NN	O	method	dobj	8	SENT_83	[p4l1457t2497r1693b2551],
13	and	CC	O	and	_	0	SENT_83	[p4l1719t2497r1830b2551],
14	then	RB	O	then	advmod	15	SENT_83	[p4l1855t2497r1994b2551],
15	preserved	VBN	O	preserve	conj_and	4	SENT_83	[p4l2019t2512r2144b2564, p4l12t2584r211b2638],
16	at	IN	O	at	_	0	SENT_83	[p4l231t2592r287b2638],
17	—	CD	NUMBER	—	number	18	SENT_83	[p4l311t2614r361b2618],
18	20	CD	NUMBER	20	num	20	SENT_83	[p4l377t2586r451b2638],
19	°	NN	O	°	nn	20	SENT_83	[p4l473t2583r536b2638],
20	C	NN	O	c	prep_at	15	SENT_83	[p4l473t2583r536b2638],
21	until	IN	O	until	_	0	SENT_83	[p4l554t2584r695b2638],
22	use	NN	O	use	prep_until	15	SENT_83	[p4l715t2599r830b2638],
23	.	.	O	.	_	0	SENT_83	[p4l715t2599r830b2638],

1	The	DT	O	the	det	2	SENT_84	[p4l848t2584r960b2638],
2	presence	NN	O	presence	nsubjpass	14	SENT_84	[p4l980t2599r1251b2651],
3	of	IN	O	of	_	0	SENT_84	[p4l1271t2583r1335b2638],
4	the	DT	O	the	det	5	SENT_84	[p4l1346t2584r1443b2638],
5	79A	NN	O	79a	prep_of	2	SENT_84	[p4l1464t2586r1676b2638],
6	>	JJR	O	>	amod	8	SENT_84	[p4l1464t2586r1676b2638],
7	C	NN	O	c	nn	8	SENT_84	[p4l1464t2586r1676b2638],
8	polymorphism	NN	O	polymorphism	dep	5	SENT_84	[p4l1694t2584r2145b2651],
9	in	IN	O	in	_	0	SENT_84	[p4l11t2671r68b2724],
10	the	DT	O	the	det	12	SENT_84	[p4l86t2670r183b2724],
11	CDA	NNP	ORGANIZATION	CDA	nn	12	SENT_84	[p4l204t2672r325b2724],
12	gene	NN	O	gene	prep_in	8	SENT_84	[p4l343t2686r488b2738],
13	was	VBD	O	be	auxpass	14	SENT_84	[p4l507t2686r625b2724],
14	genotyped	VBN	O	genotype	_	0	SENT_84	[p4l644t2670r969b2738],
15	by	IN	O	by	_	0	SENT_84	[p4l988t2670r1062b2738],
16	using	VBG	O	use	agent	14	SENT_84	[p4l1080t2671r1244b2738],
17	an	DT	O	a	det	22	SENT_84	[p4l1262t2686r1334b2724],
18	allele-speciﬁc	JJ	O	allele-speciﬁc	amod	22	SENT_84	[p4l1353t2670r1771b2738],
19	polymerase	NN	O	polymerase	nn	22	SENT_84	[p4l1790t2670r2144b2738],
20	chain	NN	O	chain	nn	22	SENT_84	[p4l11t2757r175b2811],
21	reaction	NN	O	reaction	nn	22	SENT_84	[p4l201t2758r449b2812],
22	method	NN	O	method	dobj	16	SENT_84	[p4l475t2757r726b2820],
23	,	,	O	,	_	0	SENT_84	[p4l475t2757r726b2820],
24	as	IN	O	as	mark	25	SENT_84	[p4l753t2773r812b2812],
25	described	VBN	O	describe	advcl	14	SENT_84	[p4l839t2757r1132b2812],
26	previously	RB	DATE	previously	advmod	25	SENT_84	[p4l1159t2757r1480b2825],
27	[	CD	NUMBER	[	num	29	SENT_84	[p4l1507t2757r1639b2825],
28	13	CD	NUMBER	13	num	29	SENT_84	[p4l1507t2757r1639b2825],
29	]	NN	O	]	dobj	25	SENT_84	[p4l1507t2757r1639b2825],
30	.	.	O	.	_	0	SENT_84	[p4l1507t2757r1639b2825],

1	The	DT	O	the	det	2	SENT_85	[p4l1663t2757r1775b2811],
2	determination	NN	O	determination	nsubjpass	11	SENT_85	[p4l1801t2757r2144b2812, p4l10t2845r130b2899],
3	of	IN	O	of	_	0	SENT_85	[p4l153t2844r217b2899],
4	the	DT	O	the	det	6	SENT_85	[p4l231t2844r327b2899],
5	CDA	NNP	ORGANIZATION	CDA	nn	6	SENT_85	[p4l351t2847r472b2899],
6	208G	NN	O	208g	prep_of	2	SENT_85	[p4l495t2847r755b2899],
7	>	JJR	O	>	amod	9	SENT_85	[p4l495t2847r755b2899],
8	A	DT	O	a	det	9	SENT_85	[p4l495t2847r755b2899],
9	polymorphism	NN	O	polymorphism	dep	6	SENT_85	[p4l776t2844r1226b2912],
10	was	VBD	O	be	auxpass	11	SENT_85	[p4l1247t2860r1366b2899],
11	performed	VBN	O	perform	_	0	SENT_85	[p4l1390t2844r1712b2912],
12	by	IN	O	by	_	0	SENT_85	[p4l1735t2844r1809b2912],
13	restriction	NN	O	restriction	nn	17	SENT_85	[p4l1830t2845r2145b2899],
14	fragment	NN	O	fragment	nn	17	SENT_85	[p4l11t2932r292b2999],
15	length	NN	O	length	nn	17	SENT_85	[p4l313t2932r507b2999],
16	polymorphism	NN	O	polymorphism	nn	17	SENT_85	[p4l530t2932r981b2999],
17	[	NN	O	[	agent	11	SENT_85	[p4l1006t2932r1138b2999],
18	14	CD	NUMBER	14	num	19	SENT_85	[p4l1006t2932r1138b2999],
19	]	NN	O	]	dep	17	SENT_85	[p4l1006t2932r1138b2999],
20	.	.	O	.	_	0	SENT_85	[p4l1006t2932r1138b2999],

1	Analyses	NNS	O	analysis	nsubjpass	3	SENT_86	[p4l1159t2932r1428b2999],
2	were	VBD	O	be	auxpass	3	SENT_86	[p4l1450t2947r1602b2986],
3	carried	VBN	O	carry	_	0	SENT_86	[p4l1626t2932r1837b2986],
4	out	RP	O	out	prt	3	SENT_86	[p4l1861t2940r1961b2986],
5	using	VBG	O	use	xcomp	3	SENT_86	[p4l1982t2933r2146b2999],
6	an	DT	O	a	det	8	SENT_86	[p4l11t3034r83b3073],
7	Applied	NNP	MISC	Applied	nn	8	SENT_86	[p4l121t3019r359b3086],
8	Biosystems	NNPS	MISC	Biosystems	dobj	5	SENT_86	[p4l402t3019r742b3086],
9	2720	CD	DATE	2720	num	12	SENT_86	[p4l784t3021r935b3073],
10	thermal	JJ	O	thermal	amod	12	SENT_86	[p4l977t3019r1218b3073],
11	cycler	NN	O	cycler	nn	12	SENT_86	[p4l1260t3019r1441b3086],
12	(	NN	O	(	dep	8	SENT_86	[p4l1484t3019r1745b3086],
13	Applied	NNP	O	Applied	nn	14	SENT_86	[p4l1484t3019r1745b3086],
14	Biosystems	NNP	O	Biosystems	dep	5	SENT_86	[p4l1788t3019r2143b3086],
15	,	,	O	,	_	0	SENT_86	[p4l1788t3019r2143b3086],
16	Foster	NNP	LOCATION	Foster	nn	17	SENT_86	[p4l11t3108r198b3159],
17	City	NNP	LOCATION	City	appos	14	SENT_86	[p4l220t3106r352b3173],
18	,	,	O	,	_	0	SENT_86	[p4l220t3106r352b3173],
19	CA	NNP	LOCATION	CA	nn	20	SENT_86	[p4l378t3105r502b3172],
20	)	NNP	O	)	appos	14	SENT_86	[p4l378t3105r502b3172],
21	.	.	O	.	_	0	SENT_86	[p4l378t3105r502b3172],

1	2.4	CD	NUMBER	2.4	_	0	SENT_87	[p4l7t3285r108b3337],
2	.	.	O	.	_	0	SENT_87	[p4l7t3285r108b3337],

1	Toxicity	NN	O	toxicity	nn	2	SENT_88	[p4l136t3284r363b3350],
2	monitoring	NN	O	monitoring	_	0	SENT_88	[p4l387t3284r716b3350],

1	All	DT	O	all	det	2	SENT_89	[p5l110t62r190b115],
2	patients	NNS	O	patient	nsubjpass	4	SENT_89	[p5l209t63r446b129],
3	were	VBD	O	be	auxpass	4	SENT_89	[p5l463t78r613b116],
4	followed	VBN	O	follow	_	0	SENT_89	[p5l631t62r889b116],
5	up	RP	O	up	prt	4	SENT_89	[p5l908t78r983b129],
6	for	IN	O	for	_	0	SENT_89	[p5l1002t62r1084b116],
7	at	IN	O	at	quantmod	9	SENT_89	[p5l1100t70r1156b116],
8	least	JJS	O	least	mwe	7	SENT_89	[p5l1173t62r1309b116],
9	3	CD	NUMBER	3	num	10	SENT_89	[p5l1325t65r1357b116],
10	cycles	NNS	O	cycle	prep_for	4	SENT_89	[p5l1379t62r1553b129],
11	of	IN	O	of	_	0	SENT_89	[p5l1572t62r1634b116],
12	treatment	NN	O	treatment	prep_of	10	SENT_89	[p5l1644t70r1945b116],
13	(	CD	NUMBER	(	num	12	SENT_89	[p5l1964t62r2144b129],
14	more	JJR	DURATION	more	mwe	15	SENT_89	[p5l1964t62r2144b129],
15	than	IN	DURATION	than	quantmod	16	SENT_89	[p5l10t149r146b203],
16	63	CD	DURATION	63	num	17	SENT_89	[p5l162t151r231b203],
17	days	NNS	NUMBER	day	tmod	12	SENT_89	[p5l254t149r412b216],
18	)	CD	NUMBER	)	tmod	4	SENT_89	[p5l254t149r412b216],
19	to	TO	O	to	aux	20	SENT_89	[p5l433t157r490b203],
20	monitor	VB	O	monitor	xcomp	4	SENT_89	[p5l509t149r751b203],
21	gemcitabine-induced	JJ	O	gemcitabine-induced	amod	22	SENT_89	[p5l764t149r1397b216],
22	toxicity	NN	O	toxicity	dobj	20	SENT_89	[p5l1414t149r1649b216],
23	,	,	O	,	_	0	SENT_89	[p5l1414t149r1649b216],
24	which	WDT	O	which	nsubjpass	26	SENT_89	[p5l1666t149r1851b203],
25	was	VBD	O	be	auxpass	26	SENT_89	[p5l1866t164r1983b203],
26	evaluated	VBN	O	evaluate	rcmod	22	SENT_89	[p5l2000t149r2144b203, p5l11t235r177b289],
27	according	VBG	O	accord	_	0	SENT_89	[p5l200t235r491b303],
28	to	TO	O	to	prepc_according_to	26	SENT_89	[p5l510t243r568b289],
29	the	DT	O	the	det	32	SENT_89	[p5l590t235r686b289],
30	National	NNP	ORGANIZATION	National	nn	32	SENT_89	[p5l708t235r957b289],
31	Cancer	NNP	ORGANIZATION	Cancer	nn	32	SENT_89	[p5l980t238r1182b289],
32	Institute	NNP	ORGANIZATION	Institute	pobj	26	SENT_89	[p5l1203t236r1450b289],
33	Common	NNP	O	Common	nn	35	SENT_89	[p5l1473t238r1745b289],
34	Terminology	NNP	O	Terminology	nn	35	SENT_89	[p5l1765t235r2146b303],
35	Criteria	NNP	O	Criteria	dep	44	SENT_89	[p5l11t323r229b376],
36	for	IN	O	for	_	0	SENT_89	[p5l263t322r346b376],
37	Adverse	JJ	O	adverse	amod	38	SENT_89	[p5l375t322r616b376],
38	Events	NNS	O	event	prep_for	35	SENT_89	[p5l650t325r845b376],
39	version	NN	O	version	dep	44	SENT_89	[p5l877t323r1097b376],
40	3.0	CD	NUMBER	3.0	num	39	SENT_89	[p5l1129t325r1216b377],
41	(	CD	NUMBER	(	num	44	SENT_89	[p5l1255t322r1383b389],
42	NCI	NN	ORGANIZATION	ncus	nn	44	SENT_89	[p5l1255t322r1383b389],
43	CT	NN	O	ct	nn	44	SENT_89	[p5l1417t325r1492b376],
44	CAE3	NN	O	cae3	dep	32	SENT_89	[p5l1494t322r1741b389],
45	.0	CD	NUMBER	.0	num	46	SENT_89	[p5l1494t322r1741b389],
46	)	NN	O	)	dep	44	SENT_89	[p5l1494t322r1741b389],
47	.	.	O	.	_	0	SENT_89	[p5l1494t322r1741b389],

1	Toxicities	NNS	O	toxicity	nsubjpass	8	SENT_90	[p5l1773t323r2055b376],
2	of	IN	O	of	_	0	SENT_90	[p5l2090t322r2152b376],
3	grade	NN	O	grade	prep_of	1	SENT_90	[p5l10t409r177b477],
4	3	CD	NUMBER	3	amod	3	SENT_90	[p5l198t412r231b463],
5	or	CC	O	or	_	0	SENT_90	[p5l257t425r319b463],
6	greater	JJR	O	greater	amod	3	SENT_90	[p5l338t417r552b477],
7	were	VBD	O	be	auxpass	8	SENT_90	[p5l571t425r720b464],
8	regarded	VBN	O	regard	_	0	SENT_90	[p5l744t409r1008b477],
9	as	IN	O	as	_	0	SENT_90	[p5l1031t425r1089b464],
10	severe	JJ	O	severe	prep_as	8	SENT_90	[p5l1114t425r1316b464],
11	.	.	O	.	_	0	SENT_90	[p5l1114t425r1316b464],

1	As	IN	O	as	_	0	SENT_91	[p5l1336t412r1407b464],
2	a	DT	O	a	det	3	SENT_91	[p5l1430t425r1461b463],
3	result	NN	O	result	prep_as	14	SENT_91	[p5l1484t409r1652b464],
4	of	IN	O	of	_	0	SENT_91	[p5l1674t409r1736b464],
5	patient	NN	O	patient	nn	6	SENT_91	[p5l1750t410r1961b477],
6	withdrawal	NN	O	withdrawal	prep_of	3	SENT_91	[p5l1980t409r2145b463, p5l11t496r230b559],
7	,	,	O	,	_	0	SENT_91	[p5l1980t409r2145b463, p5l11t496r230b559],
8	37	CD	NUMBER	37	nsubjpass	14	SENT_91	[p5l267t499r339b550],
9	out	IN	O	out	_	0	SENT_91	[p5l379t504r477b551],
10	of	IN	O	of	_	0	SENT_91	[p5l514t496r576b551],
11	50	CD	NUMBER	50	num	12	SENT_91	[p5l607t499r679b551],
12	patients	NNS	O	patient	prep_out_of	8	SENT_91	[p5l717t497r955b564],
13	were	VBD	O	be	auxpass	14	SENT_91	[p5l992t512r1141b551],
14	followed	VBN	O	follow	_	0	SENT_91	[p5l1180t496r1438b551],
15	up	RB	O	up	advmod	14	SENT_91	[p5l1477t512r1551b564],
16	and	CC	O	and	_	0	SENT_91	[p5l1590t496r1698b551],
17	evaluated	VBN	O	evaluate	conj_and	14	SENT_91	[p5l1737t496r2025b551],
18	for	IN	O	for	_	0	SENT_91	[p5l2064t496r2147b551],
19	toxicity	NN	O	toxicity	prep_for	17	SENT_91	[p5l10t585r246b651],
20	.	.	O	.	_	0	SENT_91	[p5l10t585r246b651],

1	2.5	CD	NUMBER	2.5	_	0	SENT_92	[p5l7t764r108b816],
2	.	.	O	.	_	0	SENT_92	[p5l7t764r108b816],

1	Statistical	JJ	O	statistical	amod	2	SENT_93	[p5l133t761r422b815],
2	analysis	NN	O	analysis	_	0	SENT_93	[p5l445t761r680b829],

1	Clinical	JJ	O	clinical	amod	3	SENT_94	[p5l113t938r335b993],
2	data	NN	O	datum	nn	3	SENT_94	[p5l363t938r493b993],
3	analysis	NN	O	analysis	nsubjpass	5	SENT_94	[p5l521t938r761b1006],
4	was	VBD	O	be	auxpass	5	SENT_94	[p5l788t954r907b993],
5	performed	VBN	O	perform	_	0	SENT_94	[p5l936t938r1259b1006],
6	by	IN	O	by	_	0	SENT_94	[p5l1286t938r1360b1006],
7	using	VBG	O	use	agent	5	SENT_94	[p5l1386t939r1550b1006],
8	the	DT	O	the	det	12	SENT_94	[p5l1577t938r1674b993],
9	IBM	NNP	ORGANIZATION	IBM	nn	12	SENT_94	[p5l1703t942r1821b992],
10	SPSS	NNP	O	SPSS	nn	12	SENT_94	[p5l1850t941r1988b993],
11	19.0	CD	NUMBER	19.0	num	12	SENT_94	[p5l2020t941r2144b993],
12	program	NN	O	program	nsubj	20	SENT_94	[p5l11t1041r275b1093],
13	(	CD	NUMBER	(	num	20	SENT_94	[p5l323t1026r488b1093],
14	SPSS	NNP	O	SPSS	nn	20	SENT_94	[p5l323t1026r488b1093],
15	lnc.	NNP	O	lnc.	nn	20	SENT_94	[p5l535t1029r654b1088],
16	,	,	O	,	_	0	SENT_94	[p5l535t1029r654b1088],
17	Chicago	NNP	LOCATION	Chicago	appos	20	SENT_94	[p5l701t1026r953b1093],
18	,	,	O	,	_	0	SENT_94	[p5l701t1026r953b1093],
19	IL	NN	LOCATION	il	dep	20	SENT_94	[p5l1000t1026r1093b1093],
20	)	NN	O	)	xcomp	7	SENT_94	[p5l1000t1026r1093b1093],
21	.	.	O	.	_	0	SENT_94	[p5l1000t1026r1093b1093],

1	Allele	NN	O	allele	nn	4	SENT_95	[p5l1137t1026r1309b1080],
2	or	CC	O	or	_	0	SENT_95	[p5l1356t1041r1419b1080],
3	genotype	NN	O	genotype	nn	4	SENT_95	[p5l1461t1034r1746b1093],
4	frequencies	NNS	O	frequency	nsubjpass	12	SENT_95	[p5l1792t1026r2144b1093],
5	were	VBD	O	be	auxpass	6	SENT_95	[p5l9t1128r162b1167],
6	calculated	VBN	O	calculate	_	0	SENT_95	[p5l209t1113r517b1167],
7	by	IN	O	by	_	0	SENT_95	[p5l563t1113r636b1180],
8	genotype	NN	O	genotype	nn	10	SENT_95	[p5l680t1121r965b1180],
9	counting	NN	O	counting	nn	10	SENT_95	[p5l1011t1114r1281b1180],
10	method	NN	O	method	agent	6	SENT_95	[p5l1327t1113r1563b1167],
11	and	CC	O	and	_	0	SENT_95	[p5l1609t1113r1720b1167],
12	assessed	VBN	O	assess	conj_and	6	SENT_95	[p5l1767t1113r2026b1167],
13	by	IN	O	by	_	0	SENT_95	[p5l2073t1113r2146b1180],
14	Hardy	NNP	PERSON	Hardy	prep_by	12	SENT_95	[p5l11t1199r540b1267],
15	.	.	O	.	_	0	SENT_95	[p5l11t1199r540b1267],

1	—	NN	O	—	_	0	SENT_96	[p5l11t1199r540b1267],
2	.	.	O	.	_	0	SENT_96	[p5l11t1199r540b1267],

1	Weinberg	NNP	PERSON	Weinberg	_	0	SENT_97	[p5l11t1199r540b1267],
2	equilibrium	NN	O	equilibrium	nn	5	SENT_97	[p5l583t1199r942b1267],
3	(	CD	NUMBER	(	num	5	SENT_97	[p5l990t1199r1215b1267],
4	HWE	NN	O	hwe	nn	5	SENT_97	[p5l990t1199r1215b1267],
5	)	NN	O	)	dep	1	SENT_97	[p5l990t1199r1215b1267],
6	.	.	O	.	_	0	SENT_97	[p5l990t1199r1215b1267],

1	Mann	NNP	PERSON	Mann	_	0	SENT_98	[p5l1260t1199r1744b1267],
2	.	.	O	.	_	0	SENT_98	[p5l1260t1199r1744b1267],

1	—	NN	O	—	_	0	SENT_99	[p5l1260t1199r1744b1267],
2	.	.	O	.	_	0	SENT_99	[p5l1260t1199r1744b1267],

1	Whitney	NNP	PERSON	Whitney	nn	3	SENT_100	[p5l1260t1199r1744b1267],
2	U	NNP	O	U	nn	3	SENT_100	[p5l1789t1203r1833b1253],
3	test	NN	O	test	nsubjpass	5	SENT_100	[p5l1872t1207r1985b1253],
4	was	VBD	O	be	auxpass	5	SENT_100	[p5l2025t1215r2144b1253],
5	used	VBN	O	use	_	0	SENT_100	[p5l11t1286r151b1340],
6	to	TO	O	to	aux	7	SENT_100	[p5l181t1294r240b1340],
7	assess	VB	O	assess	xcomp	5	SENT_100	[p5l271t1302r454b1340],
8	the	DT	O	the	det	9	SENT_100	[p5l484t1286r581b1340],
9	difference	NN	O	difference	dobj	7	SENT_100	[p5l611t1286r916b1340],
10	in	IN	O	in	_	0	SENT_100	[p5l947t1287r1003b1340],
11	allele	NN	O	allele	nn	12	SENT_100	[p5l1033t1286r1193b1340],
12	frequencies	NNS	O	frequency	prep_in	7	SENT_100	[p5l1223t1286r1575b1354],
13	between	IN	O	between	_	0	SENT_100	[p5l1605t1286r1870b1340],
14	patients	NNS	O	patient	prep_between	12	SENT_100	[p5l1899t1287r2144b1354],
15	and	CC	O	and	_	0	SENT_100	[p5l11t1373r122b1428],
16	healthy	JJ	O	healthy	amod	17	SENT_100	[p5l150t1373r380b1441],
17	volunteers	NNS	O	volunteer	prep_between	12	SENT_100	[p5l403t1373r744b1428],
18	.	.	O	.	_	0	SENT_100	[p5l403t1373r744b1428],

1	Fisher	NNP	PERSON	Fisher	poss	4	SENT_101	[p5l772t1373r999b1428],
2	's	POS	O	's	_	0	SENT_101	[p5l772t1373r999b1428],
3	exact	JJ	O	exact	amod	4	SENT_101	[p5l1028t1381r1188b1428],
4	test	NN	O	test	nsubjpass	6	SENT_101	[p5l1213t1381r1325b1428],
5	was	VBD	O	be	auxpass	6	SENT_101	[p5l1350t1389r1468b1428],
6	used	VBN	O	use	_	0	SENT_101	[p5l1496t1373r1636b1428],
7	to	TO	O	to	aux	8	SENT_101	[p5l1664t1381r1722b1427],
8	correlate	VB	O	correlate	xcomp	6	SENT_101	[p5l1750t1373r2020b1428],
9	the	DT	O	the	det	10	SENT_101	[p5l2047t1373r2144b1428],
10	SNPs	NNS	O	snp	dobj	8	SENT_101	[p5l11t1463r158b1515],
11	with	IN	O	with	_	0	SENT_101	[p5l188t1460r328b1515],
12	toxicities	NNS	O	toxicity	prep_with	8	SENT_101	[p5l358t1461r649b1515],
13	.	.	O	.	_	0	SENT_101	[p5l358t1461r649b1515],

1	A	DT	O	a	det	3	SENT_102	[p5l677t1463r722b1514],
2	two-sided	JJ	O	two-sided	amod	3	SENT_102	[p5l750t1460r1058b1515],
3	p-value	NN	O	p-value	nsubjpass	8	SENT_102	[p5l1084t1460r1316b1528],
4	of	IN	O	of	_	0	SENT_102	[p5l1346t1460r1409b1514],
5	<	JJR	O	<	prep_of	3	SENT_102	[p5l1430t1463r1602b1515],
6	0.05	CD	NUMBER	0.05	dep	5	SENT_102	[p5l1430t1463r1602b1515],
7	was	VBD	O	be	auxpass	8	SENT_102	[p5l1633t1476r1751b1515],
8	regarded	VBN	O	regard	_	0	SENT_102	[p5l1782t1460r2054b1528],
9	as	IN	O	as	_	0	SENT_102	[p5l2084t1476r2144b1515],
10	statistically	RB	O	statistically	advmod	11	SENT_102	[p5l12t1548r358b1615],
11	signiﬁcant	JJ	O	signiﬁcant	prep_as	8	SENT_102	[p5l382t1548r711b1615],
12	.	.	O	.	_	0	SENT_102	[p5l382t1548r711b1615],

1	3	LS	NUMBER	3	_	0	SENT_103	[p5l9t1728r63b1780],
2	.	.	O	.	_	0	SENT_103	[p5l9t1728r63b1780],

1	Results	NNS	O	result	_	0	SENT_104	[p5l86t1725r316b1779],

1	3.1	CD	NUMBER	3.1	_	0	SENT_105	[p5l8t1905r108b1957],
2	.	.	O	.	_	0	SENT_105	[p5l8t1905r108b1957],

1	CDA	NNP	ORGANIZATION	CDA	_	0	SENT_106	[p5l137t1905r258b1956],
2	gene	NN	O	gene	nn	4	SENT_106	[p5l277t1918r417b1970],
3	polymorphism	NN	O	polymorphism	nn	4	SENT_106	[p5l436t1902r863b1970],
4	distribution	NN	O	distribution	dep	1	SENT_106	[p5l888t1902r1228b1957],

1	The	DT	O	the	det	2	SENT_107	[p5l110t2080r224b2134],
2	incidence	NN	O	incidence	nsubj	14	SENT_107	[p5l248t2080r548b2134],
3	of	IN	O	of	_	0	SENT_107	[p5l572t2080r637b2134],
4	CDA	NNP	ORGANIZATION	CDA	nn	5	SENT_107	[p5l654t2082r777b2134],
5	79A	NNP	O	79A	prep_of	2	SENT_107	[p5l802t2082r1018b2134],
6	>	JJR	O	>	amod	8	SENT_107	[p5l802t2082r1018b2134],
7	C	NN	O	c	nn	8	SENT_107	[p5l802t2082r1018b2134],
8	SNP	NN	O	snp	dep	5	SENT_107	[p5l1040t2083r1162b2134],
9	was	VBD	O	be	cop	14	SENT_107	[p5l1182t2096r1304b2134],
10	12.0	CD	PERCENT	12.0	number	14	SENT_107	[p5l1331t2083r1502b2135],
11	%	NN	PERCENT	%	dep	14	SENT_107	[p5l1331t2083r1502b2135],
12	and	CC	O	and	_	0	SENT_107	[p5l1525t2080r1638b2134],
13	12.3	CD	PERCENT	12.3	conj_and	14	SENT_107	[p5l1666t2083r1837b2135],
14	%	NN	PERCENT	%	_	0	SENT_107	[p5l1666t2083r1837b2135],
15	in	IN	O	in	_	0	SENT_107	[p5l1860t2081r1918b2133],
16	cancer	NN	O	cancer	nn	17	SENT_107	[p5l1940t2096r2146b2134],
17	patients	NNS	O	patient	prep_in	14	SENT_107	[p5l11t2167r265b2234],
18	and	CC	O	and	_	0	SENT_107	[p5l315t2167r428b2221],
19	in	IN	O	in	_	0	SENT_107	[p5l480t2167r537b2220],
20	healthy	JJ	O	healthy	amod	21	SENT_107	[p5l587t2167r825b2234],
21	volunteers	NNS	O	volunteer	prep_in	14	SENT_107	[p5l871t2167r1223b2229],
22	,	,	O	,	_	0	SENT_107	[p5l871t2167r1223b2229],
23	respectively	RB	O	respectively	advmod	14	SENT_107	[p5l1275t2167r1673b2234],
24	.	.	O	.	_	0	SENT_107	[p5l1275t2167r1673b2234],

1	For	IN	O	for	_	0	SENT_108	[p5l1724t2170r1823b2221],
2	the	DT	O	the	det	4	SENT_108	[p5l1871t2167r1970b2221],
3	CDA	NNP	ORGANIZATION	CDA	nn	4	SENT_108	[p5l2021t2169r2144b2221],
4	208G	NN	O	208g	prep_for	25	SENT_108	[p5l11t2255r277b2307],
5	>	JJR	O	>	amod	7	SENT_108	[p5l11t2255r277b2307],
6	A	DT	O	a	det	7	SENT_108	[p5l11t2255r277b2307],
7	SNP	NN	ORGANIZATION	snp	tmod	4	SENT_108	[p5l295t2256r431b2316],
8	,	,	O	,	_	0	SENT_108	[p5l295t2256r431b2316],
9	while	IN	O	while	mark	13	SENT_108	[p5l450t2253r626b2307],
10	it	PRP	O	it	nsubjpass	13	SENT_108	[p5l646t2254r689b2307],
11	is	VBZ	O	be	auxpass	13	SENT_108	[p5l708t2254r753b2307],
12	not	RB	O	not	neg	13	SENT_108	[p5l774t2261r877b2307],
13	detected	VBN	O	detect	dep	7	SENT_108	[p5l896t2253r1166b2307],
14	in	IN	O	in	_	0	SENT_108	[p5l1188t2254r1246b2307],
15	cancer	NN	O	cancer	nn	16	SENT_108	[p5l1265t2269r1471b2307],
16	patients	NNS	O	patient	prep_in	13	SENT_108	[p5l1489t2254r1759b2321],
17	,	,	O	,	_	0	SENT_108	[p5l1489t2254r1759b2321],
18	its	PRP$	O	its	poss	19	SENT_108	[p5l1780t2254r1851b2307],
19	frequency	NN	O	frequency	nsubj	25	SENT_108	[p5l1872t2253r2144b2321, p5l11t2356r78b2408],
20	in	IN	O	in	_	0	SENT_108	[p5l99t2341r156b2394],
21	healthy	JJ	O	healthy	amod	22	SENT_108	[p5l178t2340r416b2408],
22	volunteers	NNS	O	volunteer	prep_in	19	SENT_108	[p5l434t2340r770b2394],
23	is	VBZ	O	be	cop	25	SENT_108	[p5l793t2341r838b2394],
24	1.9	CD	PERCENT	1.9	num	25	SENT_108	[p5l864t2343r996b2395],
25	%	NN	PERCENT	%	_	0	SENT_108	[p5l864t2343r996b2395],
26	(	CD	NUMBER	(	num	27	SENT_108	[p5l1021t2340r1215b2407],
27	Table	NNP	O	Table	dep	25	SENT_108	[p5l1021t2340r1215b2407],
28	2	CD	NUMBER	2	number	29	SENT_108	[p5l1237t2340r1318b2407],
29	)	CD	NUMBER	)	dep	27	SENT_108	[p5l1237t2340r1318b2407],
30	.	.	O	.	_	0	SENT_108	[p5l1237t2340r1318b2407],

1	No	DT	O	no	det	3	SENT_109	[p5l1342t2343r1426b2394],
2	signiﬁcant	NN	O	signiﬁcant	nn	3	SENT_109	[p5l1449t2340r1777b2408],
3	differences	NNS	O	difference	nsubjpass	5	SENT_109	[p5l1797t2340r2144b2394],
4	were	VBD	O	be	auxpass	5	SENT_109	[p5l9t2443r166b2482],
5	found	VBN	O	find	_	0	SENT_109	[p5l204t2427r385b2482],
6	in	IN	O	in	_	0	SENT_109	[p5l424t2428r481b2481],
7	SNP	NN	O	snp	nn	8	SENT_109	[p5l518t2430r640b2481],
8	frequencies	NNS	O	frequency	prep_in	5	SENT_109	[p5l676t2427r1039b2495],
9	between	IN	O	between	_	0	SENT_109	[p5l1077t2427r1349b2482],
10	healthy	JJ	O	healthy	amod	11	SENT_109	[p5l1386t2427r1624b2495],
11	volunteers	NNS	O	volunteer	prep_between	8	SENT_109	[p5l1657t2427r1993b2482],
12	and	CC	O	and	_	0	SENT_109	[p5l2031t2427r2144b2481],
13	cancer	NN	O	cancer	nn	14	SENT_109	[p5l11t2530r217b2569],
14	patients	NNS	O	patient	prep_in	5	SENT_109	[p5l245t2515r499b2582],
15	(	CD	NUMBER	(	num	16	SENT_109	[p5l533t2515r593b2582],
16	p	NN	O	p	npadvmod	29	SENT_109	[p5l533t2515r593b2582],
17	=	JJ	O	=	amod	16	SENT_109	[p5l612t2537r665b2558],
18	0.862	CD	NUMBER	0.862	tmod	17	SENT_109	[p5l684t2517r854b2569],
19	for	IN	O	for	_	0	SENT_109	[p5l886t2514r974b2569],
20	79A	CD	NUMBER	79a	num	22	SENT_109	[p5l1003t2517r1219b2569],
21	>	JJR	O	>	amod	22	SENT_109	[p5l1003t2517r1219b2569],
22	C	NN	O	c	prep_for	17	SENT_109	[p5l1003t2517r1219b2569],
23	and	CC	O	and	_	0	SENT_109	[p5l1248t2514r1361b2568],
24	p	NN	O	p	prep_for	17	SENT_109	[p5l1387t2530r1425b2582],
25	=	JJ	O	=	amod	24	SENT_109	[p5l1444t2537r1497b2558],
26	0.163	CD	NUMBER	0.163	tmod	25	SENT_109	[p5l1516t2517r1684b2569],
27	for	IN	O	for	_	0	SENT_109	[p5l1718t2514r1805b2568],
28	208G	NN	O	208g	prep_for	24	SENT_109	[p5l1833t2514r2144b2582],
29	>	JJR	O	>	amod	31	SENT_109	[p5l1833t2514r2144b2582],
30	A	DT	O	a	det	31	SENT_109	[p5l1833t2514r2144b2582],
31	)	NN	O	)	dep	14	SENT_109	[p5l1833t2514r2144b2582],
32	.	.	O	.	_	0	SENT_109	[p5l1833t2514r2144b2582],

1	When	WRB	O	when	advmod	2	SENT_110	[p5l8t2602r198b2656],
2	combining	VBG	O	combine	advcl	29	SENT_110	[p5l227t2602r563b2669],
3	the	DT	O	the	det	5	SENT_110	[p5l590t2602r690b2656],
4	two	CD	NUMBER	two	num	5	SENT_110	[p5l718t2610r838b2656],
5	populations	NNS	O	population	dobj	2	SENT_110	[p5l868t2602r1257b2669],
6	,	,	O	,	_	0	SENT_110	[p5l868t2602r1257b2669],
7	the	DT	O	the	det	10	SENT_110	[p5l1286t2602r1386b2656],
8	minor	JJ	O	minor	amod	10	SENT_110	[p5l1416t2603r1607b2656],
9	allele	NN	O	allele	nn	10	SENT_110	[p5l1634t2602r1800b2656],
10	frequency	NN	O	frequency	appos	5	SENT_110	[p5l1830t2602r2146b2669],
11	of	IN	O	of	_	0	SENT_110	[p5l11t2688r76b2743],
12	CDA	NNP	ORGANIZATION	CDA	nn	13	SENT_110	[p5l106t2691r229b2743],
13	79A	NNP	O	79A	prep_of	10	SENT_110	[p5l267t2691r484b2743],
14	>	JJR	O	>	amod	15	SENT_110	[p5l267t2691r484b2743],
15	C	NN	O	c	dep	2	SENT_110	[p5l267t2691r484b2743],
16	and	CC	O	and	_	0	SENT_110	[p5l519t2689r632b2743],
17	CDA	NNP	ORGANIZATION	CDA	nn	18	SENT_110	[p5l670t2691r794b2743],
18	208G	NN	O	208g	dep	2	SENT_110	[p5l831t2691r1097b2743],
19	>	JJR	O	>	nsubj	29	SENT_110	[p5l831t2691r1097b2743],
20	A	DT	O	a	dep	19	SENT_110	[p5l831t2691r1097b2743],
21	in	IN	O	in	_	0	SENT_110	[p5l1131t2689r1188b2742],
22	Chinese	JJ	LOCATION	chinese	amod	23	SENT_110	[p5l1225t2689r1470b2743],
23	population	NN	O	population	prep_in	19	SENT_110	[p5l1507t2689r1851b2756],
24	is	VBZ	O	be	cop	29	SENT_110	[p5l1888t2689r1933b2743],
25	12.2	CD	PERCENT	12.2	number	29	SENT_110	[p5l1974t2691r2145b2743],
26	%	NN	PERCENT	%	dep	29	SENT_110	[p5l1974t2691r2145b2743],
27	and	CC	O	and	_	0	SENT_110	[p5l11t2775r124b2829],
28	1.0	CD	PERCENT	1.0	conj_and	29	SENT_110	[p5l152t2778r299b2838],
29	%	NN	PERCENT	%	_	0	SENT_110	[p5l152t2778r299b2838],
30	,	,	O	,	_	0	SENT_110	[p5l152t2778r299b2838],
31	respectively	RB	O	respectively	advmod	29	SENT_110	[p5l324t2775r722b2843],
32	.	.	O	.	_	0	SENT_110	[p5l324t2775r722b2843],

1	3.2	CD	NUMBER	3.2	_	0	SENT_111	[p5l8t2955r108b3007],
2	.	.	O	.	_	0	SENT_111	[p5l8t2955r108b3007],

1	Adverse	JJ	O	adverse	amod	3	SENT_112	[p5l129t2952r364b3007],
2	drug	NN	O	drug	nn	3	SENT_112	[p5l388t2952r525b3020],
3	reactions	NNS	O	reaction	_	0	SENT_112	[p5l546t2953r812b3007],
4	in	IN	O	in	_	0	SENT_112	[p5l836t2954r889b3007],
5	patients	NNS	O	patient	prep_in	3	SENT_112	[p5l909t2954r1149b3020],

1	Among	IN	O	among	_	0	SENT_113	[p5l110t3132r327b3197],
2	the	DT	O	the	det	3	SENT_113	[p5l341t3130r436b3184],
3	37	CD	NUMBER	37	prep_among	16	SENT_113	[p5l451t3133r523b3184],
4	evaluated	VBN	O	evaluate	partmod	3	SENT_113	[p5l541t3130r827b3184],
5	patients	NNS	O	patient	dobj	4	SENT_113	[p5l844t3131r1093b3197],
6	,	,	O	,	_	0	SENT_113	[p5l844t3131r1093b3197],
7	the	DT	O	the	det	11	SENT_113	[p5l1110t3130r1205b3184],
8	most	RBS	O	most	advmod	9	SENT_113	[p5l1222t3138r1369b3184],
9	common	JJ	O	common	amod	11	SENT_113	[p5l1384t3145r1647b3184],
10	adverse	JJ	O	adverse	amod	11	SENT_113	[p5l1663t3130r1889b3184],
11	reaction	NN	O	reaction	nsubj	16	SENT_113	[p5l1906t3131r2145b3184],
12	after	IN	O	after	_	0	SENT_113	[p5l11t3216r147b3270],
13	drug	NN	O	drug	nn	14	SENT_113	[p5l184t3216r321b3284],
14	administration	NN	O	administration	prep_after	11	SENT_113	[p5l358t3216r794b3270],
15	was	VBD	O	be	cop	16	SENT_113	[p5l830t3232r946b3270],
16	neutropenia	NN	O	neutropenia	_	0	SENT_113	[p5l985t3217r1358b3284],
17	,	,	O	,	_	0	SENT_113	[p5l985t3217r1358b3284],
18	which	WDT	O	which	nsubjpass	20	SENT_113	[p5l1396t3216r1579b3270],
19	was	VBD	O	be	auxpass	20	SENT_113	[p5l1615t3232r1731b3270],
20	found	VBN	O	find	rcmod	16	SENT_113	[p5l1770t3216r1941b3270],
21	in	IN	O	in	_	0	SENT_113	[p5l1979t3217r2035b3270],
22	29	CD	PERCENT	29	prep_in	20	SENT_113	[p5l2072t3219r2143b3270],
23	(	CD	PERCENT	(	number	24	SENT_113	[p5l15t3303r228b3370],
24	78.4	CD	PERCENT	78.4	num	25	SENT_113	[p5l15t3303r228b3370],
25	%	NN	PERCENT	%	dep	16	SENT_113	[p5l15t3303r228b3370],
26	)	CD	NUMBER	)	num	27	SENT_113	[p5l15t3303r228b3370],
27	patients	NNS	O	patient	dep	25	SENT_113	[p5l252t3304r501b3371],
28	.	.	O	.	_	0	SENT_113	[p5l252t3304r501b3371],

1	Severe	JJ	O	severe	amod	2	SENT_114	[p5l522t3306r715b3357],
2	toxicities	NNS	O	toxicity	nsubjpass	10	SENT_114	[p5l734t3304r999b3357],
3	such	JJ	O	such	_	0	SENT_114	[p5l1020t3303r1155b3357],
4	as	IN	O	as	_	0	SENT_114	[p5l1172t3319r1230b3357],
5	leukopenia	NN	O	leukopenia	prep_such_as	2	SENT_114	[p5l1251t3303r1576b3371],
6	and	CC	O	and	_	0	SENT_114	[p5l1594t3303r1702b3357],
7	thrombopenia	NN	O	thrombopenia	prep_such_as	2	SENT_114	[p5l1722t3303r2145b3371],
8	were	VBD	O	be	auxpass	10	SENT_114	[p5l9t3406r159b3445],
9	also	RB	O	also	advmod	10	SENT_114	[p5l179t3390r292b3445],
10	found	VBN	O	find	_	0	SENT_114	[p5l314t3390r498b3445],
11	.	.	O	.	_	0	SENT_114	[p5l314t3390r498b3445],

1	In	IN	O	in	_	0	SENT_115	[p5l520t3394r575b3444],
2	addition	NN	O	addition	_	0	SENT_115	[p5l594t3390r840b3444],
3	to	TO	O	to	_	0	SENT_115	[p5l859t3398r917b3445],
4	myelotoxicity	NN	O	myelotoxicity	prep_in_addition_to	8	SENT_115	[p5l938t3390r1356b3458],
5	,	,	O	,	_	0	SENT_115	[p5l938t3390r1356b3458],
6	gemcitabine	NN	O	gemcitabine	nsubjpass	8	SENT_115	[p5l1376t3390r1739b3458],
7	was	VBD	O	be	auxpass	8	SENT_115	[p5l1757t3406r1874b3445],
8	found	VBN	O	find	_	0	SENT_115	[p5l1895t3390r2066b3445],
9	to	TO	O	to	aux	10	SENT_115	[p5l2087t3398r2144b3445],
10	induce	VB	O	induce	xcomp	8	SENT_115	[p5l11t3477r208b3532],
11	some	DT	O	some	det	14	SENT_115	[p5l228t3493r384b3532],
12	non-hematologic	JJ	O	non-hematologic	amod	14	SENT_115	[p5l403t3477r910b3545],
13	adverse	JJ	O	adverse	amod	14	SENT_115	[p5l928t3477r1154b3532],
14	reaction	NN	O	reaction	dobj	10	SENT_115	[p5l1174t3478r1412b3532],
15	such	JJ	O	such	_	0	SENT_115	[p5l1431t3477r1565b3532],
16	as	IN	O	as	_	0	SENT_115	[p5l1583t3493r1641b3532],
17	nausea	NN	O	nausea	prep_such_as	14	SENT_115	[p5l1661t3493r1878b3540],
18	,	,	O	,	_	0	SENT_115	[p5l1661t3493r1878b3540],
19	diarrhea	NN	O	diarrhea	prep_such_as	14	SENT_115	[p5l1897t3477r2145b3532],
20	and	CC	O	and	_	0	SENT_115	[p5l11t3565r119b3619],
21	rash	NN	O	rash	prep_such_as	14	SENT_115	[p5l145t3565r282b3619],
22	.	.	O	.	_	0	SENT_115	[p5l145t3565r282b3619],

1	Other	JJ	O	other	amod	2	SENT_116	[p5l307t3565r476b3619],
2	toxicities	NNS	O	toxicity	nsubjpass	27	SENT_116	[p5l498t3566r763b3619],
3	with	IN	O	with	_	0	SENT_116	[p5l787t3565r924b3619],
4	mild	JJ	O	mild	amod	7	SENT_116	[p5l948t3565r1081b3619],
5	severity	NN	O	severity	nn	7	SENT_116	[p5l1107t3566r1340b3632],
6	(	NN	O	(	nn	7	SENT_116	[p5l1367t3565r1556b3632],
7	grade	NN	O	grade	prep_with	2	SENT_116	[p5l1367t3565r1556b3632],
8	1	CD	NUMBER	1	dep	7	SENT_116	[p5l1584t3568r1607b3618],
9	and	CC	O	and	_	0	SENT_116	[p5l1639t3565r1747b3619],
10	grade	NN	O	grade	nn	12	SENT_116	[p5l1771t3565r1937b3632],
11	2	CD	NUMBER	2	num	12	SENT_116	[p5l1962t3565r2038b3632],
12	)	NN	O	)	conj_and	7	SENT_116	[p5l1962t3565r2038b3632],
13	,	,	O	,	_	0	SENT_116	[p5l1962t3565r2038b3632],
14	including	VBG	O	include	conj_and	12	SENT_116	[p5l2064t3566r2144b3618, p5l11t3652r230b3719],
15	drug	NN	O	drug	nn	16	SENT_116	[p5l268t3652r406b3719],
16	fever	NN	O	fever	pobj	14	SENT_116	[p5l446t3652r606b3714],
17	,	,	O	,	_	0	SENT_116	[p5l446t3652r606b3714],
18	hepatic	JJ	O	hepatic	amod	19	SENT_116	[p5l648t3652r863b3719],
19	dysfunction	NN	O	dysfunction	appos	16	SENT_116	[p5l903t3652r1263b3719],
20	,	,	O	,	_	0	SENT_116	[p5l903t3652r1263b3719],
21	and	CC	O	and	_	0	SENT_116	[p5l1304t3652r1413b3706],
22	transient	JJ	O	transient	amod	23	SENT_116	[p5l1453t3653r1718b3706],
23	eye	NN	O	eye	conj_and	12	SENT_116	[p5l1757t3667r1857b3719],
24	swelling	VBG	O	swell	amod	23	SENT_116	[p5l1899t3652r2145b3719],
25	were	VBD	O	be	auxpass	27	SENT_116	[p5l9t3754r159b3792],
26	also	RB	O	also	advmod	27	SENT_116	[p5l180t3738r293b3792],
27	found	VBN	O	find	dep	31	SENT_116	[p5l315t3738r487b3792],
28	in	IN	O	in	_	0	SENT_116	[p5l509t3739r563b3792],
29	some	DT	O	some	det	30	SENT_116	[p5l585t3754r741b3792],
30	individuals	NNS	O	individual	prep_in	27	SENT_116	[p5l763t3738r1086b3792],
31	(	VBP	O	(	_	0	SENT_116	[p5l1112t3738r1294b3806],
32	Table	NNP	O	Table	dobj	31	SENT_116	[p5l1112t3738r1294b3806],
33	3	CD	NUMBER	3	num	34	SENT_116	[p5l1314t3738r1391b3806],
34	)	NN	O	)	nsubj	31	SENT_116	[p5l1314t3738r1391b3806],
35	.	.	O	.	_	0	SENT_116	[p5l1314t3738r1391b3806],

1	3.3	CD	NUMBER	3.3	_	0	SENT_117	[p6l8t105r108b157],
2	.	.	O	.	_	0	SENT_117	[p6l8t105r108b157],

1	Genotypes	NNS	O	genotype	_	0	SENT_118	[p6l133t105r426b170],
2	and	CC	O	and	_	0	SENT_118	[p6l443t102r550b156],
3	adverse	JJ	O	adverse	amod	5	SENT_118	[p6l567t102r782b157],
4	drug	NN	O	drug	nn	5	SENT_118	[p6l800t102r934b170],
5	reaction	NN	O	reaction	conj_and	1	SENT_118	[p6l948t104r1176b157],
6	under	IN	O	under	_	0	SENT_118	[p6l1195t102r1364b157],
7	gemcitabine	NN	O	gemcitabine	nn	8	SENT_118	[p6l1372t102r1722b170],
8	chemotherapy	NN	O	chemotherapy	prep_under	1	SENT_118	[p6l1739t102r2145b170],

1	According	VBG	O	accord	_	0	SENT_119	[p6l110t280r426b347],
2	to	TO	O	to	prepc_according_to	11	SENT_119	[p6l454t288r512b334],
3	CDA	NNP	ORGANIZATION	CDA	nn	7	SENT_119	[p6l542t282r665b334],
4	79A	NNP	O	79A	nn	7	SENT_119	[p6l695t282r909b334],
5	>	JJR	O	>	dep	6	SENT_119	[p6l695t282r909b334],
6	C	NN	O	c	amod	7	SENT_119	[p6l695t282r909b334],
7	genotypes	NNS	O	genotype	pobj	11	SENT_119	[p6l936t288r1271b347],
8	,	,	O	,	_	0	SENT_119	[p6l936t288r1271b347],
9	patients	NNS	O	patient	nsubjpass	11	SENT_119	[p6l1301t281r1550b347],
10	were	VBD	O	be	auxpass	11	SENT_119	[p6l1579t296r1733b334],
11	divided	VBN	O	divide	_	0	SENT_119	[p6l1762t280r1993b334],
12	into	IN	O	into	_	0	SENT_119	[p6l2024t281r2144b334],
13	two	CD	NUMBER	two	num	14	SENT_119	[p6l10t375r128b421],
14	groups	NNS	O	group	prep_into	11	SENT_119	[p6l151t382r383b434],
15	:	:	O	:	_	0	SENT_119	[p6l151t382r383b434],
16	wild	JJ	O	wild	amod	18	SENT_119	[p6l410t367r715b434],
17	—	NN	O	—	nn	18	SENT_119	[p6l410t367r715b434],
18	type	NN	O	type	dep	14	SENT_119	[p6l410t367r715b434],
19	group	NN	O	group	dep	18	SENT_119	[p6l738t382r920b434],
20	(	CD	NUMBER	(	num	19	SENT_119	[p6l949t366r1063b434],
21	for	IN	O	for	_	0	SENT_119	[p6l949t366r1063b434],
22	patients	NNS	O	patient	prep_for	19	SENT_119	[p6l1084t367r1334b434],
23	with	IN	O	with	_	0	SENT_119	[p6l1357t367r1500b421],
24	A/A	NN	O	a/a	nn	25	SENT_119	[p6l1521t369r1636b430],
25	genotypes	NNS	O	genotype	prep_with	22	SENT_119	[p6l1657t367r2003b434],
26	)	CD	NUMBER	)	dep	30	SENT_119	[p6l1657t367r2003b434],
27	and	CC	O	and	_	0	SENT_119	[p6l2031t367r2144b421],
28	mutation	NN	O	mutation	dep	30	SENT_119	[p6l11t454r296b507],
29	group	NN	O	group	dep	30	SENT_119	[p6l341t469r523b521],
30	(	CD	NUMBER	(	dep	38	SENT_119	[p6l574t453r688b520],
31	for	IN	O	for	_	0	SENT_119	[p6l574t453r688b520],
32	patients	NNS	O	patient	prep_for	30	SENT_119	[p6l732t454r981b521],
33	with	IN	O	with	_	0	SENT_119	[p6l1026t453r1169b507],
34	A/C	NN	O	a/c	nn	37	SENT_119	[p6l1212t456r1322b516],
35	or	CC	O	or	_	0	SENT_119	[p6l1367t469r1430b507],
36	C/C	NN	O	c/c	conj_or	34	SENT_119	[p6l1474t456r1577b516],
37	genotypes	NNS	O	genotype	prep_with	32	SENT_119	[p6l1621t453r1987b521],
38	)	CD	NUMBER	)	dep	19	SENT_119	[p6l1621t453r1987b521],
39	.	.	O	.	_	0	SENT_119	[p6l1621t453r1987b521],

1	The	DT	O	the	det	3	SENT_120	[p6l2031t453r2144b507],
2	follow-up	NN	O	follow-up	nn	3	SENT_120	[p6l11t540r315b608],
3	rates	NNS	O	rate	nsubj	13	SENT_120	[p6l338t548r486b594],
4	in	IN	O	in	_	0	SENT_120	[p6l509t541r565b594],
5	these	DT	O	these	det	7	SENT_120	[p6l586t540r751b594],
6	two	CD	NUMBER	two	num	7	SENT_120	[p6l772t548r890b594],
7	groups	NNS	O	group	prep_in	3	SENT_120	[p6l911t556r1123b608],
8	are	VBP	O	be	cop	13	SENT_120	[p6l1144t556r1239b594],
9	71.8	CD	PERCENT	71.8	number	13	SENT_120	[p6l1262t543r1434b595],
10	%	NN	PERCENT	%	dep	13	SENT_120	[p6l1262t543r1434b595],
11	and	CC	O	and	_	0	SENT_120	[p6l1454t540r1566b594],
12	72.7	CD	PERCENT	72.7	conj_and	13	SENT_120	[p6l1590t543r1776b603],
13	%	NN	PERCENT	%	_	0	SENT_120	[p6l1590t543r1776b603],
14	,	,	O	,	_	0	SENT_120	[p6l1590t543r1776b603],
15	respectively	RB	O	respectively	advmod	13	SENT_120	[p6l1798t541r2144b608, p6l11t628r79b695],
16	.	.	O	.	_	0	SENT_120	[p6l1798t541r2144b608, p6l11t628r79b695],

1	The	DT	O	the	det	2	SENT_121	[p6l116t628r229b682],
2	development	NN	O	development	nsubj	10	SENT_121	[p6l267t628r681b695],
3	of	IN	O	of	_	0	SENT_121	[p6l717t627r782b682],
4	severe	JJ	O	severe	amod	6	SENT_121	[p6l813t643r1011b682],
5	(	JJ	O	(	amod	6	SENT_121	[p6l1053t628r1283b695],
6	grades	NNS	O	grade	prep_of	2	SENT_121	[p6l1053t628r1283b695],
7	3-4	CD	NUMBER	3-4	num	9	SENT_121	[p6l1321t628r1462b695],
8	)	CD	NUMBER	)	num	9	SENT_121	[p6l1321t628r1462b695],
9	toxicities	NNS	O	toxicity	dep	6	SENT_121	[p6l1504t628r1787b682],
10	was	VBD	O	be	_	0	SENT_121	[p6l1825t643r1945b682],
11	more	RBR	O	more	advmod	10	SENT_121	[p6l1984t643r2144b682],

1	1286	CD	DATE	1286	num	2	SENT_122	[p6l6t771r64b792],
2	]	CD	NUMBER	]	_	0	SENT_122	[p6l748t771r764b797],
3	.	.	O	.	_	0	SENT_122	[p6l748t771r764b797],

1	Xu	NNP	O	Xu	_	0	SENT_123	[p6l773t771r804b792],
2	et	FW	O	et	nn	3	SENT_123	[p6l814t773r836b792],
3	al.	FW	O	al.	dep	1	SENT_123	[p6l844t770r868b792],
4	/	:	O	/	punct	1	SENT_123	[p6l878t771r887b795],
5	Clinica	NNP	PERSON	Clinica	nn	7	SENT_123	[p6l896t770r972b792],
6	Chimica	NNP	PERSON	Chimica	nn	7	SENT_123	[p6l982t770r1074b792],
7	Acta	NNP	PERSON	Acta	dep	1	SENT_123	[p6l1082t771r1133b792],
8	413	CD	NUMBER	413	number	9	SENT_123	[p6l1142t771r1185b792],
9	(	CD	NUMBER	(	num	10	SENT_123	[p6l1196t770r1275b797],
10	2012	CD	DATE	2012	dep	7	SENT_123	[p6l1196t770r1275b797],
11	)	CD	NUMBER	)	number	12	SENT_123	[p6l1196t770r1275b797],
12	1284-1287	CD	DATE	1284-1287	num	10	SENT_123	[p6l1288t771r1418b792],

1	Table	NNP	O	Table	_	0	SENT_124	[p6l6t853r74b875],
2	2	CD	NUMBER	2	num	3	SENT_124	[p6l83t854r97b875],
3	Frequencies	NNS	O	frequency	dep	1	SENT_124	[p6l6t888r149b915],
4	of	IN	O	of	_	0	SENT_124	[p6l159t888r184b910],
5	CDA	NNP	ORGANIZATION	CDA	nn	6	SENT_124	[p6l191t889r238b910],
6	208G	NN	O	208g	prep_of	3	SENT_124	[p6l248t889r350b910],
7	>	JJR	O	>	dep	1	SENT_124	[p6l248t889r350b910],
8	A	DT	O	a	dep	7	SENT_124	[p6l248t889r350b910],
9	and	CC	O	and	_	0	SENT_124	[p6l358t888r402b910],
10	CDA	NNP	ORGANIZATION	CDA	nn	11	SENT_124	[p6l412t889r460b910],
11	79A	NNP	O	79A	dep	1	SENT_124	[p6l470t889r553b910],
12	>	JJR	O	>	amod	13	SENT_124	[p6l470t889r553b910],
13	C	NN	O	c	dep	1	SENT_124	[p6l470t889r553b910],
14	in	IN	O	in	_	0	SENT_124	[p6l563t888r585b909],
15	cancer	NN	O	cancer	nn	16	SENT_124	[p6l594t894r672b910],
16	patients	NNS	O	patient	prep_in	13	SENT_124	[p6l681t888r777b915],
17	and	CC	O	and	_	0	SENT_124	[p6l787t888r831b910],
18	healthy	JJ	O	healthy	amod	19	SENT_124	[p6l841t888r931b915],
19	volunteers	NNS	O	volunteer	prep_in	13	SENT_124	[p6l940t888r1073b910],
20	.	.	O	.	_	0	SENT_124	[p6l940t888r1073b910],

1	Gene	NNP	O	Gene	nn	4	SENT_125	[p6l33t957r94b978],
2	SNP	NN	O	snp	nn	4	SENT_125	[p6l234t957r281b978],
3	Amino	NN	O	amino	nn	4	SENT_125	[p6l475t956r614b978],
4	—	NN	O	—	_	0	SENT_125	[p6l475t956r614b978],
5	acid	NN	O	acid	nn	7	SENT_125	[p6l475t956r614b978],
6	Study	NN	O	study	nn	7	SENT_125	[p6l755t956r823b983],
7	population	NN	O	population	dep	4	SENT_125	[p6l832t956r963b983],
8	Genotype	NNP	O	Genotype	nn	11	SENT_125	[p6l1125t957r1241b983],
9	Allele	NNP	O	Allele	nn	11	SENT_125	[p6l1667t956r1735b978],
10	frequency	NN	O	frequency	nn	11	SENT_125	[p6l1745t951r1876b983],
11	”	NN	O	”	dep	4	SENT_125	[p6l1745t951r1876b983],

1	a	DT	O	a	det	6	SENT_126	[p6l570t991r579b1001],
2	Change	NNP	O	Change	nn	6	SENT_126	[p6l484t991r569b1018],
3	Wt	NNP	O	Wt	nn	6	SENT_126	[p6l1135t1011r1169b1032],
4	Het	NNP	O	Het	nn	6	SENT_126	[p6l1317t1011r1359b1032],
5	Var	NNP	O	Var	nn	6	SENT_126	[p6l1498t1011r1538b1032],
6	p	NN	O	p	nsubj	7	SENT_126	[p6l1675t1016r1689b1037],
7	q	VB	O	q	_	0	SENT_126	[p6l1882t1016r1894b1037],
8	HWE	NNP	O	HWE	nn	10	SENT_126	[p6l2088t1011r2148b1031],
9	CDA	NNP	O	CDA	nn	10	SENT_126	[p6l34t1061r81b1082],
10	79A	NNP	O	79A	dobj	7	SENT_126	[p6l235t1061r318b1082],
11	>	JJR	O	>	amod	14	SENT_126	[p6l235t1061r318b1082],
12	C	NN	O	c	nn	14	SENT_126	[p6l235t1061r318b1082],
13	Lys27Gln	NN	O	lys27gln	nn	14	SENT_126	[p6l476t1060r585b1087],
14	Patients	NNS	O	patient	dep	10	SENT_126	[p6l756t1060r850b1082],
15	39	CD	NUMBER	39	number	16	SENT_126	[p6l1140t1061r1169b1082],
16	10	CD	NUMBER	10	num	18	SENT_126	[p6l1311t1061r1339b1082],
17	1	CD	NUMBER	1	number	18	SENT_126	[p6l1491t1061r1500b1082],
18	0.880	CD	NUMBER	0.880	dep	14	SENT_126	[p6l1668t1061r1734b1082],
19	0.120	CD	NUMBER	0.120	num	22	SENT_126	[p6l1874t1061r1939b1082],
20	0.708	CD	NUMBER	0.708	num	22	SENT_126	[p6l2080t1061r2144b1082],
21	Healthy	JJ	O	healthy	amod	22	SENT_126	[p6l7t1096r100b1123],
22	volunteers	NNS	O	volunteer	dep	32	SENT_126	[p6l109t1096r236b1118],
23	78	CD	NUMBER	78	number	24	SENT_126	[p6l392t1097r420b1118],
24	23	CD	NUMBER	23	num	26	SENT_126	[p6l561t1097r589b1118],
25	1	CD	NUMBER	1	number	26	SENT_126	[p6l742t1097r751b1117],
26	0.877	CD	NUMBER	0.877	dep	22	SENT_126	[p6l920t1097r985b1118],
27	0.123	CD	NUMBER	0.123	number	28	SENT_126	[p6l1125t1097r1190b1118],
28	0.624	CD	NUMBER	0.624	num	29	SENT_126	[p6l1331t1097r1397b1118],
29	Total	JJ	O	total	dep	26	SENT_126	[p6l1406t1096r1466b1117],
30	117	CD	NUMBER	117	dep	32	SENT_126	[p6l1779t1097r1821b1117],
31	33	CD	NUMBER	33	num	32	SENT_126	[p6l1962t1097r1990b1117],
32	2	CD	NUMBER	2	dep	38	SENT_126	[p6l2141t1097r2154b1117],
33	0.878	CD	NUMBER	0.878	number	34	SENT_126	[p6l1678t1133r1743b1154],
34	0.122	CD	NUMBER	0.122	dep	32	SENT_126	[p6l1884t1133r1948b1154],
35	0.849	CD	NUMBER	0.849	num	37	SENT_126	[p6l2089t1133r2154b1154],
36	CDA	NNP	ORGANIZATION	CDA	nn	37	SENT_126	[p6l34t1168r81b1188],
37	208G	NN	O	208g	dep	34	SENT_126	[p6l234t1168r336b1188],
38	>	JJR	O	>	dep	43	SENT_126	[p6l234t1168r336b1188],
39	A	DT	O	a	det	41	SENT_126	[p6l234t1168r336b1188],
40	Ala7OThr	NN	O	ala7othr	nn	41	SENT_126	[p6l474t1167r585b1188],
41	Patients	NNS	O	patient	dep	38	SENT_126	[p6l755t1167r850b1188],
42	50	CD	NUMBER	50	num	43	SENT_126	[p6l1141t1168r1169b1188],
43	o	NN	O	o	dep	44	SENT_126	[p6l1325t1168r1338b1188],
44	o	NN	O	o	dep	49	SENT_126	[p6l1489t1168r1502b1188],
45	1.000	CD	NUMBER	1.000	num	44	SENT_126	[p6l1669t1168r1733b1189],
46	o	NN	O	o	nn	49	SENT_126	[p6l1874t1168r1887b1188],
47	N/A	NN	O	n/a	nn	49	SENT_126	[p6l2079t1168r2125b1192],
48	Healthy	JJ	O	healthy	amod	49	SENT_126	[p6l6t1202r99b1229],
49	volunteers	NNS	O	volunteer	dep	51	SENT_126	[p6l108t1202r235b1224],
50	50	CD	NUMBER	50	num	51	SENT_126	[p6l391t1203r420b1224],
51	2	CD	NUMBER	2	dep	59	SENT_126	[p6l575t1203r588b1223],
52	o	NN	O	o	dep	51	SENT_126	[p6l739t1203r753b1224],
53	0.981	CD	NUMBER	0.981	num	52	SENT_126	[p6l919t1203r981b1224],
54	0.019	CD	NUMBER	0.019	number	55	SENT_126	[p6l1124t1203r1189b1224],
55	0.890	CD	NUMBER	0.890	num	56	SENT_126	[p6l1330t1203r1395b1224],
56	Total	JJ	O	total	dep	52	SENT_126	[p6l1405t1202r1465b1223],
57	100	CD	NUMBER	100	num	59	SENT_126	[p6l1778t1203r1821b1223],
58	2	CD	NUMBER	2	num	59	SENT_126	[p6l1976t1203r1989b1223],
59	O	NN	O	o	dep	10	SENT_126	[p6l2140t1203r2154b1223],
60	0.990	CD	NUMBER	0.990	number	61	SENT_126	[p6l1677t1239r1742b1260],
61	0.010	CD	NUMBER	0.010	dep	59	SENT_126	[p6l1883t1239r1948b1260],
62	0.920	CD	NUMBER	0.920	dep	61	SENT_126	[p6l2089t1239r2154b1260],

1	Abbrev.	NNP	O	Abbrev.	_	0	SENT_127	[p6l6t1289r102b1311],
2	:	:	O	:	_	0	SENT_127	[p6l6t1289r102b1311],
3	CDA	NNP	O	CDA	dep	1	SENT_127	[p6l113t1290r167b1314],
4	.	.	O	.	_	0	SENT_127	[p6l113t1290r167b1314],

1	cytidine	NN	O	cytidine	nn	2	SENT_128	[p6l177t1289r276b1316],
2	deaminase	NN	O	deaminase	_	0	SENT_128	[p6l285t1289r425b1314],
3	;	:	O	;	_	0	SENT_128	[p6l285t1289r425b1314],
4	SNP	NN	O	snp	dep	2	SENT_128	[p6l436t1290r490b1314],
5	,	,	O	,	_	0	SENT_128	[p6l436t1290r490b1314],
6	single	JJ	O	single	amod	9	SENT_128	[p6l500t1289r714b1316],
7	—	NN	O	—	nn	9	SENT_128	[p6l500t1289r714b1316],
8	nucleotide	NN	O	nucleotide	nn	9	SENT_128	[p6l500t1289r714b1316],
9	polymorphism	NN	O	polymorphism	appos	4	SENT_128	[p6l723t1289r912b1316],
10	;	:	O	;	_	0	SENT_128	[p6l723t1289r912b1316],
11	RS	NN	O	r	nn	12	SENT_128	[p6l924t1290r952b1311],
12	No.	NN	O	no.	dep	2	SENT_128	[p6l962t1290r1008b1314],
13	,	,	O	,	_	0	SENT_128	[p6l962t1290r1008b1314],
14	reference	NN	O	reference	nn	17	SENT_128	[p6l1018t1289r1133b1311],
15	SNP	NN	O	snp	nn	17	SENT_128	[p6l1142t1290r1190b1311],
16	identiﬁcation	NN	O	identiﬁcation	nn	17	SENT_128	[p6l1199t1289r1364b1311],
17	number	NN	O	number	appos	12	SENT_128	[p6l1373t1289r1477b1314],
18	;	:	O	;	_	0	SENT_128	[p6l1373t1289r1477b1314],
19	Wt	NNP	O	Wt	dep	2	SENT_128	[p6l1489t1290r1529b1314],
20	,	,	O	,	_	0	SENT_128	[p6l1489t1290r1529b1314],
21	homozygous	JJ	O	homozygous	amod	24	SENT_128	[p6l1538t1289r1694b1316],
22	wild	JJ	O	wild	amod	24	SENT_128	[p6l1704t1289r1832b1316],
23	—	NN	O	—	nn	24	SENT_128	[p6l1704t1289r1832b1316],
24	type	NN	O	type	appos	19	SENT_128	[p6l1704t1289r1832b1316],
25	;	:	O	;	_	0	SENT_128	[p6l1704t1289r1832b1316],
26	Het	NNP	O	Het	dep	2	SENT_128	[p6l1842t1290r1889b1314],
27	,	,	O	,	_	0	SENT_128	[p6l1842t1290r1889b1314],
28	heterozygous	JJ	O	heterozygous	amod	29	SENT_128	[p6l1899t1289r2064b1316],
29	variant	NN	O	variant	appos	26	SENT_128	[p6l6t1324r101b1349],
30	;	:	O	;	_	0	SENT_128	[p6l6t1324r101b1349],
31	Var	NNP	O	Var	dep	2	SENT_128	[p6l111t1325r156b1349],
32	,	,	O	,	_	0	SENT_128	[p6l111t1325r156b1349],
33	homozygous	JJ	O	homozygous	amod	34	SENT_128	[p6l167t1324r323b1351],
34	variant	NN	O	variant	appos	31	SENT_128	[p6l332t1324r427b1349],
35	;	:	O	;	_	0	SENT_128	[p6l332t1324r427b1349],
36	N/A	NNP	O	N/A	dep	2	SENT_128	[p6l439t1325r491b1350],
37	,	,	O	,	_	0	SENT_128	[p6l439t1325r491b1350],
38	not	RB	O	not	neg	39	SENT_128	[p6l501t1327r541b1346],
39	applicable	JJ	O	applicable	amod	36	SENT_128	[p6l551t1324r682b1351],
40	.	.	O	.	_	0	SENT_128	[p6l551t1324r682b1351],

1	3	CD	NUMBER	3	amod	4	SENT_129	[p6l31t1359r40b1369],
2	The	DT	O	the	det	4	SENT_129	[p6l57t1360r102b1382],
3	ﬁrst	NN	O	ﬁrst	nn	4	SENT_129	[p6l112t1360r160b1382],
4	methionine	NN	O	methionine	nsubjpass	9	SENT_129	[p6l170t1360r311b1382],
5	of	IN	O	of	_	0	SENT_129	[p6l322t1360r347b1382],
6	a	DT	O	a	det	7	SENT_129	[p6l354t1366r366b1382],
7	protein	NN	O	protein	prep_of	4	SENT_129	[p6l376t1360r465b1387],
8	is	VBZ	O	be	auxpass	9	SENT_129	[p6l475t1360r493b1382],
9	numbered	VBN	O	number	_	0	SENT_129	[p6l503t1360r636b1382],
10	.	.	O	.	_	0	SENT_129	[p6l503t1360r636b1382],
11	"	''	O	"	punct	9	SENT_129	[p6l31t1390r41b1405],

1	Hardy	NNP	PERSON	Hardy	_	0	SENT_130	[p6l59t1395r272b1422],
2	.	.	O	.	_	0	SENT_130	[p6l59t1395r272b1422],

1	—	NN	O	—	_	0	SENT_131	[p6l59t1395r272b1422],
2	.	.	O	.	_	0	SENT_131	[p6l59t1395r272b1422],

1	Weinberg	NNP	PERSON	Weinberg	nn	2	SENT_132	[p6l59t1395r272b1422],
2	notation	NN	O	notation	nsubj	6	SENT_132	[p6l282t1395r385b1417],
3	for	IN	O	for	_	0	SENT_132	[p6l395t1395r429b1417],
4	allele	NN	O	allele	nn	5	SENT_132	[p6l438t1395r503b1417],
5	frequencies	NNS	O	frequency	prep_for	2	SENT_132	[p6l513t1395r655b1422],
6	(	VBP	O	(	_	0	SENT_132	[p6l667t1395r697b1422],
7	17	CD	NUMBER	17	dobj	6	SENT_132	[p6l667t1395r697b1422],
8	,	,	O	,	_	0	SENT_132	[p6l667t1395r697b1422],
9	frequency	NN	O	frequency	appos	7	SENT_132	[p6l707t1395r831b1422],
10	for	IN	O	for	_	0	SENT_132	[p6l840t1395r874b1417],
11	wild	JJ	O	wild	amod	14	SENT_132	[p6l883t1395r1003b1422],
12	—	NN	O	—	nn	14	SENT_132	[p6l883t1395r1003b1422],
13	type	NN	O	type	nn	14	SENT_132	[p6l883t1395r1003b1422],
14	allele	NN	O	allele	prep_for	9	SENT_132	[p6l1013t1395r1086b1420],
15	:	:	O	:	_	0	SENT_132	[p6l1013t1395r1086b1420],
16	q.	VB	O	q.	parataxis	6	SENT_132	[p6l1098t1401r1116b1422],
17	frequency	NN	O	frequency	dobj	16	SENT_132	[p6l1127t1395r1250b1422],
18	for	IN	O	for	_	0	SENT_132	[p6l1259t1395r1294b1417],
19	variant	JJ	O	variant	amod	21	SENT_132	[p6l1302t1395r1390b1417],
20	allele	NN	O	allele	nn	21	SENT_132	[p6l1399t1395r1482b1422],
21	)	NN	O	)	prep_for	16	SENT_132	[p6l1399t1395r1482b1422],
22	.	.	O	.	_	0	SENT_132	[p6l1399t1395r1482b1422],

1	frequent	JJ	O	frequent	_	0	SENT_133	[p6l10t1576r278b1644],
2	in	IN	O	in	_	0	SENT_133	[p6l299t1577r356b1630],
3	mutation	NN	O	mutation	nn	4	SENT_133	[p6l379t1577r665b1631],
4	group	NN	O	group	prep_in	1	SENT_133	[p6l687t1592r869b1644],
5	than	IN	O	than	prep	1	SENT_133	[p6l892t1576r1032b1631],
6	in	IN	O	in	pcomp	5	SENT_133	[p6l1055t1577r1111b1630],
7	wild	JJ	O	wild	amod	12	SENT_133	[p6l1132t1576r1438b1644],
8	—	NN	O	—	nn	12	SENT_133	[p6l1132t1576r1438b1644],
9	type	NN	O	type	nn	12	SENT_133	[p6l1132t1576r1438b1644],
10	group	NN	O	group	nn	12	SENT_133	[p6l1460t1592r1642b1644],
11	(	CD	NUMBER	(	num	12	SENT_133	[p6l1669t1576r1799b1644],
12	Fig	NN	O	fig	pobj	6	SENT_133	[p6l1669t1576r1799b1644],
13	.	.	O	.	_	0	SENT_133	[p6l1669t1576r1799b1644],

1	1	CD	NUMBER	1	_	0	SENT_134	[p6l1826t1576r1903b1644],
2	)	NN	O	)	dep	1	SENT_134	[p6l1826t1576r1903b1644],
3	.	.	O	.	_	0	SENT_134	[p6l1826t1576r1903b1644],

1	The	DT	O	the	det	2	SENT_135	[p6l1924t1576r2037b1631],
2	incidence	NN	O	incidence	nsubj	8	SENT_135	[p6l2061t1577r2145b1630, p6l10t1664r245b1720],
3	of	IN	O	of	_	0	SENT_135	[p6l277t1664r341b1720],
4	severe	JJ	O	severe	amod	5	SENT_135	[p6l366t1680r564b1720],
5	neutropenia	NN	O	neutropenia	prep_of	2	SENT_135	[p6l597t1665r977b1733],
6	was	VBD	O	be	cop	8	SENT_135	[p6l1008t1680r1128b1720],
7	signiﬁcantly	RB	O	signiﬁcantly	advmod	8	SENT_135	[p6l1161t1664r1544b1733],
8	higher	JJR	O	higher	ccomp	28	SENT_135	[p6l1574t1665r1776b1733],
9	in	IN	O	in	_	0	SENT_135	[p6l1807t1665r1863b1719],
10	patients	NNS	O	patient	prep_in	8	SENT_135	[p6l1895t1665r2146b1733],
11	with	IN	O	with	_	0	SENT_135	[p6l8t1753r150b1808],
12	A/C	NN	O	a/c	prep_with	10	SENT_135	[p6l176t1755r287b1817],
13	and	CC	O	and	_	0	SENT_135	[p6l313t1753r425b1808],
14	C/C	NN	O	c/c	nn	15	SENT_135	[p6l454t1756r557b1817],
15	genotypes	NNS	O	genotype	nsubj	16	SENT_135	[p6l582t1761r902b1822],
16	(	VBP	O	(	ccomp	28	SENT_135	[p6l935t1753r1149b1821],
17	62.5	CD	PERCENT	62.5	num	18	SENT_135	[p6l935t1753r1149b1821],
18	%	NN	PERCENT	%	dobj	16	SENT_135	[p6l935t1753r1149b1821],
19	,	,	O	,	_	0	SENT_135	[p6l935t1753r1149b1821],
20	5/8	CD	NUMBER	5/8	num	21	SENT_135	[p6l1179t1753r1304b1821],
21	)	NN	O	)	npadvmod	22	SENT_135	[p6l1179t1753r1304b1821],
22	than	IN	O	than	advmod	28	SENT_135	[p6l1335t1753r1475b1808],
23	in	IN	O	in	_	0	SENT_135	[p6l1503t1754r1560b1807],
24	patients	NNS	O	patient	prep_in	22	SENT_135	[p6l1588t1754r1838b1822],
25	with	IN	O	with	_	0	SENT_135	[p6l1864t1753r2008b1808],
26	A/A	NN	O	a/a	nn	27	SENT_135	[p6l2033t1755r2148b1817],
27	genotypes	NNS	O	genotype	prep_with	24	SENT_135	[p6l8t1850r327b1911],
28	(	VBP	O	(	_	0	SENT_135	[p6l366t1842r580b1910],
29	17.2	CD	PERCENT	17.2	num	30	SENT_135	[p6l366t1842r580b1910],
30	%	NN	PERCENT	%	nsubj	28	SENT_135	[p6l366t1842r580b1910],
31	,	,	O	,	_	0	SENT_135	[p6l366t1842r580b1910],
32	5/29	CD	NUMBER	5/29	number	33	SENT_135	[p6l617t1842r781b1910],
33	)	CD	NUMBER	)	num	38	SENT_135	[p6l617t1842r781b1910],
34	(	NN	O	(	nn	38	SENT_135	[p6l823t1842r1188b1911],
35	p	NN	O	p	nn	38	SENT_135	[p6l823t1842r1188b1911],
36	=	JJ	O	=	amod	38	SENT_135	[p6l823t1842r1188b1911],
37	0.021	CD	NUMBER	0.021	num	38	SENT_135	[p6l823t1842r1188b1911],
38	)	NN	O	)	appos	30	SENT_135	[p6l823t1842r1188b1911],
39	.	.	O	.	_	0	SENT_135	[p6l823t1842r1188b1911],

1	In	IN	O	in	_	0	SENT_136	[p6l1223t1845r1281b1896],
2	25.0	CD	PERCENT	25.0	num	3	SENT_136	[p6l1314t1845r1487b1898],
3	%	NN	PERCENT	%	prep_in	18	SENT_136	[p6l1314t1845r1487b1898],
4	(	CD	NUMBER	(	number	5	SENT_136	[p6l1524t1842r1677b1910],
5	2/8	CD	NUMBER	2/8	num	6	SENT_136	[p6l1524t1842r1677b1910],
6	)	NN	O	)	npadvmod	3	SENT_136	[p6l1524t1842r1677b1910],
7	of	IN	O	of	_	0	SENT_136	[p6l1715t1842r1780b1897],
8	patients	NNS	O	patient	prep_of	3	SENT_136	[p6l1805t1843r2055b1911],
9	in	IN	O	in	_	0	SENT_136	[p6l2090t1843r2146b1896],
10	the	DT	O	the	det	12	SENT_136	[p6l9t1931r107b1986],
11	mutation	NN	O	mutation	nn	12	SENT_136	[p6l142t1932r427b1986],
12	group	NN	O	group	prep_in	8	SENT_136	[p6l459t1947r657b2000],
13	,	,	O	,	_	0	SENT_136	[p6l459t1947r657b2000],
14	a	DT	O	a	det	16	SENT_136	[p6l692t1947r723b1986],
15	severe	JJ	O	severe	amod	16	SENT_136	[p6l756t1947r955b1986],
16	leukopenia	NN	O	leukopenia	nsubjpass	18	SENT_136	[p6l989t1931r1333b2000],
17	was	VBD	O	be	auxpass	18	SENT_136	[p6l1365t1947r1485b1986],
18	observed	VBN	O	observe	_	0	SENT_136	[p6l1519t1931r1800b1986],
19	compared	VBN	O	compare	_	0	SENT_136	[p6l1835t1931r2146b2000],
20	to	TO	O	to	prepc_compared_to	18	SENT_136	[p6l9t2029r69b2075],
21	13.8	CD	PERCENT	13.8	num	22	SENT_136	[p6l93t2023r263b2076],
22	%	NN	PERCENT	%	nn	25	SENT_136	[p6l93t2023r263b2076],
23	(	CD	NUMBER	(	number	24	SENT_136	[p6l286t2020r479b2089],
24	4/29	CD	NUMBER	4/29	num	22	SENT_136	[p6l286t2020r479b2089],
25	)	NN	O	)	pobj	18	SENT_136	[p6l286t2020r479b2089],
26	in	IN	O	in	_	0	SENT_136	[p6l504t2021r561b2075],
27	the	DT	O	the	det	31	SENT_136	[p6l581t2020r680b2075],
28	wild	JJ	O	wild	amod	31	SENT_136	[p6l699t2020r1004b2089],
29	—	NN	O	—	nn	31	SENT_136	[p6l699t2020r1004b2089],
30	type	NN	O	type	nn	31	SENT_136	[p6l699t2020r1004b2089],
31	group	NN	O	group	prep_in	25	SENT_136	[p6l1024t2036r1222b2089],
32	,	,	O	,	_	0	SENT_136	[p6l1024t2036r1222b2089],
33	although	IN	O	although	mark	37	SENT_136	[p6l1243t2020r1520b2089],
34	it	PRP	O	it	nsubj	37	SENT_136	[p6l1542t2021r1583b2075],
35	did	VBD	O	do	aux	37	SENT_136	[p6l1603t2020r1699b2075],
36	not	RB	O	not	neg	37	SENT_136	[p6l1721t2029r1824b2075],
37	reach	VB	O	reach	advcl	18	SENT_136	[p6l1843t2020r2011b2075],
38	statistical	JJ	O	statistical	amod	41	SENT_136	[p6l2032t2028r2145b2075, p6l9t2110r215b2165],
39	signiﬁcance	NN	O	signiﬁcance	nn	41	SENT_136	[p6l235t2110r600b2178],
40	(	NN	O	(	nn	41	SENT_136	[p6l622t2110r682b2178],
41	p	NN	O	p	dobj	37	SENT_136	[p6l622t2110r682b2178],
42	=	JJ	O	=	advmod	37	SENT_136	[p6l700t2133r754b2154],
43	0.591	CD	NUMBER	0.591	num	44	SENT_136	[p6l772t2110r988b2178],
44	)	NN	O	)	dep	42	SENT_136	[p6l772t2110r988b2178],
45	.	.	O	.	_	0	SENT_136	[p6l772t2110r988b2178],

1	Similarly	RB	O	similarly	advmod	7	SENT_137	[p6l1007t2110r1300b2178],
2	,	,	O	,	_	0	SENT_137	[p6l1007t2110r1300b2178],
3	grade	NN	O	grade	nsubjpass	7	SENT_137	[p6l1318t2110r1492b2178],
4	3	CD	NUMBER	3	num	5	SENT_137	[p6l1509t2113r1542b2165],
5	thrombopenia	NN	O	thrombopenia	dep	3	SENT_137	[p6l1562t2110r2009b2178],
6	was	VBD	O	be	auxpass	7	SENT_137	[p6l2025t2126r2146b2165],
7	observed	VBN	O	observe	_	0	SENT_137	[p6l10t2199r291b2254],
8	in	IN	O	in	_	0	SENT_137	[p6l316t2199r372b2253],
9	6.9	CD	PERCENT	6.9	number	10	SENT_137	[p6l396t2201r528b2254],
10	%	NN	PERCENT	%	amod	13	SENT_137	[p6l396t2201r528b2254],
11	(	CD	NUMBER	(	number	12	SENT_137	[p6l554t2199r746b2267],
12	2/29	CD	NUMBER	2/29	num	13	SENT_137	[p6l554t2199r746b2267],
13	)	NN	O	)	prep_in	7	SENT_137	[p6l554t2199r746b2267],
14	and	CC	O	and	_	0	SENT_137	[p6l774t2198r886b2254],
15	12.5	CD	PERCENT	12.5	num	16	SENT_137	[p6l913t2201r1083b2254],
16	%	NN	PERCENT	%	prep_in	7	SENT_137	[p6l913t2201r1083b2254],
17	(	CD	NUMBER	(	number	18	SENT_137	[p6l1109t2199r1262b2267],
18	1/8	CD	NUMBER	1/8	num	16	SENT_137	[p6l1109t2199r1262b2267],
19	)	NN	O	)	dep	13	SENT_137	[p6l1109t2199r1262b2267],
20	of	IN	O	of	_	0	SENT_137	[p6l1288t2198r1353b2254],
21	patients	NNS	O	patient	prep_of	19	SENT_137	[p6l1368t2199r1618b2267],
22	in	IN	O	in	_	0	SENT_137	[p6l1642t2199r1699b2253],
23	the	DT	O	the	det	27	SENT_137	[p6l1721t2199r1819b2254],
24	wild	JJ	O	wild	amod	27	SENT_137	[p6l1841t2199r2146b2267],
25	—	NN	O	—	nn	27	SENT_137	[p6l1841t2199r2146b2267],
26	type	NN	O	type	nn	27	SENT_137	[p6l1841t2199r2146b2267],
27	group	NN	O	group	prep_in	21	SENT_137	[p6l8t2303r190b2356],
28	and	CC	O	and	_	0	SENT_137	[p6l238t2287r350b2342],
29	mutation	NN	O	mutation	nn	30	SENT_137	[p6l397t2288r684b2342],
30	group	NN	O	group	conj_and	27	SENT_137	[p6l729t2303r927b2356],
31	,	,	O	,	_	0	SENT_137	[p6l729t2303r927b2356],
32	respectively	RB	O	respectively	advmod	13	SENT_137	[p6l975t2287r1352b2356],
33	(	CD	NUMBER	(	num	34	SENT_137	[p6l1401t2287r1766b2356],
34	p	NN	O	p	dep	13	SENT_137	[p6l1401t2287r1766b2356],
35	=	JJ	O	=	amod	37	SENT_137	[p6l1401t2287r1766b2356],
36	0.530	CD	NUMBER	0.530	tmod	35	SENT_137	[p6l1401t2287r1766b2356],
37	)	NN	O	)	dep	34	SENT_137	[p6l1401t2287r1766b2356],
38	.	.	O	.	_	0	SENT_137	[p6l1401t2287r1766b2356],

1	Since	IN	O	since	_	0	SENT_138	[p6l1814t2288r1976b2342],
2	CDA	NNP	ORGANIZATION	CDA	nn	3	SENT_138	[p6l2023t2289r2146b2342],
3	208G	NN	O	208g	prep_since	15	SENT_138	[p6l10t2378r273b2431],
4	>	JJR	O	>	dep	3	SENT_138	[p6l10t2378r273b2431],
5	A	DT	O	a	dep	4	SENT_138	[p6l10t2378r273b2431],
6	was	VBD	O	be	auxpass	8	SENT_138	[p6l304t2392r424b2431],
7	not	RB	O	not	neg	8	SENT_138	[p6l459t2384r562b2431],
8	detected	VBN	O	detect	rcmod	3	SENT_138	[p6l593t2376r861b2431],
9	in	IN	O	in	_	0	SENT_138	[p6l896t2377r953b2430],
10	patients	NNS	O	patient	prep_in	8	SENT_138	[p6l987t2377r1253b2445],
11	,	,	O	,	_	0	SENT_138	[p6l987t2377r1253b2445],
12	it	PRP	O	it	nsubjpass	15	SENT_138	[p6l1289t2377r1330b2431],
13	was	VBD	O	be	auxpass	15	SENT_138	[p6l1362t2392r1482b2431],
14	not	RB	O	not	neg	15	SENT_138	[p6l1517t2384r1619b2431],
15	included	VBN	O	include	_	0	SENT_138	[p6l1653t2376r1921b2431],
16	in	IN	O	in	_	0	SENT_138	[p6l1956t2377r2013b2430],
17	the	DT	O	the	det	18	SENT_138	[p6l2047t2376r2146b2431],
18	analysis	NN	O	analysis	prep_in	15	SENT_138	[p6l9t2465r272b2534],
19	.	.	O	.	_	0	SENT_138	[p6l9t2465r272b2534],

1	4	LS	NUMBER	4	_	0	SENT_139	[p6l7t2647r61b2698],
2	.	.	O	.	_	0	SENT_139	[p6l7t2647r61b2698],

1	Discussion	NN	O	discussion	_	0	SENT_140	[p6l85t2644r428b2698],

1	Gemcitabine	NNP	O	Gemcitabine	nsubjpass	4	SENT_141	[p6l112t2821r497b2876],
2	is	VBZ	O	be	auxpass	4	SENT_141	[p6l524t2822r568b2876],
3	primarily	RB	O	primarily	advmod	4	SENT_141	[p6l595t2821r880b2890],
4	detoxicated	VBN	O	detoxicate	_	0	SENT_141	[p6l904t2821r1261b2876],
5	by	IN	O	by	_	0	SENT_141	[p6l1287t2821r1361b2890],
6	CDA	NNP	ORGANIZATION	CDA	nn	7	SENT_141	[p6l1385t2823r1516b2876],
7	enzyme	NN	O	enzyme	agent	4	SENT_141	[p6l1540t2837r1793b2890],
8	,	,	O	,	_	0	SENT_141	[p6l1540t2837r1793b2890],
9	the	DT	O	the	det	11	SENT_141	[p6l1819t2821r1917b2876],
10	coding	NN	O	coding	nn	11	SENT_141	[p6l1943t2821r2148b2890],
11	gene	NN	O	gene	appos	7	SENT_141	[p6l8t2926r154b2979],
12	of	IN	O	of	_	0	SENT_141	[p6l180t2910r244b2965],
13	which	WDT	O	which	nsubj	15	SENT_141	[p6l260t2910r449b2965],
14	is	VBZ	O	be	cop	15	SENT_141	[p6l476t2911r519b2965],
15	prone	JJ	O	prone	prepc_of	11	SENT_141	[p6l547t2926r725b2979],
16	to	TO	O	to	aux	18	SENT_141	[p6l750t2918r809b2965],
17	be	VB	O	be	cop	18	SENT_141	[p6l835t2910r906b2965],
18	polymorphic	JJ	O	polymorphic	xcomp	15	SENT_141	[p6l932t2910r1338b2979],
19	.	.	O	.	_	0	SENT_141	[p6l932t2910r1338b2979],

1	To	TO	O	to	_	0	SENT_142	[p6l1362t2914r1436b2965],
2	date	NN	O	date	prep_to	7	SENT_142	[p6l1462t2910r1608b2974],
3	,	,	O	,	_	0	SENT_142	[p6l1462t2910r1608b2974],
4	few	JJ	O	few	amod	5	SENT_142	[p6l1635t2910r1747b2965],
5	publications	NNS	O	publication	nsubj	7	SENT_142	[p6l1772t2910r2146b2979],
6	have	VBP	O	have	aux	7	SENT_142	[p6l10t2999r153b3054],
7	reported	VBN	O	report	_	0	SENT_142	[p6l181t2999r445b3068],
8	the	DT	O	the	det	10	SENT_142	[p6l473t2999r570b3054],
9	allele	NN	O	allele	nn	10	SENT_142	[p6l598t2999r758b3054],
10	frequencies	NNS	O	frequency	dobj	7	SENT_142	[p6l787t2999r1139b3068],
11	of	IN	O	of	_	0	SENT_142	[p6l1168t2999r1231b3054],
12	SNPs	NNS	O	snp	prep_of	10	SENT_142	[p6l1252t3002r1399b3054],
13	in	IN	O	in	_	0	SENT_142	[p6l1428t3000r1485b3054],
14	this	DT	O	this	det	15	SENT_142	[p6l1512t2999r1623b3054],
15	gene	NN	O	gene	prep_in	7	SENT_142	[p6l1650t3015r1795b3068],
16	in	IN	O	in	_	0	SENT_142	[p6l1824t3000r1880b3054],
17	Chinese	JJ	LOCATION	chinese	amod	18	SENT_142	[p6l1908t2999r2146b3054],
18	population	NN	O	population	prep_in	15	SENT_142	[p6l10t3089r357b3157],
19	.	.	O	.	_	0	SENT_142	[p6l10t3089r357b3157],

1	In	IN	O	in	_	0	SENT_143	[p6l381t3092r438b3143],
2	Japanese	JJ	MISC	japanese	prep_in	13	SENT_143	[p6l454t3092r743b3157],
3	,	,	O	,	_	0	SENT_143	[p6l454t3092r743b3157],
4	the	DT	O	the	det	6	SENT_143	[p6l767t3089r864b3144],
5	CDA	NNP	ORGANIZATION	CDA	nn	6	SENT_143	[p6l888t3091r1009b3144],
6	208G	NN	O	208g	appos	2	SENT_143	[p6l1032t3091r1293b3144],
7	>	JJR	O	>	dep	6	SENT_143	[p6l1032t3091r1293b3144],
8	A	DT	O	a	det	10	SENT_143	[p6l1032t3091r1293b3144],
9	allele	NN	O	allele	nn	10	SENT_143	[p6l1314t3089r1474b3144],
10	frequency	NN	O	frequency	nsubj	13	SENT_143	[p6l1498t3089r1804b3157],
11	is	VBZ	O	be	cop	13	SENT_143	[p6l1826t3090r1870b3144],
12	4.3	CD	PERCENT	4.3	num	13	SENT_143	[p6l1892t3092r2025b3144],
13	%	NN	PERCENT	%	_	0	SENT_143	[p6l1892t3092r2025b3144],
14	[	CD	NUMBER	[	number	15	SENT_143	[p6l2051t3089r2145b3157],
15	7	CD	NUMBER	7	num	16	SENT_143	[p6l2051t3089r2145b3157],
16	]	NN	O	]	dep	13	SENT_143	[p6l2051t3089r2145b3157],
17	.	.	O	.	_	0	SENT_143	[p6l2051t3089r2145b3157],

1	It	PRP	O	it	nsubjpass	4	SENT_144	[p6l10t3181r52b3233],
2	has	VBZ	O	have	aux	4	SENT_144	[p6l71t3178r171b3233],
3	been	VBN	O	be	auxpass	4	SENT_144	[p6l191t3178r338b3233],
4	demonstrated	VBN	O	demonstrate	_	0	SENT_144	[p6l359t3178r787b3233],
5	to	TO	O	to	aux	7	SENT_144	[p6l807t3186r866b3233],
6	be	VB	O	be	auxpass	7	SENT_144	[p6l886t3178r957b3233],
7	associated	VBN	O	associate	xcomp	4	SENT_144	[p6l977t3178r1291b3233],
8	with	IN	O	with	_	0	SENT_144	[p6l1310t3178r1451b3233],
9	gemcitabine	NN	O	gemcitabine	nn	10	SENT_144	[p6l1469t3178r1846b3246],
10	exposure	NN	O	exposure	prep_with	7	SENT_144	[p6l1866t3194r2146b3246],
11	[	CD	NUMBER	[	number	12	SENT_144	[p6l13t3266r143b3335],
12	6,7	CD	NUMBER	6,7	num	13	SENT_144	[p6l13t3266r143b3335],
13	]	NN	O	]	nsubj	18	SENT_144	[p6l13t3266r143b3335],
14	and	CC	O	and	_	0	SENT_144	[p6l164t3266r275b3321],
15	subsequent	JJ	O	subsequent	amod	17	SENT_144	[p6l294t3266r646b3335],
16	severe	JJ	O	severe	amod	17	SENT_144	[p6l662t3282r857b3321],
17	toxicities	NNS	O	toxicity	conj_and	13	SENT_144	[p6l874t3267r1151b3321],
18	[	VBP	O	[	rcmod	10	SENT_144	[p6l1172t3266r1398b3335],
19	15,16	CD	NUMBER	15,16	number	20	SENT_144	[p6l1172t3266r1398b3335],
20	]	CD	NUMBER	]	dobj	18	SENT_144	[p6l1172t3266r1398b3335],
21	.	.	O	.	_	0	SENT_144	[p6l1172t3266r1398b3335],

1	However	RB	O	however	advmod	26	SENT_145	[p6l1417t3270r1709b3330],
2	,	,	O	,	_	0	SENT_145	[p6l1417t3270r1709b3330],
3	the	DT	O	the	det	4	SENT_145	[p6l1726t3266r1824b3321],
4	frequency	NN	O	frequency	nsubjpass	26	SENT_145	[p6l1842t3266r2148b3335],
5	for	IN	O	for	_	0	SENT_145	[p6l10t3355r95b3411],
6	208G	NN	O	208g	prep_for	4	SENT_145	[p6l119t3358r379b3411],
7	>	JJR	O	>	amod	6	SENT_145	[p6l119t3358r379b3411],
8	A	DT	O	a	det	9	SENT_145	[p6l119t3358r379b3411],
9	polymorphism	NN	O	polymorphism	nsubj	15	SENT_145	[p6l402t3356r854b3424],
10	in	IN	O	in	_	0	SENT_145	[p6l879t3356r935b3410],
11	Chinese	JJ	LOCATION	chinese	amod	12	SENT_145	[p6l961t3356r1199b3411],
12	population	NN	O	population	prep_in	9	SENT_145	[p6l1225t3356r1558b3424],
13	is	VBZ	O	be	cop	15	SENT_145	[p6l1583t3356r1627b3411],
14	1.0	CD	PERCENT	1.0	num	15	SENT_145	[p6l1657t3358r1785b3411],
15	%	NN	PERCENT	%	ccomp	7	SENT_145	[p6l1657t3358r1785b3411],
16	in	IN	O	in	_	0	SENT_145	[p6l1811t3356r1867b3410],
17	our	PRP$	O	we	poss	19	SENT_145	[p6l1892t3371r1996b3411],
18	present	JJ	DATE	present	amod	19	SENT_145	[p6l2020t3371r2146b3424, p6l10t3452r138b3499],
19	study	NN	O	study	prep_in	7	SENT_145	[p6l154t3444r322b3513],
20	and	CC	O	and	_	0	SENT_145	[p6l338t3444r449b3499],
21	no	DT	O	no	det	24	SENT_145	[p6l467t3460r541b3499],
22	Chinese	JJ	MISC	chinese	amod	24	SENT_145	[p6l559t3444r797b3499],
23	cancer	NN	O	cancer	nn	24	SENT_145	[p6l814t3460r1014b3499],
24	patient	NN	O	patient	prep_in	7	SENT_145	[p6l1030t3445r1248b3513],
25	was	VBD	O	be	auxpass	26	SENT_145	[p6l1261t3460r1381b3499],
26	found	VBN	O	find	_	0	SENT_145	[p6l1399t3444r1575b3499],
27	to	TO	O	to	aux	29	SENT_145	[p6l1593t3452r1652b3499],
28	be	VB	O	be	cop	29	SENT_145	[p6l1669t3444r1739b3499],
29	homozygous	JJ	O	homozygous	xcomp	26	SENT_145	[p6l1757t3444r2146b3513],
30	or	CC	O	or	_	0	SENT_145	[p6l10t3550r73b3589],
31	heterozygous	JJ	O	heterozygous	xcomp	26	SENT_145	[p6l95t3534r506b3602],
32	for	IN	O	for	_	0	SENT_145	[p6l531t3534r616b3589],
33	the	DT	O	the	det	35	SENT_145	[p6l637t3534r734b3589],
34	variant	JJ	O	variant	amod	35	SENT_145	[p6l756t3535r974b3589],
35	allele	NN	O	allele	prep_for	29	SENT_145	[p6l996t3534r1171b3589],
36	.	.	O	.	_	0	SENT_145	[p6l996t3534r1171b3589],

1	The	DT	O	the	det	2	SENT_146	[p6l1193t3534r1305b3589],
2	frequency	NN	O	frequency	nsubjpass	4	SENT_146	[p6l1329t3534r1636b3602],
3	was	VBD	O	be	auxpass	4	SENT_146	[p6l1656t3550r1775b3589],
4	reported	VBN	O	report	dep	34	SENT_146	[p6l1800t3534r2064b3602],
5	to	TO	O	to	aux	8	SENT_146	[p6l2087t3542r2146b3589],
6	be	VB	O	be	cop	8	SENT_146	[p7l9t17r79b72],
7	0.5	CD	PERCENT	0.5	num	8	SENT_146	[p7l107t20r238b72],
8	%	NN	PERCENT	%	xcomp	4	SENT_146	[p7l107t20r238b72],
9	in	IN	O	in	_	0	SENT_146	[p7l265t18r321b71],
10	one	CD	NUMBER	one	num	11	SENT_146	[p7l349t33r459b72],
11	study	NN	O	study	prep_in	8	SENT_146	[p7l487t17r656b85],
12	in	IN	O	in	_	0	SENT_146	[p7l681t18r738b71],
13	Chinese	JJ	MISC	chinese	amod	14	SENT_146	[p7l765t17r1003b72],
14	population	NN	O	population	prep_in	11	SENT_146	[p7l1030t17r1363b85],
15	(	CD	NUMBER	(	nsubj	23	SENT_146	[p7l1394t17r1708b85],
16	including	VBG	O	include	_	0	SENT_146	[p7l1394t17r1708b85],
17	patients	NNS	O	patient	prep_including	15	SENT_146	[p7l1734t18r1979b85],
18	with	IN	O	with	_	0	SENT_146	[p7l2005t17r2146b72],
19	acute	JJ	O	acute	amod	20	SENT_146	[p7l9t113r172b160],
20	leukemia	NN	O	leukemia	prep_with	17	SENT_146	[p7l198t105r492b169],
21	,	,	O	,	_	0	SENT_146	[p7l198t105r492b169],
22	n	NN	O	n	appos	20	SENT_146	[p7l520t121r557b160],
23	=	JJ	O	=	rcmod	11	SENT_146	[p7l573t128r627b149],
24	286	CD	NUMBER	286	num	26	SENT_146	[p7l645t105r783b173],
25	)	CD	NUMBER	)	num	26	SENT_146	[p7l645t105r783b173],
26	[	NN	O	[	iobj	23	SENT_146	[p7l816t105r931b174],
27	17	CD	NUMBER	17	num	28	SENT_146	[p7l816t105r931b174],
28	]	NN	O	]	dobj	23	SENT_146	[p7l816t105r931b174],
29	and	CC	O	and	_	0	SENT_146	[p7l960t105r1071b160],
30	the	DT	O	the	det	31	SENT_146	[p7l1097t105r1194b160],
31	allele	NN	O	allele	prep_in	8	SENT_146	[p7l1220t105r1380b160],
32	was	VBD	O	be	auxpass	34	SENT_146	[p7l1405t121r1524b160],
33	not	RB	O	not	neg	34	SENT_146	[p7l1550t113r1651b160],
34	detected	VBN	O	detect	_	0	SENT_146	[p7l1676t105r1938b160],
35	in	IN	O	in	_	0	SENT_146	[p7l1965t106r2021b160],
36	another	DT	O	another	det	38	SENT_146	[p7l2047t121r2146b160, p7l10t194r174b249],
37	(	NN	O	(	nn	38	SENT_146	[p7l200t194r263b263],
38	n	NN	O	n	prep_in	34	SENT_146	[p7l200t194r263b263],
39	=	JJ	O	=	amod	38	SENT_146	[p7l279t217r333b238],
40	200	CD	NUMBER	200	tmod	39	SENT_146	[p7l351t194r488b262],
41	)	CD	NUMBER	)	num	44	SENT_146	[p7l351t194r488b262],
42	[	NN	O	[	nn	44	SENT_146	[p7l520t194r653b263],
43	16	CD	NUMBER	16	num	44	SENT_146	[p7l520t194r653b263],
44	]	NN	O	]	nsubjpass	34	SENT_146	[p7l520t194r653b263],
45	.	.	O	.	_	0	SENT_146	[p7l520t194r653b263],

1	The	DT	O	the	det	2	SENT_147	[p7l674t194r787b249],
2	discrepancies	NNS	O	discrepancy	nsubjpass	11	SENT_147	[p7l811t194r1222b263],
3	between	IN	O	between	_	0	SENT_147	[p7l1246t194r1511b249],
4	the	DT	O	the	det	6	SENT_147	[p7l1534t194r1631b249],
5	reported	VBN	O	report	amod	6	SENT_147	[p7l1655t194r1919b263],
6	results	NNS	O	result	prep_between	2	SENT_147	[p7l1944t194r2146b249],
7	and	CC	O	and	_	0	SENT_147	[p7l9t284r121b339],
8	ours	JJ	O	ours	prep_between	2	SENT_147	[p7l140t299r270b339],
9	might	MD	O	might	aux	11	SENT_147	[p7l290t284r472b352],
10	be	VB	O	be	auxpass	11	SENT_147	[p7l487t284r557b339],
11	caused	VBN	O	cause	_	0	SENT_147	[p7l576t284r783b339],
12	by	IN	O	by	_	0	SENT_147	[p7l802t284r876b352],
13	the	DT	O	the	det	14	SENT_147	[p7l892t284r989b339],
14	rarity	NN	O	rarity	agent	11	SENT_147	[p7l1008t284r1176b352],
15	of	IN	O	of	_	0	SENT_147	[p7l1193t283r1256b339],
16	the	DT	O	the	det	17	SENT_147	[p7l1266t284r1363b339],
17	SNP	NN	O	snp	prep_of	14	SENT_147	[p7l1382t286r1516b339],
18	.	.	O	.	_	0	SENT_147	[p7l1382t286r1516b339],

1	The	DT	O	the	det	3	SENT_148	[p7l1532t283r1644b339],
2	allele	NN	O	allele	nn	3	SENT_148	[p7l1662t284r1823b339],
3	frequency	NN	O	frequency	nsubj	11	SENT_148	[p7l1842t283r2148b352],
4	for	IN	O	for	_	0	SENT_148	[p7l10t372r95b427],
5	CDA	NNP	ORGANIZATION	CDA	nn	6	SENT_148	[p7l113t375r235b427],
6	79A	NNP	O	79A	prep_for	3	SENT_148	[p7l256t375r468b427],
7	>	JJR	O	>	dep	8	SENT_148	[p7l256t375r468b427],
8	C	NN	O	c	amod	6	SENT_148	[p7l256t375r468b427],
9	was	VBD	O	be	cop	11	SENT_148	[p7l484t388r603b427],
10	12.2	CD	PERCENT	12.2	num	11	SENT_148	[p7l627t375r794b428],
11	%	NN	PERCENT	%	_	0	SENT_148	[p7l627t375r794b428],
12	in	IN	O	in	_	0	SENT_148	[p7l813t373r869b427],
13	our	PRP$	O	we	poss	15	SENT_148	[p7l889t388r993b427],
14	present	JJ	DATE	present	amod	15	SENT_148	[p7l1011t380r1242b441],
15	study	NN	O	study	prep_in	11	SENT_148	[p7l1261t372r1442b441],
16	.	.	O	.	_	0	SENT_148	[p7l1261t372r1442b441],

1	It	PRP	O	it	nsubj	3	SENT_149	[p7l1463t376r1505b427],
2	is	VBZ	O	be	cop	3	SENT_149	[p7l1523t373r1567b427],
3	comparable	JJ	O	comparable	_	0	SENT_149	[p7l1588t372r1946b441],
4	to	TO	O	to	_	0	SENT_149	[p7l1966t380r2024b427],
5	our	PRP$	O	we	poss	7	SENT_149	[p7l2044t388r2148b427],
6	previous	JJ	O	previous	amod	7	SENT_149	[p7l10t463r272b530],
7	report	NN	O	report	prep_to	3	SENT_149	[p7l296t470r486b530],
8	(	CD	PERCENT	(	number	9	SENT_149	[p7l511t462r733b530],
9	14.8	CD	PERCENT	14.8	num	10	SENT_149	[p7l511t462r733b530],
10	%	NN	PERCENT	%	dep	7	SENT_149	[p7l511t462r733b530],
11	)	CD	NUMBER	)	number	12	SENT_149	[p7l511t462r733b530],
12	[	CD	NUMBER	[	dep	7	SENT_149	[p7l763t462r878b530],
13	13	CD	NUMBER	13	num	14	SENT_149	[p7l763t462r878b530],
14	]	NN	O	]	dep	12	SENT_149	[p7l763t462r878b530],
15	and	CC	O	and	_	0	SENT_149	[p7l903t462r1014b517],
16	to	TO	O	to	_	0	SENT_149	[p7l1037t470r1096b517],
17	others	NNS	O	other	conj_and	7	SENT_149	[p7l1119t462r1310b517],
18	[	VBP	O	[	rcmod	17	SENT_149	[p7l1336t462r1562b530],
19	17,18	CD	NUMBER	17,18	number	20	SENT_149	[p7l1336t462r1562b530],
20	]	CD	NUMBER	]	dobj	18	SENT_149	[p7l1336t462r1562b530],
21	.	.	O	.	_	0	SENT_149	[p7l1336t462r1562b530],

1	While	IN	O	while	mark	15	SENT_150	[p7l109t551r291b606],
2	the	DT	O	the	det	3	SENT_150	[p7l313t551r409b606],
3	inﬂuence	NN	O	inﬂuence	nsubjpass	15	SENT_150	[p7l433t551r709b606],
4	of	IN	O	of	_	0	SENT_150	[p7l731t551r794b606],
5	208G	NN	O	208g	npadvmod	6	SENT_150	[p7l810t553r1067b606],
6	>	JJR	O	>	prep_of	3	SENT_150	[p7l810t553r1067b606],
7	A	DT	O	a	dep	6	SENT_150	[p7l810t553r1067b606],
8	on	IN	O	on	_	0	SENT_150	[p7l1087t567r1161b606],
9	clinical	JJ	O	clinical	amod	10	SENT_150	[p7l1184t551r1392b606],
10	outcome	NN	O	outcome	prep_on	6	SENT_150	[p7l1416t559r1677b606],
11	of	IN	O	of	_	0	SENT_150	[p7l1700t551r1763b606],
12	gemcitabine	NN	O	gemcitabine	prep_of	10	SENT_150	[p7l1777t551r2147b619],
13	has	VBZ	O	have	aux	15	SENT_150	[p7l10t638r108b692],
14	been	VBN	O	be	auxpass	15	SENT_150	[p7l125t638r270b692],
15	demonstrated	VBN	O	demonstrate	csubj	33	SENT_150	[p7l287t638r722b701],
16	,	,	O	,	_	0	SENT_150	[p7l287t638r722b701],
17	whether	IN	O	whether	complm	22	SENT_150	[p7l739t638r996b692],
18	79A	NNP	O	79A	nsubj	22	SENT_150	[p7l1013t641r1222b692],
19	>	JJR	O	>	dep	20	SENT_150	[p7l1013t641r1222b692],
20	C	NN	O	c	amod	18	SENT_150	[p7l1013t641r1222b692],
21	could	MD	O	could	aux	22	SENT_150	[p7l1238t638r1400b692],
22	account	VB	O	account	ccomp	15	SENT_150	[p7l1417t646r1653b692],
23	for	IN	O	for	_	0	SENT_150	[p7l1669t638r1753b692],
24	the	DT	O	the	det	25	SENT_150	[p7l1767t638r1863b692],
25	variation	NN	O	variation	prep_for	22	SENT_150	[p7l1878t639r2146b692],
26	in	IN	O	in	_	0	SENT_150	[p7l10t727r65b781],
27	its	PRP$	O	its	poss	28	SENT_150	[p7l83t727r149b781],
28	efﬁcacy	NN	O	efﬁcacy	prep_in	25	SENT_150	[p7l167t726r394b795],
29	and	CC	O	and	_	0	SENT_150	[p7l408t726r518b781],
30	safety	NN	O	safety	prep_in	25	SENT_150	[p7l535t726r712b795],
31	is	VBZ	O	be	cop	33	SENT_150	[p7l727t727r771b781],
32	still	RB	O	still	advmod	33	SENT_150	[p7l788t726r893b781],
33	controversial	JJ	O	controversial	_	0	SENT_150	[p7l910t726r1315b782],
34	.	.	O	.	_	0	SENT_150	[p7l910t726r1315b782],

1	Since	IN	O	since	mark	6	SENT_151	[p7l1333t727r1488b781],
2	only	RB	O	only	quantmod	3	SENT_151	[p7l1505t726r1636b795],
3	37	CD	NUMBER	37	num	4	SENT_151	[p7l1649t729r1722b781],
4	patients	NNS	O	patient	nsubjpass	6	SENT_151	[p7l1740t727r1979b795],
5	were	VBD	O	be	auxpass	6	SENT_151	[p7l1995t742r2146b781],
6	included	VBN	O	include	advcl	13	SENT_151	[p7l10t815r268b870],
7	in	IN	O	in	_	0	SENT_151	[p7l296t816r352b870],
8	the	DT	O	the	det	10	SENT_151	[p7l378t815r474b870],
9	ﬁnal	JJ	O	ﬁnal	amod	10	SENT_151	[p7l502t815r631b870],
10	analysis	NN	O	analysis	prep_in	6	SENT_151	[p7l659t815r910b884],
11	,	,	O	,	_	0	SENT_151	[p7l659t815r910b884],
12	we	PRP	O	we	nsubj	13	SENT_151	[p7l936t831r1025b870],
13	tested	VBD	O	test	_	0	SENT_151	[p7l1053t815r1234b870],
14	the	DT	O	the	det	15	SENT_151	[p7l1262t815r1357b870],
15	correlation	NN	O	correlation	dobj	13	SENT_151	[p7l1385t815r1712b870],
16	between	IN	O	between	_	0	SENT_151	[p7l1738t815r1998b870],
17	CDA	NNP	ORGANIZATION	CDA	nn	18	SENT_151	[p7l2027t818r2147b870],
18	79A	NNP	O	79A	prep_between	15	SENT_151	[p7l11t907r219b959],
19	>	JJR	O	>	amod	21	SENT_151	[p7l11t907r219b959],
20	C	NN	O	c	nn	21	SENT_151	[p7l11t907r219b959],
21	polymorphism	NN	O	polymorphism	dep	18	SENT_151	[p7l247t904r691b973],
22	and	CC	O	and	_	0	SENT_151	[p7l717t904r827b959],
23	gemcitabine	NN	O	gemcitabine	nn	24	SENT_151	[p7l854t904r1561b973],
24	—	NN	O	—	conj_and	18	SENT_151	[p7l854t904r1561b973],
25	associated	VBN	O	associate	partmod	24	SENT_151	[p7l854t904r1561b973],
26	myelotoxicities	NNS	O	myelotoxicity	dobj	25	SENT_151	[p7l1590t904r2046b973],
27	by	IN	O	by	_	0	SENT_151	[p7l2075t904r2149b973],
28	using	VBG	O	use	agent	25	SENT_151	[p7l10t995r171b1062],
29	Fisher	NNP	PERSON	Fisher	poss	32	SENT_151	[p7l192t994r414b1049],
30	's	POS	O	's	_	0	SENT_151	[p7l192t994r414b1049],
31	exact	JJ	O	exact	amod	32	SENT_151	[p7l436t1002r594b1049],
32	test	NN	O	test	dobj	28	SENT_151	[p7l613t1002r735b1049],
33	.	.	O	.	_	0	SENT_151	[p7l613t1002r735b1049],

1	Our	PRP$	O	we	poss	2	SENT_152	[p7l758t997r871b1049],
2	study	NN	O	study	nsubj	3	SENT_152	[p7l890t994r1055b1062],
3	validated	VBD	O	validate	_	0	SENT_152	[p7l1073t994r1351b1049],
4	that	IN	O	that	advmod	3	SENT_152	[p7l1372t994r1492b1049],
5	despite	IN	O	despite	_	0	SENT_152	[p7l1512t994r1729b1062],
6	the	DT	O	the	det	10	SENT_152	[p7l1750t994r1846b1049],
7	relatively	RB	O	relatively	advmod	8	SENT_152	[p7l1868t994r2148b1062],
8	low	JJ	O	low	amod	10	SENT_152	[p7l10t1083r122b1138],
9	allele	NN	O	allele	nn	10	SENT_152	[p7l140t1083r296b1138],
10	frequency	NN	O	frequency	prep_despite	4	SENT_152	[p7l317t1083r617b1151],
11	of	IN	O	of	_	0	SENT_152	[p7l635t1083r698b1138],
12	79A	NN	O	79a	prep_of	10	SENT_152	[p7l711t1085r920b1138],
13	>	JJR	O	>	amod	14	SENT_152	[p7l711t1085r920b1138],
14	C	NN	O	c	dobj	3	SENT_152	[p7l711t1085r920b1138],
15	in	IN	O	in	_	0	SENT_152	[p7l939t1084r995b1137],
16	Asians	NNPS	MISC	Asians	prep_in	3	SENT_152	[p7l1012t1084r1205b1138],
17	(	RB	O	(	advmod	3	SENT_152	[p7l1229t1083r1313b1151],
18	as	IN	O	as	mark	32	SENT_152	[p7l1229t1083r1313b1151],
19	compared	VBN	O	compare	_	0	SENT_152	[p7l1334t1083r1633b1151],
20	to	TO	O	to	prepc_compared_to	32	SENT_152	[p7l1654t1091r1712b1138],
21	the	DT	O	the	det	22	SENT_152	[p7l1731t1083r1827b1138],
22	frequency	NN	O	frequency	pobj	32	SENT_152	[p7l1848t1083r2148b1151],
23	in	IN	O	in	_	0	SENT_152	[p7l10t1172r65b1226],
24	Caucasians	NNPS	MISC	Caucasians	prep_in	22	SENT_152	[p7l94t1171r461b1239],
25	)	RB	O	)	advmod	24	SENT_152	[p7l94t1171r461b1239],
26	,	,	O	,	_	0	SENT_152	[p7l94t1171r461b1239],
27	patients	NNS	O	patient	nsubj	32	SENT_152	[p7l491t1172r730b1240],
28	carrying	VBG	O	carry	partmod	27	SENT_152	[p7l760t1172r1007b1240],
29	variant	JJ	O	variant	amod	31	SENT_152	[p7l1032t1172r1245b1226],
30	C	NN	O	c	nn	31	SENT_152	[p7l1272t1174r1309b1226],
31	allele	NN	O	allele	dobj	28	SENT_152	[p7l1336t1171r1493b1226],
32	were	VBD	O	be	advcl	3	SENT_152	[p7l1520t1187r1671b1226],
33	at	IN	O	at	_	0	SENT_152	[p7l1699t1179r1756b1226],
34	signiﬁcantly	RB	O	signiﬁcantly	advmod	35	SENT_152	[p7l1782t1171r2148b1240],
35	higher	JJR	O	higher	amod	36	SENT_152	[p7l10t1260r205b1329],
36	risk	NN	O	risk	prep_at	32	SENT_152	[p7l276t1260r386b1315],
37	of	IN	O	of	_	0	SENT_152	[p7l455t1260r519b1315],
38	developing	VBG	O	develop	amod	40	SENT_152	[p7l583t1260r916b1329],
39	gemcitabine	NN	O	gemcitabine	nn	40	SENT_152	[p7l986t1260r1692b1329],
40	—	NN	O	—	prep_of	36	SENT_152	[p7l986t1260r1692b1329],
41	associated	VBN	O	associate	partmod	40	SENT_152	[p7l986t1260r1692b1329],
42	neutropenia	NN	O	neutropenia	dobj	41	SENT_152	[p7l1766t1261r2146b1329],
43	.	.	O	.	_	0	SENT_152	[p7l1766t1261r2146b1329],

1	Table	NNP	O	Table	nn	3	SENT_153	[p7l6t1483r145b1527],
2	3	CD	NUMBER	3	num	3	SENT_153	[p7l163t1486r192b1527],
3	Toxicity	NN	O	toxicity	_	0	SENT_153	[p7l7t1556r204b1609],
4	of	IN	O	of	_	0	SENT_153	[p7l223t1555r274b1598],
5	gemcitabine-based	JJ	O	gemcitabine-based	amod	6	SENT_153	[p7l286t1555r752b1609],
6	chemotherapy	NN	O	chemotherapy	prep_of	3	SENT_153	[p7l774t1555r1131b1609],
7	by	IN	O	by	_	0	SENT_153	[p7l1150t1555r1209b1609],
8	NCI	NNP	ORGANIZATION	NCI	nn	10	SENT_153	[p7l1227t1557r1311b1598],
9	CTCAE	NNP	O	CTCAE	nn	10	SENT_153	[p7l1332t1557r1489b1598],
10	v3	NN	O	v3	prep_by	3	SENT_153	[p7l1507t1557r1621b1599],
11	.0	CD	NUMBER	.0	num	10	SENT_153	[p7l1507t1557r1621b1599],
12	.	.	O	.	_	0	SENT_153	[p7l1507t1557r1621b1599],

1	Toxicity	NN	O	toxicity	nsubj	2	SENT_154	[p7l58t1692r255b1746],
2	NCI	NN	O	ncus	_	0	SENT_154	[p7l1275t1693r1543b1735],
3	.	.	O	.	_	0	SENT_154	[p7l1275t1693r1543b1735],

1	—	NN	O	—	_	0	SENT_155	[p7l1275t1693r1543b1735],
2	.	.	O	.	_	0	SENT_155	[p7l1275t1693r1543b1735],

1	CTCAE	NNP	O	CTCAE	_	0	SENT_156	[p7l1275t1693r1543b1735],
2	grade	NN	O	grade	dep	1	SENT_156	[p7l1561t1691r1699b1746],

1	1	CD	NUMBER	1	number	2	SENT_157	[p7l1277t1830r1296b1871],
2	2	CD	NUMBER	2	num	4	SENT_157	[p7l1443t1830r1469b1871],
3	3	CD	NUMBER	3	number	4	SENT_157	[p7l1641t1830r1668b1871],
4	4	CD	NUMBER	4	npadvmod	5	SENT_157	[p7l1809t1830r1839b1871],
5	Total	JJ	O	total	_	0	SENT_157	[p7l1977t1828r2100b1871],

1	Hematologic	JJ	O	hematologic	amod	2	SENT_158	[p7l60t1938r371b1993],
2	Leukopenia	NN	O	leukopenia	dep	9	SENT_158	[p7l623t1938r905b1993],
3	6	CD	NUMBER	6	number	4	SENT_158	[p7l1275t1941r1302b1982],
4	18	CD	NUMBER	18	dep	2	SENT_158	[p7l1446t1941r1500b1982],
5	6	CD	NUMBER	6	num	6	SENT_158	[p7l1643t1941r1670b1982],
6	o	NN	O	o	dep	4	SENT_158	[p7l1811t1941r1838b1982],
7	30	CD	NUMBER	30	num	8	SENT_158	[p7l1978t1941r2038b1982],
8	Neutropenia	NN	O	neutropenia	dep	9	SENT_158	[p7l623t2011r930b2064],
9	7	CD	NUMBER	7	dep	14	SENT_158	[p7l1276t2013r1301b2053],
10	8	CD	NUMBER	8	number	11	SENT_158	[p7l1474t2012r1500b2053],
11	8	CD	NUMBER	8	dep	9	SENT_158	[p7l1643t2012r1669b2053],
12	2	CD	NUMBER	2	num	13	SENT_158	[p7l1811t2012r1837b2053],
13	25	CD	NUMBER	25	dep	11	SENT_158	[p7l1979t2012r2036b2053],
14	Anemia	NN	O	anemia	dep	17	SENT_158	[p7l621t2083r811b2126],
15	5	CD	NUMBER	5	num	14	SENT_158	[p7l1276t2085r1301b2126],
16	10	CD	NUMBER	10	num	17	SENT_158	[p7l1446t2084r1501b2126],
17	O	NN	O	o	dep	18	SENT_158	[p7l1643t2084r1670b2126],
18	o	NN	O	o	dep	20	SENT_158	[p7l1811t2084r1838b2126],
19	15	CD	NUMBER	15	num	18	SENT_158	[p7l1982t2085r2036b2126],
20	Thrombopenia	NNP	O	Thrombopenia	dep	28	SENT_158	[p7l621t2153r985b2208],
21	5	CD	NUMBER	5	num	20	SENT_158	[p7l1276t2156r1301b2197],
22	1	CD	NUMBER	1	number	23	SENT_158	[p7l1477t2156r1495b2197],
23	3	CD	NUMBER	3	dep	20	SENT_158	[p7l1642t2156r1668b2197],
24	O	NN	O	o	nn	26	SENT_158	[p7l1811t2156r1838b2197],
25	9	CD	NUMBER	9	num	26	SENT_158	[p7l2010t2156r2037b2197],
26	Non	NNP	O	Non	dep	23	SENT_158	[p7l60t2228r160b2269],
27	hematologic	JJ	O	hematologic	amod	28	SENT_158	[p7l180t2225r483b2280],
28	Nausea	NN	MISC	nausea	dep	39	SENT_158	[p7l623t2228r799b2269],
29	and	CC	O	and	_	0	SENT_158	[p7l819t2225r908b2269],
30	diarrhea	NN	O	diarrhea	conj_and	28	SENT_158	[p7l929t2225r1135b2269],
31	7	CD	NUMBER	7	number	32	SENT_158	[p7l1276t2228r1301b2268],
32	1	CD	NUMBER	1	num	34	SENT_158	[p7l1477t2228r1495b2268],
33	O	NN	O	o	nn	34	SENT_158	[p7l1643t2227r1670b2269],
34	O	NN	O	o	dep	28	SENT_158	[p7l1811t2227r1838b2269],
35	8	CD	NUMBER	8	num	36	SENT_158	[p7l2011t2227r2036b2269],
36	Rash	NNP	O	Rash	dep	34	SENT_158	[p7l623t2298r738b2341],
37	2	CD	NUMBER	2	num	36	SENT_158	[p7l1275t2300r1301b2341],
38	4	CD	NUMBER	4	num	39	SENT_158	[p7l1472t2300r1502b2341],
39	o	NN	O	o	dep	40	SENT_158	[p7l1643t2300r1670b2341],
40	o	NN	O	o	dep	43	SENT_158	[p7l1811t2300r1838b2341],
41	6	CD	NUMBER	6	num	40	SENT_158	[p7l2011t2300r2038b2341],
42	Other	JJ	O	other	amod	43	SENT_158	[p7l623t2370r763b2414],
43	4	CD	NUMBER	4	dep	46	SENT_158	[p7l1273t2372r1303b2413],
44	1	CD	NUMBER	1	num	45	SENT_158	[p7l1477t2372r1496b2413],
45	O	NN	O	o	dep	43	SENT_158	[p7l1643t2372r1670b2414],
46	o	NN	O	o	_	0	SENT_158	[p7l1811t2372r1838b2414],
47	5	CD	NUMBER	5	num	46	SENT_158	[p7l2011t2373r2036b2414],

1	Although	IN	O	although	mark	32	SENT_159	[p7l6t2605r286b2673],
2	due	JJ	O	due	_	0	SENT_159	[p7l311t2605r420b2660],
3	to	TO	O	to	_	0	SENT_159	[p7l446t2613r505b2660],
4	the	DT	O	the	det	7	SENT_159	[p7l530t2605r626b2660],
5	small	JJ	O	small	amod	7	SENT_159	[p7l652t2605r809b2660],
6	sample	NN	O	sample	nn	7	SENT_159	[p7l836t2605r1048b2673],
7	size	NN	O	size	prep_due_to	21	SENT_159	[p7l1075t2606r1187b2660],
8	in	IN	O	in	_	0	SENT_159	[p7l1212t2606r1268b2659],
9	the	DT	O	the	det	13	SENT_159	[p7l1292t2605r1388b2660],
10	mutation	NN	O	mutation	nn	13	SENT_159	[p7l1414t2606r1690b2660],
11	group	NN	O	group	nn	13	SENT_159	[p7l1714t2621r1890b2673],
12	(	CD	NUMBER	(	num	13	SENT_159	[p7l1920t2605r2053b2673],
13	n	NN	O	n	prep_in	7	SENT_159	[p7l1920t2605r2053b2673],
14	:	:	O	:	_	0	SENT_159	[p7l1920t2605r2053b2673],
15	8	CD	NUMBER	8	num	16	SENT_159	[p7l2070t2605r2147b2673],
16	)	NN	O	)	dep	13	SENT_159	[p7l2070t2605r2147b2673],
17	,	,	O	,	_	0	SENT_159	[p7l2070t2605r2147b2673],
18	thrombopenia	NN	O	thrombopenia	conj_and	16	SENT_159	[p7l8t2694r439b2762],
19	and	CC	O	and	_	0	SENT_159	[p7l478t2694r587b2749],
20	leul	NN	O	leul	dep	13	SENT_159	[p7l629t2694r960b2762],
21	<	JJR	O	<	nsubj	32	SENT_159	[p7l629t2694r960b2762],
22	openia	CD	NUMBER	openia	dep	21	SENT_159	[p7l629t2694r960b2762],
23	developed	VBN	O	develop	partmod	21	SENT_159	[p7l999t2694r1311b2762],
24	in	IN	O	in	_	0	SENT_159	[p7l1351t2694r1408b2748],
25	patients	NNS	O	patient	prep_in	23	SENT_159	[p7l1447t2694r1687b2762],
26	in	IN	O	in	_	0	SENT_159	[p7l1728t2694r1784b2748],
27	this	DT	O	this	det	28	SENT_159	[p7l1823t2694r1932b2749],
28	group	NN	O	group	prep_in	25	SENT_159	[p7l1971t2709r2149b2762],
29	were	VBD	O	be	cop	32	SENT_159	[p7l7t2798r159b2837],
30	not	RB	O	not	neg	32	SENT_159	[p7l186t2790r286b2837],
31	statistically	RB	O	statistically	advmod	32	SENT_159	[p7l313t2782r651b2851],
32	signiﬁcant	JJ	O	signiﬁcant	advcl	43	SENT_159	[p7l677t2782r989b2851],
33	as	IN	O	as	prep	32	SENT_159	[p7l1014t2798r1073b2837],
34	compared	VBN	O	compare	_	0	SENT_159	[p7l1101t2782r1402b2851],
35	to	TO	O	to	prepc_compared_to	32	SENT_159	[p7l1429t2790r1488b2837],
36	the	DT	O	the	det	40	SENT_159	[p7l1514t2782r1611b2837],
37	wild	JJ	O	wild	amod	40	SENT_159	[p7l1636t2782r1930b2851],
38	—	NN	O	—	nn	40	SENT_159	[p7l1636t2782r1930b2851],
39	type	NN	O	type	nn	40	SENT_159	[p7l1636t2782r1930b2851],
40	group	NN	O	group	pobj	32	SENT_159	[p7l1956t2798r2147b2851],
41	,	,	O	,	_	0	SENT_159	[p7l1956t2798r2147b2851],
42	we	PRP	O	we	nsubj	43	SENT_159	[p7l7t2887r96b2926],
43	observed	VBD	O	observe	_	0	SENT_159	[p7l114t2871r379b2926],
44	the	DT	O	the	det	45	SENT_159	[p7l397t2871r490b2926],
45	tendency	NN	O	tendency	dobj	43	SENT_159	[p7l508t2871r781b2940],
46	that	IN	O	that	complm	62	SENT_159	[p7l796t2871r914b2926],
47	in	IN	O	in	_	0	SENT_159	[p7l931t2872r985b2925],
48	Chinese	JJ	LOCATION	chinese	amod	49	SENT_159	[p7l1003t2871r1230b2926],
49	population	NN	O	population	prep_in	62	SENT_159	[p7l1248t2871r1578b2940],
50	,	,	O	,	_	0	SENT_159	[p7l1248t2871r1578b2940],
51	a	DT	O	a	det	53	SENT_159	[p7l1597t2887r1628b2926],
52	larger	JJR	O	larger	amod	53	SENT_159	[p7l1646t2871r1816b2940],
53	proportion	NN	O	proportion	nsubj	62	SENT_159	[p7l1832t2872r2148b2940],
54	of	IN	O	of	_	0	SENT_159	[p7l9t2960r71b3015],
55	patients	NNS	O	patient	prep_of	53	SENT_159	[p7l83t2961r316b3029],
56	with	IN	O	with	_	0	SENT_159	[p7l334t2960r470b3015],
57	A/C	NN	O	a/c	nn	60	SENT_159	[p7l486t2963r592b3025],
58	and	CC	O	and	_	0	SENT_159	[p7l611t2960r718b3015],
59	C/C	NN	O	c/c	nn	60	SENT_159	[p7l738t2963r837b3025],
60	genotypes	NNS	O	genotype	prep_with	55	SENT_159	[p7l854t2968r1154b3029],
61	had	VBD	O	have	aux	62	SENT_159	[p7l1175t2960r1282b3015],
62	experienced	VBN	O	experience	ccomp	43	SENT_159	[p7l1302t2960r1660b3029],
63	severe	JJ	O	severe	amod	64	SENT_159	[p7l1681t2976r1867b3015],
64	toxicities	NNS	O	toxicity	dobj	62	SENT_159	[p7l1886t2961r2148b3015],
65	after	IN	O	after	_	0	SENT_159	[p7l9t3049r144b3104],
66	gemcitabine	NN	O	gemcitabine	nn	67	SENT_159	[p7l157t3049r518b3118],
67	administration	NN	O	administration	prep_after	62	SENT_159	[p7l534t3049r966b3104],
68	than	IN	O	than	_	0	SENT_159	[p7l982t3049r1115b3104],
69	patients	NNS	O	patient	prep_than	62	SENT_159	[p7l1132t3050r1365b3118],
70	with	IN	O	with	_	0	SENT_159	[p7l1381t3049r1517b3104],
71	wild	JJ	O	wild	amod	74	SENT_159	[p7l1532t3049r1818b3118],
72	—	NN	O	—	nn	74	SENT_159	[p7l1532t3049r1818b3118],
73	type	NN	O	type	nn	74	SENT_159	[p7l1532t3049r1818b3118],
74	genotypes	NNS	O	genotype	prep_with	69	SENT_159	[p7l1833t3057r2148b3118],
75	.	.	O	.	_	0	SENT_159	[p7l1833t3057r2148b3118],

1	Meanwhile	RB	O	meanwhile	advmod	16	SENT_160	[p7l9t3139r352b3202],
2	,	,	O	,	_	0	SENT_160	[p7l9t3139r352b3202],
3	although	IN	O	although	mark	8	SENT_160	[p7l371t3139r631b3207],
4	the	DT	O	the	det	5	SENT_160	[p7l649t3139r742b3194],
5	patients	NNS	O	patient	nsubj	8	SENT_160	[p7l761t3139r994b3207],
6	we	PRP	O	we	nsubj	7	SENT_160	[p7l1011t3154r1100b3194],
7	collected	VBD	O	collect	rcmod	5	SENT_160	[p7l1119t3139r1377b3194],
8	suffered	VBN	O	suffer	advcl	16	SENT_160	[p7l1397t3138r1632b3194],
9	from	IN	O	from	_	0	SENT_160	[p7l1651t3138r1791b3194],
10	many	JJ	O	many	amod	11	SENT_160	[p7l1810t3154r1977b3207],
11	types	NNS	O	type	prep_from	8	SENT_160	[p7l1992t3147r2148b3207],
12	of	IN	O	of	_	0	SENT_160	[p7l9t3227r71b3283],
13	cancer	NN	O	cancer	prep_of	11	SENT_160	[p7l83t3243r284b3291],
14	,	,	O	,	_	0	SENT_160	[p7l83t3243r284b3291],
15	there	EX	O	there	expl	16	SENT_160	[p7l305t3227r457b3283],
16	is	VBZ	O	be	_	0	SENT_160	[p7l477t3228r520b3283],
17	no	DT	O	no	det	18	SENT_160	[p7l541t3243r613b3283],
18	evidence	NN	O	evidence	nsubj	16	SENT_160	[p7l633t3227r892b3283],
19	showing	VBG	O	show	partmod	18	SENT_160	[p7l913t3228r1163b3296],
20	that	IN	O	that	complm	27	SENT_160	[p7l1180t3228r1299b3283],
21	the	DT	O	the	det	23	SENT_160	[p7l1316t3228r1409b3283],
22	allele	NN	O	allele	nn	23	SENT_160	[p7l1429t3228r1580b3283],
23	frequencies	NNS	O	frequency	nsubj	27	SENT_160	[p7l1601t3227r1935b3296],
24	of	IN	O	of	_	0	SENT_160	[p7l1956t3227r2018b3283],
25	CDA	NNP	ORGANIZATION	CDA	nn	26	SENT_160	[p7l2031t3230r2148b3283],
26	polymorphisms	NNS	O	polymorphism	prep_of	23	SENT_160	[p7l9t3316r469b3385],
27	vary	VBP	O	vary	ccomp	19	SENT_160	[p7l485t3332r615b3385],
28	in	IN	O	in	_	0	SENT_160	[p7l629t3317r684b3370],
29	different	JJ	O	different	amod	30	SENT_160	[p7l700t3316r952b3371],
30	types	NNS	O	type	prep_in	27	SENT_160	[p7l965t3324r1121b3385],
31	of	IN	O	of	_	0	SENT_160	[p7l1138t3316r1200b3371],
32	cancer	NN	O	cancer	nn	33	SENT_160	[p7l1209t3332r1400b3371],
33	patients	NNS	O	patient	prep_of	30	SENT_160	[p7l1415t3317r1662b3385],
34	.	.	O	.	_	0	SENT_160	[p7l1415t3317r1662b3385],

1	In	IN	O	in	_	0	SENT_161	[p7l1679t3319r1735b3370],
2	addition	NN	O	addition	prep_in	7	SENT_161	[p7l1750t3316r2006b3379],
3	,	,	O	,	_	0	SENT_161	[p7l1750t3316r2006b3379],
4	CDA	NNP	ORGANIZATION	CDA	nsubjpass	7	SENT_161	[p7l2024t3318r2151b3371],
5	is	VBZ	O	be	auxpass	7	SENT_161	[p7l9t3406r51b3460],
6	not	RB	O	not	neg	7	SENT_161	[p7l68t3413r166b3460],
7	involved	VBN	O	involve	dep	12	SENT_161	[p7l180t3405r430b3460],
8	in	IN	O	in	_	0	SENT_161	[p7l447t3406r502b3459],
9	the	DT	O	the	det	11	SENT_161	[p7l517t3405r610b3460],
10	concomitant	JJ	O	concomitant	amod	11	SENT_161	[p7l626t3406r994b3460],
11	drugs	NNS	O	drug	prep_in	7	SENT_161	[p7l1008t3405r1185b3474],
12	‘	VBP	O	‘	_	0	SENT_161	[p7l1008t3405r1185b3474],
13	(	CD	NUMBER	(	num	14	SENT_161	[p7l1205t3405r1486b3474],
14	cisplatin	NN	O	cisplatin	nsubj	12	SENT_161	[p7l1205t3405r1486b3474],
15	,	,	O	,	_	0	SENT_161	[p7l1205t3405r1486b3474],
16	carboplatin	NN	O	carboplatin	nn	25	SENT_161	[p7l1502t3405r1846b3474],
17	,	,	O	,	_	0	SENT_161	[p7l1502t3405r1846b3474],
18	oxaplatin	NN	O	oxaplatin	nn	25	SENT_161	[p7l1862t3405r2147b3474],
19	,	,	O	,	_	0	SENT_161	[p7l1862t3405r2147b3474],
20	nadaplatin	NN	O	nadaplatin	nn	25	SENT_161	[p7l9t3494r333b3563],
21	,	,	O	,	_	0	SENT_161	[p7l9t3494r333b3563],
22	docetaxel	NN	O	docetaxel	nn	25	SENT_161	[p7l369t3494r648b3549],
23	or	CC	O	or	_	0	SENT_161	[p7l683t3510r745b3549],
24	ﬂuoracil	NN	O	ﬂuoracil	nn	25	SENT_161	[p7l778t3494r1039b3563],
25	)	NN	O	)	appos	14	SENT_161	[p7l778t3494r1039b3563],
26	metabolism	NN	O	metabolism	nn	27	SENT_161	[p7l1078t3494r1425b3549],
27	pathway	NN	O	pathway	dep	25	SENT_161	[p7l1459t3494r1727b3563],
28	.	.	O	.	_	0	SENT_161	[p7l1459t3494r1727b3563],

1	Even	RB	O	even	advmod	7	SENT_162	[p7l1763t3498r1904b3549],
2	though	IN	O	though	dep	7	SENT_162	[p7l1939t3494r2149b3563],
3	CDA	NNP	ORGANIZATION	CDA	nn	4	SENT_162	[p7l9t3586r136b3638],
4	enzyme	NN	O	enzyme	nsubj	7	SENT_162	[p7l153t3599r384b3652],
5	might	MD	O	might	aux	7	SENT_162	[p7l403t3583r578b3652],
6	have	VB	O	have	aux	7	SENT_162	[p7l595t3583r733b3638],
7	increased	VBN	O	increase	advcl	24	SENT_162	[p7l752t3583r1029b3638],
8	risk	NN	O	risk	dobj	7	SENT_162	[p7l1049t3583r1155b3638],
9	of	IN	O	of	_	0	SENT_162	[p7l1172t3583r1234b3638],
10	capecitabine	NN	O	capecitabine	nn	11	SENT_162	[p7l1245t3583r1609b3652],
11	toxicity	NN	O	toxicity	prep_of	8	SENT_162	[p7l1628t3584r1847b3652],
12	according	VBG	O	accord	_	0	SENT_162	[p7l1864t3583r2149b3652],
13	to	TO	O	to	prepc_according_to	7	SENT_162	[p7l8t3681r65b3728],
14	some	DT	O	some	det	15	SENT_162	[p7l93t3688r248b3728],
15	reports	NNS	O	report	pobj	7	SENT_162	[p7l275t3681r482b3741],
16	[	VBP	O	[	dep	15	SENT_162	[p7l513t3672r638b3741],
17	19	CD	NUMBER	19	num	18	SENT_162	[p7l513t3672r638b3741],
18	]	CD	NUMBER	]	dobj	16	SENT_162	[p7l513t3672r638b3741],
19	,	,	O	,	_	0	SENT_162	[p7l513t3672r638b3741],
20	no	DT	O	no	det	22	SENT_162	[p7l666t3688r738b3728],
21	severe	JJ	O	severe	amod	22	SENT_162	[p7l766t3688r952b3728],
22	toxicity	NN	O	toxicity	nsubjpass	24	SENT_162	[p7l978t3673r1198b3741],
23	was	VBD	O	be	auxpass	24	SENT_162	[p7l1220t3688r1336b3728],
24	observed	VBN	O	observe	_	0	SENT_162	[p7l1363t3672r1628b3728],
25	in	IN	O	in	_	0	SENT_162	[p7l1656t3673r1710b3727],
26	the	DT	O	the	det	27	SENT_162	[p7l1736t3673r1829b3728],
27	individual	NN	O	individual	prep_in	24	SENT_162	[p7l1856t3673r2148b3728],
28	who	WP	O	who	nsubj	29	SENT_162	[p7l7t3762r138b3817],
29	received	VBD	O	receive	rcmod	27	SENT_162	[p7l160t3762r405b3817],
30	the	DT	O	the	det	31	SENT_162	[p7l426t3761r520b3817],
31	treatment	NN	O	treatment	dobj	29	SENT_162	[p7l541t3770r836b3817],
32	of	IN	O	of	_	0	SENT_162	[p7l855t3761r917b3817],
33	gemcitabine	NN	O	gemcitabine	prep_of	31	SENT_162	[p7l929t3762r1289b3830],
34	plus	CC	O	plus	prep	33	SENT_162	[p7l1310t3762r1430b3830],
35	capecitabine	NN	O	capecitabine	dep	34	SENT_162	[p7l1452t3762r1830b3830],
36	.	.	O	.	_	0	SENT_162	[p7l1452t3762r1830b3830],

1	Therefore	RB	O	therefore	_	0	SENT_163	[p7l1849t3761r2147b3825],
2	,	,	O	,	_	0	SENT_163	[p7l1849t3761r2147b3825],

1	our	PRP$	O	we	poss	3	SENT_164	[p8l9t41r109b80],
2	study	NN	O	study	nn	3	SENT_164	[p8l133t25r295b94],
3	results	NNS	O	result	nsubj	5	SENT_164	[p8l319t25r510b80],
4	are	VBP	O	be	cop	5	SENT_164	[p8l536t41r625b80],
5	reasonable	JJ	O	reasonable	_	0	SENT_164	[p8l651t25r966b80],
6	and	CC	O	and	_	0	SENT_164	[p8l991t25r1099b80],
7	not	RB	O	not	conj_and	5	SENT_164	[p8l1125t33r1223b80],
8	biased	VBN	O	bias	dep	5	SENT_164	[p8l1245t25r1431b80],
9	due	JJ	O	due	_	0	SENT_164	[p8l1457t25r1564b80],
10	to	TO	O	to	_	0	SENT_164	[p8l1589t33r1647b80],
11	the	DT	O	the	det	14	SENT_164	[p8l1671t25r1765b80],
12	complicated	JJ	O	complicated	amod	14	SENT_164	[p8l1791t25r2147b94],
13	baseline	NN	O	baseline	nn	14	SENT_164	[p8l8t114r247b169],
14	proﬁle	NN	O	proﬁle	prep_due_to	8	SENT_164	[p8l268t114r458b183],
15	of	IN	O	of	_	0	SENT_164	[p8l479t114r541b169],
16	patients	NNS	O	patient	prep_of	14	SENT_164	[p8l554t115r787b183],
17	and	CC	O	and	_	0	SENT_164	[p8l809t114r917b169],
18	the	DT	O	the	det	21	SENT_164	[p8l938t114r1032b169],
19	different	JJ	O	different	amod	21	SENT_164	[p8l1053t114r1305b169],
20	treatment	NN	O	treatment	nn	21	SENT_164	[p8l1324t122r1618b169],
21	plan	NN	O	plan	prep_of	14	SENT_164	[p8l1637t114r1777b183],
22	.	.	O	.	_	0	SENT_164	[p8l1637t114r1777b183],

1	Our	PRP$	O	we	poss	2	SENT_165	[p8l111t206r224b258],
2	ﬁnding	NN	O	ﬁnding	nsubj	4	SENT_165	[p8l246t203r460b272],
3	is	VBZ	O	be	cop	4	SENT_165	[p8l482t204r526b258],
4	consistent	JJ	O	consistent	_	0	SENT_165	[p8l551t204r858b258],
5	to	TO	O	to	_	0	SENT_165	[p8l879t212r938b258],
6	other	JJ	O	other	amod	7	SENT_165	[p8l962t203r1123b258],
7	reports	NNS	O	report	prep_to	4	SENT_165	[p8l1146t211r1360b272],
8	[	VBP	O	[	rcmod	7	SENT_165	[p8l1387t203r1608b272],
9	20,21	CD	NUMBER	20,21	number	10	SENT_165	[p8l1387t203r1608b272],
10	]	CD	NUMBER	]	dobj	8	SENT_165	[p8l1387t203r1608b272],
11	,	,	O	,	_	0	SENT_165	[p8l1387t203r1608b272],
12	which	WDT	O	which	nsubjpass	14	SENT_165	[p8l1632t203r1819b258],
13	were	VBD	O	be	auxpass	14	SENT_165	[p8l1841t219r1992b258],
14	conducted	VBN	O	conduct	rcmod	10	SENT_165	[p8l2016t219r2149b258, p8l9t292r212b347],
15	in	IN	O	in	_	0	SENT_165	[p8l238t293r293b347],
16	Caucasian	JJ	LOCATION	caucasian	amod	17	SENT_165	[p8l317t293r615b347],
17	patients	NNS	O	patient	prep_in	14	SENT_165	[p8l637t293r877b361],
18	with	IN	O	with	_	0	SENT_165	[p8l900t292r1039b347],
19	pancreatic	JJ	O	pancreatic	amod	20	SENT_165	[p8l1063t293r1374b361],
20	cancer	NN	O	cancer	prep_with	14	SENT_165	[p8l1396t308r1604b348],
21	.	.	O	.	_	0	SENT_165	[p8l1396t308r1604b348],

1	Our	PRP$	O	we	poss	2	SENT_166	[p8l1629t295r1742b347],
2	results	NNS	O	result	nsubjpass	5	SENT_166	[p8l1763t292r1960b347],
3	could	MD	O	could	aux	5	SENT_166	[p8l1985t292r2147b347],
4	be	VB	O	be	auxpass	5	SENT_166	[p8l8t382r78b437],
5	supported	VBN	O	support	_	0	SENT_166	[p8l106t382r411b450],
6	by	IN	O	by	_	0	SENT_166	[p8l437t382r511b450],
7	several	JJ	O	several	agent	5	SENT_166	[p8l537t382r746b437],
8	in	FW	O	in	nn	9	SENT_166	[p8l774t383r826b437],
9	vitro	FW	O	vitro	advmod	10	SENT_166	[p8l853t383r986b437],
10	studies	NNS	O	study	rcmod	7	SENT_166	[p8l1014t382r1239b445],
11	,	,	O	,	_	0	SENT_166	[p8l1014t382r1239b445],
12	which	WDT	O	which	nsubj	13	SENT_166	[p8l1264t382r1451b437],
13	showed	VBD	O	show	rcmod	7	SENT_166	[p8l1479t382r1711b437],
14	that	IN	O	that	complm	23	SENT_166	[p8l1739t382r1859b437],
15	the	DT	O	the	det	19	SENT_166	[p8l1884t382r1980b437],
16	nonsynonymous	JJ	O	nonsynonymous	amod	19	SENT_166	[p8l2008t398r2149b437, p8l10t486r391b539],
17	coding	VBG	O	code	amod	19	SENT_166	[p8l409t470r610b539],
18	variant	JJ	O	variant	amod	19	SENT_166	[p8l624t471r837b526],
19	79A	NN	O	79a	nsubj	23	SENT_166	[p8l854t473r1063b526],
20	>	JJR	O	>	dep	21	SENT_166	[p8l854t473r1063b526],
21	C	NN	O	c	amod	19	SENT_166	[p8l854t473r1063b526],
22	might	MD	O	might	aux	23	SENT_166	[p8l1080t471r1259b539],
23	lead	VB	O	lead	ccomp	13	SENT_166	[p8l1274t470r1397b526],
24	to	TO	O	to	_	0	SENT_166	[p8l1414t479r1472b526],
25	decreased	VBN	O	decrease	amod	27	SENT_166	[p8l1490t471r1789b526],
26	enzyme	NN	O	enzyme	nn	27	SENT_166	[p8l1807t486r2043b539],
27	activity	NN	O	activity	prep_to	23	SENT_166	[p8l2060t486r2148b526, p8l8t560r166b628],
28	[	CD	NUMBER	[	num	30	SENT_166	[p8l196t559r310b628],
29	10	CD	NUMBER	10	num	30	SENT_166	[p8l196t559r310b628],
30	]	NN	O	]	dep	27	SENT_166	[p8l196t559r310b628],
31	and	CC	O	and	_	0	SENT_166	[p8l342t559r452b614],
32	that	IN	O	that	complm	38	SENT_166	[p8l482t559r603b614],
33	patients	NNS	O	patient	nsubj	38	SENT_166	[p8l632t560r871b628],
34	with	IN	O	with	_	0	SENT_166	[p8l900t559r1040b614],
35	decreased	VBN	O	decrease	amod	37	SENT_166	[p8l1069t559r1369b614],
36	enzyme	NN	O	enzyme	nn	37	SENT_166	[p8l1399t575r1635b628],
37	activity	NN	O	activity	prep_with	33	SENT_166	[p8l1664t560r1886b628],
38	were	VBD	O	be	ccomp	13	SENT_166	[p8l1913t575r2063b614],
39	at	IN	O	at	_	0	SENT_166	[p8l2094t567r2151b614],
40	higher	JJR	O	higher	amod	41	SENT_166	[p8l9t648r204b717],
41	risk	NN	O	risk	prep_at	38	SENT_166	[p8l233t648r342b703],
42	[	CD	NUMBER	[	number	43	SENT_166	[p8l375t648r649b717],
43	6,22,23	CD	NUMBER	6,22,23	num	44	SENT_166	[p8l375t648r649b717],
44	]	NN	O	]	dep	41	SENT_166	[p8l375t648r649b717],
45	.	.	O	.	_	0	SENT_166	[p8l375t648r649b717],

1	However	RB	O	however	advmod	4	SENT_167	[p8l681t651r966b712],
2	,	,	O	,	_	0	SENT_167	[p8l681t651r966b712],
3	there	EX	O	there	expl	4	SENT_167	[p8l998t648r1156b703],
4	exist	VBP	O	exist	_	0	SENT_167	[p8l1186t649r1328b703],
5	conﬂicting	VBG	O	conﬂicting	xcomp	4	SENT_167	[p8l1357t648r1674b717],
6	reports	NNS	O	report	dobj	5	SENT_167	[p8l1703t656r1916b717],
7	on	IN	O	on	_	0	SENT_167	[p8l1948t664r2023b703],
8	the	DT	O	the	det	9	SENT_167	[p8l2052t648r2148b703],
9	issue	NN	O	issue	prep_on	5	SENT_167	[p8l9t738r171b793],
10	.	.	O	.	_	0	SENT_167	[p8l9t738r171b793],

1	A	DT	O	a	det	2	SENT_168	[p8l185t740r231b792],
2	series	NN	O	series	nsubj	5	SENT_168	[p8l246t738r414b792],
3	of	IN	O	of	_	0	SENT_168	[p8l432t737r495b792],
4	studies	NNS	O	study	prep_of	2	SENT_168	[p8l504t737r714b792],
5	showed	VBD	O	show	_	0	SENT_168	[p8l732t737r965b792],
6	that	IN	O	that	complm	26	SENT_168	[p8l983t737r1103b792],
7	A	DT	O	a	det	11	SENT_168	[p8l1117t740r1162b792],
8	allele	NN	O	allele	nn	11	SENT_168	[p8l1176t737r1332b792],
9	(	CD	NUMBER	(	num	11	SENT_168	[p8l1354t737r1592b806],
10	Lys27	NN	O	lys27	nn	11	SENT_168	[p8l1354t737r1592b806],
11	)	NN	O	)	nsubj	26	SENT_168	[p8l1354t737r1592b806],
12	,	,	O	,	_	0	SENT_168	[p8l1354t737r1592b806],
13	instead	RB	O	instead	_	0	SENT_168	[p8l1611t737r1827b792],
14	of	IN	O	of	_	0	SENT_168	[p8l1844t737r1907b792],
15	the	DT	O	the	det	18	SENT_168	[p8l1915t737r2011b792],
16	variant	JJ	O	variant	amod	18	SENT_168	[p8l2027t753r2148b792, p8l9t827r124b881],
17	C	NN	O	c	nn	18	SENT_168	[p8l149t829r186b881],
18	allele	NN	O	allele	prep_instead_of	11	SENT_168	[p8l212t826r382b890],
19	,	,	O	,	_	0	SENT_168	[p8l212t826r382b890],
20	being	VBG	O	be	cop	22	SENT_168	[p8l410t826r576b895],
21	the	DT	O	the	det	22	SENT_168	[p8l601t826r697b881],
22	culprit	NN	O	culprit	partmod	11	SENT_168	[p8l723t826r921b895],
23	of	IN	O	of	_	0	SENT_168	[p8l946t826r1009b881],
24	reduced	VBN	O	reduce	amod	25	SENT_168	[p8l1028t826r1269b881],
25	deaminase	NN	O	deaminase	prep_of	22	SENT_168	[p8l1297t826r1619b881],
26	activity	NN	O	activity	ccomp	5	SENT_168	[p8l1646t827r1868b895],
27	[	CD	NUMBER	[	num	29	SENT_168	[p8l1896t826r2008b895],
28	24	CD	NUMBER	24	num	29	SENT_168	[p8l1896t826r2008b895],
29	]	NN	O	]	dobj	26	SENT_168	[p8l1896t826r2008b895],
30	and	CC	O	and	_	0	SENT_168	[p8l2038t826r2148b881],
31	that	IN	O	that	complm	39	SENT_168	[p8l8t916r129b971],
32	patients	NNS	O	patient	nsubj	39	SENT_168	[p8l152t917r392b984],
33	harboring	VBG	O	harbor	partmod	32	SENT_168	[p8l417t916r713b984],
34	wild	JJ	O	wild	amod	37	SENT_168	[p8l734t916r1028b984],
35	—	NN	O	—	nn	37	SENT_168	[p8l734t916r1028b984],
36	type	NN	O	type	nn	37	SENT_168	[p8l734t916r1028b984],
37	genotype	NN	O	genotype	dobj	33	SENT_168	[p8l1051t924r1331b984],
38	were	VBD	O	be	cop	39	SENT_168	[p8l1354t932r1506b971],
39	prone	JJ	O	prone	ccomp	5	SENT_168	[p8l1530t932r1705b984],
40	to	TO	O	to	aux	41	SENT_168	[p8l1729t924r1787b971],
41	have	VB	O	have	xcomp	39	SENT_168	[p8l1812t916r1952b971],
42	lower	JJR	O	lower	amod	45	SENT_168	[p8l1977t916r2151b971],
43	CDA	NNP	O	CDA	nn	45	SENT_168	[p8l9t1007r138b1059],
44	enzyme	NN	O	enzyme	nn	45	SENT_168	[p8l168t1020r404b1073],
45	activity	NN	O	activity	iobj	41	SENT_168	[p8l436t1005r658b1073],
46	[	CD	NUMBER	[	num	48	SENT_168	[p8l690t1004r820b1073],
47	25	CD	NUMBER	25	num	48	SENT_168	[p8l690t1004r820b1073],
48	]	NN	O	]	dobj	41	SENT_168	[p8l690t1004r820b1073],
49	.	.	O	.	_	0	SENT_168	[p8l690t1004r820b1073],

1	Furthermore	RB	O	furthermore	advmod	28	SENT_169	[p8l853t1004r1249b1068],
2	,	,	O	,	_	0	SENT_169	[p8l853t1004r1249b1068],
3	while	IN	O	while	mark	6	SENT_169	[p8l1280t1004r1448b1059],
4	some	DT	O	some	det	5	SENT_169	[p8l1481t1020r1640b1059],
5	studies	NNS	O	study	nsubj	6	SENT_169	[p8l1672t1004r1881b1059],
6	showed	VBD	O	show	advcl	28	SENT_169	[p8l1915t1004r2148b1059],
7	the	DT	O	the	det	9	SENT_169	[p8l8t1093r104b1148],
8	signiﬁcant	JJ	O	signiﬁcant	amod	9	SENT_169	[p8l126t1093r438b1162],
9	impact	NN	O	impact	nsubj	21	SENT_169	[p8l457t1094r664b1162],
10	of	IN	O	of	_	0	SENT_169	[p8l683t1093r747b1148],
11	the	DT	O	the	det	13	SENT_169	[p8l759t1093r855b1148],
12	A79C	NN	O	a79c	nn	13	SENT_169	[p8l874t1095r1034b1148],
13	polymorphism	NN	O	polymorphism	prep_of	9	SENT_169	[p8l1054t1093r1499b1162],
14	on	IN	O	on	_	0	SENT_169	[p8l1518t1109r1594b1148],
15	pharmacokinetics	NNS	O	pharmacokinetic	prep_on	13	SENT_169	[p8l1615t1093r2148b1162],
16	of	IN	O	of	_	0	SENT_169	[p8l9t1182r72b1237],
17	gemcitabine	NN	O	gemcitabine	prep_of	15	SENT_169	[p8l88t1182r458b1251],
18	or	CC	O	or	_	0	SENT_169	[p8l483t1198r545b1237],
19	its	PRP$	O	its	poss	20	SENT_169	[p8l569t1183r637b1237],
20	metabolites	NNS	O	metabolite	conj_or	17	SENT_169	[p8l663t1182r1013b1237],
21	[	VBP	O	[	ccomp	6	SENT_169	[p8l1042t1182r1263b1251],
22	26,27	CD	NUMBER	26,27	number	23	SENT_169	[p8l1042t1182r1263b1251],
23	]	CD	NUMBER	]	dobj	21	SENT_169	[p8l1042t1182r1263b1251],
24	,	,	O	,	_	0	SENT_169	[p8l1042t1182r1263b1251],
25	others	NNS	O	other	nsubj	28	SENT_169	[p8l1289t1182r1477b1237],
26	were	VBD	O	be	cop	28	SENT_169	[p8l1501t1198r1652b1237],
27	not	RB	O	not	neg	28	SENT_169	[p8l1677t1190r1777b1237],
28	able	JJ	O	able	_	0	SENT_169	[p8l1800t1182r1923b1237],
29	to	TO	O	to	aux	30	SENT_169	[p8l1947t1190r2006b1237],
30	ﬁnd	VB	O	ﬁnd	xcomp	28	SENT_169	[p8l2032t1182r2148b1237],
31	the	DT	O	the	det	35	SENT_169	[p8l8t1271r104b1326],
32	inﬂuence	NN	O	inﬂuence	nn	35	SENT_169	[p8l128t1271r405b1326],
33	[	NN	O	[	nn	35	SENT_169	[p8l430t1271r666b1340],
34	8,9,28	CD	NUMBER	8,9,28	num	35	SENT_169	[p8l430t1271r666b1340],
35	]	NN	O	]	dobj	30	SENT_169	[p8l430t1271r666b1340],
36	.	.	O	.	_	0	SENT_169	[p8l430t1271r666b1340],

1	In	IN	O	in	_	0	SENT_170	[p8l690t1275r746b1326],
2	a	DT	O	a	det	5	SENT_170	[p8l769t1287r800b1326],
3	recently	RB	DATE	recently	advmod	4	SENT_170	[p8l822t1271r1063b1340],
4	published	VBN	O	publish	amod	5	SENT_170	[p8l1084t1271r1374b1340],
5	study	NN	O	study	prep_in	34	SENT_170	[p8l1398t1271r1573b1340],
6	,	,	O	,	_	0	SENT_170	[p8l1398t1271r1573b1340],
7	even	RB	O	even	advmod	11	SENT_170	[p8l1597t1287r1738b1326],
8	though	IN	O	though	dep	11	SENT_170	[p8l1760t1271r1972b1340],
9	A79C	NN	O	a79c	nsubjpass	11	SENT_170	[p8l1991t1274r2149b1326],
10	was	VBD	O	be	auxpass	11	SENT_170	[p8l7t1377r124b1416],
11	found	VBN	O	find	dep	34	SENT_170	[p8l160t1361r331b1416],
12	to	TO	O	to	aux	13	SENT_170	[p8l366t1369r423b1416],
13	cause	VB	O	cause	xcomp	11	SENT_170	[p8l458t1377r620b1416],
14	increased	VBN	O	increase	amod	15	SENT_170	[p8l655t1361r935b1416],
15	exposure	NN	O	exposure	dobj	13	SENT_170	[p8l971t1377r1241b1429],
16	to	TO	O	to	_	0	SENT_170	[p8l1276t1369r1333b1416],
17	gemcitabine	NN	O	gemcitabine	prep_to	13	SENT_170	[p8l1367t1361r1731b1429],
18	in	IN	O	in	_	0	SENT_170	[p8l1767t1362r1821b1415],
19	Caucasian	JJ	LOCATION	caucasian	amod	20	SENT_170	[p8l1856t1362r2148b1416],
20	patients	NNS	O	patient	prep_in	17	SENT_170	[p8l9t1451r245b1518],
21	with	IN	O	with	_	0	SENT_170	[p8l267t1450r405b1505],
22	non	JJ	O	non	amod	28	SENT_170	[p8l428t1450r854b1505],
23	—	JJ	O	—	amod	28	SENT_170	[p8l428t1450r854b1505],
24	small	JJ	O	small	amod	28	SENT_170	[p8l428t1450r854b1505],
25	—	NN	O	—	nn	28	SENT_170	[p8l428t1450r854b1505],
26	cell	NN	O	cell	nn	28	SENT_170	[p8l428t1450r854b1505],
27	lung	NN	O	lung	nn	28	SENT_170	[p8l878t1450r1009b1518],
28	cancer	NN	O	cancer	prep_with	13	SENT_170	[p8l1031t1466r1235b1513],
29	,	,	O	,	_	0	SENT_170	[p8l1031t1466r1235b1513],
30	no	DT	O	no	det	32	SENT_170	[p8l1259t1466r1332b1505],
31	signiﬁcant	JJ	O	signiﬁcant	amod	32	SENT_170	[p8l1357t1450r1663b1518],
32	association	NN	O	association	nsubjpass	34	SENT_170	[p8l1684t1451r2010b1505],
33	was	VBD	O	be	auxpass	34	SENT_170	[p8l2031t1466r2148b1505],
34	found	VBN	O	find	_	0	SENT_170	[p8l9t1538r180b1593],
35	between	IN	O	between	_	0	SENT_170	[p8l224t1538r482b1593],
36	the	DT	O	the	det	37	SENT_170	[p8l525t1538r620b1593],
37	genotypes	NNS	O	genotype	prep_between	34	SENT_170	[p8l663t1546r967b1607],
38	and	CC	O	and	_	0	SENT_170	[p8l1012t1538r1121b1593],
39	neutropenia	NN	O	neutropenia	conj_and	37	SENT_170	[p8l1166t1539r1528b1607],
40	[	CD	NUMBER	[	number	41	SENT_170	[p8l1575t1538r1702b1607],
41	27	CD	NUMBER	27	num	42	SENT_170	[p8l1575t1538r1702b1607],
42	]	NN	O	]	dep	39	SENT_170	[p8l1575t1538r1702b1607],
43	.	.	O	.	_	0	SENT_170	[p8l1575t1538r1702b1607],

1	Therefore	RB	O	therefore	_	0	SENT_171	[p8l1745t1538r2046b1602],
2	,	,	O	,	_	0	SENT_171	[p8l1745t1538r2046b1602],
3	to	TO	O	to	dep	1	SENT_171	[p8l2090t1546r2148b1593],

1	100	CD	PERCENT	100	num	2	SENT_172	[p8l43t1736r188b1782],
2	%	NN	PERCENT	%	_	0	SENT_172	[p8l43t1736r188b1782],
3	I	CD	NUMBER	i	dep	2	SENT_172	[p8l645t1770r686b1813],
4	A	DT	O	a	det	5	SENT_172	[p8l701t1757r799b1816],
5	_	NN	O	_	dep	3	SENT_172	[p8l701t1757r799b1816],
6	/	:	O	/	punct	9	SENT_172	[p8l701t1757r799b1816],
7	A	DT	O	a	det	9	SENT_172	[p8l701t1757r799b1816],
8	(	NN	O	(	nn	9	SENT_172	[p8l817t1761r984b1819],
9	r1229	NN	O	r1229	dep	5	SENT_172	[p8l817t1761r984b1819],
10	)	CD	NUMBER	)	number	11	SENT_172	[p8l817t1761r984b1819],
11	:1	CD	NUMBER	:1	dep	9	SENT_172	[p8l1063t1767r1103b1810],
12	Alt	NN	O	alt	dep	11	SENT_172	[p8l1115t1757r1210b1816],
13	3	CD	NUMBER	3	num	12	SENT_172	[p8l1226t1761r1268b1807],
14	.	.	O	.	_	0	SENT_172	[p8l1226t1761r1268b1807],

1	we	PRP	O	we	nsubj	2	SENT_173	[p8l1287t1757r1376b1816],
2	[	VBP	O	[	_	0	SENT_173	[p8l1398t1761r1530b1819],
3	n28	NN	O	n28	dobj	2	SENT_173	[p8l1398t1761r1530b1819],
4	]	CD	PERCENT	]	number	5	SENT_173	[p8l1398t1761r1530b1819],
5	oo	CD	PERCENT	oo	dep	6	SENT_173	[p8l71t1859r185b1905],
6	%	NN	PERCENT	%	dep	3	SENT_173	[p8l71t1859r185b1905],

1	10	CD	PERCENT	10	_	0	SENT_174	[p8l105t2970r185b3017],
2	%	NN	PERCENT	%	dep	1	SENT_174	[p8l105t2970r185b3017],
3	T	NN	O	t	dep	2	SENT_174	[p8l218t2997r350b2998],
4	,	,	O	,	_	0	SENT_174	[p8l218t2997r350b2998],

1	Leuk,ope-inia	NNP	O	Leuk,ope-inia	nn	3	SENT_175	[p8l402t2996r713b3081],
2	é	NNP	O	é	nn	3	SENT_175	[p8l402t2996r713b3081],
3	Neu	NNP	PERSON	Neu	poss	5	SENT_175	[p8l1024t2997r1361b3081],
4	'	POS	O	'	_	0	SENT_175	[p8l1024t2997r1361b3081],
5	tropen	NN	O	tropen	_	0	SENT_175	[p8l1024t2997r1361b3081],
6	:	:	O	:	_	0	SENT_175	[p8l1024t2997r1361b3081],
7	iao	FW	O	iao	nn	8	SENT_175	[p8l1024t2997r1361b3081],
8	Thrombope-nia	FW	O	thrombope-nia	dep	5	SENT_175	[p8l1628t3022r2016b3081],

1	Fig	NN	O	fig	_	0	SENT_176	[p8l8t3174r96b3228],
2	.	.	O	.	_	0	SENT_176	[p8l8t3174r96b3228],

1	1	LS	NUMBER	1	_	0	SENT_177	[p8l121t3176r161b3217],
2	.	.	O	.	_	0	SENT_177	[p8l121t3176r161b3217],

1	Comparison	NN	O	comparison	nsubj	19	SENT_178	[p8l185t3174r479b3228],
2	of	IN	O	of	_	0	SENT_178	[p8l503t3173r554b3217],
3	the	DT	O	the	det	4	SENT_178	[p8l571t3174r649b3217],
4	incidences	NNS	O	incidence	prep_of	1	SENT_178	[p8l673t3174r930b3217],
5	of	IN	O	of	_	0	SENT_178	[p8l954t3173r1005b3217],
6	grade	NN	O	grade	npadvmod	8	SENT_178	[p8l1022t3174r1159b3228],
7	3-4	CD	NUMBER	3-4	num	6	SENT_178	[p8l1182t3176r1274b3217],
8	gemcitabine-associated	JJ	O	gemcitabine-associated	amod	9	SENT_178	[p8l1296t3174r1876b3228],
9	toxicity	NN	O	toxicity	prep_of	4	SENT_178	[p8l1900t3174r2085b3228],
10	in	IN	O	in	_	0	SENT_178	[p8l2108t3174r2153b3217],
11	patients	NNS	O	patient	prep_in	9	SENT_178	[p8l8t3246r205b3299],
12	based	VBN	O	base	partmod	11	SENT_178	[p8l225t3245r365b3289],
13	on	IN	O	on	_	0	SENT_178	[p8l385t3258r446b3289],
14	CDA	NNP	ORGANIZATION	CDA	nn	18	SENT_178	[p8l466t3247r563b3289],
15	79A	NNP	O	79A	nn	18	SENT_178	[p8l584t3247r754b3289],
16	>	JJR	O	>	dep	17	SENT_178	[p8l584t3247r754b3289],
17	C	NN	O	c	amod	18	SENT_178	[p8l584t3247r754b3289],
18	genotypes	NNS	O	genotype	prep_on	12	SENT_178	[p8l772t3251r1024b3299],
19	(	VBP	O	(	_	0	SENT_178	[p8l1048t3245r1304b3299],
20	*	CD	NUMBER	*	num	21	SENT_178	[p8l1048t3245r1304b3299],
21	p	NN	O	p	npadvmod	22	SENT_178	[p8l1048t3245r1304b3299],
22	<	JJR	O	<	acomp	19	SENT_178	[p8l1048t3245r1304b3299],
23	0.05	CD	NUMBER	0.05	num	24	SENT_178	[p8l1048t3245r1304b3299],
24	)	NN	O	)	dep	19	SENT_178	[p8l1048t3245r1304b3299],
25	.	.	O	.	_	0	SENT_178	[p8l1048t3245r1304b3299],

1	J.	NNP	PERSON	J.	nn	2	SENT_179	[p8l371t3375r387b3401],
2	Xu	NNP	PERSON	Xu	_	0	SENT_179	[p8l395t3375r427b3396],
3	et	FW	O	et	nn	4	SENT_179	[p8l437t3377r459b3396],
4	al.	FW	O	al.	dep	2	SENT_179	[p8l466t3374r491b3396],
5	/	:	O	/	punct	2	SENT_179	[p8l500t3375r510b3399],
6	Clinica	NNP	PERSON	Clinica	nn	8	SENT_179	[p8l518t3374r595b3396],
7	Chimica	NNP	PERSON	Chimica	nn	8	SENT_179	[p8l605t3374r697b3396],
8	Acta	NNP	PERSON	Acta	dep	2	SENT_179	[p8l704t3375r756b3396],
9	413	CD	NUMBER	413	number	10	SENT_179	[p8l765t3375r808b3396],
10	(	CD	NUMBER	(	num	11	SENT_179	[p8l819t3374r897b3401],
11	2012	CD	DATE	2012	dep	8	SENT_179	[p8l819t3374r897b3401],
12	)	CD	NUMBER	)	number	13	SENT_179	[p8l819t3374r897b3401],
13	1284-1287 1287	CD	DURATION	1284-1287 1287	num	11	SENT_179	[p8l1730t3375r1788b3396],[p8l911t3375r1041b3396],

1	demonstrate	VB	O	demonstrate	ccomp	19	SENT_180	[p9l11t63r387b118],
2	the	DT	O	the	det	3	SENT_180	[p9l406t63r501b118],
3	inﬂuence	NN	O	inﬂuence	nsubj	9	SENT_180	[p9l521t63r793b118],
4	of	IN	O	of	_	0	SENT_180	[p9l813t63r876b118],
5	CDA	NNP	ORGANIZATION	CDA	nn	6	SENT_180	[p9l888t65r1007b118],
6	79A	NNP	O	79A	prep_of	3	SENT_180	[p9l1028t65r1235b118],
7	>	JJR	O	>	amod	9	SENT_180	[p9l1028t65r1235b118],
8	C	NN	O	c	nn	9	SENT_180	[p9l1028t65r1235b118],
9	polymorphism	NN	O	polymorphism	xcomp	1	SENT_180	[p9l1253t63r1692b132],
10	on	IN	O	on	_	0	SENT_180	[p9l1710t79r1784b118],
11	clinical	JJ	O	clinical	amod	12	SENT_180	[p9l1803t63r2008b118],
12	outcomes	NNS	O	outcome	prep_on	9	SENT_180	[p9l2028t71r2150b118, p9l11t168r199b207],
13	of	IN	O	of	_	0	SENT_180	[p9l224t152r286b207],
14	gemcitabine	NN	O	gemcitabine	prep_of	12	SENT_180	[p9l301t152r679b221],
15	,	,	O	,	_	0	SENT_180	[p9l301t152r679b221],
16	future	JJ	DATE	future	amod	17	SENT_180	[p9l705t152r884b207],
17	studies	NNS	O	study	nsubjpass	19	SENT_180	[p9l910t152r1116b207],
18	are	VBP	O	be	auxpass	19	SENT_180	[p9l1141t168r1232b207],
19	needed	VBN	O	need	_	0	SENT_180	[p9l1257t152r1473b207],
20	to	TO	O	to	aux	21	SENT_180	[p9l1497t160r1555b207],
21	test	VB	O	test	xcomp	19	SENT_180	[p9l1579t160r1688b207],
22	the	DT	O	the	det	23	SENT_180	[p9l1710t152r1805b207],
23	correlation	NN	O	correlation	dobj	21	SENT_180	[p9l1829t152r2151b207],
24	among	IN	O	among	_	0	SENT_180	[p9l11t257r215b310],
25	the	DT	O	the	det	26	SENT_180	[p9l234t241r328b296],
26	genotypes	NNS	O	genotype	prep_among	23	SENT_180	[p9l348t250r666b310],
27	,	,	O	,	_	0	SENT_180	[p9l348t250r666b310],
28	the	DT	O	the	det	30	SENT_180	[p9l688t241r782b296],
29	gene	NN	O	gene	nn	30	SENT_180	[p9l801t257r943b310],
30	expression	NN	O	expression	dobj	21	SENT_180	[p9l963t242r1283b310],
31	in	IN	O	in	_	0	SENT_180	[p9l1303t242r1358b296],
32	patients	NNS	O	patient	prep_in	30	SENT_180	[p9l1379t242r1628b310],
33	‘	CD	NUMBER	‘	num	34	SENT_180	[p9l1379t242r1628b310],
34	plasma	NN	O	plasma	dep	30	SENT_180	[p9l1650t241r1873b310],
35	,	,	O	,	_	0	SENT_180	[p9l1650t241r1873b310],
36	pharmaco1	NN	O	pharmaco1	dobj	21	SENT_180	[p9l1895t241r2149b310, p9l11t330r305b385],
37	<	JJR	O	<	amod	38	SENT_180	[p9l1895t241r2149b310, p9l11t330r305b385],
38	inetics	NNS	O	inetic	rcmod	36	SENT_180	[p9l1895t241r2149b310, p9l11t330r305b385],
39	proﬁle	NN	O	proﬁle	dobj	38	SENT_180	[p9l323t330r514b399],
40	of	IN	O	of	_	0	SENT_180	[p9l532t330r594b385],
41	both	CC	O	both	preconj	42	SENT_180	[p9l603t330r739b385],
42	gemcitabine	NN	O	gemcitabine	prep_of	39	SENT_180	[p9l754t330r1119b399],
43	and	CC	O	and	_	0	SENT_180	[p9l1136t330r1245b385],
44	its	PRP$	O	its	poss	46	SENT_180	[p9l1264t331r1330b385],
45	active	JJ	O	active	amod	46	SENT_180	[p9l1348t331r1520b385],
46	metabolites	NNS	O	metabolite	prep_of	39	SENT_180	[p9l1539t330r1884b385],
47	after	IN	O	after	_	0	SENT_180	[p9l1902t330r2039b385],
48	administration	NN	O	administration	prep_after	38	SENT_180	[p9l2055t330r2150b385, p9l11t421r389b483],
49	,	,	O	,	_	0	SENT_180	[p9l2055t330r2150b385, p9l11t421r389b483],
50	as	RB	O	as	_	0	SENT_180	[p9l413t436r470b475],
51	well	RB	O	well	_	0	SENT_180	[p9l493t420r619b475],
52	as	IN	O	as	_	0	SENT_180	[p9l642t436r701b475],
53	adverse	JJ	O	adverse	amod	55	SENT_180	[p9l724t420r952b475],
54	drug	NN	O	drug	nn	55	SENT_180	[p9l975t420r1113b488],
55	reactions	NNS	O	reaction	dobj	21	SENT_180	[p9l1135t421r1402b475],
56	and	CC	O	and	_	0	SENT_180	[p9l1426t420r1534b475],
57	efﬁcacy	NN	O	efﬁcacy	conj_and	55	SENT_180	[p9l1558t420r1782b488],
58	observed	VBN	O	observe	dep	21	SENT_180	[p9l1803t420r2071b475],
59	in	IN	O	in	_	0	SENT_180	[p9l2095t421r2150b474],
60	patients	NNS	O	patient	prep_in	58	SENT_180	[p9l11t509r261b577],
61	.	.	O	.	_	0	SENT_180	[p9l11t509r261b577],

1	5	CD	NUMBER	5	_	0	SENT_181	[p9l10t712r63b763],
2	.	.	O	.	_	0	SENT_181	[p9l10t712r63b763],

1	Conclusions	NNS	O	conclusion	_	0	SENT_182	[p9l87t709r475b763],

1	The	DT	O	the	det	3	SENT_183	[p9l110t888r222b943],
2	allele	NN	O	allele	nn	3	SENT_183	[p9l245t888r405b943],
3	frequencies	NNS	O	frequency	nsubjpass	21	SENT_183	[p9l428t887r780b956],
4	of	IN	O	of	_	0	SENT_183	[p9l803t887r867b943],
5	CDA	NNP	ORGANIZATION	CDA	nn	6	SENT_183	[p9l881t890r1003b943],
6	208G	NN	O	208g	prep_of	3	SENT_183	[p9l1025t890r1285b943],
7	>	JJR	O	>	amod	8	SENT_183	[p9l1025t890r1285b943],
8	A	NN	O	a	dep	6	SENT_183	[p9l1025t890r1285b943],
9	and	CC	O	and	_	0	SENT_183	[p9l1305t887r1416b943],
10	79A	NN	O	79a	prep_of	3	SENT_183	[p9l1440t890r1652b943],
11	>	JJR	O	>	amod	12	SENT_183	[p9l1440t890r1652b943],
12	C	NN	O	c	dep	10	SENT_183	[p9l1440t890r1652b943],
13	in	IN	O	in	_	0	SENT_183	[p9l1673t888r1730b942],
14	both	CC	O	both	preconj	16	SENT_183	[p9l1751t887r1891b943],
15	Chinese	JJ	LOCATION	chinese	amod	16	SENT_183	[p9l1912t888r2150b943],
16	patients	NNS	O	patient	prep_in	12	SENT_183	[p9l11t977r256b1045],
17	and	CC	O	and	_	0	SENT_183	[p9l280t976r391b1031],
18	healthy	JJ	O	healthy	amod	19	SENT_183	[p9l416t976r647b1045],
19	volunteers	NNS	O	volunteer	conj_and	16	SENT_183	[p9l667t976r992b1031],
20	are	VBP	O	be	auxpass	21	SENT_183	[p9l1016t992r1109b1031],
21	reported	VBN	O	report	_	0	SENT_183	[p9l1134t976r1413b1045],
22	.	.	O	.	_	0	SENT_183	[p9l1134t976r1413b1045],

1	Chinese	JJ	MISC	chinese	amod	2	SENT_184	[p9l1438t976r1675b1031],
2	patients	NNS	O	patient	nsubjpass	9	SENT_184	[p9l1699t977r1945b1045],
3	carrying	VBG	O	carry	partmod	2	SENT_184	[p9l1969t992r2150b1045, p9l11t1067r105b1134],
4	A79C	NN	O	a79c	nn	7	SENT_184	[p9l122t1068r284b1121],
5	variant	NN	O	variant	nn	7	SENT_184	[p9l301t1067r520b1121],
6	C	NN	O	c	nn	7	SENT_184	[p9l538t1069r575b1121],
7	allele	NN	O	allele	dobj	3	SENT_184	[p9l593t1066r754b1121],
8	were	VBD	O	be	auxpass	9	SENT_184	[p9l772t1082r926b1121],
9	found	VBN	O	find	_	0	SENT_184	[p9l947t1066r1123b1121],
10	to	TO	O	to	aux	11	SENT_184	[p9l1143t1074r1202b1121],
11	be	VB	O	be	xcomp	9	SENT_184	[p9l1222t1066r1292b1121],
12	at	IN	O	at	_	0	SENT_184	[p9l1312t1074r1369b1121],
13	higher	JJR	O	higher	amod	14	SENT_184	[p9l1388t1066r1587b1134],
14	risk	NN	O	risk	prep_at	11	SENT_184	[p9l1606t1066r1717b1121],
15	of	IN	O	of	_	0	SENT_184	[p9l1736t1066r1799b1121],
16	developing	VBG	O	develop	prepc_of	14	SENT_184	[p9l1812t1066r2152b1134],
17	severe	JJ	O	severe	amod	18	SENT_184	[p9l12t1171r206b1210],
18	neutropenia	NN	O	neutropenia	dobj	16	SENT_184	[p9l231t1156r606b1223],
19	after	IN	O	after	_	0	SENT_184	[p9l630t1155r772b1210],
20	gemcitabine	NN	O	gemcitabine	nn	21	SENT_184	[p9l793t1155r1376b1223],
21	—	NN	O	—	prep_after	16	SENT_184	[p9l793t1155r1376b1223],
22	based	VBN	O	base	partmod	21	SENT_184	[p9l793t1155r1376b1223],
23	chemotherapy	NN	O	chemotherapy	dobj	22	SENT_184	[p9l1402t1155r1861b1223],
24	.	.	O	.	_	0	SENT_184	[p9l1402t1155r1861b1223],

1	Conﬂict	NN	O	conﬂict	_	0	SENT_185	[p9l10t1355r259b1409],
2	of	IN	O	of	_	0	SENT_185	[p9l281t1355r351b1409],
3	interest	NN	O	interest	prep_of	1	SENT_185	[p9l368t1355r619b1409],

1	None	NN	O	none	nsubj	2	SENT_186	[p9l113t1537r273b1587],
2	declared	VBD	O	declare	_	0	SENT_186	[p9l298t1533r573b1588],
3	.	.	O	.	_	0	SENT_186	[p9l298t1533r573b1588],

1	Acknowledgments	NNS	O	acknowledgment	_	0	SENT_187	[p9l7t1732r612b1801],

1	We	PRP	O	we	nsubj	3	SENT_188	[p9l110t1914r213b1966],
2	sincerely	RB	O	sincerely	advmod	3	SENT_188	[p9l237t1911r505b1979],
3	appreciate	VBP	O	appreciate	_	0	SENT_188	[p9l526t1912r839b1979],
4	the	DT	O	the	det	9	SENT_188	[p9l861t1911r957b1966],
5	physicians	NNS	O	physician	dep	9	SENT_188	[p9l980t1911r1312b1979],
6	:	:	O	:	_	0	SENT_188	[p9l980t1911r1312b1979],
7	Drs.	NNP	O	Drs.	nn	9	SENT_188	[p9l1339t1914r1453b1966],
8	Wen	NNP	PERSON	Wen	nn	9	SENT_188	[p9l1473t1914r1618b1966],
9	Jin	NNP	PERSON	Jin	dobj	3	SENT_188	[p9l1632t1912r1729b1979],
10	,	,	O	,	_	0	SENT_188	[p9l1632t1912r1729b1979],
11	Yuehong	NNP	PERSON	Yuehong	nn	12	SENT_188	[p9l1750t1911r2020b1979],
12	Cui	NNP	PERSON	Cui	dobj	3	SENT_188	[p9l2041t1912r2150b1974],
13	,	,	O	,	_	0	SENT_188	[p9l2041t1912r2150b1974],
14	Yan	NNP	O	Yan	nn	15	SENT_188	[p9l8t2003r123b2054],
15	Song	NN	O	song	dobj	3	SENT_188	[p9l147t2002r305b2068],
16	,	,	O	,	_	0	SENT_188	[p9l147t2002r305b2068],
17	Xi	NN	PERSON	xi	nn	18	SENT_188	[p9l328t2000r389b2054],
18	Guo	NNP	PERSON	Guo	dobj	3	SENT_188	[p9l414t2002r547b2063],
19	,	,	O	,	_	0	SENT_188	[p9l414t2002r547b2063],
20	Qian	NNP	PERSON	Qian	nn	21	SENT_188	[p9l573t2000r709b2065],
21	Li	NNP	PERSON	Li	dobj	3	SENT_188	[p9l734t2000r795b2063],
22	,	,	O	,	_	0	SENT_188	[p9l734t2000r795b2063],
23	Yi	NNP	PERSON	Yi	nn	24	SENT_188	[p9l817t2000r877b2054],
24	Feng	NNP	PERSON	Feng	dobj	3	SENT_188	[p9l900t2003r1054b2068],
25	,	,	O	,	_	0	SENT_188	[p9l900t2003r1054b2068],
26	Yan	NNP	PERSON	Yan	nn	27	SENT_188	[p9l1077t2003r1192b2054],
27	Wang	NNP	PERSON	Wang	dobj	3	SENT_188	[p9l1212t2003r1406b2068],
28	,	,	O	,	_	0	SENT_188	[p9l1212t2003r1406b2068],
29	Yong	NNP	PERSON	Yong	nn	30	SENT_188	[p9l1427t2003r1583b2068],
30	Chen	NNP	PERSON	Chen	conj_and	9	SENT_188	[p9l1606t1999r1771b2063],
31	,	,	O	,	_	0	SENT_188	[p9l1606t1999r1771b2063],
32	Yiyi	NNP	PERSON	Yiyi	nn	33	SENT_188	[p9l1792t2000r1906b2068],
33	Yu	NNP	PERSON	Yu	conj_and	9	SENT_188	[p9l1927t2003r2021b2063],
34	,	,	O	,	_	0	SENT_188	[p9l1927t2003r2021b2063],
35	Tao	NNP	PERSON	Tao	nn	36	SENT_188	[p9l2043t2003r2150b2054],
36	Ye	NNP	PERSON	Ye	conj_and	9	SENT_188	[p9l8t2091r83b2143],
37	and	CC	O	and	_	0	SENT_188	[p9l101t2088r211b2143],
38	all	PDT	O	all	predet	40	SENT_188	[p9l230t2088r298b2143],
39	the	DT	O	the	det	40	SENT_188	[p9l316t2088r413b2143],
40	nurses	NNS	O	nurse	conj_and	9	SENT_188	[p9l431t2104r626b2143],
41	in	IN	O	in	_	0	SENT_188	[p9l646t2089r701b2142],
42	the	DT	O	the	det	43	SENT_188	[p9l719t2088r815b2143],
43	Department	NNP	ORGANIZATION	Department	prep_in	9	SENT_188	[p9l834t2091r1199b2157],
44	of	IN	ORGANIZATION	of	_	0	SENT_188	[p9l1215t2088r1279b2143],
45	Oncology	NNP	ORGANIZATION	Oncology	prep_of	43	SENT_188	[p9l1289t2088r1583b2157],
46	,	,	O	,	_	0	SENT_188	[p9l1289t2088r1583b2157],
47	Zhongshan	NNP	LOCATION	Zhongshan	nn	48	SENT_188	[p9l1602t2088r1935b2157],
48	Hospital	NNP	LOCATION	Hospital	conj_and	43	SENT_188	[p9l1953t2089r2150b2157, p9l10t2177r98b2241],
49	,	,	O	,	_	0	SENT_188	[p9l1953t2089r2150b2157, p9l10t2177r98b2241],
50	Shanghai	NNP	LOCATION	Shanghai	appos	48	SENT_188	[p9l120t2177r408b2246],
51	,	,	O	,	_	0	SENT_188	[p9l120t2177r408b2246],
52	China	NNP	LOCATION	China	appos	48	SENT_188	[p9l430t2177r600b2232],
53	for	IN	O	for	_	0	SENT_188	[p9l620t2177r703b2232],
54	assistance	NN	O	assistance	prep_for	52	SENT_188	[p9l722t2178r1022b2232],
55	in	IN	O	in	_	0	SENT_188	[p9l1043t2178r1098b2232],
56	patient	NN	O	patient	nn	57	SENT_188	[p9l1119t2178r1332b2246],
57	enrollment	NN	O	enrollment	prep_in	54	SENT_188	[p9l1351t2177r1699b2241],
58	,	,	O	,	_	0	SENT_188	[p9l1351t2177r1699b2241],
59	sample	NN	O	sample	nn	60	SENT_188	[p9l1721t2177r1934b2246],
60	collection	NN	O	collection	appos	48	SENT_188	[p9l1955t2177r2150b2232, p9l10t2267r128b2321],
61	and	CC	O	and	_	0	SENT_188	[p9l160t2266r270b2321],
62	evaluation	NN	O	evaluation	conj_and	43	SENT_188	[p9l303t2266r618b2321],
63	of	IN	O	of	_	0	SENT_188	[p9l649t2266r713b2321],
64	toxicities	NNS	O	toxicity	prep_of	62	SENT_188	[p9l736t2267r1021b2322],
65	.	.	O	.	_	0	SENT_188	[p9l736t2267r1021b2322],

1	We	PRP	O	we	nsubj	3	SENT_189	[p9l1051t2270r1155b2321],
2	also	RB	O	also	advmod	3	SENT_189	[p9l1187t2266r1303b2321],
3	thank	VBP	O	thank	_	0	SENT_189	[p9l1335t2266r1508b2321],
4	all	PDT	O	all	predet	6	SENT_189	[p9l1539t2266r1607b2321],
5	the	DT	O	the	det	6	SENT_189	[p9l1639t2266r1735b2321],
6	patients	NNS	O	patient	nsubj	10	SENT_189	[p9l1768t2267r2007b2335],
7	and	CC	O	and	_	0	SENT_189	[p9l2040t2266r2150b2321],
8	healthy	JJ	O	healthy	amod	9	SENT_189	[p9l11t2356r238b2424],
9	volunteers	NNS	O	volunteer	nsubj	10	SENT_189	[p9l255t2356r574b2411],
10	involved	VBN	O	involve	dep	3	SENT_189	[p9l597t2356r854b2411],
11	in	IN	O	in	_	0	SENT_189	[p9l878t2357r933b2410],
12	the	DT	O	the	det	13	SENT_189	[p9l954t2356r1049b2411],
13	study	NN	O	study	prep_in	10	SENT_189	[p9l1073t2356r1250b2424],
14	.	.	O	.	_	0	SENT_189	[p9l1073t2356r1250b2424],

1	References	NNS	O	reference	_	0	SENT_190	[p9l10t2556r359b2610],

1	[	NN	O	[	nn	5	SENT_191	[p9l40t2702r101b2756],
2	1	CD	NUMBER	1	num	5	SENT_191	[p9l40t2702r101b2756],
3	]	CD	NUMBER	]	num	5	SENT_191	[p9l40t2702r101b2756],
4	Ciccolini	NNP	PERSON	Ciccolini	nn	5	SENT_191	[p9l135t2702r336b2746],
5	J	NNP	PERSON	J	_	0	SENT_191	[p9l347t2705r378b2756],
6	,	,	O	,	_	0	SENT_191	[p9l347t2705r378b2756],
7	Mercier	NNP	PERSON	Mercier	nn	8	SENT_191	[p9l395t2703r582b2746],
8	C	NNP	O	C	appos	5	SENT_191	[p9l597t2704r638b2752],
9	,	,	O	,	_	0	SENT_191	[p9l597t2704r638b2752],
10	Dahan	NNP	PERSON	Dahan	nn	11	SENT_191	[p9l656t2702r809b2746],
11	L	NNP	O	L	appos	5	SENT_191	[p9l827t2705r860b2752],
12	,	,	O	,	_	0	SENT_191	[p9l827t2705r860b2752],
13	et	FW	O	et	nn	14	SENT_191	[p9l879t2708r924b2746],
14	al.	FW	O	al.	appos	5	SENT_191	[p9l940t2702r990b2746],
15	.	.	O	.	_	0	SENT_191	[p9l940t2702r990b2746],

1	Integrating	VBG	O	integrate	amod	2	SENT_192	[p9l1008t2703r1274b2756],
2	phannacogenetics	NNS	O	phannacogenetic	_	0	SENT_192	[p9l1290t2702r1728b2756],
3	into	IN	O	into	_	0	SENT_192	[p9l1746t2703r1839b2746],
4	gemcitabine	NN	O	gemcitabine	nn	5	SENT_192	[p9l1856t2702r2151b2756],
5	dosing	NN	O	dosing	prep_into	2	SENT_192	[p9l135t2768r447b2823],
6	—	CD	NUMBER	—	num	7	SENT_192	[p9l135t2768r447b2823],
7	time	NN	O	time	tmod	5	SENT_192	[p9l135t2768r447b2823],
8	for	IN	O	for	_	0	SENT_192	[p9l465t2768r531b2812],
9	a	DT	O	a	det	10	SENT_192	[p9l547t2781r572b2812],
10	change	NN	O	change	prep_for	5	SENT_192	[p9l589t2768r786b2823],
11	?	.	O	?	_	0	SENT_192	[p9l589t2768r786b2823],

1	Nat	NNP	PERSON	Nat	nn	4	SENT_193	[p9l804t2771r889b2812],
2	Rev	NN	PERSON	rev	nn	4	SENT_193	[p9l905t2771r992b2812],
3	Clin	NNP	O	Clin	nn	4	SENT_193	[p9l1008t2768r1100b2812],
4	Oncol	NNP	O	Oncol	_	0	SENT_193	[p9l1117t2768r1253b2812],
5	2011	CD	DATE	2011	num	4	SENT_193	[p9l1271t2770r1650b2818],
6	;	:	O	;	_	0	SENT_193	[p9l1271t2770r1650b2818],
7	8:439	CD	NUMBER	8:439	number	8	SENT_193	[p9l1271t2770r1650b2818],
8	—	CD	NUMBER	—	dep	4	SENT_193	[p9l1271t2770r1650b2818],
9	44	CD	NUMBER	44	dep	8	SENT_193	[p9l1271t2770r1650b2818],
10	.	.	O	.	_	0	SENT_193	[p9l1271t2770r1650b2818],

1	[	NN	O	[	nn	5	SENT_194	[p9l40t2834r101b2888],
2	2	CD	NUMBER	2	num	5	SENT_194	[p9l40t2834r101b2888],
3	]	CD	NUMBER	]	num	5	SENT_194	[p9l40t2834r101b2888],
4	Sandler	NNP	ORGANIZATION	Sandler	nn	5	SENT_194	[p9l135t2834r321b2877],
5	AB	NNP	ORGANIZATION	AB	_	0	SENT_194	[p9l337t2836r415b2884],
6	,	,	O	,	_	0	SENT_194	[p9l337t2836r415b2884],
7	Nemunaitis	NNP	PERSON	Nemunaitis	nn	8	SENT_194	[p9l437t2835r719b2877],
8	J	NNP	PERSON	J	appos	5	SENT_194	[p9l733t2837r765b2888],
9	,	,	O	,	_	0	SENT_194	[p9l733t2837r765b2888],
10	Denham	NNP	PERSON	Denham	nn	11	SENT_194	[p9l786t2834r993b2877],
11	C	NNP	O	C	appos	5	SENT_194	[p9l1014t2836r1054b2884],
12	,	,	O	,	_	0	SENT_194	[p9l1014t2836r1054b2884],
13	et	FW	O	et	nn	14	SENT_194	[p9l1075t2840r1121b2877],
14	al.	FW	O	al.	appos	5	SENT_194	[p9l1140t2834r1192b2878],
15	.	.	O	.	_	0	SENT_194	[p9l1140t2834r1192b2878],

1	Phase	NN	O	phase	_	0	SENT_195	[p9l1213t2834r1353b2877],
2	III	CD	NUMBER	iii	num	3	SENT_195	[p9l1374t2837r1419b2877],
3	trial	NN	O	trial	dobj	10	SENT_195	[p9l1440t2834r1538b2877],
4	of	IN	O	of	_	0	SENT_195	[p9l1558t2834r1609b2877],
5	gemcitabine	NN	O	gemcitabine	prep_of	3	SENT_195	[p9l1623t2834r1925b2888],
6	plus	CC	O	plus	prep	5	SENT_195	[p9l1946t2834r2046b2888],
7	cisplatin	NN	O	cisplatin	dep	6	SENT_195	[p9l2067t2835r2150b2877, p9l135t2899r276b2954],
8	versus	CC	O	versus	prep	7	SENT_195	[p9l307t2912r465b2943],
9	cisplatin	NN	O	cisplatin	dep	8	SENT_195	[p9l498t2900r705b2954],
10	alone	RB	O	alone	dep	1	SENT_195	[p9l738t2899r870b2943],
11	in	IN	O	in	_	0	SENT_195	[p9l904t2900r949b2943],
12	patients	NNS	O	patient	prep_in	10	SENT_195	[p9l981t2900r1178b2954],
13	with	IN	O	with	prep	12	SENT_195	[p9l1210t2900r1323b2943],
14	locally	RB	O	locally	advmod	12	SENT_195	[p9l1357t2899r1515b2954],
15	advanced	VBN	O	advance	amod	19	SENT_195	[p9l1547t2899r1779b2943],
16	or	CC	O	or	_	0	SENT_195	[p9l1814t2912r1864b2943],
17	metastatic	JJ	O	metastatic	conj_or	15	SENT_195	[p9l1896t2900r2151b2943],
18	non-small-cell	JJ	O	non-small-cell	amod	19	SENT_195	[p9l135t2966r490b3009],
19	lung	NN	O	lung	dep	12	SENT_195	[p9l511t2966r619b3020],
20	cancer	NN	O	cancer	dep	19	SENT_195	[p9l638t2968r842b3020],
21	.	.	O	.	_	0	SENT_195	[p9l638t2968r842b3020],
22	]	SYM	O	]	dep	1	SENT_195	[p9l638t2968r842b3020],

1	Clin	NNP	O	Clin	nn	2	SENT_196	[p9l862t2966r955b3009],
2	Oncol	NNP	O	Oncol	_	0	SENT_196	[p9l975t2966r1115b3009],
3	2000	CD	DATE	2000	num	2	SENT_196	[p9l1135t2968r1555b3016],
4	;	:	O	;	_	0	SENT_196	[p9l1135t2968r1555b3016],
5	l8	CD	NUMBER	l8	num	6	SENT_196	[p9l1135t2968r1555b3016],
6	:122	CD	NUMBER	:122	dep	2	SENT_196	[p9l1135t2968r1555b3016],
7	—	CD	NUMBER	—	number	8	SENT_196	[p9l1135t2968r1555b3016],
8	30	CD	NUMBER	30	dep	6	SENT_196	[p9l1135t2968r1555b3016],
9	.	.	O	.	_	0	SENT_196	[p9l1135t2968r1555b3016],

1	[	NN	O	[	nn	3	SENT_197	[p9l40t3032r101b3087],
2	3	CD	NUMBER	3	num	3	SENT_197	[p9l40t3032r101b3087],
3	]	NN	O	]	_	0	SENT_197	[p9l40t3032r101b3087],
4	Mazzanti	NNP	PERSON	Mazzanti	nn	5	SENT_197	[p9l135t3033r359b3076],
5	P	NN	PERSON	p	dep	3	SENT_197	[p9l387t3035r425b3083],
6	,	,	O	,	_	0	SENT_197	[p9l387t3035r425b3083],
7	Massacesi	NN	PERSON	massacesus	nn	8	SENT_197	[p9l454t3033r697b3076],
8	C	NN	PERSON	c	appos	5	SENT_197	[p9l725t3034r765b3082],
9	,	,	O	,	_	0	SENT_197	[p9l725t3034r765b3082],
10	Rocchi	NNP	ORGANIZATION	Rocchi	nn	11	SENT_197	[p9l794t3032r953b3076],
11	MBL	NNP	ORGANIZATION	MBL	appos	5	SENT_197	[p9l981t3035r1098b3082],
12	,	,	O	,	_	0	SENT_197	[p9l981t3035r1098b3082],
13	et	FW	O	et	nn	14	SENT_197	[p9l1126t3039r1172b3076],
14	al.	FW	O	al.	appos	5	SENT_197	[p9l1198t3032r1250b3076],
15	.	.	O	.	_	0	SENT_197	[p9l1198t3032r1250b3076],

1	Randomized	NNP	O	Randomized	nn	3	SENT_198	[p9l1279t3032r1597b3082],
2	,	,	O	,	_	0	SENT_198	[p9l1279t3032r1597b3082],
3	multicenter	NNP	O	multicenter	_	0	SENT_198	[p9l1625t3032r1924b3082],
4	,	,	O	,	_	0	SENT_198	[p9l1625t3032r1924b3082],
5	phase	NN	O	phase	nn	7	SENT_198	[p9l1953t3032r2094b3087],
6	II	CD	NUMBER	ii	num	7	SENT_198	[p9l2122t3035r2150b3075],
7	study	NN	O	study	appos	3	SENT_198	[p9l135t3097r271b3152],
8	of	IN	O	of	_	0	SENT_198	[p9l296t3097r346b3141],
9	gemcitabine	NN	O	gemcitabine	prep_of	7	SENT_198	[p9l366t3097r669b3152],
10	plus	CC	O	plus	_	0	SENT_198	[p9l696t3097r795b3152],
11	cisplatin	NN	O	cisplatin	conj_plus	7	SENT_198	[p9l823t3097r1029b3152],
12	versus	CC	O	versus	prep	11	SENT_198	[p9l1054t3110r1211b3141],
13	gemcitabine	NN	O	gemcitabine	dep	12	SENT_198	[p9l1238t3097r1540b3152],
14	plus	CC	O	plus	_	0	SENT_198	[p9l1568t3097r1668b3152],
15	carboplatin	NN	O	carboplatin	conj_plus	7	SENT_198	[p9l1695t3097r1973b3152],
16	in	IN	O	in	_	0	SENT_198	[p9l2000t3098r2045b3141],
17	patients	NNS	O	patient	prep_in	15	SENT_198	[p9l2072t3110r2150b3152, p9l134t3165r271b3208],
18	with	IN	O	with	_	0	SENT_198	[p9l290t3164r404b3208],
19	advanced	JJ	O	advanced	amod	23	SENT_198	[p9l423t3164r655b3208],
20	non-small	JJ	O	non-small	amod	23	SENT_198	[p9l676t3164r924b3208],
21	cell	NN	O	cell	nn	23	SENT_198	[p9l945t3164r1027b3208],
22	lung	NN	O	lung	nn	23	SENT_198	[p9l1047t3164r1155b3218],
23	cancer	NN	O	cancer	prep_with	17	SENT_198	[p9l1174t3177r1344b3208],
24	.	.	O	.	_	0	SENT_198	[p9l1174t3177r1344b3208],

1	Lung	NN	O	lung	nn	2	SENT_199	[p9l1365t3167r1483b3218],
2	Cancer	NN	O	cancer	_	0	SENT_199	[p9l1503t3166r1670b3208],
3	2003	CD	DATE	2003	dep	2	SENT_199	[p9l1688t3166r2046b3214],
4	;	:	O	;	_	0	SENT_199	[p9l1688t3166r2046b3214],
5	41:81	CD	NUMBER	41:81	number	6	SENT_199	[p9l1688t3166r2046b3214],
6	—	CD	NUMBER	—	dep	2	SENT_199	[p9l1688t3166r2046b3214],
7	9	CD	NUMBER	9	dep	6	SENT_199	[p9l1688t3166r2046b3214],
8	.	.	O	.	_	0	SENT_199	[p9l1688t3166r2046b3214],

1	[	NN	O	[	nn	4	SENT_200	[p9l40t3230r101b3284],
2	4	CD	NUMBER	4	num	4	SENT_200	[p9l40t3230r101b3284],
3	]	NN	O	]	nn	4	SENT_200	[p9l40t3230r101b3284],
4	Zatloukal	NN	O	zatloukal	_	0	SENT_200	[p9l134t3230r362b3274],
5	P	NN	O	p	nn	4	SENT_200	[p9l395t3233r434b3280],
6	,	,	O	,	_	0	SENT_200	[p9l395t3233r434b3280],
7	Petruzelka	FW	ORGANIZATION	petruzelka	dep	4	SENT_200	[p9l468t3230r727b3274],
8	L	NN	ORGANIZATION	l	dep	4	SENT_200	[p9l760t3233r794b3280],
9	,	,	O	,	_	0	SENT_200	[p9l760t3233r794b3280],
10	Zemanova	NN	O	zemanova	nn	11	SENT_200	[p9l827t3233r1082b3274],
11	M	NN	O	m	appos	8	SENT_200	[p9l1116t3233r1174b3280],
12	,	,	O	,	_	0	SENT_200	[p9l1116t3233r1174b3280],
13	et	FW	O	et	nn	14	SENT_200	[p9l1208t3236r1254b3274],
14	al.	FW	O	al.	appos	8	SENT_200	[p9l1286t3230r1337b3274],
15	.	.	O	.	_	0	SENT_200	[p9l1286t3230r1337b3274],

1	Gemcitabine	NN	O	gemcitabine	_	0	SENT_201	[p9l1372t3230r1681b3274],
2	plus	CC	O	plus	prep	1	SENT_201	[p9l1715t3230r1815b3284],
3	cisplatin	NN	O	cisplatin	dep	2	SENT_201	[p9l1849t3230r2055b3284],
4	vs.	CC	O	vs.	prep	3	SENT_201	[p9l2087t3243r2150b3274],
5	gemcitabine	NN	O	gemcitabine	dep	4	SENT_201	[p9l134t3296r436b3350],
6	plus	CC	O	plus	_	0	SENT_201	[p9l462t3296r562b3350],
7	carboplatin	NN	O	carboplatin	conj_plus	1	SENT_201	[p9l589t3296r867b3350],
8	in	IN	O	in	_	0	SENT_201	[p9l893t3296r939b3339],
9	stage	NN	O	stage	nn	10	SENT_201	[p9l965t3302r1090b3350],
10	Illb	NN	O	illb	prep_in	7	SENT_201	[p9l1116t3296r1193b3339],
11	and	CC	O	and	_	0	SENT_201	[p9l1218t3296r1307b3339],
12	IV	CD	NUMBER	iv	num	14	SENT_201	[p9l1334t3298r1385b3339],
13	non-small	JJ	O	non-small	amod	14	SENT_201	[p9l1409t3296r1656b3339],
14	cell	NN	O	cell	conj_and	1	SENT_201	[p9l1682t3296r1764b3339],
15	lung	NN	O	lung	nn	16	SENT_201	[p9l1790t3296r1898b3350],
16	cancer	NN	O	cancer	dep	14	SENT_201	[p9l1923t3308r2097b3340],
17	:	:	O	:	_	0	SENT_201	[p9l1923t3308r2097b3340],
18	a	DT	O	a	det	19	SENT_201	[p9l2126t3308r2151b3339],
19	phase	NN	O	phase	dep	1	SENT_201	[p9l135t3361r276b3416],
20	III	CD	NUMBER	iii	num	22	SENT_201	[p9l297t3364r342b3405],
21	randomized	JJ	O	randomized	amod	22	SENT_201	[p9l362t3361r657b3405],
22	trial	NN	O	trial	dep	19	SENT_201	[p9l677t3362r787b3405],
23	.	.	O	.	_	0	SENT_201	[p9l677t3362r787b3405],

1	Lung	NN	O	lung	nn	2	SENT_202	[p9l808t3364r927b3416],
2	Cancer	NN	O	cancer	_	0	SENT_202	[p9l946t3364r1113b3405],
3	2003	CD	DATE	2003	dep	2	SENT_202	[p9l1131t3364r1551b3412],
4	;	:	O	;	_	0	SENT_202	[p9l1131t3364r1551b3412],
5	41:321	CD	NUMBER	41:321	number	6	SENT_202	[p9l1131t3364r1551b3412],
6	—	CD	NUMBER	—	dep	2	SENT_202	[p9l1131t3364r1551b3412],
7	3l	NN	O	3l	dep	6	SENT_202	[p9l1131t3364r1551b3412],
8	.	.	O	.	_	0	SENT_202	[p9l1131t3364r1551b3412],

1	[	NN	O	[	nn	5	SENT_203	[p9l40t3427r101b3482],
2	5	CD	NUMBER	5	num	5	SENT_203	[p9l40t3427r101b3482],
3	]	CD	NUMBER	]	num	5	SENT_203	[p9l40t3427r101b3482],
4	Wong	NNP	O	Wong	nn	5	SENT_203	[p9l133t3430r279b3482],
5	A	NNP	O	A	_	0	SENT_203	[p9l290t3429r336b3478],
6	,	,	O	,	_	0	SENT_203	[p9l290t3429r336b3478],
7	Soo	NNP	O	Soo	nn	8	SENT_203	[p9l349t3430r434b3471],
8	RA	NN	O	ra	conj_and	5	SENT_203	[p9l448t3429r524b3478],
9	,	,	O	,	_	0	SENT_203	[p9l448t3429r524b3478],
10	Yong	NNP	PERSON	Yong	nn	11	SENT_203	[p9l536t3430r659b3482],
11	WP	NNP	O	WP	conj_and	5	SENT_203	[p9l670t3430r766b3478],
12	,	,	O	,	_	0	SENT_203	[p9l670t3430r766b3478],
13	Innocenti	NNP	PERSON	Innocenti	nn	16	SENT_203	[p9l780t3428r1005b3471],
14	F.	NNP	O	F.	nn	16	SENT_203	[p9l1019t3430r1055b3471],
15	Clinical	JJ	O	clinical	amod	16	SENT_203	[p9l1068t3427r1242b3471],
16	pharmacology	NN	O	pharmacology	conj_and	5	SENT_203	[p9l1255t3427r1599b3482],
17	and	CC	O	and	_	0	SENT_203	[p9l1611t3427r1698b3471],
18	pharmacogenetics	NNS	O	pharmacogenetic	conj_and	5	SENT_203	[p9l1712t3427r2150b3482],
19	of	IN	O	of	_	0	SENT_203	[p9l135t3494r185b3538],
20	gemcitabine	NN	O	gemcitabine	prep_of	18	SENT_203	[p9l195t3494r502b3548],
21	.	.	O	.	_	0	SENT_203	[p9l195t3494r502b3548],

1	Drug	NN	O	drug	_	0	SENT_204	[p9l519t3497r638b3548],
2	Metab	NNP	O	Metab	nn	3	SENT_204	[p9l654t3494r806b3538],
3	Rev	NN	O	rev	dep	1	SENT_204	[p9l823t3497r910b3538],
4	2009	CD	DATE	2009	num	3	SENT_204	[p9l926t3496r1118b3544],
5	;	:	O	;	_	0	SENT_204	[p9l926t3496r1118b3544],
6	41	CD	NUMBER	41	num	7	SENT_204	[p9l926t3496r1118b3544],
7	177-88	CD	NUMBER	177-88	dep	1	SENT_204	[p9l1131t3496r1306b3538],
8	.	.	O	.	_	0	SENT_204	[p9l1131t3496r1306b3538],

1	[	NN	O	[	nn	5	SENT_205	[p9l40t3560r101b3615],
2	6	CD	NUMBER	6	num	5	SENT_205	[p9l40t3560r101b3615],
3	]	CD	NUMBER	]	num	5	SENT_205	[p9l40t3560r101b3615],
4	Ciccolini	NNP	PERSON	Ciccolini	nn	5	SENT_205	[p9l135t3560r341b3604],
5	J	NNP	PERSON	J	_	0	SENT_205	[p9l351t3563r382b3615],
6	,	,	O	,	_	0	SENT_205	[p9l351t3563r382b3615],
7	Dahan	NNP	PERSON	Dahan	nn	8	SENT_205	[p9l399t3560r555b3604],
8	L	NNP	PERSON	L	appos	5	SENT_205	[p9l571t3563r605b3610],
9	,	,	O	,	_	0	SENT_205	[p9l571t3563r605b3610],
10	Andre	NNP	PERSON	Andre	nn	11	SENT_205	[p9l620t3560r770b3604],
11	N	NNP	PERSON	N	appos	5	SENT_205	[p9l786t3563r834b3610],
12	,	,	O	,	_	0	SENT_205	[p9l786t3563r834b3610],
13	et	FW	O	et	nn	14	SENT_205	[p9l850t3567r897b3604],
14	al.	FW	O	al.	appos	5	SENT_205	[p9l911t3560r963b3604],
15	.	.	O	.	_	0	SENT_205	[p9l911t3560r963b3604],

1	Cytidine	NN	O	cytidine	nn	2	SENT_206	[p9l979t3560r1182b3615],
2	deaminase	NN	O	deaminase	_	0	SENT_206	[p9l1199t3560r1462b3604],
3	residual	JJ	O	residual	amod	4	SENT_206	[p9l1478t3560r1672b3604],
4	activity	NN	O	activity	nsubj	10	SENT_206	[p9l1689t3561r1871b3615],
5	in	IN	O	in	_	0	SENT_206	[p9l1885t3561r1930b3603],
6	serum	NN	O	serum	prep_in	4	SENT_206	[p9l1946t3573r2099b3604],
7	is	VBZ	O	be	cop	10	SENT_206	[p9l2115t3561r2150b3604],
8	a	DT	O	a	det	10	SENT_206	[p9l135t3638r160b3669],
9	predictive	JJ	O	predictive	amod	10	SENT_206	[p9l184t3626r430b3680],
10	marker	NN	O	marker	rcmod	2	SENT_206	[p9l456t3626r634b3669],
11	of	IN	O	of	_	0	SENT_206	[p9l658t3626r709b3669],
12	early	JJ	O	early	amod	14	SENT_206	[p9l727t3626r849b3680],
13	severe	JJ	O	severe	amod	14	SENT_206	[p9l873t3638r1029b3669],
14	toxicities	NNS	O	toxicity	prep_of	10	SENT_206	[p9l1054t3627r1276b3669],
15	in	IN	O	in	_	0	SENT_206	[p9l1302t3627r1348b3669],
16	adults	NNS	O	adult	prep_in	14	SENT_206	[p9l1372t3626r1520b3669],
17	after	IN	O	after	_	0	SENT_206	[p9l1545t3626r1659b3669],
18	gemcitabine	NN	O	gemcitabine	nn	19	SENT_206	[p9l1682t3626r2149b3680],
19	—	NN	O	—	prep_after	16	SENT_206	[p9l1682t3626r2149b3680],
20	based	VBN	O	base	partmod	19	SENT_206	[p9l1682t3626r2149b3680],
21	chemotherapies	NNS	O	chemotherapy	dep	2	SENT_206	[p9l135t3691r575b3746],
22	]	CD	NUMBER	]	num	24	SENT_206	[p9l135t3691r575b3746],
23	Clin	NNP	O	Clin	nn	24	SENT_206	[p9l595t3691r689b3735],
24	Oncol	NNP	O	Oncol	dep	21	SENT_206	[p9l709t3691r848b3735],
25	2010	CD	DATE	2010	num	24	SENT_206	[p9l868t3694r1258b3742],
26	;	:	O	;	_	0	SENT_206	[p9l868t3694r1258b3742],
27	28:160	CD	NUMBER	28:160	number	28	SENT_206	[p9l868t3694r1258b3742],
28	—	CD	NUMBER	—	dep	2	SENT_206	[p9l868t3694r1258b3742],
29	5	CD	NUMBER	5	dep	28	SENT_206	[p9l868t3694r1258b3742],
30	.	.	O	.	_	0	SENT_206	[p9l868t3694r1258b3742],

1	[	NN	O	[	_	0	SENT_207	[p9l40t3757r101b3812],
2	7	CD	NUMBER	7	num	1	SENT_207	[p9l40t3757r101b3812],
3	]	CD	NUMBER	]	num	5	SENT_207	[p9l40t3757r101b3812],
4	Yue	NN	O	yue	nn	5	SENT_207	[p9l133t3760r224b3801],
5	L	NN	O	l	nn	1	SENT_207	[p9l245t3760r280b3808],
6	,	,	O	,	_	0	SENT_207	[p9l245t3760r280b3808],
7	Saikawa	FW	O	saikawa	dep	1	SENT_207	[p9l300t3758r497b3801],
8	Y	NN	O	y	dep	1	SENT_207	[p9l516t3760r558b3808],
9	,	,	O	,	_	0	SENT_207	[p9l516t3760r558b3808],
10	Ota	NN	PERSON	ota	nn	11	SENT_207	[p9l581t3760r662b3801],
11	K	NN	O	k	appos	8	SENT_207	[p9l683t3760r726b3808],
12	,	,	O	,	_	0	SENT_207	[p9l683t3760r726b3808],
13	et	FW	O	et	nn	14	SENT_207	[p9l746t3764r792b3801],
14	al.	FW	O	al.	appos	8	SENT_207	[p9l811t3758r862b3802],
15	.	.	O	.	_	0	SENT_207	[p9l811t3758r862b3802],

1	A	DT	O	a	det	4	SENT_208	[p9l881t3760r917b3801],
2	functional	JJ	O	functional	amod	3	SENT_208	[p9l937t3757r1177b3801],
3	single-nucleotide	JJ	O	single-nucleotide	amod	4	SENT_208	[p9l1199t3758r1613b3812],
4	polymorphism	NN	O	polymorphism	_	0	SENT_208	[p9l1634t3758r1989b3812],
5	in	IN	O	in	_	0	SENT_208	[p9l2009t3758r2055b3801],
6	the	DT	O	the	det	10	SENT_208	[p9l2074t3758r2151b3801],
7	human	JJ	O	human	amod	10	SENT_208	[p10l135t13r304b57],
8	cytidine	NN	O	cytidine	nn	10	SENT_208	[p10l319t13r510b68],
9	deaminase	NN	O	deaminase	nn	10	SENT_208	[p10l526t13r783b57],
10	gene	NN	O	gene	prep_in	4	SENT_208	[p10l798t26r913b68],
11	contributing	VBG	O	contribute	partmod	4	SENT_208	[p10l928t13r1227b68],
12	to	TO	O	to	_	0	SENT_208	[p10l1240t20r1286b57],
13	ara-C	NN	O	ara-c	nn	14	SENT_208	[p10l1301t15r1428b57],
14	sensitivity	NN	O	sensitivity	prep_to	11	SENT_208	[p10l1443t14r1699b68],
15	.	.	O	.	_	0	SENT_208	[p10l1443t14r1699b68],

1	Pharmacogenetics	NNS	O	pharmacogenetic	_	0	SENT_209	[p10l1714t13r2151b68],
2	2003	CD	DATE	2003	num	1	SENT_209	[p10l135t81r514b129],
3	;	:	O	;	_	0	SENT_209	[p10l135t81r514b129],
4	13:29	CD	TIME	13:29	number	5	SENT_209	[p10l135t81r514b129],
5	—	CD	NUMBER	—	dep	1	SENT_209	[p10l135t81r514b129],
6	38	CD	NUMBER	38	dep	5	SENT_209	[p10l135t81r514b129],
7	.	.	O	.	_	0	SENT_209	[p10l135t81r514b129],

1	[	NN	O	[	nn	4	SENT_210	[p10l40t145r101b199],
2	8	CD	NUMBER	8	num	4	SENT_210	[p10l40t145r101b199],
3	]	NN	O	]	nn	4	SENT_210	[p10l40t145r101b199],
4	Sugiyama	NN	PERSON	sugiyama	_	0	SENT_210	[p10l135t146r373b199],
5	E	NN	O	e	dep	4	SENT_210	[p10l389t148r428b195],
6	,	,	O	,	_	0	SENT_210	[p10l389t148r428b195],
7	Kaniwa	NN	PERSON	kaniwa	nn	8	SENT_210	[p10l445t146r628b189],
8	N	NN	O	n	appos	5	SENT_210	[p10l645t148r693b195],
9	,	,	O	,	_	0	SENT_210	[p10l645t148r693b195],
10	Kim	NNP	PERSON	Kim	nn	11	SENT_210	[p10l710t146r808b188],
11	SR	NN	O	sr	appos	5	SENT_210	[p10l824t147r894b195],
12	,	,	O	,	_	0	SENT_210	[p10l824t147r894b195],
13	et	FW	O	et	nn	14	SENT_210	[p10l911t151r957b189],
14	al.	FW	O	al.	appos	5	SENT_210	[p10l972t145r1024b189],
15	.	.	O	.	_	0	SENT_210	[p10l972t145r1024b189],

1	Pharmacokinetics	NNS	O	pharmacokinetic	_	0	SENT_211	[p10l1042t145r1478b189],
2	of	IN	O	of	_	0	SENT_211	[p10l1495t145r1546b189],
3	gemcitabine	NN	O	gemcitabine	prep_of	1	SENT_211	[p10l1555t145r1857b199],
4	in	IN	O	in	_	0	SENT_211	[p10l1875t146r1920b188],
5	Japanese	JJ	MISC	japanese	amod	7	SENT_211	[p10l1930t148r2150b199],
6	cancer	NN	O	cancer	nn	7	SENT_211	[p10l135t224r295b255],
7	patients	NNS	O	patient	prep_in	3	SENT_211	[p10l318t212r530b265],
8	:	:	O	:	_	0	SENT_211	[p10l318t212r530b265],
9	the	DT	O	the	det	10	SENT_211	[p10l558t211r636b255],
10	impact	NN	O	impact	dep	1	SENT_211	[p10l662t212r830b265],
11	of	IN	O	of	_	0	SENT_211	[p10l854t211r905b255],
12	a	DT	O	a	det	18	SENT_211	[p10l923t224r948b255],
13	cytidine	NN	O	cytidine	nn	18	SENT_211	[p10l972t211r1169b265],
14	deaminse	NN	O	deaminse	nn	18	SENT_211	[p10l1194t211r1430b255],
15	polymorphism	NN	O	polymorphism	nn	18	SENT_211	[p10l1455t211r1868b265],
16	]	NN	O	]	nn	18	SENT_211	[p10l1455t211r1868b265],
17	Clin	NN	O	clin	nn	18	SENT_211	[p10l1893t211r1986b255],
18	Oncol	NN	O	oncol	prep_of	10	SENT_211	[p10l2011t211r2150b255],
19	2007:25:32	CD	NUMBER	2007:25:32	number	20	SENT_211	[p10l135t279r524b325],
20	—	CD	NUMBER	—	dep	10	SENT_211	[p10l135t279r524b325],
21	42	CD	NUMBER	42	dep	20	SENT_211	[p10l135t279r524b325],
22	.	.	O	.	_	0	SENT_211	[p10l135t279r524b325],

1	[	NN	O	[	nn	4	SENT_212	[p10l33t342r95b398],
2	9	CD	NUMBER	9	num	4	SENT_212	[p10l33t342r95b398],
3	]	NN	O	]	nn	4	SENT_212	[p10l33t342r95b398],
4	Sugiyama	NN	PERSON	sugiyama	_	0	SENT_212	[p10l128t343r367b398],
5	E	NN	O	e	dep	4	SENT_212	[p10l384t345r423b394],
6	,	,	O	,	_	0	SENT_212	[p10l384t345r423b394],
7	Kaniwa	NN	PERSON	kaniwa	nn	8	SENT_212	[p10l442t343r624b387],
8	N	NN	O	n	appos	5	SENT_212	[p10l643t345r690b394],
9	,	,	O	,	_	0	SENT_212	[p10l643t345r690b394],
10	Kim	NNP	PERSON	Kim	nn	11	SENT_212	[p10l709t343r806b387],
11	SR	NN	O	sr	appos	5	SENT_212	[p10l824t345r894b394],
12	,	,	O	,	_	0	SENT_212	[p10l824t345r894b394],
13	et	FW	O	et	nn	14	SENT_212	[p10l912t349r958b387],
14	al.	FW	O	al.	appos	5	SENT_212	[p10l974t343r1026b388],
15	.	.	O	.	_	0	SENT_212	[p10l974t343r1026b388],

1	Population	NNP	O	Population	nn	2	SENT_213	[p10l1045t343r1311b398],
2	pharmacokinetics	NNS	O	pharmacokinetic	_	0	SENT_213	[p10l1329t343r1767b398],
3	of	IN	O	of	_	0	SENT_213	[p10l1786t342r1837b387],
4	gemcitabine	NN	O	gemcitabine	prep_of	2	SENT_213	[p10l1847t343r2151b398],
5	and	CC	O	and	_	0	SENT_213	[p10l128t410r217b455],
6	its	PRP$	O	its	poss	7	SENT_213	[p10l251t411r306b455],
7	metabolite	NN	O	metabolite	conj_and	4	SENT_213	[p10l340t410r604b455],
8	in	IN	O	in	_	0	SENT_213	[p10l637t411r683b454],
9	Japanese	JJ	MISC	japanese	amod	11	SENT_213	[p10l709t413r930b466],
10	cancer	NN	O	cancer	nn	11	SENT_213	[p10l963t423r1124b455],
11	patients	NNS	O	patient	prep_in	2	SENT_213	[p10l1155t411r1364b466],
12	.	.	O	.	_	0	SENT_213	[p10l1155t411r1364b466],

1	Clin	NNP	O	Clin	nn	2	SENT_214	[p10l1398t410r1491b455],
2	Pharmacokinet	NNP	O	Pharmacokinet	_	0	SENT_214	[p10l1524t410r1897b455],
3	2010	CD	DATE	2010	num	2	SENT_214	[p10l1929t412r2147b461],
4	;	:	O	;	_	0	SENT_214	[p10l1929t412r2147b461],
5	49	CD	NUMBER	49	num	7	SENT_214	[p10l1929t412r2147b461],
6	:	:	O	:	_	0	SENT_214	[p10l1929t412r2147b461],
7	549-58	CD	NUMBER	549-58	dep	2	SENT_214	[p10l129t480r324b521],
8	.	.	O	.	_	0	SENT_214	[p10l129t480r324b521],

1	[	NN	O	[	nn	5	SENT_215	[p10l6t544r99b598],
2	10	CD	NUMBER	10	num	5	SENT_215	[p10l6t544r99b598],
3	]	CD	NUMBER	]	num	5	SENT_215	[p10l6t544r99b598],
4	Gilbert	NNP	PERSON	Gilbert	nn	5	SENT_215	[p10l132t544r302b588],
5	JA	NNP	PERSON	JA	_	0	SENT_215	[p10l314t546r382b598],
6	,	,	O	,	_	0	SENT_215	[p10l314t546r382b598],
7	Salavaggione	NNP	ORGANIZATION	Salavaggione	nn	8	SENT_215	[p10l404t544r725b598],
8	OE	NNP	ORGANIZATION	OE	appos	5	SENT_215	[p10l746t546r823b594],
9	,	,	O	,	_	0	SENT_215	[p10l746t546r823b594],
10	Ji	NNP	O	Ji	nn	11	SENT_215	[p10l839t545r874b598],
11	Y	NN	O	y	appos	5	SENT_215	[p10l892t547r937b594],
12	,	,	O	,	_	0	SENT_215	[p10l892t547r937b594],
13	et	FW	O	et	nn	14	SENT_215	[p10l959t550r1005b588],
14	al.	FW	O	al.	appos	5	SENT_215	[p10l1024t544r1076b588],
15	.	.	O	.	_	0	SENT_215	[p10l1024t544r1076b588],

1	Gemcitabine	JJ	O	gemcitabine	amod	2	SENT_216	[p10l1098t544r1409b588],
2	pharmacogenomics	NNS	O	pharmacogenomic	_	0	SENT_216	[p10l1430t544r1929b598],
3	:	:	O	:	_	0	SENT_216	[p10l1430t544r1929b598],
4	cytidine	NN	O	cytidine	nn	5	SENT_216	[p10l1953t544r2150b598],
5	deaminase	NN	O	deaminase	dep	2	SENT_216	[p10l132t610r396b655],
6	and	CC	O	and	_	0	SENT_216	[p10l415t610r504b655],
7	deoxycytidylate	JJ	O	deoxycytidylate	amod	10	SENT_216	[p10l523t610r916b666],
8	deaminase	NN	O	deaminase	nn	10	SENT_216	[p10l935t610r1199b655],
9	gene	NN	O	gene	nn	10	SENT_216	[p10l1216t623r1333b666],
10	resequencing	NN	O	resequencing	conj_and	5	SENT_216	[p10l1352t611r1681b666],
11	and	CC	O	and	_	0	SENT_216	[p10l1699t610r1788b655],
12	functional	JJ	O	functional	amod	13	SENT_216	[p10l1807t610r2055b655],
13	genomics	NNS	O	genomic	conj_and	5	SENT_216	[p10l2074t623r2151b666, p10l132t678r320b721],
14	.	.	O	.	_	0	SENT_216	[p10l2074t623r2151b666, p10l132t678r320b721],

1	Clin	NNP	O	Clin	nn	3	SENT_217	[p10l341t677r434b720],
2	Cancer	NNP	O	Cancer	nn	3	SENT_217	[p10l454t679r622b720],
3	Res	NNP	O	Res	_	0	SENT_217	[p10l640t680r722b720],
4	2006	CD	DATE	2006	num	3	SENT_217	[p10l743t679r1227b727],
5	;	:	O	;	_	0	SENT_217	[p10l743t679r1227b727],
6	12:1794	CD	NUMBER	12:1794	num	7	SENT_217	[p10l743t679r1227b727],
7	—	NN	O	—	dep	3	SENT_217	[p10l743t679r1227b727],
8	803	CD	NUMBER	803	dep	7	SENT_217	[p10l743t679r1227b727],
9	.	.	O	.	_	0	SENT_217	[p10l743t679r1227b727],

1	[	NN	O	[	nn	4	SENT_218	[p10l6t743r99b797],
2	11	CD	NUMBER	11	num	4	SENT_218	[p10l6t743r99b797],
3	]	NN	O	]	nn	4	SENT_218	[p10l6t743r99b797],
4	Tibaldi	NN	MISC	tibaldus	_	0	SENT_218	[p10l130t743r298b786],
5	C	NN	O	c	dep	4	SENT_218	[p10l318t745r358b793],
6	,	,	O	,	_	0	SENT_218	[p10l318t745r358b793],
7	Giovannetti	NNP	PERSON	Giovannetti	nn	8	SENT_218	[p10l379t743r667b786],
8	E	NNP	O	E	appos	5	SENT_218	[p10l688t746r726b793],
9	,	,	O	,	_	0	SENT_218	[p10l688t746r726b793],
10	Vasile	NNP	PERSON	Vasile	nn	11	SENT_218	[p10l744t743r891b786],
11	E	NNP	PERSON	E	appos	5	SENT_218	[p10l911t746r950b793],
12	,	,	O	,	_	0	SENT_218	[p10l911t746r950b793],
13	et	FW	O	et	nn	14	SENT_218	[p10l970t749r1017b786],
14	al.	FW	O	al.	appos	5	SENT_218	[p10l1035t743r1087b787],
15	.	.	O	.	_	0	SENT_218	[p10l1035t743r1087b787],

1	Correlation	NN	O	correlation	_	0	SENT_219	[p10l1107t743r1383b786],
2	of	IN	O	of	_	0	SENT_219	[p10l1403t743r1454b786],
3	CDA	NNP	ORGANIZATION	CDA	prep_of	1	SENT_219	[p10l1467t745r1582b793],
4	,	,	O	,	_	0	SENT_219	[p10l1467t745r1582b793],
5	ERCC1	NN	O	ercc1	conj_and	3	SENT_219	[p10l1603t745r1772b793],
6	,	,	O	,	_	0	SENT_219	[p10l1603t745r1772b793],
7	and	CC	O	and	_	0	SENT_219	[p10l1792t743r1881b786],
8	XPD	NN	O	xpd	nn	9	SENT_219	[p10l1900t746r2003b786],
9	polymorphisms	NNS	O	polymorphism	conj_and	3	SENT_219	[p10l2023t743r2150b797, p10l132t808r410b864],
10	with	IN	O	with	_	0	SENT_219	[p10l425t808r539b853],
11	response	NN	O	response	prep_with	1	SENT_219	[p10l555t821r773b864],
12	and	CC	O	and	_	0	SENT_219	[p10l790t808r879b853],
13	survival	NN	O	survival	conj_and	11	SENT_219	[p10l896t808r1089b853],
14	in	IN	O	in	_	0	SENT_219	[p10l1106t809r1151b852],
15	gemcitabine/cisplatin-treated	JJ	O	gemcitabine/cisplatin-treated	amod	23	SENT_219	[p10l1166t808r1899b864],
16	advanced	JJ	O	advanced	amod	23	SENT_219	[p10l1917t808r2150b853],
17	non	JJ	O	non	amod	23	SENT_219	[p10l132t876r381b921],
18	—	NN	O	—	nn	23	SENT_219	[p10l132t876r381b921],
19	small	JJ	O	small	amod	23	SENT_219	[p10l132t876r381b921],
20	cell	NN	O	cell	nn	23	SENT_219	[p10l401t876r483b921],
21	lung	NN	O	lung	nn	23	SENT_219	[p10l504t876r612b932],
22	cancer	NN	O	cancer	nn	23	SENT_219	[p10l631t889r792b921],
23	patients	NNS	O	patient	prep_in	1	SENT_219	[p10l811t877r1020b932],
24	.	.	O	.	_	0	SENT_219	[p10l811t877r1020b932],

1	Clin	NNP	O	Clin	nn	3	SENT_220	[p10l1041t876r1134b921],
2	Cancer	NNP	O	Cancer	nn	3	SENT_220	[p10l1155t878r1322b921],
3	Res	NNP	O	Res	_	0	SENT_220	[p10l1341t879r1423b921],
4	2008	CD	DATE	2008	num	3	SENT_220	[p10l1443t878r1927b928],
5	;	:	O	;	_	0	SENT_220	[p10l1443t878r1927b928],
6	14:1797	CD	NUMBER	14:1797	num	7	SENT_220	[p10l1443t878r1927b928],
7	—	NN	O	—	dep	3	SENT_220	[p10l1443t878r1927b928],
8	803	CD	NUMBER	803	dep	7	SENT_220	[p10l1443t878r1927b928],
9	.	.	O	.	_	0	SENT_220	[p10l1443t878r1927b928],

1	[	NN	O	[	_	0	SENT_221	[p10l6t943r99b999],
2	12	CD	NUMBER	12	num	1	SENT_221	[p10l6t943r99b999],
3	]	CD	NUMBER	]	num	5	SENT_221	[p10l6t943r99b999],
4	Soo	NNP	O	Soo	nn	5	SENT_221	[p10l132t945r218b988],
5	RA	NN	O	ra	dep	1	SENT_221	[p10l239t945r316b994],
6	,	,	O	,	_	0	SENT_221	[p10l239t945r316b994],
7	Wang	NNP	PERSON	Wang	nn	8	SENT_221	[p10l335t946r481b999],
8	LZ	NNP	PERSON	LZ	appos	5	SENT_221	[p10l501t946r566b994],
9	,	,	O	,	_	0	SENT_221	[p10l501t946r566b994],
10	Ng	NNP	O	Ng	nn	11	SENT_221	[p10l587t946r653b999],
11	SS	NNP	O	SS	appos	5	SENT_221	[p10l672t945r737b994],
12	,	,	O	,	_	0	SENT_221	[p10l672t945r737b994],
13	et	FW	O	et	nn	14	SENT_221	[p10l758t950r805b988],
14	al.	FW	O	al.	appos	5	SENT_221	[p10l823t943r875b988],
15	.	.	O	.	_	0	SENT_221	[p10l823t943r875b988],

1	Distribution	NN	O	distribution	_	0	SENT_222	[p10l896t943r1192b988],
2	of	IN	O	of	_	0	SENT_222	[p10l1212t943r1263b988],
3	gemcitabine	NN	O	gemcitabine	nn	5	SENT_222	[p10l1276t943r1579b999],
4	pathway	NN	O	pathway	nn	5	SENT_222	[p10l1600t943r1815b999],
5	genotypes	NNS	O	genotype	prep_of	1	SENT_222	[p10l1832t950r2085b999],
6	in	IN	O	in	_	0	SENT_222	[p10l2106t944r2151b987],
7	ethnic	JJ	O	ethnic	amod	8	SENT_222	[p10l132t1010r286b1053],
8	Asians	NNPS	MISC	Asians	prep_in	5	SENT_222	[p10l306t1011r464b1053],
9	and	CC	O	and	_	0	SENT_222	[p10l489t1010r579b1053],
10	their	PRP$	O	they	poss	11	SENT_222	[p10l602t1010r720b1053],
11	association	NN	O	association	conj_and	5	SENT_222	[p10l742t1010r1014b1053],
12	with	IN	O	with	_	0	SENT_222	[p10l1037t1010r1150b1053],
13	outcome	NN	O	outcome	prep_with	11	SENT_222	[p10l1174t1016r1388b1053],
14	in	IN	O	in	_	0	SENT_222	[p10l1413t1011r1458b1053],
15	non	JJ	O	non	amod	21	SENT_222	[p10l1481t1010r1730b1053],
16	—	JJ	O	—	amod	21	SENT_222	[p10l1481t1010r1730b1053],
17	small	JJ	O	small	amod	21	SENT_222	[p10l1481t1010r1730b1053],
18	cell	NN	O	cell	nn	21	SENT_222	[p10l1754t1010r1836b1053],
19	lung	NN	O	lung	nn	21	SENT_222	[p10l1861t1010r1968b1064],
20	cancer	NN	O	cancer	nn	21	SENT_222	[p10l1992t1022r2152b1053],
21	patients	NNS	O	patient	prep_in	1	SENT_222	[p10l132t1077r342b1130],
22	.	.	O	.	_	0	SENT_222	[p10l132t1077r342b1130],

1	Lung	NN	O	lung	nn	2	SENT_223	[p10l363t1079r481b1130],
2	Cancer	NN	O	cancer	_	0	SENT_223	[p10l501t1078r668b1120],
3	2009	CD	DATE	2009	dep	2	SENT_223	[p10l687t1078r1077b1126],
4	;	:	O	;	_	0	SENT_223	[p10l687t1078r1077b1126],
5	63:121	CD	NUMBER	63:121	number	6	SENT_223	[p10l687t1078r1077b1126],
6	—	CD	NUMBER	—	dep	2	SENT_223	[p10l687t1078r1077b1126],
7	8	CD	NUMBER	8	dep	6	SENT_223	[p10l687t1078r1077b1126],
8	.	.	O	.	_	0	SENT_223	[p10l687t1078r1077b1126],

1	[	RB	O	[	dep	5	SENT_224	[p10l6t1141r99b1197],
2	13	CD	NUMBER	13	num	5	SENT_224	[p10l6t1141r99b1197],
3	]	CD	NUMBER	]	num	5	SENT_224	[p10l6t1141r99b1197],
4	Carpi	NNP	O	Carpi	nn	5	SENT_224	[p10l132t1142r259b1197],
5	FM	NNP	O	FM	_	0	SENT_224	[p10l282t1144r368b1193],
6	,	,	O	,	_	0	SENT_224	[p10l282t1144r368b1193],
7	Xu	NNP	PERSON	Xu	nn	8	SENT_224	[p10l389t1144r456b1186],
8	J	NNP	PERSON	J	appos	5	SENT_224	[p10l472t1144r503b1197],
9	,	,	O	,	_	0	SENT_224	[p10l472t1144r503b1197],
10	Vincenzetti	NNP	O	Vincenzetti	nn	11	SENT_224	[p10l523t1142r804b1186],
11	S	NNP	O	S	appos	5	SENT_224	[p10l827t1144r864b1193],
12	,	,	O	,	_	0	SENT_224	[p10l827t1144r864b1193],
13	et	FW	O	et	nn	14	SENT_224	[p10l887t1148r933b1186],
14	al.	FW	O	al.	appos	11	SENT_224	[p10l954t1142r1006b1187],
15	.	.	O	.	_	0	SENT_224	[p10l954t1142r1006b1187],

1	Rapid	JJ	O	rapid	amod	4	SENT_225	[p10l1029t1142r1166b1197],
2	allele-speciﬁc	JJ	O	allele-speciﬁc	amod	4	SENT_225	[p10l1189t1141r1527b1197],
3	PCR	NN	O	pcr	nn	4	SENT_225	[p10l1548t1144r1644b1186],
4	method	NN	O	method	_	0	SENT_225	[p10l1664t1142r1854b1186],
5	for	IN	O	for	_	0	SENT_225	[p10l1877t1141r1946b1186],
6	CDA	NNP	ORGANIZATION	CDA	prep_for	4	SENT_225	[p10l1966t1144r2071b1186],
7	79	CD	NUMBER	79	num	6	SENT_225	[p10l2093t1144r2150b1186],
8	A	DT	O	a	det	10	SENT_225	[p10l130t1211r241b1254],
9	>	JJR	O	>	dep	10	SENT_225	[p10l130t1211r241b1254],
10	C	NN	O	c	dep	6	SENT_225	[p10l130t1211r241b1254],
11	(	CD	NUMBER	(	num	10	SENT_225	[p10l269t1209r443b1264],
12	I	PRP	O	I	nsubj	13	SENT_225	[p10l269t1209r443b1264],
13	(	VBP	O	(	rcmod	6	SENT_225	[p10l269t1209r443b1264],
14	27Q	NN	O	27q	nn	16	SENT_225	[p10l269t1209r443b1264],
15	)	CD	NUMBER	)	num	16	SENT_225	[p10l269t1209r443b1264],
16	genotyping	NN	O	genotyping	dobj	13	SENT_225	[p10l472t1210r767b1265],
17	:	:	O	:	_	0	SENT_225	[p10l472t1210r767b1265],
18	a	DT	O	a	det	21	SENT_225	[p10l796t1222r821b1254],
19	useful	JJ	O	useful	amod	20	SENT_225	[p10l846t1209r993b1254],
20	pharmacogenetic	JJ	O	pharmacogenetic	amod	21	SENT_225	[p10l1020t1209r1447b1265],
21	tool	NN	O	tool	dep	4	SENT_225	[p10l1472t1209r1566b1254],
22	and	CC	O	and	_	0	SENT_225	[p10l1592t1209r1681b1254],
23	world	NN	O	world	dep	4	SENT_225	[p10l1706t1209r1997b1254],
24	—	CD	NUMBER	—	num	27	SENT_225	[p10l1706t1209r1997b1254],
25	wide	JJ	O	wide	amod	27	SENT_225	[p10l1706t1209r1997b1254],
26	polymorphism	NN	O	polymorphism	nn	27	SENT_225	[p10l2023t1209r2150b1265, p10l132t1275r387b1331],
27	distribution	NN	O	distribution	dep	23	SENT_225	[p10l407t1275r709b1320],
28	.	.	O	.	_	0	SENT_225	[p10l407t1275r709b1320],

1	Clin	NNP	PERSON	Clin	nn	3	SENT_226	[p10l730t1275r824b1320],
2	Chim	NNP	PERSON	Chim	nn	3	SENT_226	[p10l844t1276r972b1320],
3	Acta	NNP	PERSON	Acta	_	0	SENT_226	[p10l989t1277r1098b1320],
4	2011	CD	DATE	2011	num	3	SENT_226	[p10l1117t1278r1602b1327],
5	;	:	O	;	_	0	SENT_226	[p10l1117t1278r1602b1327],
6	412:2237	CD	NUMBER	412:2237	number	7	SENT_226	[p10l1117t1278r1602b1327],
7	—	CD	NUMBER	—	dep	3	SENT_226	[p10l1117t1278r1602b1327],
8	40	CD	NUMBER	40	dep	7	SENT_226	[p10l1117t1278r1602b1327],
9	.	.	O	.	_	0	SENT_226	[p10l1117t1278r1602b1327],

1	[	RB	O	[	dep	5	SENT_227	[p10l6t1343r99b1397],
2	14	CD	NUMBER	14	num	5	SENT_227	[p10l6t1343r99b1397],
3	]	CD	NUMBER	]	num	5	SENT_227	[p10l6t1343r99b1397],
4	Carpi	NNP	O	Carpi	nn	5	SENT_227	[p10l132t1344r259b1397],
5	FM	NNP	O	FM	_	0	SENT_227	[p10l281t1346r368b1393],
6	,	,	O	,	_	0	SENT_227	[p10l281t1346r368b1393],
7	Vincenzetti	NNP	PERSON	Vincenzetti	nn	8	SENT_227	[p10l388t1344r670b1387],
8	S	NNP	O	S	appos	5	SENT_227	[p10l692t1345r728b1393],
9	,	,	O	,	_	0	SENT_227	[p10l692t1345r728b1393],
10	Micozzi	NNP	PERSON	Micozzi	nn	11	SENT_227	[p10l751t1344r940b1387],
11	D	NNP	O	D	appos	5	SENT_227	[p10l962t1346r1009b1393],
12	,	,	O	,	_	0	SENT_227	[p10l962t1346r1009b1393],
13	et	FW	O	et	nn	14	SENT_227	[p10l1031t1349r1078b1387],
14	al.	FW	O	al.	appos	11	SENT_227	[p10l1098t1343r1151b1387],
15	.	.	O	.	_	0	SENT_227	[p10l1098t1343r1151b1387],

1	PCR-based	JJ	O	pcr-based	amod	2	SENT_228	[p10l1174t1343r1432b1387],
2	methods	NNS	O	method	_	0	SENT_228	[p10l1455t1343r1669b1387],
3	for	IN	O	for	_	0	SENT_228	[p10l1692t1343r1760b1387],
4	CDA	NNP	O	CDA	nn	5	SENT_228	[p10l1781t1345r1886b1387],
5	K27Q	NN	O	k27q	prep_for	2	SENT_228	[p10l1906t1345r2046b1395],
6	and	CC	O	and	_	0	SENT_228	[p10l2061t1343r2150b1387],
7	A70T	NN	O	a70t	nn	8	SENT_228	[p10l130t1411r259b1454],
8	genotyping	NN	O	genotyping	prep_for	2	SENT_228	[p10l274t1410r569b1465],
9	:	:	O	:	_	0	SENT_228	[p10l274t1410r569b1465],
10	genotypes	NNS	O	genotype	nn	13	SENT_228	[p10l591t1416r843b1465],
11	and	CC	O	and	_	0	SENT_228	[p10l862t1409r952b1454],
12	alleles	NNS	O	allele	conj_and	10	SENT_228	[p10l971t1409r1123b1454],
13	distribution	NN	O	distribution	dep	2	SENT_228	[p10l1143t1409r1432b1454],
14	in	IN	O	in	_	0	SENT_228	[p10l1452t1410r1496b1453],
15	a	DT	O	a	det	18	SENT_228	[p10l1515t1422r1540b1454],
16	central	JJ	O	central	amod	18	SENT_228	[p10l1557t1409r1726b1454],
17	Italy	NNP	LOCATION	Italy	nn	18	SENT_228	[p10l1746t1409r1853b1465],
18	population	NN	O	population	prep_in	13	SENT_228	[p10l1871t1409r2150b1465],
19	.	.	O	.	_	0	SENT_228	[p10l1871t1409r2150b1465],

1	Mol	NNP	O	Mol	nn	3	SENT_229	[p10l132t1476r226b1519],
2	Biol	NNP	O	Biol	nn	3	SENT_229	[p10l246t1476r337b1519],
3	Rep	NNP	O	Rep	_	0	SENT_229	[p10l357t1479r447b1530],
4	2010	CD	DATE	2010	num	3	SENT_229	[p10l468t1478r890b1526],
5	;	:	O	;	_	0	SENT_229	[p10l468t1478r890b1526],
6	37:3363	CD	NUMBER	37:3363	number	7	SENT_229	[p10l468t1478r890b1526],
7	—	CD	NUMBER	—	dep	3	SENT_229	[p10l468t1478r890b1526],
8	8	CD	NUMBER	8	dep	7	SENT_229	[p10l468t1478r890b1526],
9	.	.	O	.	_	0	SENT_229	[p10l468t1478r890b1526],

1	[	RB	O	[	dep	5	SENT_230	[p10l6t1541r99b1597],
2	15	CD	NUMBER	15	num	5	SENT_230	[p10l6t1541r99b1597],
3	]	CD	NUMBER	]	num	5	SENT_230	[p10l6t1541r99b1597],
4	Ueno	NNP	PERSON	Ueno	nn	5	SENT_230	[p10l131t1544r259b1586],
5	H	NNP	PERSON	H	_	0	SENT_230	[p10l280t1544r328b1593],
6	,	,	O	,	_	0	SENT_230	[p10l280t1544r328b1593],
7	Kaniwa	NNP	ORGANIZATION	Kaniwa	nn	8	SENT_230	[p10l350t1542r533b1586],
8	N	NNP	ORGANIZATION	N	appos	5	SENT_230	[p10l554t1544r601b1593],
9	,	,	O	,	_	0	SENT_230	[p10l554t1544r601b1593],
10	Okusaka	NNP	ORGANIZATION	Okusaka	nn	11	SENT_230	[p10l623t1541r830b1586],
11	T	NN	ORGANIZATION	t	appos	5	SENT_230	[p10l848t1544r889b1593],
12	,	,	O	,	_	0	SENT_230	[p10l848t1544r889b1593],
13	et	FW	O	et	nn	14	SENT_230	[p10l910t1548r956b1586],
14	al.	FW	O	al.	appos	11	SENT_230	[p10l975t1541r1027b1586],
15	.	.	O	.	_	0	SENT_230	[p10l975t1541r1027b1586],

1	Homozygous	JJ	O	homozygous	amod	2	SENT_231	[p10l1049t1544r1369b1597],
2	CDA	NNP	O	CDA	nsubj	8	SENT_231	[p10l1391t1541r1545b1586],
3	*	CD	NUMBER	*	num	4	SENT_231	[p10l1391t1541r1545b1586],
4	3	CD	NUMBER	3	dep	2	SENT_231	[p10l1391t1541r1545b1586],
5	is	VBZ	O	be	cop	8	SENT_231	[p10l1569t1542r1604b1586],
6	a	DT	O	a	det	8	SENT_231	[p10l1625t1554r1650b1586],
7	major	JJ	O	major	amod	8	SENT_231	[p10l1670t1542r1815b1597],
8	cause	NN	O	cause	_	0	SENT_231	[p10l1834t1554r1968b1586],
9	of	IN	O	of	_	0	SENT_231	[p10l1989t1541r2040b1586],
10	lifethreatening	VBG	O	lifethreaten	prepc_of	8	SENT_231	[p10l2054t1541r2150b1586, p10l131t1608r421b1664],
11	toxicities	NNS	O	toxicity	dobj	10	SENT_231	[p10l435t1609r658b1653],
12	in	IN	O	in	_	0	SENT_231	[p10l675t1609r720b1652],
13	gemcitabine	NN	O	gemcitabine	nn	14	SENT_231	[p10l735t1608r1240b1664],
14	—	NN	O	—	prep_in	10	SENT_231	[p10l735t1608r1240b1664],
15	treated	VBN	O	treat	partmod	14	SENT_231	[p10l735t1608r1240b1664],
16	Japanese	JJ	MISC	japanese	amod	18	SENT_231	[p10l1250t1611r1471b1664],
17	cancer	NN	O	cancer	nn	18	SENT_231	[p10l1488t1621r1648b1653],
18	patients	NNS	O	patient	dobj	15	SENT_231	[p10l1663t1609r1872b1664],
19	.	.	O	.	_	0	SENT_231	[p10l1663t1609r1872b1664],

1	BrJ	NN	O	brj	nn	2	SENT_232	[p10l1889t1611r1969b1664],
2	Cancer	NN	O	cancer	_	0	SENT_232	[p10l1985t1611r2152b1653],
3	2009	CD	DATE	2009	dep	2	SENT_232	[p10l132t1678r553b1727],
4	;	:	O	;	_	0	SENT_232	[p10l132t1678r553b1727],
5	100:870	CD	NUMBER	100:870	number	6	SENT_232	[p10l132t1678r553b1727],
6	—	CD	NUMBER	—	dep	2	SENT_232	[p10l132t1678r553b1727],
7	3	CD	NUMBER	3	dep	6	SENT_232	[p10l132t1678r553b1727],
8	.	.	O	.	_	0	SENT_232	[p10l132t1678r553b1727],

1	[	RB	O	[	dep	5	SENT_233	[p10l6t1742r99b1798],
2	16	CD	NUMBER	16	num	5	SENT_233	[p10l6t1742r99b1798],
3	]	CD	NUMBER	]	num	5	SENT_233	[p10l6t1742r99b1798],
4	Yonemori	NNP	PERSON	Yonemori	nn	5	SENT_233	[p10l130t1743r373b1787],
5	K	NNP	PERSON	K	_	0	SENT_233	[p10l402t1745r445b1793],
6	,	,	O	,	_	0	SENT_233	[p10l402t1745r445b1793],
7	Ueno	NNP	PERSON	Ueno	nn	8	SENT_233	[p10l473t1745r600b1787],
8	H	NNP	PERSON	H	appos	5	SENT_233	[p10l629t1745r677b1793],
9	,	,	O	,	_	0	SENT_233	[p10l629t1745r677b1793],
10	Okusaka	NNP	ORGANIZATION	Okusaka	nn	11	SENT_233	[p10l706t1742r914b1787],
11	T	NN	ORGANIZATION	t	appos	5	SENT_233	[p10l939t1745r980b1793],
12	,	,	O	,	_	0	SENT_233	[p10l939t1745r980b1793],
13	et	FW	O	et	nn	14	SENT_233	[p10l1008t1749r1055b1787],
14	al.	FW	O	al.	appos	11	SENT_233	[p10l1081t1742r1133b1787],
15	.	.	O	.	_	0	SENT_233	[p10l1081t1742r1133b1787],

1	Severe	JJ	O	severe	amod	3	SENT_234	[p10l1162t1744r1324b1787],
2	drug	NN	O	drug	nn	3	SENT_234	[p10l1352t1742r1466b1798],
3	toxicity	NN	O	toxicity	nsubj	19	SENT_234	[p10l1493t1743r1679b1798],
4	associated	VBN	O	associate	partmod	3	SENT_234	[p10l1705t1742r1958b1787],
5	with	IN	O	with	_	0	SENT_234	[p10l1985t1742r2099b1787],
6	a	DT	O	a	det	8	SENT_234	[p10l2126t1755r2151b1787],
7	single-nucleotide	JJ	O	single-nucleotide	amod	8	SENT_234	[p10l133t1809r560b1863],
8	polymorphism	NN	O	polymorphism	prep_with	4	SENT_234	[p10l588t1809r951b1863],
9	of	IN	O	of	_	0	SENT_234	[p10l978t1809r1029b1852],
10	the	DT	O	the	det	13	SENT_234	[p10l1049t1809r1127b1852],
11	cytidine	NN	O	cytidine	nn	13	SENT_234	[p10l1154t1809r1351b1863],
12	deaminase	NN	O	deaminase	nn	13	SENT_234	[p10l1378t1809r1642b1852],
13	gene	NN	O	gene	prep_of	8	SENT_234	[p10l1669t1821r1785b1863],
14	in	IN	O	in	_	0	SENT_234	[p10l1813t1810r1858b1852],
15	a	DT	O	a	det	18	SENT_234	[p10l1885t1821r1910b1852],
16	Japanese	JJ	MISC	japanese	amod	18	SENT_234	[p10l1930t1812r2150b1863],
17	cancer	NN	O	cancer	nn	18	SENT_234	[p10l132t1888r293b1919],
18	patient	NN	O	patient	prep_in	13	SENT_234	[p10l312t1876r488b1929],
19	treated	VBN	O	treat	_	0	SENT_234	[p10l507t1875r682b1919],
20	with	IN	O	with	_	0	SENT_234	[p10l703t1875r816b1919],
21	gemcitabine	NN	O	gemcitabine	prep_with	19	SENT_234	[p10l836t1875r1139b1929],
22	plus	CC	O	plus	prep	21	SENT_234	[p10l1161t1875r1262b1929],
23	cisplatin	NN	O	cisplatin	dep	22	SENT_234	[p10l1283t1875r1501b1929],
24	.	.	O	.	_	0	SENT_234	[p10l1283t1875r1501b1929],

1	Clin	NNP	O	Clin	nn	3	SENT_235	[p10l1524t1875r1618b1919],
2	Cancer	NNP	O	Cancer	nn	3	SENT_235	[p10l1639t1877r1806b1919],
3	Res	NNP	O	Res	_	0	SENT_235	[p10l1826t1878r1907b1919],
4	2005	CD	DATE	2005	num	3	SENT_235	[p10l1929t1877r2147b1925],
5	;	:	O	;	_	0	SENT_235	[p10l1929t1877r2147b1925],
6	11	CD	NUMBER	11	num	8	SENT_235	[p10l1929t1877r2147b1925],
7	:	:	O	:	_	0	SENT_235	[p10l1929t1877r2147b1925],
8	2620-4	CD	NUMBER	2620-4	dep	3	SENT_235	[p10l132t1944r328b1986],
9	.	.	O	.	_	0	SENT_235	[p10l132t1944r328b1986],

1	[	NN	O	[	_	0	SENT_236	[p10l6t2008r99b2064],
2	17	CD	NUMBER	17	num	1	SENT_236	[p10l6t2008r99b2064],
3	]	CD	NUMBER	]	num	6	SENT_236	[p10l6t2008r99b2064],
4	Yue	NN	O	yue	nn	6	SENT_236	[p10l130t2011r223b2053],
5	L	NN	O	l	nn	6	SENT_236	[p10l240t2011r291b2064],
6	]	NN	O	]	dep	1	SENT_236	[p10l240t2011r291b2064],
7	,	,	O	,	_	0	SENT_236	[p10l240t2011r291b2064],
8	Chen	NNP	O	Chen	nn	9	SENT_236	[p10l309t2008r432b2053],
9	XW	NNP	O	XW	appos	6	SENT_236	[p10l447t2011r550b2059],
10	,	,	O	,	_	0	SENT_236	[p10l447t2011r550b2059],
11	Li	NNP	PERSON	Li	nn	12	SENT_236	[p10l568t2009r607b2052],
12	CR	NN	PERSON	cr	appos	6	SENT_236	[p10l624t2011r698b2060],
13	,	,	O	,	_	0	SENT_236	[p10l624t2011r698b2060],
14	et	FW	O	et	nn	15	SENT_236	[p10l716t2015r762b2053],
15	al.	FW	O	al.	appos	6	SENT_236	[p10l777t2008r829b2053],
16	.	.	O	.	_	0	SENT_236	[p10l777t2008r829b2053],

1	Single	JJ	O	single	amod	4	SENT_237	[p10l847t2008r1279b2064],
2	—	NN	O	—	nn	4	SENT_237	[p10l847t2008r1279b2064],
3	nucleotide	NN	O	nucleotide	nn	4	SENT_237	[p10l847t2008r1279b2064],
4	polymorphisms	NNS	O	polymorphism	_	0	SENT_237	[p10l1297t2008r1683b2064],
5	of	IN	O	of	_	0	SENT_237	[p10l1701t2008r1752b2053],
6	the	DT	O	the	det	9	SENT_237	[p10l1762t2008r1840b2053],
7	cytidine	NN	O	cytidine	nn	9	SENT_237	[p10l1857t2008r2054b2064],
8	deaminase	NN	O	deaminase	nn	9	SENT_237	[p10l2072t2008r2150b2053, p10l132t2075r335b2119],
9	gene	NN	O	gene	prep_of	4	SENT_237	[p10l362t2087r478b2130],
10	in	IN	O	in	_	0	SENT_237	[p10l505t2075r550b2118],
11	childhood	NN	O	childhood	prep_in	4	SENT_237	[p10l577t2074r822b2119],
12	with	IN	O	with	_	0	SENT_237	[p10l848t2074r962b2119],
13	acute	JJ	O	acute	amod	14	SENT_237	[p10l988t2081r1119b2119],
14	leukemia	NN	O	leukemia	prep_with	4	SENT_237	[p10l1146t2075r1372b2119],
15	and	CC	O	and	_	0	SENT_237	[p10l1397t2074r1487b2119],
16	normal	JJ	O	normal	amod	18	SENT_237	[p10l1515t2074r1690b2119],
17	Chinese	JJ	MISC	chinese	amod	18	SENT_237	[p10l1717t2074r1908b2119],
18	children	NNS	O	child	prep_with	4	SENT_237	[p10l1935t2074r2150b2119],
19	.	.	O	.	_	0	SENT_237	[p10l1935t2074r2150b2119],

1	Zhonghua	NNP	PERSON	Zhonghua	nn	8	SENT_238	[p10l131t2142r379b2196],
2	Yi	NNP	PERSON	Yi	nn	8	SENT_238	[p10l397t2143r444b2185],
3	Xue	NNP	PERSON	Xue	nn	8	SENT_238	[p10l463t2145r558b2186],
4	Yi	NNP	PERSON	Yi	nn	8	SENT_238	[p10l576t2143r624b2185],
5	Chuan	NNP	PERSON	Chuan	nn	8	SENT_238	[p10l645t2142r800b2186],
6	Xue	NNP	PERSON	Xue	nn	8	SENT_238	[p10l818t2145r913b2186],
7	Za	NNP	PERSON	Za	nn	8	SENT_238	[p10l933t2145r989b2186],
8	Zhi	NNP	PERSON	Zhi	_	0	SENT_238	[p10l1007t2142r1085b2185],
9	2007	CD	DATE	2007	num	8	SENT_238	[p10l1105t2144r1544b2192],
10	;	:	O	;	_	0	SENT_238	[p10l1105t2144r1544b2192],
11	24:699	CD	NUMBER	24:699	num	12	SENT_238	[p10l1105t2144r1544b2192],
12	—	NN	O	—	dep	8	SENT_238	[p10l1105t2144r1544b2192],
13	702	CD	NUMBER	702	num	15	SENT_238	[p10l1105t2144r1544b2192],
14	[	NN	O	[	nn	15	SENT_238	[p10l1568t2142r1745b2196],
15	Article	NN	O	article	dep	12	SENT_238	[p10l1568t2142r1745b2196],
16	in	IN	O	in	_	0	SENT_238	[p10l1766t2143r1812b2185],
17	Chinese	JJ	MISC	chinese	amod	18	SENT_238	[p10l1831t2142r2053b2196],
18	]	NN	O	]	prep_in	15	SENT_238	[p10l1831t2142r2053b2196],
19	.	.	O	.	_	0	SENT_238	[p10l1831t2142r2053b2196],

1	[	NN	O	[	_	0	SENT_239	[p10l6t2208r99b2264],
2	18	CD	NUMBER	18	num	1	SENT_239	[p10l6t2208r99b2264],
3	]	CD	NUMBER	]	num	5	SENT_239	[p10l6t2208r99b2264],
4	Sugiyama	NN	PERSON	sugiyama	nn	5	SENT_239	[p10l132t2209r371b2264],
5	E	NN	PERSON	e	dep	1	SENT_239	[p10l388t2211r427b2259],
6	,	,	O	,	_	0	SENT_239	[p10l388t2211r427b2259],
7	Lee	NNP	PERSON	Lee	nn	8	SENT_239	[p10l445t2211r524b2253],
8	SJ	NNP	O	SJ	appos	5	SENT_239	[p10l542t2210r595b2264],
9	,	,	O	,	_	0	SENT_239	[p10l542t2210r595b2264],
10	Lee	NNP	PERSON	Lee	nn	11	SENT_239	[p10l613t2211r693b2253],
11	SS	NNP	O	SS	appos	5	SENT_239	[p10l710t2211r775b2260],
12	,	,	O	,	_	0	SENT_239	[p10l710t2211r775b2260],
13	et	FW	O	et	nn	14	SENT_239	[p10l793t2215r840b2253],
14	al.	FW	O	al.	appos	5	SENT_239	[p10l855t2208r908b2253],
15	.	.	O	.	_	0	SENT_239	[p10l855t2208r908b2253],

1	Ethnic	JJ	O	ethnic	amod	2	SENT_240	[p10l926t2208r1081b2253],
2	differences	NNS	O	difference	_	0	SENT_240	[p10l1097t2208r1367b2253],
3	of	IN	O	of	_	0	SENT_240	[p10l1385t2208r1436b2253],
4	two	CD	NUMBER	two	num	10	SENT_240	[p10l1446t2215r1540b2253],
5	non	JJ	O	non	amod	10	SENT_240	[p10l1558t2221r1990b2264],
6	—	NN	O	—	nn	10	SENT_240	[p10l1558t2221r1990b2264],
7	synonymous	JJ	O	synonymous	amod	10	SENT_240	[p10l1558t2221r1990b2264],
8	single	JJ	O	single	amod	10	SENT_240	[p10l2009t2208r2151b2264],
9	nucleotide	NN	O	nucleotide	nn	10	SENT_240	[p10l132t2275r391b2318],
10	polymorphisms	NNS	O	polymorphism	prep_of	2	SENT_240	[p10l420t2275r806b2329],
11	in	IN	O	in	_	0	SENT_240	[p10l836t2276r881b2318],
12	CDA	NNP	ORGANIZATION	CDA	nn	13	SENT_240	[p10l910t2277r1015b2318],
13	gene	NN	O	gene	prep_in	10	SENT_240	[p10l1040t2287r1169b2329],
14	.	.	O	.	_	0	SENT_240	[p10l1040t2287r1169b2329],

1	Drug	NN	O	drug	nn	3	SENT_241	[p10l1198t2278r1318b2329],
2	Metab	NNP	O	Metab	nn	3	SENT_241	[p10l1346t2275r1500b2318],
3	Pharmacokinet	NNP	O	Pharmacokinet	_	0	SENT_241	[p10l1529t2275r1902b2318],
4	2009	CD	DATE	2009	num	3	SENT_241	[p10l1929t2277r2146b2325],
5	;	:	O	;	_	0	SENT_241	[p10l1929t2277r2146b2325],
6	24	CD	NUMBER	24	num	8	SENT_241	[p10l1929t2277r2146b2325],
7	:	:	O	:	_	0	SENT_241	[p10l1929t2277r2146b2325],
8	553-6	CD	NUMBER	553-6	dep	3	SENT_241	[p10l133t2344r297b2385],
9	.	.	O	.	_	0	SENT_241	[p10l133t2344r297b2385],

1	[	NN	O	[	_	0	SENT_242	[p10l6t2407r99b2463],
2	19	CD	NUMBER	19	num	1	SENT_242	[p10l6t2407r99b2463],
3	]	CD	NUMBER	]	num	5	SENT_242	[p10l6t2407r99b2463],
4	Mercier	NN	PERSON	mercier	nn	5	SENT_242	[p10l132t2408r324b2452],
5	C	NN	O	c	dep	1	SENT_242	[p10l343t2410r384b2459],
6	,	,	O	,	_	0	SENT_242	[p10l343t2410r384b2459],
7	Dupuis	NNP	PERSON	Dupuis	nn	8	SENT_242	[p10l405t2408r577b2463],
8	C	NNP	O	C	appos	5	SENT_242	[p10l598t2410r639b2459],
9	,	,	O	,	_	0	SENT_242	[p10l598t2410r639b2459],
10	Blesius	NNP	MISC	Blesius	nn	11	SENT_242	[p10l661t2408r829b2452],
11	A	NNP	MISC	A	appos	5	SENT_242	[p10l848t2409r894b2459],
12	,	,	O	,	_	0	SENT_242	[p10l848t2409r894b2459],
13	et	FW	O	et	nn	14	SENT_242	[p10l916t2414r962b2452],
14	al.	FW	O	al.	appos	5	SENT_242	[p10l981t2407r1033b2452],
15	.	.	O	.	_	0	SENT_242	[p10l981t2407r1033b2452],

1	Early	RB	O	early	advmod	3	SENT_243	[p10l1055t2407r1179b2463],
2	severe	JJ	O	severe	amod	3	SENT_243	[p10l1199t2420r1356b2452],
3	toxicities	NNS	O	toxicity	_	0	SENT_243	[p10l1376t2408r1599b2452],
4	after	IN	O	after	_	0	SENT_243	[p10l1620t2407r1734b2452],
5	capecitabine	NN	O	capecitabine	nn	6	SENT_243	[p10l1754t2407r2062b2463],
6	intake	NN	O	intake	prep_after	3	SENT_243	[p10l2083t2408r2150b2451, p10l131t2475r250b2520],
7	:	:	O	:	_	0	SENT_243	[p10l2083t2408r2150b2451, p10l131t2475r250b2520],
8	possible	JJ	O	possible	amod	9	SENT_243	[p10l275t2475r473b2531],
9	implication	NN	O	implication	dep	3	SENT_243	[p10l494t2475r774b2531],
10	of	IN	O	of	_	0	SENT_243	[p10l795t2475r846b2520],
11	a	DT	O	a	det	16	SENT_243	[p10l860t2488r885b2520],
12	cytidine	NN	O	cytidine	nn	16	SENT_243	[p10l905t2475r1102b2531],
13	deaminase	NN	O	deaminase	nn	16	SENT_243	[p10l1123t2475r1387b2520],
14	extensive	JJ	O	extensive	amod	16	SENT_243	[p10l1408t2476r1642b2520],
15	metabolizer	NN	O	metabolizer	nn	16	SENT_243	[p10l1664t2475r1959b2520],
16	proﬁle	NN	O	proﬁle	prep_of	9	SENT_243	[p10l1979t2475r2150b2531],
17	.	.	O	.	_	0	SENT_243	[p10l1979t2475r2150b2531],

1	Cancer	NNP	O	Cancer	nn	3	SENT_244	[p10l132t2544r300b2586],
2	Chemother	NNP	O	Chemother	nn	3	SENT_244	[p10l318t2542r594b2586],
3	Pharmacol	NNP	O	Pharmacol	_	0	SENT_244	[p10l613t2542r873b2586],
4	2009	CD	DATE	2009	num	3	SENT_244	[p10l893t2544r1347b2593],
5	;	:	O	;	_	0	SENT_244	[p10l893t2544r1347b2593],
6	63:1177	CD	NUMBER	63:1177	number	7	SENT_244	[p10l893t2544r1347b2593],
7	—	CD	NUMBER	—	dep	3	SENT_244	[p10l893t2544r1347b2593],
8	80	CD	NUMBER	80	dep	7	SENT_244	[p10l893t2544r1347b2593],
9	.	.	O	.	_	0	SENT_244	[p10l893t2544r1347b2593],

1	[	RB	O	[	dep	4	SENT_245	[p10l6t2608r99b2662],
2	20	CD	NUMBER	20	num	4	SENT_245	[p10l6t2608r99b2662],
3	]	CD	NUMBER	]	num	4	SENT_245	[p10l6t2608r99b2662],
4	FarrellJJ	NN	O	farrelljj	_	0	SENT_245	[p10l132t2608r338b2662],
5	,	,	O	,	_	0	SENT_245	[p10l132t2608r338b2662],
6	Bae	NNP	ORGANIZATION	Bae	nn	7	SENT_245	[p10l353t2611r436b2651],
7	K	NNP	ORGANIZATION	K	appos	4	SENT_245	[p10l451t2611r495b2658],
8	,	,	O	,	_	0	SENT_245	[p10l451t2611r495b2658],
9	Wong	NNP	PERSON	Wong	nn	10	SENT_245	[p10l506t2611r692b2662],
10	]	NNP	O	]	appos	4	SENT_245	[p10l506t2611r692b2662],
11	,	,	O	,	_	0	SENT_245	[p10l506t2611r692b2662],
12	et	FW	O	et	nn	13	SENT_245	[p10l706t2614r752b2651],
13	al.	FW	O	al.	appos	10	SENT_245	[p10l764t2608r815b2652],
14	.	.	O	.	_	0	SENT_245	[p10l764t2608r815b2652],

1	Cytidine	NN	O	cytidine	nn	2	SENT_246	[p10l830t2608r1029b2662],
2	deaminase	NN	O	deaminase	nsubj	6	SENT_246	[p10l1042t2608r1301b2651],
3	single-nucleotide	JJ	O	single-nucleotide	amod	4	SENT_246	[p10l1316t2608r1732b2662],
4	polymorphism	NN	O	polymorphism	dep	2	SENT_246	[p10l1746t2608r2102b2662],
5	is	VBZ	O	be	cop	6	SENT_246	[p10l2116t2609r2151b2651],
6	predictive	JJ	O	predictive	_	0	SENT_246	[p10l132t2674r372b2728],
7	of	IN	O	of	_	0	SENT_246	[p10l397t2674r448b2718],
8	toxicity	NN	O	toxicity	prep_of	6	SENT_246	[p10l464t2675r646b2728],
9	from	IN	O	from	_	0	SENT_246	[p10l668t2674r784b2718],
10	gemcitabine	NN	O	gemcitabine	prep_from	8	SENT_246	[p10l806t2674r1102b2728],
11	in	IN	O	in	_	0	SENT_246	[p10l1127t2675r1172b2717],
12	patients	NNS	O	patient	prep_in	10	SENT_246	[p10l1195t2675r1388b2728],
13	with	IN	O	with	_	0	SENT_246	[p10l1410t2674r1523b2718],
14	pancreatic	JJ	O	pancreatic	amod	15	SENT_246	[p10l1546t2675r1796b2728],
15	cancer	NN	O	cancer	prep_with	12	SENT_246	[p10l1819t2687r1988b2718],
16	:	:	O	:	_	0	SENT_246	[p10l1819t2687r1988b2718],
17	RTOG	NNP	O	RTOG	dep	6	SENT_246	[p10l2016t2676r2152b2718],
18	9704	CD	NUMBER	9704	num	17	SENT_246	[p10l132t2742r263b2784],
19	.	.	O	.	_	0	SENT_246	[p10l132t2742r263b2784],

1	Pharmacogenomics	NNS	O	pharmacogenomic	_	0	SENT_247	[p10l281t2740r751b2794],
2	J	NNP	O	J	dep	1	SENT_247	[p10l763t2742r782b2794],
3	2011	CD	DATE	2011	num	2	SENT_247	[p10l800t2742r930b2790],
4	,	,	O	,	_	0	SENT_247	[p10l800t2742r930b2790],
5	http://dx.doi.org/10.1038/tpj.2011.22	NN	O	http://dx.doi.org/10.1038/tpj.2011.22	appos	2	SENT_247	[p10l949t2740r1863b2794],
6	.	.	O	.	_	0	SENT_247	[p10l949t2740r1863b2794],

1	[	NN	O	[	_	0	SENT_248	[p10l6t2805r99b2861],
2	21	CD	NUMBER	21	num	1	SENT_248	[p10l6t2805r99b2861],
3	]	CD	NUMBER	]	num	5	SENT_248	[p10l6t2805r99b2861],
4	Tanaka	NNP	PERSON	Tanaka	nn	5	SENT_248	[p10l130t2805r306b2850],
5	M	NN	O	m	dep	1	SENT_248	[p10l331t2808r390b2857],
6	,	,	O	,	_	0	SENT_248	[p10l331t2808r390b2857],
7	Javle	NN	O	javle	nn	8	SENT_248	[p10l409t2806r530b2861],
8	M	NN	O	m	appos	5	SENT_248	[p10l556t2808r614b2857],
9	,	,	O	,	_	0	SENT_248	[p10l556t2808r614b2857],
10	Dong	NNP	PERSON	Dong	nn	11	SENT_248	[p10l640t2808r769b2861],
11	X	NNP	PERSON	X	appos	5	SENT_248	[p10l791t2808r838b2857],
12	,	,	O	,	_	0	SENT_248	[p10l791t2808r838b2857],
13	et	FW	O	et	nn	14	SENT_248	[p10l864t2812r910b2850],
14	al.	FW	O	al.	appos	5	SENT_248	[p10l933t2806r986b2850],
15	.	.	O	.	_	0	SENT_248	[p10l933t2806r986b2850],

1	Gemcitabine	JJ	O	gemcitabine	amod	6	SENT_249	[p10l1011t2805r1322b2850],
2	metabolic	JJ	O	metabolic	amod	6	SENT_249	[p10l1349t2805r1591b2850],
3	and	CC	O	and	_	0	SENT_249	[p10l1615t2805r1704b2850],
4	transporter	NN	O	transporter	conj_and	2	SENT_249	[p10l1730t2812r2011b2861],
5	gene	NN	O	gene	nn	6	SENT_249	[p10l2034t2818r2151b2861],
6	polymorphisms	NNS	O	polymorphism	nsubjpass	8	SENT_249	[p10l132t2872r518b2928],
7	are	VBP	O	be	auxpass	8	SENT_249	[p10l538t2885r613b2917],
8	associated	VBN	O	associate	_	0	SENT_249	[p10l630t2872r883b2917],
9	with	IN	O	with	_	0	SENT_249	[p10l901t2872r1014b2917],
10	drug	NN	O	drug	nn	11	SENT_249	[p10l1032t2872r1146b2928],
11	toxicity	NN	O	toxicity	prep_with	8	SENT_249	[p10l1163t2873r1348b2928],
12	and	CC	O	and	_	0	SENT_249	[p10l1365t2872r1455b2917],
13	efﬁcacy	NN	O	efﬁcacy	conj_and	11	SENT_249	[p10l1473t2872r1660b2928],
14	in	IN	O	in	_	0	SENT_249	[p10l1676t2873r1721b2916],
15	patients	NNS	O	patient	prep_in	8	SENT_249	[p10l1740t2873r1937b2928],
16	with	IN	O	with	_	0	SENT_249	[p10l1954t2872r2068b2917],
17	10cally	RB	O	10cally	advmod	18	SENT_249	[p10l2086t2872r2150b2917, p10l132t2940r245b2994],
18	advanced	VBN	O	advance	amod	20	SENT_249	[p10l263t2940r496b2984],
19	pancreatic	JJ	O	pancreatic	amod	20	SENT_249	[p10l518t2941r773b2994],
20	cancer	NN	O	cancer	prep_with	15	SENT_249	[p10l793t2953r964b2984],
21	.	.	O	.	_	0	SENT_249	[p10l793t2953r964b2984],

1	Cancer	NN	O	cancer	_	0	SENT_250	[p10l985t2942r1152b2984],
2	2010	CD	DATE	2010	num	1	SENT_250	[p10l1171t2942r1655b2990],
3	;	:	O	;	_	0	SENT_250	[p10l1171t2942r1655b2990],
4	116:5325	CD	NUMBER	116:5325	number	5	SENT_250	[p10l1171t2942r1655b2990],
5	—	CD	NUMBER	—	dep	1	SENT_250	[p10l1171t2942r1655b2990],
6	35	CD	NUMBER	35	dep	5	SENT_250	[p10l1171t2942r1655b2990],
7	.	.	O	.	_	0	SENT_250	[p10l1171t2942r1655b2990],

1	[	NN	O	[	nn	5	SENT_251	[p10l6t3006r99b3062],
2	22	CD	NUMBER	22	num	5	SENT_251	[p10l6t3006r99b3062],
3	]	CD	NUMBER	]	num	5	SENT_251	[p10l6t3006r99b3062],
4	Ganti	NNP	MISC	Ganti	nn	5	SENT_251	[p10l132t3007r263b3051],
5	A	NNP	MISC	A	_	0	SENT_251	[p10l278t3008r324b3057],
6	,	,	O	,	_	0	SENT_251	[p10l278t3008r324b3057],
7	Parr	NNP	PERSON	Parr	nn	8	SENT_251	[p10l341t3009r442b3051],
8	A	NNP	O	A	appos	5	SENT_251	[p10l455t3008r501b3057],
9	,	,	O	,	_	0	SENT_251	[p10l455t3008r501b3057],
10	Nguyen	NNP	PERSON	Nguyen	nn	11	SENT_251	[p10l519t3009r708b3062],
11	D	NNP	PERSON	D	appos	5	SENT_251	[p10l725t3009r771b3058],
12	,	,	O	,	_	0	SENT_251	[p10l725t3009r771b3058],
13	Grem	NNP	PERSON	Grem	nn	17	SENT_251	[p10l789t3008r925b3051],
14	J.	NNP	PERSON	J.	nn	17	SENT_251	[p10l934t3009r965b3062],
15	Gene	NNP	PERSON	Gene	nn	17	SENT_251	[p10l983t3009r1107b3051],
16	expression	NN	O	expression	nn	17	SENT_251	[p10l1124t3007r1389b3062],
17	proﬁle	NN	O	proﬁle	appos	5	SENT_251	[p10l1406t3006r1565b3062],
18	of	IN	O	of	_	0	SENT_251	[p10l1582t3006r1634b3051],
19	enzymes	NNS	O	enzyme	prep_of	17	SENT_251	[p10l1643t3019r1859b3062],
20	involved	VBN	O	involve	partmod	19	SENT_251	[p10l1877t3006r2088b3051],
21	in	IN	O	in	_	0	SENT_251	[p10l2106t3007r2151b3050],
22	gemcitabine	NN	O	gemcitabine	nn	24	SENT_251	[p10l131t3073r434b3127],
23	(	CD	NUMBER	(	num	24	SENT_251	[p10l457t3073r612b3127],
24	Gem	NNP	MISC	Gem	prep_in	20	SENT_251	[p10l457t3073r612b3127],
25	)	CD	NUMBER	)	num	26	SENT_251	[p10l457t3073r612b3127],
26	metabolism	NN	O	metabolism	dep	24	SENT_251	[p10l635t3073r925b3116],
27	in	IN	O	in	_	0	SENT_251	[p10l944t3073r989b3116],
28	bone	NN	O	bone	nn	31	SENT_251	[p10l1008t3073r1128b3116],
29	marrow	NN	O	marrow	nn	31	SENT_251	[p10l1148t3085r1345b3116],
30	mononuclear	JJ	O	mononuclear	amod	31	SENT_251	[p10l1363t3073r1691b3116],
31	cells	NNS	O	cell	prep_in	26	SENT_251	[p10l1708t3073r1814b3116],
32	as	IN	O	as	_	0	SENT_251	[p10l1833t3085r1881b3116],
33	predictors	NNS	O	predictor	prep_as	20	SENT_251	[p10l1901t3073r2150b3127],
34	of	IN	O	of	_	0	SENT_251	[p10l132t3138r183b3183],
35	myelosuppression	NN	O	myelosuppression	prep_of	33	SENT_251	[p10l197t3139r693b3194],
36	.	.	O	.	_	0	SENT_251	[p10l197t3139r693b3194],

1	J	NNP	O	J	nn	3	SENT_252	[p10l197t3139r693b3194],
2	Clin	NNP	O	Clin	nn	3	SENT_252	[p10l713t3139r807b3183],
3	Oncol	NNP	O	Oncol	_	0	SENT_252	[p10l827t3139r967b3183],
4	2007	CD	DATE	2007	num	3	SENT_252	[p10l987t3141r1191b3190],
5	;	:	O	;	_	0	SENT_252	[p10l987t3141r1191b3190],
6	24	CD	NUMBER	24	num	7	SENT_252	[p10l987t3141r1191b3190],
7	[	CD	NUMBER	[	dep	3	SENT_252	[p10l1213t3138r1433b3194],
8	Meeting	VBG	O	meet	partmod	7	SENT_252	[p10l1213t3138r1433b3194],
9	Abstracts	NNS	O	abstract	dobj	8	SENT_252	[p10l1450t3138r1710b3194],
10	]	CD	NUMBER	]	tmod	8	SENT_252	[p10l1450t3138r1710b3194],
11	.	.	O	.	_	0	SENT_252	[p10l1450t3138r1710b3194],

1	[	NN	O	[	nn	5	SENT_253	[p10l6t3205r99b3261],
2	23	CD	NUMBER	23	num	5	SENT_253	[p10l6t3205r99b3261],
3	]	NNP	O	]	nn	5	SENT_253	[p10l6t3205r99b3261],
4	Mercier	NNP	PERSON	Mercier	nn	5	SENT_253	[p10l132t3206r324b3250],
5	C	NNP	O	C	_	0	SENT_253	[p10l350t3208r391b3257],
6	,	,	O	,	_	0	SENT_253	[p10l350t3208r391b3257],
7	Raynal	NNP	PERSON	Raynal	nn	8	SENT_253	[p10l420t3206r584b3261],
8	C	NNP	O	C	appos	5	SENT_253	[p10l612t3208r653b3257],
9	,	,	O	,	_	0	SENT_253	[p10l612t3208r653b3257],
10	Dahan	NNP	PERSON	Dahan	nn	11	SENT_253	[p10l682t3206r839b3250],
11	L	NNP	O	L	appos	5	SENT_253	[p10l867t3208r902b3257],
12	,	,	O	,	_	0	SENT_253	[p10l867t3208r902b3257],
13	et	FW	O	et	nn	14	SENT_253	[p10l931t3212r977b3250],
14	al.	FW	O	al.	appos	5	SENT_253	[p10l1003t3206r1056b3251],
15	.	.	O	.	_	0	SENT_253	[p10l1003t3206r1056b3251],

1	Toxic	JJ	O	toxic	amod	3	SENT_254	[p10l1082t3206r1215b3250],
2	death	NN	O	death	nn	3	SENT_254	[p10l1242t3206r1380b3250],
3	case	NN	O	case	nsubj	10	SENT_254	[p10l1408t3218r1511b3250],
4	in	IN	O	in	_	0	SENT_254	[p10l1539t3206r1584b3250],
5	a	DT	O	a	det	6	SENT_254	[p10l1612t3218r1637b3250],
6	patient	NN	O	patient	prep_in	3	SENT_254	[p10l1665t3206r1840b3261],
7	undergoing	VBG	O	undergo	partmod	6	SENT_254	[p10l1867t3206r2151b3261],
8	gemcitabine	NN	O	gemcitabine	nn	9	SENT_254	[p10l131t3273r600b3329],
9	—	NN	O	—	dobj	7	SENT_254	[p10l131t3273r600b3329],
10	based	VBN	O	base	_	0	SENT_254	[p10l131t3273r600b3329],
11	chemotherapy	NN	O	chemotherapy	dobj	10	SENT_254	[p10l632t3273r991b3329],
12	in	IN	O	in	_	0	SENT_254	[p10l1023t3274r1067b3317],
13	relation	NN	O	relation	prep_in	10	SENT_254	[p10l1099t3273r1289b3318],
14	with	IN	O	with	_	0	SENT_254	[p10l1320t3273r1433b3318],
15	cytidine	NN	O	cytidine	nn	17	SENT_254	[p10l1464t3273r1661b3329],
16	deaminase	NN	O	deaminase	nn	17	SENT_254	[p10l1693t3273r1957b3318],
17	downregulation	NN	O	downregulation	prep_with	10	SENT_254	[p10l1989t3273r2150b3318, p10l132t3339r396b3395],
18	.	.	O	.	_	0	SENT_254	[p10l1989t3273r2150b3318, p10l132t3339r396b3395],

1	Pharmacogenet	NNP	O	Pharmacogenet	nn	2	SENT_255	[p10l418t3340r802b3395],
2	Genomics	NNP	O	Genomics	_	0	SENT_255	[p10l821t3340r1063b3384],
3	2007	CD	DATE	2007	num	2	SENT_255	[p10l1084t3342r1220b3391],
4	;	:	O	;	_	0	SENT_255	[p10l1084t3342r1220b3391],
5	1	CD	NUMBER	1	number	6	SENT_255	[p10l1230t3342r1249b3383],
6	7:841	CD	NUMBER	7:841	dep	2	SENT_255	[p10l1260t3342r1393b3384],
7	-4	CD	NUMBER	-4	dep	6	SENT_255	[p10l1403t3342r1474b3384],
8	.	.	O	.	_	0	SENT_255	[p10l1403t3342r1474b3384],

1	[	NN	O	[	nn	5	SENT_256	[p10l6t3407r99b3461],
2	24	CD	NUMBER	24	num	5	SENT_256	[p10l6t3407r99b3461],
3	]	CD	NUMBER	]	num	5	SENT_256	[p10l6t3407r99b3461],
4	Giovannetti	NNP	PERSON	Giovannetti	nn	5	SENT_256	[p10l132t3408r421b3451],
5	E	NNP	PERSON	E	_	0	SENT_256	[p10l438t3410r476b3457],
6	,	,	O	,	_	0	SENT_256	[p10l438t3410r476b3457],
7	Laan	NNP	ORGANIZATION	Laan	nn	8	SENT_256	[p10l493t3410r605b3451],
8	AC	NN	ORGANIZATION	ac	appos	5	SENT_256	[p10l619t3409r697b3457],
9	,	,	O	,	_	0	SENT_256	[p10l619t3409r697b3457],
10	Vasile	NNP	PERSON	Vasile	nn	11	SENT_256	[p10l712t3407r858b3451],
11	E	NNP	PERSON	E	appos	5	SENT_256	[p10l875t3410r913b3457],
12	,	,	O	,	_	0	SENT_256	[p10l875t3410r913b3457],
13	et	FW	O	et	nn	14	SENT_256	[p10l930t3413r976b3451],
14	al.	FW	O	al.	appos	5	SENT_256	[p10l991t3407r1043b3451],
15	.	.	O	.	_	0	SENT_256	[p10l991t3407r1043b3451],

1	Correlation	NN	O	correlation	_	0	SENT_257	[p10l1060t3407r1336b3451],
2	between	IN	O	between	_	0	SENT_257	[p10l1351t3407r1564b3451],
3	cytidine	NN	O	cytidine	nn	5	SENT_257	[p10l1580t3407r1777b3461],
4	deaminase	NN	O	deaminase	nn	5	SENT_257	[p10l1794t3407r2058b3451],
5	genotype	NN	O	genotype	prep_between	1	SENT_257	[p10l2074t3420r2151b3461, p10l132t3479r302b3527],
6	and	CC	O	and	_	0	SENT_257	[p10l323t3473r412b3517],
7	gemcitabine	NN	O	gemcitabine	nn	8	SENT_257	[p10l433t3473r736b3527],
8	deamination	NN	O	deamination	prep_between	1	SENT_257	[p10l757t3473r1068b3517],
9	in	IN	O	in	_	0	SENT_257	[p10l1090t3474r1135b3516],
10	blood	NN	O	blood	nn	11	SENT_257	[p10l1154t3473r1292b3517],
11	samples	NNS	O	sample	prep_in	5	SENT_257	[p10l1314t3473r1524b3527],
12	.	.	O	.	_	0	SENT_257	[p10l1314t3473r1524b3527],

1	Nucleosides	NNPS	MISC	Nucleosides	nn	2	SENT_258	[p10l1546t3473r1839b3517],
2	Nucleotides	NNPS	MISC	Nucleotides	_	0	SENT_258	[p10l1861t3473r2150b3517],
3	Nucleic	NNP	MISC	Nucleic	nn	4	SENT_258	[p10l132t3539r313b3582],
4	Acids	NNPS	MISC	Acids	dep	2	SENT_258	[p10l330t3539r462b3582],
5	2008	CD	DATE	2008	dep	2	SENT_258	[p10l482t3541r873b3589],
6	;	:	O	;	_	0	SENT_258	[p10l482t3541r873b3589],
7	27:720	CD	NUMBER	27:720	number	8	SENT_258	[p10l482t3541r873b3589],
8	—	CD	NUMBER	—	dep	2	SENT_258	[p10l482t3541r873b3589],
9	5	CD	NUMBER	5	dep	8	SENT_258	[p10l482t3541r873b3589],
10	.	.	O	.	_	0	SENT_258	[p10l482t3541r873b3589],

1	[	NN	O	[	_	0	SENT_259	[p10l6t3605r99b3661],
2	25	CD	NUMBER	25	num	1	SENT_259	[p10l6t3605r99b3661],
3	]	CD	NUMBER	]	num	5	SENT_259	[p10l6t3605r99b3661],
4	Toffalorio	NNP	O	Toffalorio	nn	5	SENT_259	[p10l130t3605r361b3650],
5	F	NN	O	f	dep	1	SENT_259	[p10l379t3608r413b3657],
6	,	,	O	,	_	0	SENT_259	[p10l379t3608r413b3657],
7	Giovannetti	NNP	PERSON	Giovannetti	nn	8	SENT_259	[p10l432t3606r714b3650],
8	E	NNP	O	E	appos	5	SENT_259	[p10l731t3608r770b3656],
9	,	,	O	,	_	0	SENT_259	[p10l731t3608r770b3656],
10	De	NNP	PERSON	De	nn	12	SENT_259	[p10l787t3608r850b3650],
11	Pas	NNP	PERSON	Pas	nn	12	SENT_259	[p10l868t3608r945b3650],
12	T	NN	PERSON	t	appos	5	SENT_259	[p10l960t3608r1001b3656],
13	,	,	O	,	_	0	SENT_259	[p10l960t3608r1001b3656],
14	et	FW	O	et	nn	15	SENT_259	[p10l1018t3612r1064b3650],
15	al.	FW	O	al.	appos	5	SENT_259	[p10l1080t3605r1131b3650],
16	.	.	O	.	_	0	SENT_259	[p10l1080t3605r1131b3650],

1	Expression	NN	O	expression	_	0	SENT_260	[p10l1149t3606r1410b3661],
2	of	IN	O	of	_	0	SENT_260	[p10l1427t3605r1479b3650],
3	gemcitabine	NN	O	gemcitabine	nn	4	SENT_260	[p10l1488t3605r1806b3661],
4	—	NN	O	—	prep_of	1	SENT_260	[p10l1488t3605r1806b3661],
5	and	CC	O	and	_	0	SENT_260	[p10l1823t3605r1910b3650],
6	cisplatinrelated	JJ	O	cisplatinrelated	amod	7	SENT_260	[p10l1929t3605r2151b3661, p10l132t3671r299b3716],
7	genes	NNS	O	gene	prep_of	1	SENT_260	[p10l316t3684r453b3727],
8	in	IN	O	in	_	0	SENT_260	[p10l472t3672r517b3715],
9	non	JJ	O	non	amod	13	SENT_260	[p10l534t3671r880b3716],
10	—	JJ	O	—	amod	13	SENT_260	[p10l534t3671r880b3716],
11	small-cell	NN	O	small-cell	nn	13	SENT_260	[p10l534t3671r880b3716],
12	lung	NN	O	lung	nn	13	SENT_260	[p10l898t3671r1006b3727],
13	cancer	NN	O	cancer	prep_in	1	SENT_260	[p10l1021t3684r1188b3716],
14	.	.	O	.	_	0	SENT_260	[p10l1021t3684r1188b3716],

1	PharmacogenomicsJ	NN	O	pharmacogenomicsj	_	0	SENT_261	[p10l1206t3671r1707b3727],
2	2010	CD	DATE	2010	num	1	SENT_261	[p10l1724t3674r2136b3723],
3	;	:	O	;	_	0	SENT_261	[p10l1724t3674r2136b3723],
4	10:180	CD	NUMBER	10:180	number	5	SENT_261	[p10l1724t3674r2136b3723],
5	—	CD	NUMBER	—	dep	1	SENT_261	[p10l1724t3674r2136b3723],
6	90	CD	NUMBER	90	dep	5	SENT_261	[p10l1724t3674r2136b3723],
7	.	.	O	.	_	0	SENT_261	[p10l1724t3674r2136b3723],

1	[	NN	O	[	_	0	SENT_262	[p10l6t3739r99b3793],
2	26	CD	NUMBER	26	num	1	SENT_262	[p10l6t3739r99b3793],
3	]	CD	NUMBER	]	num	5	SENT_262	[p10l6t3739r99b3793],
4	Metharom	NN	O	metharom	nn	5	SENT_262	[p10l132t3739r392b3783],
5	E	NN	O	e	dep	1	SENT_262	[p10l412t3742r451b3789],
6	,	,	O	,	_	0	SENT_262	[p10l412t3742r451b3789],
7	Galettis	NNP	PERSON	Galettis	nn	8	SENT_262	[p10l472t3739r657b3783],
8	P	NN	PERSON	p	appos	5	SENT_262	[p10l679t3742r718b3789],
9	,	,	O	,	_	0	SENT_262	[p10l679t3742r718b3789],
10	Manners	NNP	O	Manners	nn	11	SENT_262	[p10l739t3742r954b3783],
11	S	NNP	O	S	appos	5	SENT_262	[p10l975t3741r1012b3789],
12	,	,	O	,	_	0	SENT_262	[p10l975t3741r1012b3789],
13	et	FW	O	et	nn	14	SENT_262	[p10l1033t3745r1079b3783],
14	al.	FW	O	al.	appos	5	SENT_262	[p10l1098t3739r1150b3783],
15	.	.	O	.	_	0	SENT_262	[p10l1098t3739r1150b3783],

1	The	DT	O	the	det	3	SENT_263	[p10l1169t3739r1259b3783],
2	pharmacological	JJ	O	pharmacological	amod	3	SENT_263	[p10l1280t3739r1687b3793],
3	advantage	NN	O	advantage	_	0	SENT_263	[p10l1708t3739r1961b3793],
4	of	IN	O	of	_	0	SENT_263	[p10l1982t3739r2033b3783],
5	prolonged	JJ	O	prolonged	prep_of	3	SENT_263	[p10l2047t3752r2150b3793, p11l132t13r298b69],

1	dose	NN	O	dose	nn	3	SENT_264	[p11l318t13r430b58],
2	rate	NN	O	rate	nn	3	SENT_264	[p11l450t20r544b58],
3	gemcitabine	NN	O	gemcitabine	_	0	SENT_264	[p11l563t13r866b69],
4	is	VBZ	O	be	cop	5	SENT_264	[p11l887t14r922b58],
5	restricted	JJ	O	restricted	rcmod	3	SENT_264	[p11l942t13r1176b58],
6	to	TO	O	to	_	0	SENT_264	[p11l1197t20r1244b58],
7	patients	NNS	O	patient	prep_to	5	SENT_264	[p11l1264t14r1461b69],
8	with	IN	O	with	_	0	SENT_264	[p11l1479t13r1593b58],
9	variant	JJ	O	variant	amod	10	SENT_264	[p11l1611t14r1787b58],
10	alleles	NNS	O	allele	prep_with	7	SENT_264	[p11l1804t13r1957b58],
11	of	IN	O	of	_	0	SENT_264	[p11l1977t13r2029b58],
12	cytidine	NN	O	cytidine	nn	14	SENT_264	[p11l2041t14r2150b69, p11l132t80r238b123],
13	deaminase	NN	O	deaminase	nn	14	SENT_264	[p11l259t80r522b123],
14	c.	NN	O	c.	prep_of	10	SENT_264	[p11l543t82r763b124],
15	79A	CD	NUMBER	79a	num	16	SENT_264	[p11l543t82r763b124],
16	>	JJR	O	>	dep	3	SENT_264	[p11l543t82r763b124],
17	C.	NNP	O	C.	nn	23	SENT_264	[p11l543t82r763b124],
18	Asia	NNP	LOCATION	Asia	nn	23	SENT_264	[p11l782t81r884b123],
19	Pac	NNP	O	Pac	nn	23	SENT_264	[p11l904t83r1018b134],
20	]	CD	NUMBER	]	num	23	SENT_264	[p11l904t83r1018b134],
21	Clin	NNP	O	Clin	nn	23	SENT_264	[p11l1038t80r1132b123],
22	Oncol	NNP	O	Oncol	nn	23	SENT_264	[p11l1152t80r1292b123],
23	201l	NN	O	201l	dep	16	SENT_264	[p11l1312t82r1671b130],
24	;	:	O	;	_	0	SENT_264	[p11l1312t82r1671b130],
25	7:65	CD	NUMBER	7:65	number	26	SENT_264	[p11l1312t82r1671b130],
26	—	CD	NUMBER	—	dep	3	SENT_264	[p11l1312t82r1671b130],
27	74	CD	NUMBER	74	dep	26	SENT_264	[p11l1312t82r1671b130],
28	.	.	O	.	_	0	SENT_264	[p11l1312t82r1671b130],

1	[	NN	O	[	_	0	SENT_265	[p11l6t145r99b201],
2	27	CD	NUMBER	27	num	1	SENT_265	[p11l6t145r99b201],
3	]	CD	NUMBER	]	num	5	SENT_265	[p11l6t145r99b201],
4	Joerger	NNP	PERSON	Joerger	nn	5	SENT_265	[p11l126t148r308b201],
5	M	NN	O	m	dep	1	SENT_265	[p11l328t148r386b197],
6	,	,	O	,	_	0	SENT_265	[p11l328t148r386b197],
7	Burgers	NNPS	O	Burgers	nn	8	SENT_265	[p11l407t148r594b201],
8	JA	NNP	O	JA	appos	5	SENT_265	[p11l609t147r676b201],
9	,	,	O	,	_	0	SENT_265	[p11l609t147r676b201],
10	Baas	NNP	PERSON	Baas	nn	11	SENT_265	[p11l698t148r805b190],
11	P	NN	O	p	appos	5	SENT_265	[p11l827t148r865b197],
12	,	,	O	,	_	0	SENT_265	[p11l827t148r865b197],
13	et	FW	O	et	nn	14	SENT_265	[p11l886t152r933b190],
14	al.	FW	O	al.	appos	5	SENT_265	[p11l952t145r1004b190],
15	.	.	O	.	_	0	SENT_265	[p11l952t145r1004b190],

1	Gene	NNP	O	Gene	nn	2	SENT_266	[p11l1025t148r1149b190],
2	Polymorphisms	NNP	O	Polymorphisms	_	0	SENT_266	[p11l1170t145r1567b201],
3	,	,	O	,	_	0	SENT_266	[p11l1170t145r1567b201],
4	pharmacokinetics	NNS	O	pharmacokinetic	appos	2	SENT_266	[p11l1589t146r2039b201],
5	,	,	O	,	_	0	SENT_266	[p11l1589t146r2039b201],
6	and	CC	O	and	_	0	SENT_266	[p11l2061t145r2150b190],
7	hematological	JJ	O	hematological	amod	8	SENT_266	[p11l132t213r479b267],
8	toxicity	NN	O	toxicity	conj_and	2	SENT_266	[p11l500t213r686b267],
9	in	IN	O	in	_	0	SENT_266	[p11l705t213r750b256],
10	advanced	JJ	O	advanced	amod	16	SENT_266	[p11l770t213r1003b256],
11	non	JJ	O	non	amod	16	SENT_266	[p11l1024t213r1381b256],
12	—	NN	O	—	nn	16	SENT_266	[p11l1024t213r1381b256],
13	small-cell	NN	O	small-cell	nn	16	SENT_266	[p11l1024t213r1381b256],
14	lung	NN	O	lung	nn	16	SENT_266	[p11l1401t213r1509b267],
15	cancer	NN	O	cancer	nn	16	SENT_266	[p11l1529t225r1689b256],
16	patients	NNS	O	patient	prep_in	8	SENT_266	[p11l1708t213r1905b267],
17	receiving	VBG	O	receive	partmod	2	SENT_266	[p11l1926t213r2152b267],
18	cisplatin/gemcitabine	NN	O	cisplatin/gemcitabine	dobj	17	SENT_266	[p11l132t279r676b335],
19	.	.	O	.	_	0	SENT_266	[p11l132t279r676b335],

1	Cancer	NNP	O	Cancer	nn	3	SENT_267	[p11l698t281r866b324],
2	Chemother	NNP	O	Chemother	nn	3	SENT_267	[p11l884t279r1160b324],
3	Pharmacol	NNP	O	Pharmacol	_	0	SENT_267	[p11l1179t279r1439b324],
4	2012	CD	DATE	2012	num	3	SENT_267	[p11l1459t281r1850b330],
5	;	:	O	;	_	0	SENT_267	[p11l1459t281r1850b330],
6	69:25	CD	NUMBER	69:25	number	7	SENT_267	[p11l1459t281r1850b330],
7	—	CD	NUMBER	—	dep	3	SENT_267	[p11l1459t281r1850b330],
8	33	CD	NUMBER	33	dep	7	SENT_267	[p11l1459t281r1850b330],
9	.	.	O	.	_	0	SENT_267	[p11l1459t281r1850b330],

1	[	NN	O	[	nn	5	SENT_268	[p11l6t345r99b401],
2	28	CD	NUMBER	28	num	5	SENT_268	[p11l6t345r99b401],
3	]	CD	NUMBER	]	num	5	SENT_268	[p11l6t345r99b401],
4	Maring	NNP	O	Maring	nn	5	SENT_268	[p11l132t346r309b401],
5	JG	NNP	O	JG	_	0	SENT_268	[p11l319t348r388b401],
6	,	,	O	,	_	0	SENT_268	[p11l319t348r388b401],
7	Wachters	NNP	O	Wachters	nn	8	SENT_268	[p11l405t345r641b390],
8	FM	NNP	O	FM	appos	5	SENT_268	[p11l660t348r745b397],
9	,	,	O	,	_	0	SENT_268	[p11l660t348r745b397],
10	Slijfer	NNP	O	Slijfer	nn	11	SENT_268	[p11l764t345r907b401],
11	M	NNP	O	M	appos	5	SENT_268	[p11l923t348r982b397],
12	,	,	O	,	_	0	SENT_268	[p11l923t348r982b397],
13	et	FW	O	et	nn	14	SENT_268	[p11l1001t352r1047b390],
14	al.	FW	O	al.	appos	5	SENT_268	[p11l1063t345r1115b390],
15	.	.	O	.	_	0	SENT_268	[p11l1063t345r1115b390],

1	Pharmacokinetics	NNS	O	pharmacokinetic	_	0	SENT_269	[p11l1134t345r1570b390],
2	of	IN	O	of	_	0	SENT_269	[p11l1589t345r1640b390],
3	gemcitabine	NN	O	gemcitabine	prep_of	1	SENT_269	[p11l1651t345r1954b401],
4	in	IN	O	in	_	0	SENT_269	[p11l1973t346r2018b389],
5	nonsmall-cell	JJ	O	nonsmall-cell	amod	8	SENT_269	[p11l2036t358r2150b390, p11l133t413r370b457],
6	lung	NN	O	lung	nn	8	SENT_269	[p11l395t413r504b467],
7	cancer	NN	O	cancer	nn	8	SENT_269	[p11l527t426r688b457],
8	patients	NNS	O	patient	prep_in	3	SENT_269	[p11l711t414r923b467],
9	:	:	O	:	_	0	SENT_269	[p11l711t414r923b467],
10	impact	NN	O	impact	dep	1	SENT_269	[p11l953t414r1122b467],
11	of	IN	O	of	_	0	SENT_269	[p11l1145t413r1196b457],
12	the	DT	O	the	det	13	SENT_269	[p11l1214t413r1292b457],
13	79A	NN	O	79a	npadvmod	14	SENT_269	[p11l1318t415r1488b457],
14	>	JJR	O	>	amod	18	SENT_269	[p11l1318t415r1488b457],
15	C	NN	O	c	nn	18	SENT_269	[p11l1318t415r1488b457],
16	cytidine	NN	O	cytidine	nn	18	SENT_269	[p11l1512t413r1709b467],
17	deaminase	NN	O	deaminase	nn	18	SENT_269	[p11l1734t413r1998b457],
18	polymorphism	NN	O	polymorphism	prep_of	10	SENT_269	[p11l2023t413r2150b467, p11l132t479r399b533],
19	.	.	O	.	_	0	SENT_269	[p11l2023t413r2150b467, p11l132t479r399b533],

1	Eur	NNP	O	Eur	nn	4	SENT_270	[p11l419t481r534b533],
2	]	NNP	O	]	nn	4	SENT_270	[p11l419t481r534b533],
3	Clin	NNP	O	Clin	nn	4	SENT_270	[p11l554t479r648b522],
4	Pharmacol	NNP	O	Pharmacol	_	0	SENT_270	[p11l668t479r928b522],
5	2010	CD	DATE	2010	num	4	SENT_270	[p11l949t481r1339b529],
6	;	:	O	;	_	0	SENT_270	[p11l949t481r1339b529],
7	66:6	CD	NUMBER	66:6	num	9	SENT_270	[p11l949t481r1339b529],
8	l1	NN	O	l1	nn	9	SENT_270	[p11l949t481r1339b529],
9	—	NN	O	—	dep	4	SENT_270	[p11l949t481r1339b529],
10	7	CD	NUMBER	7	dep	9	SENT_270	[p11l949t481r1339b529],
11	.	.	O	.	_	0	SENT_270	[p11l949t481r1339b529],

